DrugID,IndicationID,DrugIndicationID,LeadCompanyID,Drug_Name,Generic_Name,Lead_Company,Ticker,State,Country,Continent,Market_Cap,Disease_Group,Sub_Disease_Group,Indication_Name,Lead_Indication,Current_Phase,Event_Phase,Likelihood_of_Approval,Molecule,Target,Drug_Classification,Imaging_Agent,Route_of_Administration,Fast_Track,SPA,Orphan,Breakthrough,RMAT,QIDP,Est_US_Approval_Date,Est_EU_Approval_Date,Est_Japan_Approval_Date,Actual_US_Approval_Date,Actual_EU_Approval_Date,Actual_Japan_Approval_Date,Future_PDUFA_Date,Future_NDA_BLA_Date,NDA_BLA_Date,Phase_III_Date,Phase_II_Date,Phase_I_Date,IND_Date,Phase_III_Event_Date,Phase_II_Event_Date,Phase_I_Event_Date,Lead_Company_Revenue_Pct_US,Peak_US_Revenue,US_2016,US_2017,US_2018,US_2019_YTD,WW_2016,WW_2017,WW_2018,WW_2019_YTD,Last_Quarter_Reported,Partner
25001,78,34751,266,Abacavir and lamivudine (Mylan),abacavir and lamivudine,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/23/14,,,,,12/23/13,,,,,07/18/12,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
1743,168,2778,636,Abilify (Oral and IM),aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Bipolar,Bipolar Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,N,N,N,,,,09/29/04,04/08/08,01/18/12,,,06/25/03,02/01/02,,,,02/01/02,,,55%,234.6,$   247.4,$   138.5,N/A,N/A,$   849.1,$   617.6,$   462.9,$    87.2,Q1 2019,"H. Lundbeck A/S, Ligand Pharmaceuticals, Inc."
1743,170,3675,636,Abilify (Oral and IM),aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,N,N,N,,,,11/15/02,06/04/04,01/23/06,,,10/31/01,07/01/97,,,,07/01/97,,,55%,73.6,$   247.4,$   138.5,N/A,N/A,$   849.1,$   617.6,$   462.9,$    87.2,Q1 2019,"H. Lundbeck A/S, Ligand Pharmaceuticals, Inc."
1743,167,6512,636,Abilify (Oral and IM),aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,N,N,N,,,,11/16/07,,06/14/13,,,05/16/07,06/01/04,,,,06/01/04,,,55%,,$   247.4,$   138.5,N/A,N/A,$   849.1,$   617.6,$   462.9,$    87.2,Q1 2019,"H. Lundbeck A/S, Ligand Pharmaceuticals, Inc."
1743,619,17227,636,Abilify (Oral and IM),aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Neurology,Neurodevelopmental Disorders,Autism Spectrum Disorders (Autism),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,N,N,N,,,,11/19/09,,09/28/16,,,01/21/09,,,,,06/01/06,,,55%,,$   247.4,$   138.5,N/A,N/A,$   849.1,$   617.6,$   462.9,$    87.2,Q1 2019,"H. Lundbeck A/S, Ligand Pharmaceuticals, Inc."
1743,3217,24525,636,Abilify (Oral and IM),aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Neurology,Other,Tourette's Syndrome,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,N,N,N,,,,12/16/14,,,,,04/03/14,10/24/11,,,,08/16/11,,06/30/11,55%,,$   247.4,$   138.5,N/A,N/A,$   849.1,$   617.6,$   462.9,$    87.2,Q1 2019,"H. Lundbeck A/S, Ligand Pharmaceuticals, Inc."
19041,170,25067,636,Abilify Maintena,aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,02/28/13,11/15/13,03/26/15,,,09/26/11,12/31/08,,,,12/31/08,,,N/A,,$   399.6,$   625.3,$   441.0,N/A,$   673.6,"$  1,432.2","$  1,490.0",$   279.1,Q1 2019,H. Lundbeck A/S
19041,168,27051,636,Abilify Maintena,aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Bipolar,Bipolar Disorder,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,07/28/17,,,,,09/28/16,10/09/12,,,,03/26/12,,,N/A,,$   399.6,$   625.3,$   441.0,N/A,$   673.6,"$  1,432.2","$  1,490.0",$   279.1,Q1 2019,H. Lundbeck A/S
26729,170,37326,636,Abilify Mycite,aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/13/17,,,,,09/11/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Proteus Digital Health, Inc."
26729,168,37329,636,Abilify Mycite,aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Bipolar,Bipolar Disorder,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/13/17,,,,,09/11/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Proteus Digital Health, Inc."
26729,167,37330,636,Abilify Mycite,aripiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/13/17,,,,,09/11/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Proteus Digital Health, Inc."
1861,214,2988,82,Abraxane,paclitaxel (albumin-bound),Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),Y,N,N,,N,N,,,,01/07/05,01/11/08,07/23/10,,,03/08/04,,,,,09/24/03,,,100%,,$   633.8,$   607.0,$   663.0,$   196.0,$   973.4,"$  1,192.0","$  1,297.1",$   345.0,Q1 2019,"BeiGene, Ltd., Biotoscana International, Otsuka Holdings Co., Ltd., Specialised Therapeutics Australia Pty, Ltd."
1861,211,2993,82,Abraxane,paclitaxel (albumin-bound),Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,Y,N,N,N,N,,,,10/11/12,03/02/15,02/21/13,,,12/09/11,,,,,10/15/07,02/25/04,,100%,,$   633.8,$   607.0,$   663.0,$   196.0,$   973.4,"$  1,192.0","$  1,297.1",$   345.0,Q1 2019,"BeiGene, Ltd., Biotoscana International, Otsuka Holdings Co., Ltd., Specialised Therapeutics Australia Pty, Ltd."
1861,220,13815,82,Abraxane,paclitaxel (albumin-bound),Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Solid,Pancreatic Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,09/06/13,12/23/13,12/18/14,,,03/21/13,03/03/09,,,,03/03/09,04/01/08,,100%,292.8,$   633.8,$   607.0,$   663.0,$   196.0,$   973.4,"$  1,192.0","$  1,297.1",$   345.0,Q1 2019,"BeiGene, Ltd., Biotoscana International, Otsuka Holdings Co., Ltd., Specialised Therapeutics Australia Pty, Ltd."
8157,603,10073,3285,Absorica,isotretinoin,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Dermatology,General,Acne,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Retinoic acid receptor (RARs),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/25/12,,,,,06/30/05,,,,,09/06/05,,,85%,69.7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2011,"Cipher Pharmaceuticals Inc., Daiichi Sankyo Co., Ltd."
3282,3125,5665,3380,Abstral,fentanyl citrate,Zydus Cadila,CDH:IN,,India,Asia,,Neurology,Pain,Cancer Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,01/07/11,03/07/08,09/20/13,,,08/06/09,,,,,12/07/05,02/14/03,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   118.1,$    53.6,Q2 2019,"Endo International plc, Gedeon Richter Plc, Hisamitsu Pharmaceutical Co., Inc., Kyowa Hakko Kirin Co., Ltd., NewBridge Pharmaceuticals, Orexo AB"
528,428,706,1298,ABthrax,raxibacumab,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Anthrax Infection (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Anthrax protective antigen^ Bacillus anthracis (Anthrax),Biologic,No,"Intramuscular (IM), Intravenous (IV)",Y,N,Y,,N,N,,,,12/14/12,,,,,05/14/09,,,,,03/13/08,,11/12/03,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,AstraZeneca PLC
769,660,899,1298,ACAM2000,,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Infectious disease,Antiviral,Smallpox,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Smallpox virus,Vaccine,No,Percutaneous Catheter/Injection,Y,N,N,,N,N,,,,08/31/07,,,,,01/18/06,12/15/03,,,,12/15/03,03/11/03,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    21.8,$    52.1,Q2 2019,N/A
24966,603,34704,470,Acanya Gel,clindamycin and benzoyl peroxide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Dermatology,General,Acne,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacteria-miscellaneous^ Bacterial ribosome^ Protein synthesis,Non-NME,No,Topical,N,N,N,N,N,N,,,,10/21/08,,,,,12/26/07,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3214,306,5501,1298,Accretropin,somatropin,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Endocrine,Short Stature,Turner Syndrome,Y,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,01/23/08,,,,,05/10/06,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Teva Pharmaceutical Industries Ltd.
3214,285,5502,1298,Accretropin,somatropin,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Endocrine,Short Stature,Short Stature / Growth Hormone Deficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,01/23/08,,,,,05/10/06,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Teva Pharmaceutical Industries Ltd.
2006,267,3310,4326,Aceon,perindopril erbumine,Symplmed Pharmaceuticals LLC,,Ohio,United States,North America,,Cardiovascular,Coronary Artery Disease (General),Coronary Artery Disease,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin Converting Enzyme (ACE),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,08/23/05,,,,,12/13/04,,,,,09/06/03,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"AbbVie Inc., XOMA Corporation"
19522,726,25752,3014,Acetadote,acetylcysteine,Cumberland Pharmaceuticals Inc.,CPIX,Tennessee,United States,North America,89128556,Not Specified,Other,Drug Toxicity,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Glutathione (GSH) synthesis^ Reactive Oxygen Species/Free Radicals,Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,01/23/04,,,,,,,,,,,,,N/A,,$     7.2,$     6.6,$     4.2,$     0.9,$     7.2,$     6.6,$     4.2,$     0.9,Q1 2019,"Harbin Gloria Pharmaceuticals Co., Ltd., Winhealth Pharma Group"
40269,644,56350,3650,AcipHex Sprinkle,rabeprazole sodium delayed-release,Cerecor Inc.,CERC,Maryland,United States,North America,136700277,Gastroenterology (non inflammatory bowel disease),General,Gastroesophageal Reflux Disease (GERD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Proton pump,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/26/13,,,,,09/27/12,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"EA Pharma Co., Ltd."
2424,154,4101,149,Actemra,tocilizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-6 Receptor (IL-6R),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,01/08/10,01/15/09,04/16/08,,,11/19/07,,,,,11/14/05,,,97%,761.2,$   660.8,$   771.6,$   870.3,$   460.1,"$  1,733.1","$  1,966.3","$  2,193.3","$  1,135.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
2424,365,13909,149,Actemra,tocilizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-6 Receptor (IL-6R),Biologic,No,Intravenous (IV),N,N,Y,,N,N,,,,04/15/11,08/03/11,04/16/08,,,10/18/10,,,,,04/28/06,,,97%,,$   660.8,$   771.6,$   870.3,$   460.1,"$  1,733.1","$  1,966.3","$  2,193.3","$  1,135.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
2424,726,49926,149,Actemra,tocilizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Not Specified,Other,Drug Toxicity,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-6 Receptor (IL-6R),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,08/30/17,08/23/18,03/26/19,,,06/01/17,,,,,,,,97%,,$   660.8,$   771.6,$   870.3,$   460.1,"$  1,733.1","$  1,966.3","$  2,193.3","$  1,135.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
15790,154,20169,149,Actemra (Subcutaneous),tocilizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-6 Receptor (IL-6R),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/02/13,04/28/14,03/25/13,,,12/21/12,09/23/10,,01/15/09,,09/23/10,02/03/10,01/15/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
15790,3356,30840,149,Actemra (Subcutaneous),tocilizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Vasculitis,Giant Cell Arteritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-6 Receptor (IL-6R),Biologic,No,Subcutaneous (SQ),N,N,N,Y,N,N,,,,05/22/17,09/22/17,08/25/17,,,11/22/16,07/25/13,,,,07/25/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
15790,365,53075,149,Actemra (Subcutaneous),tocilizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-6 Receptor (IL-6R),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,05/11/18,10/29/18,,,,11/14/17,,,07/13/13,,,,07/13/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
32276,3121,44579,774,Acticlate,doxycycline hyclate USP,"Almirall Prodesfarma, S.A.",ALM:SM,,Spain,Europe,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/25/14,,,,,09/25/13,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
32276,467,44626,774,Acticlate,doxycycline hyclate USP,"Almirall Prodesfarma, S.A.",ALM:SM,,Spain,Europe,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Malaria,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/25/14,,,,,09/25/13,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
32276,603,44627,774,Acticlate,doxycycline hyclate USP,"Almirall Prodesfarma, S.A.",ALM:SM,,Spain,Europe,,Dermatology,General,Acne,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/25/14,,,,,09/25/13,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
72,540,779,2878,Actimmune,interferon gamma-1b,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteopetrosis,N,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,"Intramuscular (IM), Intravenous (IV), Subcutaneous (SQ)",N,N,Y,,N,N,,,,02/10/00,,,,,,,,,,,,,98.75%,,N/A,N/A,$   105.6,$    21.7,N/A,N/A,$   105.6,$    21.7,Q1 2019,"Boehringer Ingelheim GmbH, Clinigen Group plc, GlaxoSmithKline plc, Roche Holding AG"
1750,242,2790,395,Actonel,risedronate sodium hydrate,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Osteoclast,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,04/14/00,04/01/00,01/01/02,,,,,,,,,,,80%,,N/A,N/A,N/A,N/A,$    72.9,$    67.5,N/A,N/A,Q4 2017,"Ajinomoto Bio-Pharma Services, Eisai Co., Ltd., Sanofi, Takeda Pharmaceutical Company Ltd"
9784,137,12181,826,Actoplus Met,metformin and pioglitazone,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,PPAR gamma,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/29/05,07/28/06,04/16/10,,,10/29/04,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
2615,137,4458,826,ACTOplus met XR,metformin and pioglitazone (extended release),Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,PPAR gamma,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/13/09,,,,,04/03/06,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Allergan plc
1295,603,1653,774,Aczone,dapsone,"Almirall Prodesfarma, S.A.",ALM:SM,,Spain,Europe,,Dermatology,General,Acne,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydropteroate Synthetase (DHPS),Non-NME,No,Topical,N,N,N,N,N,N,,,,07/07/05,,,,,08/31/04,10/15/01,,05/07/01,,03/28/02,,,100%,,$   217.3,$   166.3,$    55.1,$    46.3,$   217.3,$   166.8,$    55.5,$    46.3,Q2 2019,N/A
23601,603,32451,774,Aczone X,dapsone,"Almirall Prodesfarma, S.A.",ALM:SM,,Spain,Europe,,Dermatology,General,Acne,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydropteroate Synthetase (DHPS),Non-NME,No,Topical,N,N,N,N,N,N,,,,02/24/16,,,,,04/28/15,12/20/13,,,,12/20/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2111,3197,3492,51,Adacel,Tdap vaccine,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Diphtheria, pertussis, and tetanus (DT, Td, DTaP and Tdap) Vaccines",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,06/10/05,,,,,08/11/04,,,,,,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2013,N/A
2896,170,4938,610,Adasuve,loxapine,"Grupo Ferrer Internacional, S.A.",,,Spain,Europe,,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,12/21/12,02/20/13,,,,12/11/09,02/25/08,,,08/31/05,09/18/07,09/22/06,,100%,11.1,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"AOP Orphan Pharmaceuticals AG, Medivir AB"
2896,168,10559,610,Adasuve,loxapine,"Grupo Ferrer Internacional, S.A.",,,Spain,Europe,,Psychiatry,Bipolar,Bipolar Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,12/21/12,02/20/13,,,,12/11/09,07/24/08,,,08/31/05,07/24/08,09/18/07,,100%,12.2,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"AOP Orphan Pharmaceuticals AG, Medivir AB"
546,204,1045,351,Adcetris,brentuximab vedotin,"Seattle Genetics, Inc.",SGEN,Washington,United States,North America,12613090138,Oncology,Hematologic,Hodgkin's Lymphoma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ Cluster of Differentiation 30 (CD30) / TNFRSF8^ Microtubules (Tubulin),Biologic,No,Intravenous (IV),Y,Y,Y,Y,N,N,,,,08/19/11,10/25/12,01/17/14,,,02/28/11,04/08/10,01/21/09,11/17/06,,04/08/10,01/15/09,11/17/06,100%,188.6,N/A,N/A,N/A,N/A,$   418.2,$   482.2,$   771.9,$   294.0,Q2 2019,Takeda Pharmaceutical Company Ltd
546,590,18005,351,Adcetris,brentuximab vedotin,"Seattle Genetics, Inc.",SGEN,Washington,United States,North America,12613090138,Oncology,Hematologic,Anaplastic Large Cell Lymphoma (ALCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ Cluster of Differentiation 30 (CD30) / TNFRSF8^ Microtubules (Tubulin),Biologic,No,Intravenous (IV),Y,N,Y,Y,N,N,,,,08/19/11,10/25/12,01/17/14,,,02/28/11,,03/19/09,,,,01/15/09,11/05/07,100%,80.2,N/A,N/A,N/A,N/A,$   418.2,$   482.2,$   771.9,$   294.0,Q2 2019,Takeda Pharmaceutical Company Ltd
546,417,23479,351,Adcetris,brentuximab vedotin,"Seattle Genetics, Inc.",SGEN,Washington,United States,North America,12613090138,Oncology,Hematologic,Cutaneous T-Cell Lymphoma (CTCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ Cluster of Differentiation 30 (CD30) / TNFRSF8^ Microtubules (Tubulin),Biologic,No,Intravenous (IV),N,Y,Y,Y,N,N,,,,11/09/17,12/15/17,,,,06/20/17,05/07/12,,,,05/07/12,06/29/11,02/08/11,100%,,N/A,N/A,N/A,N/A,$   418.2,$   482.2,$   771.9,$   294.0,Q2 2019,Takeda Pharmaceutical Company Ltd
546,3097,29403,351,Adcetris,brentuximab vedotin,"Seattle Genetics, Inc.",SGEN,Washington,United States,North America,12613090138,Oncology,Hematologic,Peripheral T-Cell Lymphoma (PTCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ Cluster of Differentiation 30 (CD30) / TNFRSF8^ Microtubules (Tubulin),Biologic,No,Intravenous (IV),Y,N,Y,Y,N,N,,,,11/16/18,,,,,11/04/18,01/24/13,,,,01/09/12,08/23/11,02/08/11,100%,,N/A,N/A,N/A,N/A,$   418.2,$   482.2,$   771.9,$   294.0,Q2 2019,Takeda Pharmaceutical Company Ltd
15503,245,19716,385,Adcirca,tadalafil,United Therapeutics Corporation,UTHR,Maryland,United States,North America,3493948188,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 5 (PDE5),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/22/09,10/01/08,10/31/09,,,07/24/08,,,,,01/10/06,,,N/A,146.9,$   392.4,$   440.0,$   482.6,$    20.0,$   492.1,$   554.3,$   587.4,$    30.1,Q1 2019,"Eli Lilly &amp; Company, Nippon Shinyaku Co., Ltd."
1671,246,2686,826,Adderall XR,amphetamine and dextroamphetamine,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine^ Norepinephrine (Noradrenaline),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/12/01,,,,,10/03/00,,,,,,,,N/A,,$   342.2,$   327.7,$   147.8,N/A,$   363.8,$   348.0,$   155.8,$    49.0,Q1 2019,N/A
12590,275,15880,3870,Addyi,flibanserin,"Sprout Pharmaceuticals, Inc.",,North Carolina,United States,North America,,Obstetrics/Gynecology,Female Sexual Arousal Disorder,Female Sexual Arousal Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 4 (D4) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/18/15,,,,,10/31/09,01/16/06,,,,01/16/06,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Bausch Health Companies Inc., Boehringer Ingelheim GmbH"
7614,245,9344,59,Adempas,riociguat,Bayer AG,BAYRY,,Germany,Europe,,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Guanylate Cyclase (sGC),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,10/08/13,03/27/14,01/17/14,,,02/08/13,02/09/09,,,,02/09/09,03/28/07,,100%,296,N/A,$   123.8,$   188.5,N/A,$   281.5,$   559.8,$   731.2,$   412.5,Q2 2019,"Merck &amp; Co., Inc."
24800,190,34462,375,"Adenovirus Type 4 and Type 7 Vaccine, Live",,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Infectious disease,Antiviral,Antiviral - Miscellaneous Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,DNA polymerase,Vaccine,No,Oral (PO),N,N,N,N,N,N,,,,03/16/11,,,,,,,,,,03/06/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
40741,246,57123,325,Adhansia XR,methylphenidate hydrochloride,Purdue Pharma L.P.,,Connecticut,United States,North America,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/27/19,,,,,04/27/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1700,137,2727,51,Adlyxin,lixisenatide,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/27/16,02/01/13,06/28/13,,,07/30/15,05/29/08,,,,06/02/08,06/25/03,,82%,392.9,N/A,N/A,N/A,N/A,$    29.0,N/A,N/A,N/A,Q3 2016,"Alkermes plc, Royalty Pharma AG, Zealand Pharma A/S"
24504,157,34025,51,Admelog,insulin lispro,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",N,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/01/17,07/19/17,,,,11/01/16,,,,,10/26/14,,07/31/13,N/A,,N/A,N/A,N/A,$   153.5,N/A,N/A,N/A,$   161.4,Q2 2019,N/A
24504,137,34026,51,Admelog,insulin lispro,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/01/17,07/19/17,,,,11/01/16,01/20/15,,,,11/18/14,,06/16/14,N/A,,N/A,N/A,N/A,$   153.5,N/A,N/A,N/A,$   161.4,Q2 2019,N/A
18682,3076,24536,618,Adrenaclick,Epinephrine,Shionogi & Co. Ltd.,4507:JP,,Japan,Asia,,Allergy,General,Anaphylaxis,N,Approved,Approved,100% (Same As Avg.),Peptide,Alpha Adrenergic Receptors^ Beta Adrenergic Receptors,Non-NME,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,,N,N,,,,05/30/03,,,,,12/05/96,,,,,,,,N/A,,N/A,N/A,$    67.6,$    15.2,N/A,N/A,$    67.6,$    15.2,Q1 2019,N/A
2073,72,3395,180,Advair Diskus/HFA,fluticasone and salmeterol,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,Asthma,Asthma,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,N,N,N,,,,08/24/00,06/19/00,04/18/07,,,,,,,,,,,100%,439.6,"$  2,487.0","$  2,093.0","$  1,459.0",$   362.0,"$  4,740.0","$  4,069.0","$  3,221.0","$  1,158.0",Q2 2019,N/A
2073,73,4021,180,Advair Diskus/HFA,fluticasone and salmeterol,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,N,N,N,,,,11/18/03,06/19/00,01/31/09,,,,,,,,,,,100%,780.2,"$  2,487.0","$  2,093.0","$  1,459.0",$   362.0,"$  4,740.0","$  4,069.0","$  3,221.0","$  1,158.0",Q2 2019,N/A
2316,511,3899,826,Advate,factor VIII (procoagulant),Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,07/25/03,03/03/04,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,$   291.4,Q1 2019,DRI Capital Inc.
19141,511,25211,826,Adynovate,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,11/13/15,01/15/18,03/28/16,,,12/01/14,02/11/13,,01/05/12,,02/11/13,,01/05/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,$    97.2,Q1 2019,Nektar Therapeutics
26267,246,36640,4638,Adzenys ER,amphetamine XR,"Neos Therapeutics, Inc.",NEOS,Texas,United States,North America,50746479,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine^ Norepinephrine (Noradrenaline),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/15/17,,,,,11/17/16,,,,,,,06/19/15,N/A,,N/A,N/A,$     0.2,$     0.2,N/A,N/A,$     0.2,$     0.2,Q1 2019,N/A
23867,246,32896,4638,Adzenys XR-ODT,amphetamine polistirex,"Neos Therapeutics, Inc.",NEOS,Texas,United States,North America,50746479,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/27/16,,,,,12/27/12,,,,,09/24/13,,,N/A,,N/A,N/A,$    26.6,$     6.7,N/A,N/A,$    26.6,$     6.7,Q1 2019,Takeda Pharmaceutical Company Ltd
16223,495,20875,2751,Aemcolo,rifamycin,Cosmo Pharmaceuticals N.V.,COPN:SW,,Italy,Europe,,Gastroenterology (non inflammatory bowel disease),General,Gastroenteritis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,Y,,,,11/16/18,,,,,03/19/18,06/02/10,,,12/30/09,06/02/10,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Dr. Falk Pharma GmbH, Pharmascience Inc."
2480,72,4207,266,Aerospan,flunisolide,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,,N,N,,,,01/27/06,,,,,04/27/00,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Allergan plc
10571,347,13238,289,Afinitor,everolimus,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Neuroendocrine Tumors (NET),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Mammalian Target of Rapamycin (mTOR)/mTORC,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/05/11,09/05/11,12/31/11,,,,,,,,11/28/06,,,100%,686.2,$   775.0,$   819.0,$   929.0,$   493.0,"$  1,516.0","$  1,525.0","$  1,556.0",$   774.0,Q2 2019,N/A
10571,216,13239,289,Afinitor,everolimus,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Renal Cell Cancer (RCC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Mammalian Target of Rapamycin (mTOR)/mTORC,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/30/09,08/03/09,01/20/10,,,06/30/08,11/29/06,,,,11/29/06,05/05/06,,100%,467.4,$   775.0,$   819.0,$   929.0,$   493.0,"$  1,516.0","$  1,525.0","$  1,556.0",$   774.0,Q2 2019,N/A
10571,214,13242,289,Afinitor,everolimus,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Mammalian Target of Rapamycin (mTOR)/mTORC,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/20/12,07/30/12,03/17/14,,,12/31/11,07/07/09,,,,07/07/09,09/20/05,,100%,515,$   775.0,$   819.0,$   929.0,$   493.0,"$  1,516.0","$  1,525.0","$  1,556.0",$   774.0,Q2 2019,N/A
10571,2719,18141,289,Afinitor,everolimus,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,General,Tuberous Sclerosis Complex (TSC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Mammalian Target of Rapamycin (mTOR)/mTORC,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,10/29/10,09/02/11,11/30/12,,,04/30/10,04/14/09,,,,04/14/09,11/17/08,,100%,,$   775.0,$   819.0,$   929.0,$   493.0,"$  1,516.0","$  1,525.0","$  1,556.0",$   774.0,Q2 2019,N/A
21746,3300,29363,254,Afluria,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,09/28/07,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,CSL Limited
30969,3300,42845,254,Afluria Quadrivalent,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,N,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,08/26/16,,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,CSL Limited
2214,137,3715,809,Afrezza,insulin,MannKind Corporation,MNKD,California,United States,North America,177153306,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Non-NME,No,Inhaled,N,Y,N,N,N,N,,,,06/27/14,,,,,03/16/09,06/29/05,,,,06/29/05,11/10/04,,N/A,,$     1.9,$     9.2,$    17.3,$     5.1,$     1.9,$     9.2,$    17.3,$     5.1,Q1 2019,Cipla Limited
2214,157,3925,809,Afrezza,insulin,MannKind Corporation,MNKD,California,United States,North America,177153306,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,06/27/14,,,,,03/16/09,06/29/05,,,,06/29/05,11/10/04,,N/A,,$     1.9,$     9.2,$    17.3,$     5.1,$     1.9,$     9.2,$    17.3,$     5.1,Q1 2019,Cipla Limited
18722,511,24598,870,Afstyla,,CSL Limited,CSL:AU,,Australia,Oceania,,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,05/25/16,01/04/17,09/28/17,,,07/28/15,06/04/13,,12/08/11,,06/04/13,,12/08/11,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18109,3300,23660,870,AgriFlu,,CSL Limited,CSL:AU,,Australia,Oceania,,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,11/27/09,12/22/98,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
21363,288,28786,30,Aimovig,erenumab-aooe,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Calcitonin Gene-Related Peptide (CGRP) / Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,05/17/18,07/26/18,,,,05/17/17,07/30/15,09/27/13,11/07/12,,07/30/15,09/27/13,11/07/12,N/A,,N/A,N/A,$   117.0,$   142.0,N/A,N/A,$   117.0,$   184.0,Q2 2019,Novartis AG
40658,72,57004,375,AirDuo Digihaler Inhalation Powder,fluticasone/salmeterol,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,Asthma,Asthma,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,N,N,N,,,,07/15/19,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23821,72,32819,375,AirDuo RespiClick,fluticasone/salmeterol,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,N,N,N,,,,01/27/17,08/18/16,,,,03/29/16,06/04/14,01/31/13,,,06/04/14,01/31/13,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
19000,288,25008,375,Ajovy,fremanezumab-vfrm,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Calcitonin Gene-Related Peptide (CGRP) / Receptor,Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,N,N,N,N,,,,09/14/18,03/28/19,,,,10/16/17,01/11/16,01/08/14,08/11/11,,12/02/15,01/08/14,08/11/11,N/A,,N/A,N/A,$     3.0,N/A,N/A,N/A,$     3.0,$    20.0,Q1 2019,"Otsuka Holdings Co., Ltd., Pfizer Inc."
27209,3577,38063,831,Akovaz,ephedrine sulfate,Avadel Pharmaceuticals plc,AVDL,,Ireland,Europe,75874628,Cardiovascular,Other,Hypotension/Shock,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Beta Adrenergic Receptors^ Norepinephrine (Noradrenaline),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,04/29/16,,,,,06/30/15,,,,,10/31/13,,,N/A,,N/A,N/A,$    33.8,$     3.8,N/A,N/A,$    33.8,$     3.8,Q1 2019,N/A
17831,767,23281,462,Akynzeo,netupitant and palonosetron,Helsinn Healthcare SA,,,Switzerland,Europe,,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Neurokinin Receptor^ Serotonin 5-HT3 receptor,Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,10/10/14,05/27/15,,,,,,,,,06/09/10,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Chugai Pharmaceutical Co., Ltd., CJ CheilJedang Corp., Eisai Co., Ltd., Especificos Stendhal S.A., Glenmark Pharmaceuticals Limited, Grünenthal GmbH, Mundipharma International Limited, Otsuka Holdings Co., Ltd., Purdue Pharma L.P., Riemser Pharma GmbH, Sinclair Pharma, plc., Vifor Pharma Group"
37946,767,52953,462,Akynzeo (IV),netupitant and palonosetron,Helsinn Healthcare SA,,,Switzerland,Europe,,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Neurokinin Receptor^ Serotonin 5-HT3 receptor,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,04/19/18,,,,,04/20/17,10/26/15,,,,12/02/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Eisai Co., Ltd., Otsuka Holdings Co., Ltd., Sinclair Pharma, plc."
3002,690,5117,470,Aldara,imiquimod,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Dermatology,General,Actinic Keratoses,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Immune system,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,03/02/04,11/29/06,,,,05/02/03,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q1 2015,Mylan N.V.
3002,360,5118,470,Aldara,imiquimod,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Oncology,Solid,Skin Cancer - Basal Cell Carcinoma (BCC),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Immune system,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,07/14/04,07/13/04,,,,06/10/03,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q1 2015,Mylan N.V.
169,289,224,65,Aldurazyme,laronidase,BioMarin Pharmaceutical Inc.,BMRN,California,United States,North America,13080442306,Metabolic,Inborn Errors Of Metabolism,Mucopolysaccharidosis I (MPS I; Hurler Syndrome),Y,Approved,Approved,100% (Same As Avg.),Protein,Unsulfated alpha-L-iduronic acid,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,04/30/03,06/09/03,10/31/06,,,,12/15/00,,,,,,,45%,155.6,N/A,$    48.0,$    56.8,$    29.3,$   168.6,$   326.4,$   355.4,$   136.8,Q2 2019,Sanofi
17617,211,22951,149,Alecensa,alectinib,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Anaplastic lymphoma kinase (ALK),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,12/11/15,02/21/17,07/04/14,,,07/06/15,07/21/14,09/30/10,,,07/21/14,10/22/10,,N/A,,$    75.6,$   213.3,$   288.3,$   149.0,$   186.0,$   371.8,$   646.8,$   421.0,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
1678,211,2697,136,Alimta,pemetrexed,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Thymidylate Synthase,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,08/19/04,09/20/04,07/01/09,,,11/04/03,,,,,,,,100%,1087,"$  1,100.9","$  1,034.3","$  1,131.0",$   623.5,"$  2,283.3","$  2,062.5","$  2,132.9","$  1,077.0",Q2 2019,N/A
1678,652,2698,136,Alimta,pemetrexed,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Mesothelioma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Thymidylate Synthase,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,02/05/04,09/22/04,,,,10/22/03,,,,,,,,100%,36.1,"$  1,100.9","$  1,034.3","$  1,131.0",$   623.5,"$  2,283.3","$  2,062.5","$  2,132.9","$  1,077.0",Q2 2019,N/A
16369,81,24925,3356,Alinia,nitazoxanide,Lupin Limited,LPC:IN,,India,Asia,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,N,Approved,Approved,100% (Same As Avg.),Small Molecule,PKR (double-stranded RNA-activated protein kinase)^ Pyruvate:ferredoxin oxidoreductase (PFOR),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,07/21/04,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Romark Laboratories, L.C."
18359,3093,27967,59,Aliqopa,copanlisib,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,PI3K/AKT pathway,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,Y,N,N,N,,,,09/14/17,,,,,03/16/17,06/12/15,08/06/12,11/25/09,,06/12/15,08/06/12,11/25/09,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
611,647,4329,51,Allegra,fexofenadine hydrochloride,Sanofi,SNY,,France,Europe,1.05588E+11,Allergy,General,Urticaria,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,02/28/00,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   206.4,$   177.7,$   152.1,$    92.8,Q2 2019,"Sumitomo Dainippon Pharma Co., Ltd."
1633,767,2620,462,Aloxi,palonosetron hydrochloride,Helsinn Healthcare SA,,,Switzerland,Europe,,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT3 receptor,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,07/25/03,03/22/05,01/20/10,,,,,,,,,,,N/A,,$   443.0,N/A,$    15.6,N/A,N/A,$   490.0,$    70.8,$    30.9,Q1 2019,"Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mundipharma International Limited, Otsuka Holdings Co., Ltd., Purdue Pharma L.P., Roche Holding AG, Swedish Orphan Biovitrum, Vifor Pharma Group"
1633,594,21671,462,Aloxi,palonosetron hydrochloride,Helsinn Healthcare SA,,,Switzerland,Europe,,Not Specified,Other,Emesis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT3 receptor,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,10/01/2014 - 11/30/2014,,02/29/08,,,,,05/04/07,,,,,07/25/06,,,N/A,,$   443.0,N/A,$    15.6,N/A,N/A,$   490.0,$    70.8,$    30.9,Q1 2019,"Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mundipharma International Limited, Otsuka Holdings Co., Ltd., Purdue Pharma L.P., Roche Holding AG, Swedish Orphan Biovitrum, Vifor Pharma Group"
3014,278,5144,395,Alphagan P,brimonidine tartrate,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor,Non-NME,No,Topical,N,N,N,,N,N,,,,03/16/01,,,,,06/30/00,,,,,,,,N/A,,N/A,N/A,$   375.4,$    83.0,N/A,N/A,$   551.4,$   120.6,Q1 2019,"Kyorin Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd."
12230,512,15424,51,Alprolix,,Sanofi,SNY,,France,Europe,1.05588E+11,Hematology,Factor Augmentation,Hemophilia B,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,03/28/14,05/12/16,07/23/14,,,01/04/13,01/25/10,,,,01/25/10,05/27/08,06/08/07,N/A,,$   267.6,N/A,$   252.1,$   162.7,$   333.2,$    26.0,$   429.7,$   303.0,Q2 2019,"Swedish Orphan Biovitrum, UCB SA"
2568,440,4363,180,Altabax,retapamulin,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,04/12/07,05/24/07,,,,11/30/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1273,181,3916,312,Altace,ramipril,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,General,Cardiovascular Disease,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin Converting Enzyme (ACE),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/05/00,,,,,01/19/00,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   244.7,$   123.1,Q2 2019,Sanofi
27348,603,38246,470,Altreno,tretinoin,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Dermatology,General,Acne,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Retinoic acid receptor (RARs),Non-NME,No,Topical,N,N,N,N,N,N,,,,08/23/18,,,,,10/23/17,,,,,07/06/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
17852,211,23312,826,Alunbrig,brigatinib,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Anaplastic lymphoma kinase (ALK)^ EGFR (Epidermal Growth Factor Receptor),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,04/28/17,11/22/18,,,,08/29/16,04/11/16,06/02/13,09/21/11,06/30/11,04/11/16,06/02/13,09/21/11,N/A,,N/A,$    13.0,$    42.0,$    10.0,N/A,$    13.0,$    42.0,$    10.0,Q1 2019,N/A
1566,72,2507,8484,Alvesco,ciclesonide,Covis Pharma B.V.,,,Switzerland,Europe,,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,,N,N,,,,01/10/08,04/22/04,04/18/07,,,12/30/03,,,,,10/26/04,,,N/A,,N/A,N/A,N/A,N/A,$    47.0,$    13.0,N/A,N/A,Q4 2017,Teijin Pharma Limited
1663,291,2675,51,Ambien CR,zolpidem (controlled release),Sanofi,SNY,,France,Europe,1.05588E+11,Neurology,Insomnia,Insomnia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/02/05,,,,,06/23/04,,,,,,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Astellas Pharma, Inc."
328,401,616,814,AmBisome,amphotericin b,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Cryptococcal Meningitis (Antifungal),N,Approved,Approved,100% (Same As Avg.),Small Molecule with Liposomal Delivery System,Cell Membrane^ Sterols,Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,07/05/00,,,,,,,,,,,,,N/A,,N/A,N/A,$    46.0,$     8.0,$   487.3,$   502.5,$   420.0,$   126.5,Q1 2019,"Biotoscana International, Gilead Sciences, Inc., Mylan N.V., Sumitomo Dainippon Pharma Co., Ltd."
19783,690,26202,3641,Ameluz,5-aminolevulinic acid hydrochloride,Biofrontera AG,BFRA,,Germany,Europe,,Dermatology,General,Actinic Keratoses,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reactive Oxygen Species/Free Radicals,Non-NME,No,Topical,N,N,N,N,N,N,,,,05/11/16,12/14/11,,,,07/10/15,,,,,06/12/12,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Desitin Pharmaceuticals GmbH, Louis Widmer AG, Maruho Co., Ltd., Pelpharma Handels GmbH, Perrigo Company PLC, PHA Farmed s.p., Pharma.MT Ltd., Pharmacenter Holding Ltd., Spirit Healthcare Ltd."
157,155,152,814,Amevive,alefacept,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Protein,Cluster of Differentiation 2 (CD2),Biologic,No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,01/31/03,06/17/04,,,,08/01/01,05/15/99,,,,,,,90%,0,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2011,"Biogen, Inc."
3246,661,5572,556,Amitiza,lubiprostone,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Gastroenterology (non inflammatory bowel disease),Other,Chronic Idiopathic Constipation,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Chloride Channel 2 (CIC-2/CLCN-2),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/31/06,11/19/09,07/05/12,,,03/31/05,,,,,,,,N/A,,$   309.0,$   304.0,$   299.7,$    53.0,$   309.0,$   304.0,$   299.7,$    53.0,Q1 2019,"Abbott Laboratories, Harbin Gloria Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Company Ltd"
3246,435,6513,556,Amitiza,lubiprostone,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Gastroenterology (non inflammatory bowel disease),Other,Irritable Bowel Syndrome (IBS),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Chloride Channel 2 (CIC-2/CLCN-2),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,04/29/08,,,,,06/29/07,,,,,05/16/05,04/01/05,,N/A,,$   309.0,$   304.0,$   299.7,$    53.0,$   309.0,$   304.0,$   299.7,$    53.0,Q1 2019,"Abbott Laboratories, Harbin Gloria Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Company Ltd"
3246,551,10518,556,Amitiza,lubiprostone,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Gastroenterology (non inflammatory bowel disease),Other,Opioid Induced Constipation (OIC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Chloride Channel 2 (CIC-2/CLCN-2),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,04/19/13,,,,,07/20/12,,,,,09/13/07,,,N/A,,$   309.0,$   304.0,$   299.7,$    53.0,$   309.0,$   304.0,$   299.7,$    53.0,Q1 2019,"Abbott Laboratories, Harbin Gloria Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Company Ltd"
23159,155,31677,30,Amjevita,adalimumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/23/16,03/22/17,,,,11/25/15,10/09/13,,,,10/09/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Orion Corporation"
23159,154,31680,30,Amjevita,adalimumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/23/16,03/22/17,,,,11/25/15,,,,,08/27/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Orion Corporation"
23159,365,41634,30,Amjevita,adalimumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/23/16,03/22/17,,,,11/25/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Orion Corporation"
23159,336,41635,30,Amjevita,adalimumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/23/16,03/22/17,,,,11/25/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Orion Corporation"
23159,252,41636,30,Amjevita,adalimumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/23/16,03/22/17,,,,11/25/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Orion Corporation"
23159,156,41637,30,Amjevita,adalimumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/23/16,03/22/17,,,,11/25/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Orion Corporation"
23159,321,41638,30,Amjevita,adalimumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/23/16,03/22/17,,,,11/25/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Orion Corporation"
2045,654,3347,2878,Ammonul,sodium benzoate/sodium phenylacetate,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Metabolic,Inborn Errors Of Metabolism,Urea Cycle Disorders and Derangements (UCD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutamine^ Glycine,Non-NME,No,Intravenous (IV),N,N,Y,,N,N,,,,02/18/05,,,,,08/10/04,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Bausch Health Companies Inc., Swedish Orphan Biovitrum"
2628,545,4489,888,Amphadase,hyaluronidase,"Amphastar Pharmaceuticals, Inc.",AMPH,California,United States,North America,961153036,Ophthalmology,Other,Spreading Agent,Y,Approved,Approved,100% (Same As Avg.),Protein,Hyaluronic acid,Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,10/26/04,,,,,06/06/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2820,153,4811,8,Ampyra,dalfampridine,"Acorda Therapeutics, Inc.",ACOR,New York,United States,North America,129834265,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Potassium channels,New Molecular Entity (NME),No,Oral (PO),N,Y,Y,N,N,N,,,,01/22/10,07/20/11,,,,01/30/09,06/30/05,11/28/00,,,06/30/05,11/28/00,,82%,408.2,$   359.7,$   543.4,$   455.1,$    84.3,$   422.5,$   637.1,$   547.7,$   131.3,Q2 2019,"Alkermes plc, Biogen, Inc., DRI Capital Inc., UCB SA"
19630,3127,25906,375,Amrix,cyclobenzaprine hydrochloride,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Pain,Acute Pain,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor^ Serotonin 5-HT2A receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,02/01/07,,,,,04/29/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q2 2011,Allergan plc
15149,244,19264,289,Amturnide,"aliskiren, amlodipine and hydrochlorothiazide",Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel^ Na/Cl transporter - Thiazide-sensitive^ Renin,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,12/21/10,11/28/11,,,,02/28/10,,,,,06/15/08,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Noden Pharma DAC
20703,1329,27684,136,Amyvid,florbetapir F 18,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Neurology,Neurodegenerative,Alzheimer's Disease - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Amyloid Beta/Amyloid Plaques^ Radiopharmaceutical,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,,N,N,,,,04/06/12,01/14/13,,,,09/17/10,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2015,Fujifilm Holdings Corp.
17704,726,23078,1984,Andexxa,andexanet alfa,"Portola Pharmaceuticals, Inc.",PTLA,California,United States,North America,2014944008,Not Specified,Other,Drug Toxicity,Y,Approved,Approved,100% (Same As Avg.),Protein,Factor X Inhibitors,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,01/01/2019 - 12/31/2019,05/03/18,04/26/19,,,,12/18/15,03/19/14,12/10/12,,,03/19/14,12/10/12,06/15/12,N/A,,N/A,N/A,$    23.9,$    20.3,N/A,N/A,$    23.9,$    20.3,Q1 2019,"Bristol-Myers Squibb Company, HealthCare Royalty Partners, Pfizer Inc."
17469,549,22734,5,AndroGel,testosterone,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Endocrine,Other,Hypogonadism,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Transdermal,N,N,N,N,N,N,,,,02/28/00,,,,,,,,,,,,,N/A,,$   675.0,$   577.0,$   469.0,$    96.0,N/A,$   577.0,$   469.0,$    96.0,Q2 2019,"Abbott Laboratories, Besins Healthcare SA"
19893,3300,26378,1379,Anflu,,Sinovac Biotech Ltd.,SVA,,China,Asia,,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,01/18/19,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    13.5,$     2.0,N/A,Q4 2018,N/A
1717,240,2748,59,Angeliq,drospirenone and estradiol,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Mineralocorticoid Receptor^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,09/28/05,12/17/02,,,,12/17/01,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
238,358,320,248,Angiomax,bivalirudin,The Medicines Company,MDCO,New Jersey,United States,North America,2406429694,Cardiovascular,"Surgical, Interventional Radiological, and Other Invasive Procedures",Percutaneous Coronary Interventions (PCIs) for Stable Angina,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Thrombin (Coagulation Factor IIa),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,12/15/00,09/20/04,,,,12/23/97,,,,,11/18/98,,,88%,93.8,N/A,$    18.8,$     6.1,N/A,$    50.7,$    18.8,$     6.1,N/A,Q4 2018,"AstraZeneca PLC, Biogen, Inc., Daiichi Sankyo Co., Ltd., SciClone Pharmaceuticals, Inc."
238,179,2647,248,Angiomax,bivalirudin,The Medicines Company,MDCO,New Jersey,United States,North America,2406429694,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Thrombin (Coagulation Factor IIa),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,12/15/00,09/22/04,,,,12/23/97,,,,,11/18/98,,,88%,117.5,N/A,$    18.8,$     6.1,N/A,$    50.7,$    18.8,$     6.1,N/A,Q4 2018,"AstraZeneca PLC, Biogen, Inc., Daiichi Sankyo Co., Ltd., SciClone Pharmaceuticals, Inc."
16458,239,21237,4309,Annovera,segesterone acetate and ethinyl estradiol,"TherapeuticsMD, Inc.",TXMD,Florida,United States,North America,711264755,Endocrine,Contraception,Contraception,Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,New Molecular Entity (NME),No,Intravaginal,N,N,N,N,N,N,,,,08/10/18,,,,,08/17/17,,,,,07/12/06,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Population Council"
17103,73,22187,180,Anoro Ellipta,umeclidinium bromide/vilanterol trifenatate,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,12/18/13,05/08/14,07/07/14,,,12/18/12,02/03/11,02/05/10,,,02/03/11,02/05/10,,92%,,$   189.0,$   304.0,$   423.0,$   179.0,$   273.0,$   445.0,$   633.0,$   297.0,Q2 2019,"Innoviva, Inc., Vectura Group plc"
2764,506,4704,3356,Antara,fenofibrate,Lupin Limited,LPC:IN,,India,Asia,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,PPAR alpha,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,11/30/04,,,,,12/01/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2008,GlaxoSmithKline plc
18772,428,24676,3413,Anthim,obiltoxaximab,"Elusys Therapeutics, Inc.",,New Jersey,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Anthrax Infection (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Anthrax protective antigen^ Bacillus anthracis (Anthrax),Biologic,No,"Intramuscular (IM), Intravenous (IV)",Y,N,Y,N,N,N,,,,03/18/16,,,,,03/20/15,08/13/13,,02/04/09,,08/13/13,,02/04/09,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
23008,428,31403,1298,Anthrasil,,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Anthrax Infection (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Polyclonal Antibody,Bacillus anthracis (Anthrax),Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,03/25/15,,,,,08/07/14,,,04/27/07,,04/27/07,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
8439,543,10484,395,Anturol,,Allergan plc,AGN,,Ireland,Europe,53945515162,Urology,Other,Overactive Bladder (OAB),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel^ Muscarinic acetylcholine receptor,Non-NME,No,Transdermal,N,Y,N,,N,N,,,,12/07/11,,,,,12/22/10,08/23/07,09/07/05,,03/31/05,07/25/07,09/07/05,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Antares Pharma, Inc., Daewoong Pharmaceutical Company Ltd."
18372,3127,24054,8829,Apadaz,benzhydrocodone hydrochloride and acetaminophen,"KVK Tech, Inc.",,Pennsylvania,United States,North America,,Neurology,Pain,Acute Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,"Intranasal, Oral (PO)",N,N,N,N,N,N,,,,02/23/18,,,,,12/15/15,,,02/22/11,01/01/11,06/13/16,,02/22/11,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Johnson Matthey Plc, KemPharm, Inc."
1699,137,2726,51,Apidra,insulin glulisine,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/19/04,09/27/04,04/22/09,,,06/18/03,,,,,02/05/03,,,N/A,136.3,$   127.8,$   116.4,$    85.8,$    28.3,$   317.6,$   432.2,$   412.7,$   195.5,Q2 2019,N/A
1699,157,3255,51,Apidra,insulin glulisine,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/16/04,10/05/04,04/22/09,,,06/18/03,,,,,02/05/03,,,N/A,64.4,$   127.8,$   116.4,$    85.8,$    28.3,$   317.6,$   432.2,$   412.7,$   195.5,Q2 2019,N/A
9505,167,11824,470,Aplenzin,bupropion hydrobromide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,04/23/08,,,,,09/28/06,,,,,11/11/05,,,N/A,,N/A,$    23.0,$    54.0,$    16.0,N/A,$    23.0,$    54.0,$    16.0,Q1 2019,Sanofi
2199,194,3684,991,Apokyn,apomorphine hydrochloride,"US WorldMeds, LLC",,Kentucky,United States,North America,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Dopamine 4 (D4) Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,Y,,N,N,,,01/01/2013 - 01/01/2013,04/20/04,,03/30/12,,,01/02/03,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    72.1,N/A,Q4 2018,"Kyowa Hakko Kirin Co., Ltd., STADA Arzneimittel AG"
7571,321,9290,470,Apriso,mesalamine,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/31/08,,,,,12/31/07,,,,,02/15/05,,02/03/04,100%,450.9,$   103.0,N/A,N/A,N/A,$   103.0,$   144.0,$    78.0,N/A,Q2 2018,"Biotoscana International, Dr. Falk Pharma GmbH"
28496,246,39733,5962,Aptensio XR,methylphenidate,Rhodes Pharmaceuticals L.P.,,Rhode Island,United States,North America,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),N,Approved,Approved,100% (Same As Avg.),Not Specified,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/17/15,,,,,06/18/14,,,,,01/03/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
9831,3009,12240,686,Aptiom,eslicarbazepine acetate,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/08/13,04/21/09,,,,03/31/09,,,,,08/01/04,,,N/A,,$    95.0,$   134.0,N/A,N/A,$   128.2,$   170.0,$   219.3,$    57.7,Q1 2019,"Bial Pharmaceuticals, Eisai Co., Ltd., WhanIn Pharmaceutical Co., Ltd."
2345,78,3952,70,Aptivus,tipranavir,Boehringer Ingelheim GmbH,,,Germany,Europe,,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV-1 protease (HIV PR),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,06/22/05,10/25/05,,,,12/22/04,,,,,02/06/03,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
35005,467,48496,4145,Arakoda,tafenoquine succinate,"60° Pharmaceuticals, LLC",,,United States,North America,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Malaria,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis^ Plasmodium,Non-NME,No,Oral (PO),Y,N,N,N,N,N,,,,08/08/18,,,,,12/08/17,,,,,05/17/17,05/08/17,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
4,187,40,30,Aranesp,darbepoetin alfa,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Dependent",Y,Approved,Approved,100% (Same As Avg.),Protein,Erythropoietin Receptor (EPOR),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,09/18/01,06/10/01,04/18/07,,,12/15/99,,04/15/99,,,,,,100%,200.7,"$  1,082.0","$  1,114.0",$   942.0,$   374.0,"$  2,093.0","$  2,053.0","$  1,877.0","$  1,112.7",Q2 2019,"Kyowa Hakko Kirin Co., Ltd."
4,372,327,30,Aranesp,darbepoetin alfa,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Hematology,Marrow Or Peripheral Blood Stimulator,Anemia Due to Oncology Treatment,N,Approved,Approved,100% (Same As Avg.),Protein,Erythropoietin Receptor (EPOR),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,,N,N,,,,07/23/02,08/29/02,,,,09/20/01,,,,,,,,100%,497.7,"$  1,082.0","$  1,114.0",$   942.0,$   374.0,"$  2,093.0","$  2,053.0","$  1,877.0","$  1,112.7",Q2 2019,"Kyowa Hakko Kirin Co., Ltd."
4,371,328,30,Aranesp,darbepoetin alfa,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Independent",Y,Approved,Approved,100% (Same As Avg.),Protein,Erythropoietin Receptor (EPOR),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,09/19/01,06/10/01,04/28/10,,,12/15/99,,,,,,,,100%,215.6,"$  1,082.0","$  1,114.0",$   942.0,$   374.0,"$  2,093.0","$  2,053.0","$  1,877.0","$  1,112.7",Q2 2019,"Kyowa Hakko Kirin Co., Ltd."
720,656,3365,330,Arcalyst,rilonacept,"Regeneron Pharmaceuticals, Inc.",REGN,New York,United States,North America,32413693800,Autoimmune/immunology,Other,Cryopyrin (CIAS1)-Associated Periodic Syndromes (CAPS),Y,Approved,Approved,100% (Same As Avg.),Protein,IL-1 (Interleukin-1),Biologic,No,Subcutaneous (SQ),Y,N,Y,,N,N,,,01/01/2010 - 01/01/2010,02/27/08,10/27/09,,,,06/08/07,02/28/06,,,,02/28/06,06/10/05,02/22/05,N/A,,N/A,$    16.6,$    14.6,$     3.5,$    10.5,$    16.6,$    14.6,$     3.5,Q1 2019,"DRI Capital Inc., Kiniksa Pharmaceuticals Corporation"
1877,73,3030,686,Arcapta Neohaler,indacaterol maleate,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,New Molecular Entity (NME),No,Inhaled,N,N,N,,N,N,,,,07/01/11,11/30/09,07/01/11,,,12/15/08,,,,,09/26/06,01/20/05,,N/A,,N/A,N/A,N/A,N/A,$   143.0,$   112.0,$   101.0,N/A,Q4 2018,"Glenmark Pharmaceuticals Limited, Novartis AG"
20487,621,27312,470,Arestin,minocycline hydrochloride,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,ENT/Dental,General,Periodontitis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,02/16/01,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$   111.0,$    96.0,$    21.0,Q1 2019,N/A
682,407,632,289,Argatroban,argatroban,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Cardiovascular,Other,Heparin-Induced Thrombocytopenia (HIT),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Thrombin (Coagulation Factor IIa),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,06/15/00,06/01/05,07/16/08,,,,,,,,,,,15%,11.7,N/A,N/A,N/A,N/A,N/A,N/A,$    18.1,N/A,Q4 2018,"Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc."
16716,407,21617,851,Argatroban Reformulation (Chiesi),Argatroban,Chiesi Farmaceutici S.p.A.,,,Italy,Europe,,Cardiovascular,Other,Heparin-Induced Thrombocytopenia (HIT),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Thrombin (Coagulation Factor IIa),Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,06/29/11,,,,,09/26/08,,,,,11/21/08,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q3 2015,"Eagle Pharmaceuticals, Inc."
8304,141,10288,134,Aricept 23mg,donepezil HCL (sustained release),"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cholinesterases,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/23/10,,,,,09/24/09,,,,,06/01/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q2 2013,Pfizer Inc.
15043,643,19902,212,Arikayce,amikacin,Insmed Incorporated,INSM,New Jersey,United States,North America,1253487123,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Respiratory Tract Infections (Excluding Pneumonia) (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule with Liposomal Delivery System,Bacterial ribosome^ Cell wall synthesis^ Protein synthesis,Non-NME,No,Inhaled,Y,N,Y,Y,N,Y,,,,09/28/18,,,,,03/29/18,01/21/15,,,,03/21/11,10/14/11,07/30/09,N/A,,N/A,N/A,$     9.3,$    50.0,N/A,N/A,$    10.3,$    52.0,Q2 2019,N/A
389,528,1576,180,Arilvax,yellow fever vaccine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,Yellow Fever,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Yellow Fever Virus,Vaccine,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,02/12/08,,,,,12/12/03,,,,,02/23/04,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Sanofi
16341,170,21071,22,Aristada (Monthly),aripiprazole lauroxil,Alkermes plc,ALKS,,Ireland,Europe,3410652174,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,Intramuscular (IM),N,N,N,N,N,N,,,,10/05/15,,,,,08/22/14,11/08/11,01/10/11,11/04/10,,11/08/11,01/10/11,11/04/10,N/A,,$    47.1,$    93.5,$   147.7,$    78.7,$    47.1,$    93.5,$   147.7,$    78.7,Q2 2019,N/A
25060,170,34842,22,Aristada (Six-Week),aripiprazole lauroxil,Alkermes plc,ALKS,,Ireland,Europe,3410652174,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,10/05/15,,,,,08/22/14,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
23532,170,32330,22,Aristada (Two-Month),aripiprazole lauroxil,Alkermes plc,ALKS,,Ireland,Europe,3410652174,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,06/05/17,,,,,08/05/16,,,,,,,01/08/14,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
36422,170,50718,22,Aristada Initio,aripiprazole lauroxil,Alkermes plc,ALKS,,Ireland,Europe,3410652174,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,07/02/18,,,,,10/26/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
261,346,417,266,Arixtra,fondaparinux,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Hematology,Antithrombotic,Venous Thromboembolism (VTE),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Coagulation Factor X,New Molecular Entity (NME),No,Subcutaneous (SQ),Y,N,N,,N,N,,,,12/10/01,03/27/02,04/18/07,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2013,"Aspen Pharmacare Holdings Limited, GlaxoSmithKline plc, Merck &amp; Co., Inc."
23823,72,32821,375,ArmonAir RespiClick,fluticasone propionate,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,N,N,N,,,,01/27/17,,,,,03/28/16,06/04/14,01/31/13,,,06/04/14,05/10/12,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
17356,72,22571,180,Arnuity Ellipta,fluticasone furoate,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,08/20/14,,03/30/17,,,10/23/13,09/21/10,,,,09/21/10,01/03/08,,N/A,,$    18.0,$    42.0,$    52.0,$    23.0,$    21.0,$    46.0,$    59.0,$    27.0,Q2 2019,N/A
1796,199,2864,289,Arranon,nelarabine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,N,N,N,,,,10/28/05,08/22/07,,,,04/29/05,,,,,,12/10/03,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
1796,205,2865,289,Arranon,nelarabine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Non-Hodgkin's Lymphoma (NHL),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,,N,N,,,,10/28/05,08/28/07,,,,04/29/05,,,,,,12/10/03,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
21176,3134,28489,3445,Arymo ER,morphine sulfate,Zyla Life Sciences,ZCOR,Pennsylvania,United States,North America,,Neurology,Pain,Moderate to Severe Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,"Intranasal, Oral (PO)",Y,N,N,N,N,N,,,,01/09/17,,,,,12/15/15,,06/04/07,,,,06/04/07,,N/A,,N/A,$     2.4,$     1.3,N/A,N/A,$     2.4,$     1.3,N/A,Q4 2018,N/A
462,200,2609,289,Arzerra (Oncology),ofatumumab,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,Y,Y,N,N,,,,10/26/09,04/19/10,03/25/13,,,01/30/09,07/06/06,,,,07/06/06,06/21/04,,75%,79.9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2014,"DRI Capital Inc., Genmab A/S"
21736,423,29340,4080,Asceniv,"Immune Globulin Intravenous, Human-slra","ADMA Biologics, Inc.",ADMA,New Jersey,United States,North America,178915797,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,"Immune system^ RSV, Respiratory Syncytial Virus",Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,04/01/19,,,,,07/31/15,03/12/13,,,,11/13/12,03/07/08,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Biotest AG
9956,1455,12436,2807,Asclera,polidocanol,Kreussler Group,,,Germany,Europe,,Cardiovascular,Peripheral Vascular Disease,Varicose Veins,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cell Membrane,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,03/30/10,,,,,10/01/99,,,,,12/01/99,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Merz Pharmaceuticals GmbH
2389,72,4039,254,Asmanex,mometasone furoate,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,,N,N,,,,03/30/05,,07/09/09,,,12/01/98,,,,,,,,N/A,88.8,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2013,N/A
21805,199,29454,354,Asparlas,calaspargase pegol,Les Laboratoires Servier,,,France,Europe,,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Y,Approved,Approved,100% (Same As Avg.),Protein,Asparagine,Biologic,No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,12/20/18,,,,,12/22/17,,,,,02/16/16,08/06/08,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
3078,380,5269,814,Astagraf XL,tacrolimus,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Autoimmune/immunology,Transplant Rejection,Kidney Transplant Rejection,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcineurin phosphatase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/19/13,04/27/07,07/17/08,,,09/24/12,,,,,05/22/05,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   247.8,$    70.8,Q1 2019,N/A
16846,236,21827,266,Astepro,azelastine,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Allergy,General,Allergic Rhinitis,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Intranasal,N,N,N,N,N,N,,,,10/15/08,03/20/12,,,,07/31/07,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q4 2013,N/A
2325,264,3922,45,Atacand,candesartan cilexetil,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,02/22/05,,,,,06/30/04,,,,,03/05/01,,,N/A,,$    36.0,$    19.0,$    13.0,$     6.0,$   315.0,$   300.0,$   260.0,$   106.0,Q2 2019,"ANI Pharmaceuticals, Inc., Cheplapharm Arzneimittel GmbH, Takeda Pharmaceutical Company Ltd"
16991,242,22037,395,Atelvia,risedronate sodium,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Osteoclast,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/08/10,,,,,09/24/09,,,,,08/24/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q2 2013,N/A
2186,78,3651,179,Atripla,"efavirenz, emtricitabine, and tenofovir","Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,01/01/2014 - 01/01/2014,07/12/06,12/13/07,,,,04/27/06,,,,,11/01/04,,,65%,1825.7,"$  1,898.0","$  1,288.0",$   967.0,$   255.0,"$  2,605.0","$  1,806.0","$  1,206.0",$   323.0,Q2 2019,"Bristol-Myers Squibb Company, Merck &amp; Co., Inc."
1439,88,2143,2742,ATryn,antithrombin alfa,LFB Group,,,France,Europe,,Hematology,Antithrombotic,Anticoagulation,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X^ Thrombin (Coagulation Factor IIa),Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,10/01/2009 - 10/01/2009,02/06/09,07/28/06,,,,08/07/08,12/15/02,,,,11/04/03,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"H. Lundbeck A/S, Knight Therapeutics Inc., Shin Poong Pharmaceutical Co., Ltd."
2068,153,3382,51,Aubagio,teriflunomide,Sanofi,SNY,,France,Europe,1.05588E+11,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/12/12,08/30/13,,,,08/12/11,,,,,03/01/05,,,100%,1275.6,"$  1,007.5","$  1,244.0","$  1,332.1",$   728.5,"$  1,399.5","$  1,797.3","$  1,896.9","$  1,019.8",Q2 2019,N/A
2571,3179,4366,2866,Auryxia,ferric citrate,"Akebia Therapeutics, Inc.",AKBA,Massachusetts,United States,North America,255624602,Renal,Chronic Renal Failure,Hyperphosphatemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphate,Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,09/05/14,09/24/15,01/17/14,,,08/07/13,,,,,01/05/10,02/15/06,,N/A,,N/A,N/A,$    96.0,$    23.1,N/A,N/A,$   156.9,$    36.0,Q1 2019,"Japan Tobacco Inc., Panion &amp; BF Biotech Inc., Torii Pharmaceutical Co., Ltd."
2571,371,33262,2866,Auryxia,ferric citrate,"Akebia Therapeutics, Inc.",AKBA,Massachusetts,United States,North America,255624602,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Independent",N,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphate,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/07/17,,,,,01/08/17,,,,,05/08/14,11/01/12,,N/A,,N/A,N/A,$    96.0,$    23.1,N/A,N/A,$   156.9,$    36.0,Q1 2019,"Japan Tobacco Inc., Panion &amp; BF Biotech Inc., Torii Pharmaceutical Co., Ltd."
21947,296,29676,375,Austedo,deutetrabenazine,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Neurodegenerative,Huntington's Disease,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Vesicular monamine transporters (VMATs),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,04/03/17,,,,,05/29/15,06/14/13,,,,11/08/12,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   204.0,$    74.0,Q1 2019,N/A
21947,3244,29685,375,Austedo,deutetrabenazine,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,"movement disorders, all",Tardive Dyskinesia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Vesicular monamine transporters (VMATs),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,08/30/17,,,,,12/30/16,07/17/14,,,,07/17/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   204.0,$    74.0,Q1 2019,N/A
18686,3076,24540,4661,Auvi-Q,Epinephrine,Kaléo Pharmaceutical Inc.,,Virginia,United States,North America,,Allergy,General,Anaphylaxis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Beta Adrenergic Receptors,Non-NME,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,N,N,N,,,,08/10/12,,,,,,,,,,11/30/09,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q3 2015,N/A
40320,665,56434,4008,Avaclyr,acyclovir,Fera Pharmaceuticals,,New York,United States,North America,,Infectious disease,Antiviral,Herpes Simplex Virus (HSV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Thymidine Kinase,Non-NME,No,Topical,N,N,Y,N,N,N,,,,03/29/19,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1738,137,2773,180,Avandamet,metformin / rosiglitazone,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ PPAR gamma,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/10/02,10/20/03,04/01/04,,,,,,,,,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2009,N/A
1696,137,2721,180,Avandaryl,rosiglitazone / glimepiride,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Potassium channels^ PPAR gamma,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,11/23/05,06/27/06,,,,10/31/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2007,Sanofi
2288,492,3838,51,Avapro,irbesartan,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,Diabetic Nephropathy,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,09/17/02,06/26/02,,,,,,,,,,,,100%,,$    16.2,$    12.5,$    12.0,$     8.0,$   872.3,$   787.9,$   780.4,$   228.2,Q1 2019,"Bristol-Myers Squibb Company, Shionogi &amp; Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd."
76,213,157,149,Avastin,bevacizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Colorectal Cancer (CRC),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV)",Y,Y,N,,N,N,,,,02/26/04,01/12/05,04/18/07,,,09/29/03,09/16/00,12/23/99,06/23/97,01/01/96,08/18/01,12/16/99,,97%,1399.3,"$  3,015.8","$  2,950.2","$  2,968.3","$  1,630.6","$  6,900.9","$  6,821.6","$  7,000.5","$  3,660.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
76,211,159,149,Avastin,bevacizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV)",N,N,N,,N,N,,,,10/11/06,08/24/07,11/06/09,,,04/11/06,08/22/01,12/23/00,06/23/97,01/01/96,10/06/04,12/16/99,,97%,1176.1,"$  3,015.8","$  2,950.2","$  2,968.3","$  1,630.6","$  6,900.9","$  6,821.6","$  7,000.5","$  3,660.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
76,216,160,149,Avastin,bevacizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Renal Cell Cancer (RCC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV)",N,N,Y,,N,N,,,01/01/2010 - 01/01/2010,07/31/09,12/19/07,,,,10/14/08,10/15/03,08/17/00,06/23/97,01/01/96,01/14/04,08/18/01,,97%,93,"$  3,015.8","$  2,950.2","$  2,968.3","$  1,630.6","$  6,900.9","$  6,821.6","$  7,000.5","$  3,660.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
76,224,2992,149,Avastin,bevacizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Ovarian Cancer,N,Approved,III,35% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV)",N,N,Y,N,N,N,,,,11/14/14,12/23/11,11/22/13,,,05/19/14,10/10/05,04/11/05,,,10/10/05,01/10/05,,97%,70.3,"$  3,015.8","$  2,950.2","$  2,968.3","$  1,630.6","$  6,900.9","$  6,821.6","$  7,000.5","$  3,660.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
76,228,4481,149,Avastin,bevacizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV)",N,N,N,N,N,N,,,,05/05/09,12/31/09,06/14/13,,,11/03/08,,,,,,05/08/05,,97%,271.6,"$  3,015.8","$  2,950.2","$  2,968.3","$  1,630.6","$  6,900.9","$  6,821.6","$  7,000.5","$  3,660.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
76,255,21721,149,Avastin,bevacizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Cervical Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV)",N,N,N,N,N,N,,,,08/14/14,04/08/15,05/23/16,,,04/24/14,,,,,04/15/14,,,97%,,"$  3,015.8","$  2,950.2","$  2,968.3","$  1,630.6","$  6,900.9","$  6,821.6","$  7,000.5","$  3,660.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., Cipla Limited, PDL BioPharma, Inc."
2785,549,4741,142,Aveed,testosterone undecanoate,Endo International plc,ENDP,,Ireland,Europe,554131557,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,New Molecular Entity (NME),No,Intramuscular (IM),N,N,N,N,N,N,,,,03/05/14,,,,,08/28/07,03/09/06,,,,07/08/04,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,Bayer AG
1921,440,3094,254,Avelox,moxifloxacin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,04/30/01,,,,,,,,,,,,,N/A,,N/A,$     7.8,$     3.6,N/A,N/A,$   378.4,$   208.9,$   206.1,Q2 2019,Bayer AG
1921,536,4150,254,Avelox,moxifloxacin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Intra-Abdominal Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,11/30/05,,,,,01/31/05,,,,,,,,N/A,,N/A,$     7.8,$     3.6,N/A,N/A,$   378.4,$   208.9,$   206.1,Q2 2019,Bayer AG
1921,488,4151,254,Avelox,moxifloxacin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,03/04/03,06/30/99,,,,,,,,,06/30/99,,,N/A,,N/A,$     7.8,$     3.6,N/A,N/A,$   378.4,$   208.9,$   206.1,Q2 2019,Bayer AG
1921,77,36283,254,Avelox,moxifloxacin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial and Antifungal - Miscellaneous Vaccines and Treatments,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,05/08/15,,,,,07/08/14,,,,,,,,N/A,,N/A,$     7.8,$     3.6,N/A,N/A,$   378.4,$   208.9,$   206.1,Q2 2019,Bayer AG
711,3128,1030,312,Avinza,morphine sulfate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Chronic Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,03/20/02,,,,,06/08/00,,,,,12/08/99,,,78.5%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2009,"Alkermes plc, Ligand Pharmaceuticals, Inc., Merck &amp; Co., Inc."
2431,569,4119,180,Avodart,dutasteride,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Urology,General,Benign Prostatic Hyperplasia (BPH),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,steroid 5a-reductase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/20/01,04/22/08,,,,,,,,,,,,N/A,,$   183.0,$    20.0,$    16.0,$     2.0,$   955.0,$   797.0,$   761.0,$   366.0,Q2 2019,N/A
27129,78,37928,266,Avonza,"Tenofovir Disoproxyl Fumarate, Lamivudine, Efavirenz",Mylan N.V.,MYL,Pennsylvania,United States,North America,,Infectious disease,Antiviral,HIV / AIDS,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/05/18,,,,,03/31/16,,,,,12/01/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16215,534,20858,395,Avycaz,ceftazidime/avibactam,Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),Non-NME,No,Intravenous (IV),Y,N,N,N,N,Y,,,,02/25/15,06/28/16,,,,06/25/14,10/18/11,11/12/08,12/18/06,,10/18/11,11/12/08,12/18/06,N/A,,$    36.1,$    61.2,$    94.6,$    56.4,N/A,$    61.2,$    94.6,$    56.4,Q2 2019,"AstraZeneca PLC, Pfizer Inc."
16215,536,20862,395,Avycaz,ceftazidime/avibactam,Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Intra-Abdominal Infections (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),Non-NME,No,Intravenous (IV),Y,N,N,N,N,Y,,,,02/25/15,06/28/16,,,,06/25/15,10/18/11,03/03/09,,,10/18/11,03/03/09,,N/A,,$    36.1,$    61.2,$    94.6,$    56.4,N/A,$    61.2,$    94.6,$    56.4,Q2 2019,"AstraZeneca PLC, Pfizer Inc."
16215,673,29864,395,Avycaz,ceftazidime/avibactam,Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),Non-NME,No,Intravenous (IV),Y,N,N,N,N,Y,,,,02/01/18,06/24/16,,,,08/02/17,06/21/13,,,,03/08/13,,,N/A,,$    36.1,$    61.2,$    94.6,$    56.4,N/A,$    61.2,$    94.6,$    56.4,Q2 2019,"AstraZeneca PLC, Pfizer Inc."
18761,288,24664,223,Axert,almotriptan malate,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Neurology,Headache,Migraine and Other Headaches,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT1 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/07/01,12/31/99,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Almirall Prodesfarma, S.A."
24438,3192,33899,3523,Axumin,,Bracco S.p.A.,,,Italy,Europe,,Oncology,Solid,Prostate Cancer - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Radiopharmaceutical^ Tumor Cells,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,05/27/16,05/22/17,,,,09/28/15,,,,,03/11/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"General Electric, Novartis AG"
16508,3023,21312,583,AzaSite,azithromycin,Akorn Inc.,AKRX,Illinois,United States,North America,352633568,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Topical,N,N,N,N,N,N,,,,04/27/07,,,,,06/28/06,06/23/05,,,,06/23/05,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2011,"Knight Therapeutics Inc., Merck &amp; Co., Inc., Senju Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., VISUfarma"
15129,347,19232,321,Azedra,iobenguane I-131,"Progenics Pharmaceuticals, Inc.",PGNX,New York,United States,North America,333097505,Oncology,Solid,Neuroendocrine Tumors (NET),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline)^ Radiopharmaceutical,New Molecular Entity (NME),No,Intravenous (IV),Y,Y,Y,Y,N,N,,,,07/30/18,,,,,10/31/17,,05/10/08,,,,05/10/08,10/18/07,100%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
597,194,1212,375,Azilect,rasagiline mesylate,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Monoamine oxidase B (MAO-B),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/16/06,02/21/05,03/23/18,,,09/05/03,,,,,,,,100%,369.4,N/A,$   130.0,$    40.0,N/A,$   410.0,$   130.0,$    44.6,N/A,Q1 2018,"H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd"
8274,244,10247,343,Azor,amlodipine besylate and olmesartan medoxomil,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1)^ Calcium Channel,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/26/07,11/01/08,,,,11/27/06,,,,,09/27/06,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q3 2015,N/A
21529,77,29012,1298,BabyBIG,botulism immune globulin,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial and Antifungal - Miscellaneous Vaccines and Treatments,Y,Approved,Approved,100% (Same As Avg.),Protein,Botulinum toxin,Biologic,No,Intravenous (IV),N,N,Y,,N,N,,,,10/23/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
39887,153,55783,9002,Bafiertam,monomethyl fumarate,"Banner Life Sciences, LLC.",,North Carolina,United States,North America,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,NF-Kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/16/18,,,06/01/20 - 06/30/20,,01/18/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
37144,239,51797,8117,Balcoltra,levonorgestrel/estradiol/bisglycinate,"Avion Pharmaceuticals, LLC",,Georgia,United States,North America,,Endocrine,Contraception,Contraception,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Estrogen Receptor Alpha (ER1 or ER alpha)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/19/18,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
21216,217,28561,223,Balversa,erdafitinib,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Oncology,Solid,Bladder Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Fibroblast Growth Factor Receptor (FGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,04/12/19,,,,,09/18/18,05/01/18,05/04/15,06/13/12,,05/01/18,05/04/15,06/13/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Immunomedics, Inc., Otsuka Holdings Co., Ltd."
2941,3008,22774,134,Banzel,rufinamide,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Neurology,Seizure Disorders (Epilepsy),Lennox-Gastaut Syndrome (LGS; Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/14/08,01/16/07,03/25/13,,,11/18/05,,,,,03/30/05,,,N/A,,$   127.0,$   151.0,$   158.3,N/A,$   149.0,$   171.9,$   186.5,N/A,Q4 2018,"Acorda Therapeutics, Inc., Biotoscana International, Novartis AG"
25749,3358,35846,136,Baqsimi,glucagon,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Y,Approved,Approved,100% (Same As Avg.),Peptide,Glucagon Receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Intranasal",N,N,N,N,N,N,,07/24/2019 - 12/31/2019,,07/24/19,,,,,06/28/18,09/30/13,03/31/12,,,09/30/13,03/31/12,,N/A,,N/A,N/A,N/A,$    62.8,N/A,N/A,N/A,$    66.3,Q2 2019,Locemia Solutions ULC
1930,319,3115,73,Baraclude,entecavir monohydrate,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Infectious disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/29/05,06/26/06,07/26/06,,,10/04/04,,,,,,,,100%,165.1,$    66.0,$    53.0,$    32.0,$    14.0,"$  1,192.0","$  1,052.0",$   744.0,$   288.0,Q2 2019,N/A
17839,137,23292,136,Basaglar,insulin glargine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/16/15,09/09/14,01/02/15,,,,08/19/11,,,,08/19/11,01/11/11,,50%,521.1,$    15.8,$   311.1,$   622.8,$   430.4,$    86.1,$   432.2,$   801.2,$   542.1,Q2 2019,"Boehringer Ingelheim GmbH, Cipla Limited"
17839,157,23762,136,Basaglar,insulin glargine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",N,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/16/15,09/09/14,01/02/15,,,,08/19/11,,,,08/19/11,01/11/11,,50%,152.6,$    15.8,$   311.1,$   622.8,$   430.4,$    86.1,$   432.2,$   801.2,$   542.1,Q2 2019,"Boehringer Ingelheim GmbH, Cipla Limited"
21679,77,29262,1298,BAT,,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial and Antifungal - Miscellaneous Vaccines and Treatments,Y,Approved,Approved,100% (Same As Avg.),Protein,Botulinum toxin,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,03/22/13,,,,,09/20/12,,,,,,,08/04/06,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
22109,3585,29922,255,Bavencio,avelumab,Merck KGaA,MKGAY,,Germany,Europe,,Oncology,Solid,Merkel Cell Carcinoma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),Y,N,Y,Y,N,N,,,,03/23/17,09/18/17,09/27/17,,,09/23/16,,07/29/14,01/18/13,,,07/29/14,03/07/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    76.3,$    25.0,Q1 2019,Pfizer Inc.
22109,217,37439,255,Bavencio,avelumab,Merck KGaA,MKGAY,,Germany,Europe,,Oncology,Solid,Bladder Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,05/09/17,,,,,12/27/16,12/22/15,,01/18/13,,12/22/15,,01/18/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    76.3,$    25.0,Q1 2019,Pfizer Inc.
22109,216,38613,255,Bavencio,avelumab,Merck KGaA,MKGAY,,Germany,Europe,,Oncology,Solid,Renal Cell Cancer (RCC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,10/01/2019 - 04/30/2020,05/14/19,,,,,12/11/18,04/05/16,,10/19/15,,02/16/16,,10/19/15,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    76.3,$    25.0,Q1 2019,Pfizer Inc.
17822,440,23263,2685,Baxdela,delafloxacin,"Melinta Therapeutics, Inc.",MLNT,Connecticut,United States,North America,141731242,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,Y,N,N,N,Y,,02/01/2019 - 08/31/2019,,06/19/17,,,,,10/24/16,05/14/13,07/15/08,,,05/14/13,07/15/08,07/14/08,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Eurofarma Laboratorios S.A., Hikma Pharmaceuticals plc, Ligand Pharmaceuticals, Inc., The Menarini Group"
8651,3629,10754,1020,Belbuca,buprenorphine hydrochloride,"BioDelivery Sciences International, Inc.",BDSI,North Carolina,United States,North America,311043119,Neurology,Pain,Chronic Low Back Pain (CLBP),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,10/23/15,,,,,12/23/14,12/07/10,07/16/09,,,12/07/10,08/09/10,11/01/07,N/A,,N/A,$    27.0,$    46.0,$    18.7,N/A,$    27.0,$    46.0,$    18.7,Q1 2019,Purdue Pharma L.P.
1941,3097,3508,9097,Beleodaq,belinostat (IV),Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Hematologic,Peripheral T-Cell Lymphoma (PTCL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histone Deacetylase (HDAC),New Molecular Entity (NME),No,Intravenous (IV),Y,Y,Y,N,N,N,,10/01/2014 - 10/01/2014,10/01/2016 - 10/01/2016,07/03/14,,,,,12/10/13,,02/01/06,06/30/04,,,02/01/06,06/30/04,75%,,$    13.3,$    12.4,$    12.3,N/A,$    13.3,$    12.4,$    12.3,N/A,Q4 2018,"Onxeo SA, Pint Pharma International S.A.,, SWK Holdings Corporation"
24236,200,33547,2403,Belrapzo,bendamustine hydrochloride,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA^ p53,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,07/02/14,,,,,09/06/13,,,,,,,,N/A,,N/A,N/A,$    22.9,$     3.2,N/A,N/A,$    22.9,$     3.2,Q1 2019,SymBio Pharmaceuticals Ltd.
24236,3093,33548,2403,Belrapzo,bendamustine hydrochloride,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA^ p53,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,07/02/14,,,,,09/06/13,,,,,08/28/13,,,N/A,,N/A,N/A,$    22.9,$     3.2,N/A,N/A,$    22.9,$     3.2,Q1 2019,SymBio Pharmaceuticals Ltd.
14388,291,18209,254,Belsomra,suvorexant,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Neurology,Insomnia,Insomnia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Hypocretin/orexin receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,08/07/2014 - 12/15/2014,08/13/14,,09/26/14,,,11/08/12,12/03/09,01/01/08,,,12/03/09,11/10/08,,N/A,,N/A,N/A,$    96.0,$    45.0,N/A,N/A,$   260.0,$   143.0,Q2 2019,N/A
1830,135,2928,134,Belviq,lorcaserin hydrochloride,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Metabolic,Obesity,Obesity,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/27/12,,,,,12/22/09,09/12/06,12/22/04,,,09/12/06,12/22/04,11/30/04,33%,,$    34.0,$    32.6,$    36.7,N/A,$    34.0,$    32.6,$    51.1,N/A,Q4 2018,"Arena Pharmaceuticals, Inc., CY Biotech Company Ltd., Eurofarma Laboratorios S.A., Ildong Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd."
24919,135,34636,134,Belviq XR,lorcaserin hydrochloride,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Metabolic,Obesity,Obesity,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/15/16,,,,,09/18/15,,,,,,,07/01/10,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Arena Pharmaceuticals, Inc., CY Biotech Company Ltd., Eurofarma Laboratorios S.A."
25445,3093,35420,375,Bendeka,bendamustine hydrochloride,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA^ p53,Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,12/07/15,,,,,02/17/15,,,,,,,07/02/14,80%,,N/A,N/A,N/A,N/A,N/A,N/A,$   642.0,$   122.0,Q1 2019,"Eagle Pharmaceuticals, Inc."
25445,200,35426,375,Bendeka,bendamustine hydrochloride,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA^ p53,Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,12/08/15,,,,,02/17/15,,,,,,,07/02/14,80%,,N/A,N/A,N/A,N/A,N/A,N/A,$   642.0,$   122.0,Q1 2019,"Eagle Pharmaceuticals, Inc."
3230,244,5545,343,Benicar,olmesartan medoxomil,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,04/25/02,,01/31/04,,,,,,,,,,,N/A,,N/A,N/A,$    98.2,N/A,$   377.6,$   403.9,$   487.0,N/A,Q4 2018,Allergan plc
6695,244,6937,343,Benicar HCT,hydrochlorothiazide and olmesartan medoxomil,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1)^ Na/Cl transporter - Thiazide-sensitive,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/05/03,10/07/05,,,,,,,,,,,,N/A,,N/A,N/A,$    98.2,N/A,N/A,N/A,$   487.0,N/A,Q4 2018,Allergan plc
90,282,202,180,Benlysta,belimumab,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,B-cell activating factor (BAFF),Biologic,No,Intravenous (IV),Y,Y,N,N,N,N,,,,03/09/11,07/13/11,09/27/17,,,06/10/10,01/18/07,09/25/03,02/28/02,,01/18/07,09/25/03,02/28/02,90%,300.5,$   377.0,$   440.0,$   559.0,$   306.0,$   446.0,$   488.0,$   629.0,$   350.0,Q2 2019,"AstraZeneca PLC, DRI Capital Inc."
12307,282,15510,180,Benlysta SC,belimumab,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,B-cell activating factor (BAFF),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/20/17,11/13/17,09/27/17,,,09/22/16,12/15/11,10/07/08,,,12/15/11,10/07/08,07/30/08,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,AstraZeneca PLC
35906,81,49915,5409,Benznidazole (Insud Pharma),benznidazole,Insud Pharma,,,Austria,Europe,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microbial DNA^ Reactive Oxygen Species/Free Radicals,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,08/29/17,,,,,12/29/16,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
2775,711,4721,470,Bepreve,bepotastine,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,General,Allergic Conjunctivitis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1)^ Mast Cell,New Molecular Entity (NME),No,"Oral (PO), Topical",N,N,N,,N,N,,,,09/08/09,,,,,11/12/08,03/01/07,,,,03/06/07,07/17/01,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2012,"Mitsubishi Tanabe Pharma Corporation, Senju Pharmaceutical Co., Ltd."
2824,556,4818,870,Berinert,C1 esterase inhibitor (human),CSL Limited,CSL:AU,,Australia,Oceania,,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Y,Approved,Approved,100% (Same As Avg.),Protein,Complement Pathway,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,10/09/09,12/31/08,,,,03/06/08,,,,,03/05/06,,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
15283,3023,19426,470,Besivance,besifloxacin hydrochloride,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,05/28/09,,,,,05/30/08,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Pfizer Inc., Sun Pharmaceutical Industries Ltd., SWK Holdings Corporation"
638,199,23983,312,Besponsa,,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ Cluster of Differentiation 22 (CD22)^ DNA,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,08/17/17,06/30/17,01/19/18,,,12/20/16,08/03/12,,06/07/10,,08/03/12,,06/07/10,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,UCB SA
21356,74,28778,851,Bethkis,tobramycin inhalation solution (generic),Chiesi Farmaceutici S.p.A.,,,Italy,Europe,,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Gram-Negative Bacteria^ Protein synthesis,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,10/12/12,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16235,73,20893,45,Bevespi Aerosphere,,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Muscarinic acetylcholine receptor,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,04/25/16,12/20/18,06/19/19,,,06/25/15,05/13/13,03/29/10,05/26/09,,05/13/13,03/29/10,05/26/09,N/A,,N/A,$    15.0,$    33.0,$    20.0,N/A,$    15.0,$    33.0,$    20.0,Q2 2019,N/A
10366,346,12971,1984,Bevyxxa,betrixaban,"Portola Pharmaceuticals, Inc.",PTLA,California,United States,North America,2014944008,Hematology,Antithrombotic,Venous Thromboembolism (VTE),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,06/23/17,,,,,10/24/16,03/30/12,,,,03/30/12,02/07/05,,N/A,,N/A,N/A,$     0.6,$     0.1,N/A,N/A,$     0.6,$     0.1,Q1 2019,Lee's Pharmaceutical Holdings Limited
1316,524,1590,180,Bexsero,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Meningococcal Vaccines and Other Meningococcus-Specific Agents (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Neisseria meningitidis - Group B,Vaccine,No,Intramuscular (IM),N,N,N,Y,N,N,,,,01/23/15,01/14/13,,,,,02/18/09,02/07/06,,,02/18/09,03/12/04,,N/A,,$   166.0,$   197.7,$   272.0,$    65.1,$   530.0,$   635.5,$   795.3,$   211.6,Q1 2019,N/A
17367,239,22587,59,Beyaz,drospirenone/ethinyl estradiol/levomefolate calcium,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Folate Receptor (FOLR1)^ Mineralocorticoid Receptor^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/24/10,,,,,08/24/09,,,,,07/09/07,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
17367,566,22590,59,Beyaz,drospirenone/ethinyl estradiol/levomefolate calcium,Bayer AG,BAYRY,,Germany,Europe,,Neurology,Other,Premenstrual Dysphoric Disorder (PMDD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Folate Receptor (FOLR1)^ Mineralocorticoid Receptor^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/24/10,,,,,08/24/09,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
17367,603,22592,59,Beyaz,drospirenone/ethinyl estradiol/levomefolate calcium,Bayer AG,BAYRY,,Germany,Europe,,Dermatology,General,Acne,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Folate Receptor (FOLR1)^ Mineralocorticoid Receptor^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/24/10,,,,,08/24/09,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
1873,488,5566,5,Biaxin,clarithromycin,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/20/00,,,,,,,,,,,,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2008,"Abbott Laboratories, Mylan N.V., Taisho Pharmaceutical Co., Ltd."
1718,264,2749,285,BiDil,isosorbide dinitrate and hydralazine,"NitroMed, Inc.",,North Carolina,United States,North America,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium metabolism^ Guanylate Cyclase (sGC),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/23/05,,,,,07/03/96,,,,,07/02/97,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,Q4 2008,"Arbor Pharmaceuticals, LLC"
22513,240,30582,4309,Bijuva,estradiol and progesterone,"TherapeuticsMD, Inc.",TXMD,Florida,United States,North America,711264755,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/28/18,,,,,12/28/17,09/05/13,,,,09/05/13,,06/05/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"CVC Capital Partners SICAV-FIS S.A., Knight Therapeutics Inc."
25407,78,35364,179,Biktarvy,bictegravir/emtricitabine/tenofovir alafenamide,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV Integrase,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,02/07/18,06/25/18,03/26/19,,,06/12/17,11/10/15,03/20/15,,,11/10/15,03/20/15,10/27/14,N/A,,N/A,N/A,"$  1,144.0","$  1,762.0",N/A,N/A,"$  1,184.0","$  1,909.0",Q2 2019,N/A
14178,242,17951,2571,Binosto,alendronate,EffRx Pharmaceuticals SA,,,Switzerland,Europe,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Osteoclast,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,03/12/12,12/20/11,,,,01/10/11,,,,,01/14/09,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Hikma Pharmaceuticals plc, Merck &amp; Co., Inc., Mission Pharmacal Company"
18194,549,23799,523,Bio-T-Gel,,"ANI Pharmaceuticals, Inc.",ANIP,Minnesota,United States,North America,853557256,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Transdermal,N,N,N,,N,N,,,,02/14/12,,,,,01/14/11,,,,,09/10/09,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Teva Pharmaceutical Industries Ltd.
19885,423,26366,4080,Bivigam,"Immune Globulin Intravenous (Human), 10% Liquid","ADMA Biologics, Inc.",ADMA,New Jersey,United States,North America,178915797,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Polyclonal Antibody,Immune system,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,12/19/12,,,,,11/03/10,,,,,10/02/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
725,199,10688,30,Blincyto,blinatumomab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 19 (CD19)^ Cluster of Differentiation 3 (CD3)^ Immune system,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,12/03/14,11/23/15,09/24/18,,,09/19/14,,,,,01/10/14,11/08/07,10/18/07,N/A,,$    85.0,$   114.0,$   134.0,$    40.0,$   115.0,$   175.0,$   233.6,$    75.3,Q1 2019,"Astellas Pharma, Inc., AstraZeneca PLC, Dr. Reddy's Laboratories"
22434,531,30438,831,Bloxiverz,neostigmine methylsulfate,Avadel Pharmaceuticals plc,AVDL,,Ireland,Europe,75874628,Neurology,Pain,Anesthesia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Not Specified,Cholinesterases,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,05/31/13,,,,,07/31/12,,,,,,,,N/A,,$    82.9,$    45.3,$    20.9,$     2.6,$    82.9,$    45.3,$    20.9,$     2.6,Q1 2019,N/A
1780,242,2836,149,Boniva,ibandronate sodium,Roche Holding AG,RHHBY,,Switzerland,Europe,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Osteoclast,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,05/16/03,06/25/96,06/28/13,,,,,,,,,,,50%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2012,"Chugai Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Taisho Pharmaceutical Co., Ltd."
37769,594,52668,4232,Bonjesta,doxylamine succinate/pyridoxine hydrochloride,Duchesnay Inc.,,Quebec,Canada,North America,,Not Specified,Other,Emesis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/07/16,,,,,10/07/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1454,3197,2183,180,Boostrix,Tdap vaccine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Diphtheria, pertussis, and tetanus (DT, Td, DTaP and Tdap) Vaccines",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,05/03/05,,,,,07/07/04,,,,,,,,N/A,,$   324.0,$   338.8,$   360.3,$    82.7,$   639.0,$   582.9,$   704.4,$   166.8,Q1 2019,N/A
2994,198,5099,312,Bosulif,bosutinib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Hematologic,Chronic Myelogenous Leukemia (CML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ Src Kinase Family,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,09/04/12,03/27/13,09/26/14,,,,01/08/08,,,,01/08/08,12/11/06,,N/A,,N/A,$   123.0,$   197.0,$   118.0,N/A,$   186.0,$   296.0,$   177.0,Q2 2019,Avillion LLP
12764,1508,16114,395,Botox - Cosmetic,onabotulinumtoxinA,Allergan plc,AGN,,Ireland,Europe,53945515162,Dermatology,General,Wrinkles,Y,Approved,Approved,100% (Same As Avg.),Natural Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Intradermal, Intraarticular",N,N,N,N,N,N,,,,04/12/02,02/25/03,05/24/16,,,,,,,,,,,100%,,N/A,$   394.1,N/A,N/A,N/A,$   664.5,N/A,N/A,Q2 2017,N/A
8016,257,9858,395,Botox - Therapeutic,onabotulinumtoxinA,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,"movement disorders, all",Cervical Dystonia,N,Approved,Approved,100% (Same As Avg.),Natural Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Intravesical, Intradermal, Intraarticular",N,N,N,,N,N,,,,12/21/00,,06/25/01,,,04/27/99,,,,,,,,100%,,"$  1,983.2","$  2,027.3","$  2,800.3","$  1,326.5","$  2,786.2","$  2,793.5","$  3,577.4","$  1,842.4",Q2 2019,"Endo International plc, GlaxoSmithKline plc"
8016,2841,9937,395,Botox - Therapeutic,onabotulinumtoxinA,Allergan plc,AGN,,Ireland,Europe,53945515162,Urology,Other,Neurogenic Bladder,N,Approved,Approved,100% (Same As Avg.),Natural Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Intravesical, Intradermal, Intraarticular",N,N,N,,N,N,,01/01/2012 - 01/01/2012,01/01/2013 - 01/01/2013,08/24/11,10/26/11,,,,,,,,,06/26/06,07/01/05,,100%,,"$  1,983.2","$  2,027.3","$  2,800.3","$  1,326.5","$  2,786.2","$  2,793.5","$  3,577.4","$  1,842.4",Q2 2019,"Endo International plc, GlaxoSmithKline plc"
8016,288,15121,395,Botox - Therapeutic,onabotulinumtoxinA,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,Headache,Migraine and Other Headaches,N,Approved,Approved,100% (Same As Avg.),Natural Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Intravesical, Intradermal, Intraarticular",N,N,N,N,N,N,,,,10/15/10,07/09/10,,,,09/29/09,,,,,02/07/05,01/27/99,,100%,,"$  1,983.2","$  2,027.3","$  2,800.3","$  1,326.5","$  2,786.2","$  2,793.5","$  3,577.4","$  1,842.4",Q2 2019,"Endo International plc, GlaxoSmithKline plc"
8016,151,16145,395,Botox - Therapeutic,onabotulinumtoxinA,Allergan plc,AGN,,Ireland,Europe,53945515162,Dermatology,General,Dermatology,N,Approved,Approved,100% (Same As Avg.),Natural Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Intravesical, Intradermal, Intraarticular",N,N,N,,N,N,,,,07/20/04,07/26/01,,,,07/23/03,,,,,10/20/00,,,100%,,"$  1,983.2","$  2,027.3","$  2,800.3","$  1,326.5","$  2,786.2","$  2,793.5","$  3,577.4","$  1,842.4",Q2 2019,"Endo International plc, GlaxoSmithKline plc"
8016,543,19689,395,Botox - Therapeutic,onabotulinumtoxinA,Allergan plc,AGN,,Ireland,Europe,53945515162,Urology,Other,Overactive Bladder (OAB),N,Approved,Approved,100% (Same As Avg.),Natural Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Intravesical, Intradermal, Intraarticular",N,N,N,,N,N,,,,01/18/13,,,,,03/28/12,10/15/09,09/14/05,,,10/15/09,09/14/05,,100%,,"$  1,983.2","$  2,027.3","$  2,800.3","$  1,326.5","$  2,786.2","$  2,793.5","$  3,577.4","$  1,842.4",Q2 2019,"Endo International plc, GlaxoSmithKline plc"
20088,221,26693,312,Braftovi,encorafenib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Raf kinase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/27/18,09/20/18,01/08/19,,,06/30/17,09/26/13,,,,09/26/13,01/28/13,09/19/11,N/A,,N/A,N/A,N/A,$    17.4,N/A,N/A,N/A,$    17.4,Q1 2019,"Ono Pharmaceutical Company, Ltd., Pierre Fabre Medicament S.A."
15499,241,19711,582,Bravelle,urofollitropin,Ferring Pharmaceuticals,,,Switzerland,Europe,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Y,Approved,Approved,100% (Same As Avg.),Protein,Follicle-Stimulating Hormone Receptor (FSHR),Non-NME,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,N,N,N,,,,05/06/02,,,,,,10/23/13,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3248,72,5576,180,Breo Ellipta,fluticasone furoate/vilanterol trifenatate,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,04/30/15,11/13/13,09/20/13,,,06/30/14,03/17/10,,,,03/17/10,11/14/05,,93%,726.3,$   468.0,$   782.0,$   773.0,$   220.0,$   843.0,"$  1,307.0","$  1,448.0",$   584.0,Q2 2019,"Innoviva, Inc., Vectura Group plc"
3248,73,5577,180,Breo Ellipta,fluticasone furoate/vilanterol trifenatate,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,05/01/2017 - 11/01/2017,05/10/13,11/13/13,,,,07/13/12,10/27/09,,,,10/27/09,02/26/08,04/03/07,93%,554.6,$   468.0,$   782.0,$   773.0,$   220.0,$   843.0,"$  1,307.0","$  1,448.0",$   584.0,Q2 2019,"Innoviva, Inc., Vectura Group plc"
8563,531,10634,254,Bridion,sugammadex,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Neurology,Pain,Anesthesia,Y,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Neuromuscular Blocking Agents,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,12/15/15,07/25/08,02/16/10,,,10/31/07,06/02/06,12/31/02,,,06/02/06,12/31/02,,100%,348.8,$    78.0,$   238.0,$   385.0,$   248.0,$   481.0,$   705.0,$   917.0,$   533.0,Q2 2019,N/A
2294,179,3845,45,Brilinta,ticagrelor,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Adenosine Diphosphate P2Y12 Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/20/11,12/06/10,09/28/16,,,11/19/09,10/26/06,,,,10/26/06,08/25/05,,N/A,,$   348.0,$   509.0,$   588.0,$   321.0,$   839.0,"$  1,079.0","$  1,321.0",$   737.0,Q2 2019,The Medicines Company
18793,278,24705,289,Brimonidine Tartrate 0.15%,brimonidine tartrate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor,Non-NME,No,Topical,N,N,N,,N,N,,,,05/22/06,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Allergan plc
19562,2864,25820,65,Brineura,cerliponase alfa,BioMarin Pharmaceutical Inc.,BMRN,California,United States,North America,13080442306,Metabolic,Inborn Errors Of Metabolism,Neuronal Ceroid Lipofuscinosis (NCL),Y,Approved,Approved,100% (Same As Avg.),Protein,Tripeptidyl Peptidase-1 (TTP1),Biologic,No,Intracerebral/cerebroventricular,N,N,Y,Y,N,N,,,,04/27/17,06/01/17,,,,05/27/16,,09/17/13,,,,04/01/13,,N/A,,N/A,N/A,N/A,N/A,N/A,$     8.6,$    39.9,$    27.0,Q2 2019,N/A
8366,240,10374,2672,Brisdelle,,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/28/13,,,,,08/29/12,04/09/10,,,,04/09/10,07/10/07,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Shionogi &amp; Co. Ltd.
8072,3009,22790,88,Briviact,brivaracetam,UCB SA,UCB:BB,,Belgium,Europe,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,SV2A synaptic vesicle protein,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/18/16,01/14/16,,,,11/19/14,09/09/05,,,,09/09/05,,,N/A,,$    12.0,$    76.4,$   120.6,N/A,$    20.0,$   104.3,$   157.2,N/A,Q4 2018,Dr. Reddy's Laboratories
18970,560,24965,4041,Brixadi,buprenorphine,Apple Tree Partners,,New York,United States,North America,,Psychiatry,Other,Substance Use Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Subcutaneous (SQ),Y,N,N,N,N,N,,,,12/21/18,,,,,07/19/17,12/16/15,,,,12/15/15,11/20/14,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Camurus AB, Medison Pharma Ltd."
17358,554,22573,470,Bromday,bromfenac sodium,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Topical,N,N,N,N,N,N,,,,10/16/10,,,,,12/16/09,,,,,05/30/06,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"CROMA Pharma GmbH, Senju Pharmaceutical Co., Ltd."
17209,554,22329,3285,BromSite,bromfenac,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Topical,N,N,N,N,N,N,,,,04/08/16,,,,,06/10/15,02/28/12,,,,02/28/12,08/23/10,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,VISUfarma
604,73,1110,686,Brovana,arformoterol tartrate,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,10/09/06,,,,,12/13/05,,,,,01/22/04,,,100%,220.6,$   305.0,N/A,N/A,N/A,$   305.0,$   299.0,$   300.0,$   150.0,Q2 2019,N/A
26542,155,37020,470,Bryhali,halobetasol propionate,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,10/08/18,,,,,12/31/17,05/25/16,,,,07/31/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
19034,560,25054,1020,Bunavail,buprenorphine/naloxone,"BioDelivery Sciences International, Inc.",BDSI,North Carolina,United States,North America,311043119,Psychiatry,Other,Substance Use Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,06/09/14,,,,,07/31/13,08/09/12,,,,08/09/12,,09/06/11,N/A,,$     6.2,$     6.2,$     5.3,$     1.1,$     6.2,$     6.2,$     5.3,$     1.1,Q1 2019,N/A
18542,3629,24325,325,Butrans,Buprenorphine,Purdue Pharma L.P.,,Connecticut,United States,North America,,Neurology,Pain,Chronic Low Back Pain (CLBP),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Transdermal,N,N,N,N,N,N,,,,06/30/10,,02/23/11,,,,,,,,08/31/01,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    18.6,N/A,Q4 2018,Mundipharma International Limited
200,137,227,45,Bydureon,exenatide,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,01/01/2015 - 07/31/2015,01/27/12,06/17/11,03/30/12,,,05/05/09,03/24/06,03/30/04,03/26/01,,03/24/06,06/25/02,03/26/01,63.5%,1068.8,$   349.0,$   458.0,$   475.0,$   234.0,$   436.0,$   574.0,$   584.0,$   283.0,Q2 2019,"3SBio Inc., Alkermes plc, Bristol-Myers Squibb Company, Eli Lilly &amp; Company"
19287,137,25414,45,Bydureon BCise,exenatide,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GLP-1 Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/23/17,08/30/18,,,,,03/08/13,,,,03/08/13,01/09/12,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Alkermes plc, Bristol-Myers Squibb Company, Eli Lilly &amp; Company"
201,137,228,45,Byetta,exenatide,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/28/05,11/20/06,10/27/10,,,06/29/04,12/10/01,06/30/99,08/18/98,01/13/99,12/10/01,06/30/99,08/18/98,70%,242.9,$   164.0,$   114.0,$    74.0,$    35.0,$   254.0,$   176.0,$   126.0,$    55.0,Q2 2019,"3SBio Inc., Bristol-Myers Squibb Company, Eli Lilly &amp; Company"
2056,244,3363,395,Bystolic,nebivolol hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/17/07,,,,,05/05/04,,,,,,,,N/A,,$   323.7,$   612.2,$   583.8,$   278.8,$   639.3,$   614.3,$   585.8,$   279.7,Q2 2019,"Kowa Company, Ltd., Mylan N.V., The Menarini Group"
21648,244,29202,395,Byvalson,nebivolol and valsartan,Allergan plc,AGN,,Ireland,Europe,53945515162,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1)^ Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/03/16,,,,,02/23/14,01/13/12,,,,08/11/11,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
21568,381,29086,51,Cablivi,caplacizumab-yhdp,Sanofi,SNY,,France,Europe,1.05588E+11,Hematology,Vessel Wall Purpuric Disorders,Thrombotic Thrombocytopenic Purpura (TTP),Y,Approved,Approved,100% (Same As Avg.),Protein,Von Willebrand Factor (vWF),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,Y,N,N,N,,,,02/06/19,09/03/18,,,,09/03/18,09/29/15,09/30/10,,,09/29/15,09/30/10,05/07/09,N/A,,N/A,N/A,N/A,$    12.4,N/A,N/A,N/A,$    22.6,Q2 2019,N/A
2338,532,3940,147,Cabometyx / Cometriq,cabozantinib,"Exelixis, Inc.",EXEL,California,United States,North America,6036469495,Oncology,Solid,Thyroid Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Angiopoietin Receptors (TIE-1 and TIE-2)^ FMS-like tyrosine kinase 3 (FLT-3)^ Hepatocyte growth factor receptor (c-Met, HGFR)^ KIT/c-KIT^ RET^ VEGF Receptor (VEGFR)",New Molecular Entity (NME),No,Oral (PO),Y,Y,Y,N,N,N,,,01/01/2016 - 01/01/2016,11/29/12,03/21/14,,,,05/30/12,07/21/08,,09/22/05,,06/16/08,,09/22/05,97%,55.5,$   135.4,$   349.1,$   619.2,$   373.3,$   143.3,$   406.4,$   783.2,$   498.1,Q2 2019,"Bristol-Myers Squibb Company, GlaxoSmithKline plc, Ipsen SA, Swedish Orphan Biovitrum, Takeda Pharmaceutical Company Ltd"
2338,297,23037,147,Cabometyx / Cometriq,cabozantinib,"Exelixis, Inc.",EXEL,California,United States,North America,6036469495,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Angiopoietin Receptors (TIE-1 and TIE-2)^ FMS-like tyrosine kinase 3 (FLT-3)^ Hepatocyte growth factor receptor (c-Met, HGFR)^ KIT/c-KIT^ RET^ VEGF Receptor (VEGFR)",New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,01/14/19,11/15/18,,,,03/14/18,09/10/13,07/30/09,,,09/10/13,07/30/09,,97%,,$   135.4,$   349.1,$   619.2,$   373.3,$   143.3,$   406.4,$   783.2,$   498.1,Q2 2019,"Bristol-Myers Squibb Company, GlaxoSmithKline plc, Ipsen SA, Swedish Orphan Biovitrum, Takeda Pharmaceutical Company Ltd"
2338,216,23111,147,Cabometyx / Cometriq,cabozantinib,"Exelixis, Inc.",EXEL,California,United States,North America,6036469495,Oncology,Solid,Renal Cell Cancer (RCC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Angiopoietin Receptors (TIE-1 and TIE-2)^ FMS-like tyrosine kinase 3 (FLT-3)^ Hepatocyte growth factor receptor (c-Met, HGFR)^ KIT/c-KIT^ RET^ VEGF Receptor (VEGFR)",New Molecular Entity (NME),No,Oral (PO),Y,N,N,Y,N,N,,,01/01/2020 - 07/31/2020,04/25/16,09/09/16,,,,12/23/15,05/31/13,,,,05/31/13,08/27/09,,97%,,$   135.4,$   349.1,$   619.2,$   373.3,$   143.3,$   406.4,$   783.2,$   498.1,Q2 2019,"Bristol-Myers Squibb Company, GlaxoSmithKline plc, Ipsen SA, Swedish Orphan Biovitrum, Takeda Pharmaceutical Company Ltd"
2397,244,4054,312,Caduet,amlodipine besylate/atorvastatin calcium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/30/04,,07/09/09,,,03/31/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2014,"Astellas Pharma, Inc."
2397,446,4055,312,Caduet,amlodipine besylate/atorvastatin calcium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,Other,Angina,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/30/04,,,,,03/31/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2014,"Astellas Pharma, Inc."
2397,506,4056,312,Caduet,amlodipine besylate/atorvastatin calcium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/30/04,,07/07/09,,,03/31/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2014,"Astellas Pharma, Inc."
2397,267,5602,312,Caduet,amlodipine besylate/atorvastatin calcium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,Coronary Artery Disease (General),Coronary Artery Disease,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/30/04,,,,,03/31/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2014,"Astellas Pharma, Inc."
2397,181,5603,312,Caduet,amlodipine besylate/atorvastatin calcium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,General,Cardiovascular Disease,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/30/04,,,,,03/31/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2014,"Astellas Pharma, Inc."
17896,3133,23377,3014,Caldolor,ibuprofen,Cumberland Pharmaceuticals Inc.,CPIX,Tennessee,United States,North America,89128556,Neurology,Pain,Mild to Moderate Pain,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,06/11/09,,,,,12/03/08,,,,,,,,N/A,,$     4.2,$     4.2,$     4.8,$     1.3,$     4.2,$     4.2,$     4.8,$     1.3,Q1 2019,"Grifols, S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Phebra Pty Ltd, Sandor Medicaids Pvt. Ltd., SOHO Group, Winhealth Pharma Group"
17896,2128,25953,3014,Caldolor,ibuprofen,Cumberland Pharmaceuticals Inc.,CPIX,Tennessee,United States,North America,89128556,Not Specified,Other,Fever,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,06/11/09,,,,,,,,,,,,,N/A,,$     4.2,$     4.2,$     4.8,$     1.3,$     4.2,$     4.2,$     4.8,$     1.3,Q1 2019,"Grifols, S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Phebra Pty Ltd, Sandor Medicaids Pvt. Ltd., SOHO Group, Winhealth Pharma Group"
17896,3130,25954,3014,Caldolor,ibuprofen,Cumberland Pharmaceuticals Inc.,CPIX,Tennessee,United States,North America,89128556,Neurology,Pain,Postsurgical Pain,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,06/11/09,,,,,,,,,,01/31/05,,,N/A,,$     4.2,$     4.2,$     4.8,$     1.3,$     4.2,$     4.2,$     4.8,$     1.3,Q1 2019,"Grifols, S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Phebra Pty Ltd, Sandor Medicaids Pvt. Ltd., SOHO Group, Winhealth Pharma Group"
23530,3094,38696,45,Calquence,acalabrutinib,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Hematologic,Mantle Cell Lymphoma - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bruton's Tyrosine Kinase (BTK),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,10/31/17,,,,,06/13/17,03/28/17,12/12/14,,,03/28/17,12/12/14,,N/A,,N/A,$     3.0,$    62.0,$    64.0,N/A,$     3.0,$    62.0,$    64.0,Q2 2019,"Acerta Pharma BV, Merck &amp; Co., Inc."
19720,288,26114,3545,Cambia,diclofenac potassium,APR Applied Pharma Research SA,,,Switzerland,Europe,,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/17/09,03/31/99,,,,,,,,,,,,N/A,,N/A,N/A,$    35.8,$     8.8,N/A,N/A,$    35.8,$     8.8,Q1 2019,"Assertio Therapeutics, Inc., Nautilus Neurosciences, Inc., Novartis AG, Nuvo Pharmaceuticals, Inc."
1662,518,2673,255,Campral,acamprosate Calcium,Merck KGaA,MKGAY,,Germany,Europe,,Psychiatry,Other,Alcohol Use Disorder,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA Receptors^ NMDA Glutamate Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/29/04,,,,,12/01/01,,,,,06/27/02,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Allergan plc
2662,321,4546,395,Canasa,mesalamine,Allergan plc,AGN,,Ireland,Europe,53945515162,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Rectal,N,N,N,,N,N,,,,01/05/01,,,,,,,,,,,,,N/A,405.1,$   178.7,$   306.7,$   331.2,$    46.2,$   196.4,$   506.0,$   373.6,$    49.8,Q1 2019,N/A
1758,3116,2797,254,Cancidas,caspofungin acetate,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Beta (1,3)-D-Glucan",New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,01/26/01,10/24/01,,,,,,,,,,,,N/A,,$    24.0,$    20.0,$    11.0,$     4.0,$   558.0,$   422.0,$   326.0,$   128.0,Q2 2019,N/A
1897,532,3340,51,Caprelsa,vandetanib,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Solid,Thyroid Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor)^ RET^ VEGF (Vascular endothelial growth factor),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,04/06/11,02/17/12,09/28/15,,,07/07/10,07/26/07,12/07/04,,,07/26/07,07/28/05,,100%,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2012,AstraZeneca PLC
17889,654,23370,1008,Carbaglu,,Recordati SpA,REC:IM,,Italy,Europe,,Metabolic,Inborn Errors Of Metabolism,Urea Cycle Disorders and Derangements (UCD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Urea cycle,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,,N,N,,,,03/18/10,01/24/03,,,,04/21/08,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22016,244,29783,470,Cardizem LA,diltiazem hydrochloride,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/06/03,,,,,06/11/01,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,AbbVie Inc.
22016,446,29784,470,Cardizem LA,diltiazem hydrochloride,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Cardiovascular,Other,Angina,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/02/04,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,AbbVie Inc.
11701,272,14743,240,Carnexiv,carbamazepine,H. Lundbeck A/S,HLUKF,,Denmark,Europe,,Neurology,Seizure Disorders (Epilepsy),Seizure Disorders (Epilepsy),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,10/07/16,,,,,03/10/14,,,,,07/31/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Ligand Pharmaceuticals, Inc."
11701,3009,22796,240,Carnexiv,carbamazepine,H. Lundbeck A/S,HLUKF,,Denmark,Europe,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,10/07/16,,,,,03/10/14,,,,,07/31/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Ligand Pharmaceuticals, Inc."
39743,264,55583,8945,CaroSpir,Spironolactone,"CMP Pharma, Inc.",,North Carolina,United States,North America,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Mineralocorticoid Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/04/17,,,,,10/04/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
39743,709,55594,8945,CaroSpir,Spironolactone,"CMP Pharma, Inc.",,North Carolina,United States,North America,,Renal,General,Edema,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Mineralocorticoid Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/04/17,,,,,10/04/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
39743,244,55595,8945,CaroSpir,Spironolactone,"CMP Pharma, Inc.",,North Carolina,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Mineralocorticoid Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/04/17,,,,,10/04/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38988,560,54513,375,Cassipa,buprenorphine hydrochloride/naloxone hydrochloride,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Psychiatry,Other,Substance Use Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,09/07/18,,,,,,,,,,09/30/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
65,2910,196,149,Cathflo Activase,alteplase,Roche Holding AG,RHHBY,,Switzerland,Europe,,Cardiovascular,Other,Catheter Complications,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrin (Coagulation Factor Ia)^ Plasminogen^ Tissue Plasminogen Activator (TPA),Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,09/10/01,05/30/08,,,,,,,,,,,,100%,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Boehringer Ingelheim GmbH
2861,74,4883,179,Cayston,aztreonam lysine,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Penicillin Binding Proteins (PBP),Non-NME,No,Inhaled,N,N,Y,N,N,N,,,,02/22/10,09/21/09,,,,11/16/07,04/25/05,,,,04/25/05,,,100%,131,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2014,N/A
1754,3127,2816,312,Celebrex,celecoxib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Acute Pain,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cyclooxygenase 2 (COX2) / Prostaglandin-Endoperoxide Synthase 2 (PTGS2),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/18/01,,06/17/09,,,,,,,,,,,N/A,,$   146.0,$   163.0,$    65.0,$    15.0,$   915.0,$   775.0,"$  1,129.4",$   270.2,Q1 2019,"Astellas Pharma, Inc."
1754,1473,25958,312,Celebrex,celecoxib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Other,Dysmenorrhea,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cyclooxygenase 2 (COX2) / Prostaglandin-Endoperoxide Synthase 2 (PTGS2),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/18/01,,,,,,,,,,,,,N/A,,$   146.0,$   163.0,$    65.0,$    15.0,$   915.0,$   775.0,"$  1,129.4",$   270.2,Q1 2019,"Astellas Pharma, Inc."
1687,727,10827,149,CellCept,mycophenolate mofetil,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Transplant Rejection,Liver Transplant Rejection,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,IMPDH I (Inosine Monophosphate Dehydrogenase 1),New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,08/09/00,11/15/00,,,,,,,,,,,,50%,,$   175.7,$   122.2,$   108.6,$    43.0,$   756.5,$   711.1,$   679.3,$   325.1,Q2 2019,"Chugai Pharmaceutical Co., Ltd., Vifor Pharma Group"
20450,440,27265,3814,Centany,mupirocin,"Medimetriks Pharmaceuticals, Inc.",,New Jersey,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Isoleucyl-tRNA synthetase (bacterial),Non-NME,No,Topical,N,N,N,,N,N,,,,12/04/02,,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Perrigo Company PLC
36138,346,50323,826,Ceprotin,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Hematology,Antithrombotic,Venous Thromboembolism (VTE),N,Approved,Approved,100% (Same As Avg.),Protein,Protein C,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,03/30/07,07/16/01,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
27691,548,38831,3285,Cequa,cyclosporine,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Ophthalmology,Other,Dry Eye (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Peptide,Calcineurin phosphatase,Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,08/14/18,,,,,,,,,,09/30/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,China Medical System Holdings Limited
1360,277,4240,51,Cerdelga,eliglustat tartrate,Sanofi,SNY,,France,Europe,1.05588E+11,Metabolic,Inborn Errors Of Metabolism,Gaucher's Disease,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucosylceramide Synthase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/19/14,01/19/15,03/30/15,,,09/19/13,08/06/09,,,,08/06/09,07/12/06,,N/A,,$    94.4,$   108.9,$   119.9,$    64.4,$   117.7,$   138.3,$   194.8,$   110.7,Q2 2019,"PDL BioPharma, Inc., University of Michigan"
1800,3080,2871,180,Cervarix,papillomavirus bivalent vaccine (human) (recombinant),GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,"Human papillomavirus (HPV) Prevention (Antiviral, Vaccines)",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Human Papillomavirus (HPV)^ Immune system,Vaccine,No,Intramuscular (IM),Y,N,N,N,N,N,,,,10/16/09,09/20/07,10/16/09,,,03/29/07,,,,,12/10/03,,,85%,,$     1.0,N/A,N/A,N/A,$   110.0,$   173.1,$   187.9,$    27.1,Q1 2019,"AstraZeneca PLC, CSL Limited"
24679,3124,34293,4851,Cetraxal,,WraSer Pharmaceuticals,,Mississippi,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Topoisomerase II (DNA gyrase) and IV,Non-NME,No,Topical,N,N,N,N,N,N,,,,05/01/09,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
985,241,1197,14,Cetrotide,cetrorelix,"Aeterna Zentaris, Inc.",AEZS,,Canada,North America,40937492,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gonadotropin-Releasing Hormone (GnRH) Receptor,New Molecular Entity (NME),No,Intramuscular (IM),N,N,N,,N,N,,,,08/11/00,04/13/99,04/20/06,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Merck KGaA, Shionogi &amp; Co. Ltd."
30829,726,42634,4042,Cetylev,acetylcysteine,"Arbor Pharmaceuticals, LLC",,Georgia,United States,North America,,Not Specified,Other,Drug Toxicity,N,Approved,Approved,100% (Same As Avg.),Not Specified,Glutathione (GSH) synthesis,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,01/29/16,,,,,03/30/15,,,,,02/24/15,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
21218,3230,28563,3759,Cevira,hexaminolevulinate hydrochloride,Photocure ASA,PHO:NO,,Norway,Europe,,Oncology,Solid,Bladder Cancer - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Unknown,Non-NME,Yes,"Topical, Intravesical",N,N,N,,N,N,,,,05/28/10,09/17/04,,,,06/30/09,,,,,09/17/04,,,N/A,,N/A,$     5.0,$     7.4,$     2.5,N/A,$    10.0,$    12.9,$     4.0,Q1 2019,"BioSyent Inc., Celgene Corporation, Ipsen SA, Jiangsu Asieris Pharmaceuticals Co. Ltd."
2309,559,3879,312,Chantix,varenicline tartrate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Other,Smoking Cessation,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Nicotinic Acetylcholine Receptor - a4ß2 subtype &lt;br&gt;(a4ß2 nAChR)^ Nicotinic Acetylcholine Receptor - a7 subtype &lt;br&gt;(a7 nAChR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/11/06,09/26/06,01/25/08,,,11/10/05,,,,,04/19/05,,,N/A,,$   597.0,$   743.0,$   838.0,$   439.0,$   843.0,$   998.0,"$  1,085.0",$   549.0,Q2 2019,N/A
23338,3382,31981,3579,Cholbam,cholic acid,"Retrophin, Inc.",RTRX,New York,United States,North America,736682296,Metabolic,Inborn Errors Of Metabolism,Disorders in Bile Acid Synthesis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bile Acids,New Molecular Entity (NME),No,,N,N,Y,N,N,N,,,,03/17/15,11/20/15,,,,,,,,,05/03/10,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Asklepion Pharmaceuticals, LLC, FGK Representative Service GmbH"
20985,3192,28159,3928,Choline C 11 Injection,,Mayo Clinic,,Minnesota,United States,North America,,Oncology,Solid,Prostate Cancer - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Tumor Cells,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,09/12/12,,,,,12/12/11,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
435,160,740,136,Cialis,tadalafil,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Urology,Male Sexual Dysfunction,Erectile Dysfunction (ED),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 5 (PDE5),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/21/03,11/14/02,07/31/07,,,06/28/01,,,,,,,,N/A,,"$  1,469.5","$  1,358.7","$  1,129.2",$   143.2,"$  2,471.7","$  2,323.2","$  1,999.6",$   342.0,Q1 2019,"Lupin Limited, Nippon Shinyaku Co., Ltd., Sanofi"
435,569,3180,136,Cialis,tadalafil,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Urology,General,Benign Prostatic Hyperplasia (BPH),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 5 (PDE5),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/06/11,10/30/12,01/31/14,,,,,10/01/04,,,03/18/09,02/03/05,,N/A,,"$  1,469.5","$  1,358.7","$  1,129.2",$   143.2,"$  2,471.7","$  2,323.2","$  1,999.6",$   342.0,Q1 2019,"Lupin Limited, Nippon Shinyaku Co., Ltd., Sanofi"
37494,78,52286,266,Cimduo,Tenofovir Disoproxil Fumarate and Lamivudine,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Infectious disease,Antiviral,HIV / AIDS,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/28/18,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
247,156,362,88,Cimzia,certolizumab pegol,UCB SA,UCB:BB,,Belgium,Europe,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,01/01/2012 - 01/01/2012,04/22/08,,,,,03/02/06,12/23/03,,,,01/07/04,05/27/03,,95%,,$   930.0,"$  1,113.4",$   991.7,$   277.1,"$  1,450.0","$  1,797.8","$  1,600.5",$   455.5,Q1 2019,"Astellas Pharma, Inc., Enzon Pharmaceuticals, Inc., Nektar Therapeutics, NewBridge Pharmaceuticals, Royalty Pharma AG"
247,154,363,88,Cimzia,certolizumab pegol,UCB SA,UCB:BB,,Belgium,Europe,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,05/13/09,10/01/09,12/25/12,,,12/14/07,12/20/02,,,,11/13/03,,,95%,,$   930.0,"$  1,113.4",$   991.7,$   277.1,"$  1,450.0","$  1,797.8","$  1,600.5",$   455.5,Q1 2019,"Astellas Pharma, Inc., Enzon Pharmaceuticals, Inc., Nektar Therapeutics, NewBridge Pharmaceuticals, Royalty Pharma AG"
247,155,4230,88,Cimzia,certolizumab pegol,UCB SA,UCB:BB,,Belgium,Europe,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,05/24/18,06/07/18,,,,07/24/17,,,,,12/12/05,08/01/08,,95%,,$   930.0,"$  1,113.4",$   991.7,$   277.1,"$  1,450.0","$  1,797.8","$  1,600.5",$   455.5,Q1 2019,"Astellas Pharma, Inc., Enzon Pharmaceuticals, Inc., Nektar Therapeutics, NewBridge Pharmaceuticals, Royalty Pharma AG"
247,336,20850,88,Cimzia,certolizumab pegol,UCB SA,UCB:BB,,Belgium,Europe,,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,02/01/2014 - 02/01/2014,,09/27/13,,,,,02/20/13,03/15/10,,,,03/15/10,12/10/09,,95%,,$   930.0,"$  1,113.4",$   991.7,$   277.1,"$  1,450.0","$  1,797.8","$  1,600.5",$   455.5,Q1 2019,"Astellas Pharma, Inc., Enzon Pharmaceuticals, Inc., Nektar Therapeutics, NewBridge Pharmaceuticals, Royalty Pharma AG"
247,252,20851,88,Cimzia,certolizumab pegol,UCB SA,UCB:BB,,Belgium,Europe,,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,02/01/2014 - 02/01/2014,,10/18/13,,,,,02/20/13,03/15/10,,,,03/15/10,12/10/09,,95%,,$   930.0,"$  1,113.4",$   991.7,$   277.1,"$  1,450.0","$  1,797.8","$  1,600.5",$   455.5,Q1 2019,"Astellas Pharma, Inc., Enzon Pharmaceuticals, Inc., Nektar Therapeutics, NewBridge Pharmaceuticals, Royalty Pharma AG"
14169,72,17938,375,Cinqair,reslizumab,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-5 (Interleukin-5) and IL-5 Receptor (IL-5R),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,03/23/16,08/15/16,,,,03/29/15,01/04/11,,,,01/04/11,11/01/07,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
2237,556,3755,826,Cinryze (IV),C1 esterase inhibitor (human),Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Y,Approved,Approved,100% (Same As Avg.),Protein,Complement Pathway,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,10/10/08,06/15/11,,,,07/31/07,,,,,03/15/05,,,100%,,$   638.6,$   656.4,$   364.0,N/A,$   680.2,$   699.2,$   400.0,$    73.1,Q1 2019,N/A
24879,767,34574,1330,Cinvanti,aprepitant,"Heron Therapeutics, Inc.",HRTX,California,United States,North America,1417605793,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Neurokinin Receptor,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,11/09/17,,,,,01/12/17,,,05/14/15,,,,02/08/16,N/A,,N/A,N/A,$    56.2,$    28.0,N/A,N/A,$    56.2,$    28.0,Q1 2019,N/A
19436,3124,25626,289,Ciprodex,ciprofloxacin/dexamethasone,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Topoisomerase II (DNA gyrase) and IV,Non-NME,No,Topical,N,N,N,,N,N,,,,07/18/03,07/19/12,,,,09/23/02,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Bayer AG
612,236,1133,254,Clarinex,desloratadine,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Allergy,General,Allergic Rhinitis,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/21/01,01/15/01,09/28/16,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q4 2015,"DRI Capital Inc., Kyorin Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd."
612,647,3150,254,Clarinex,desloratadine,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Allergy,General,Urticaria,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/11/02,08/06/01,09/28/16,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q4 2015,"DRI Capital Inc., Kyorin Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd."
36742,3359,51198,582,Clenpiq,"sodium picosulfate, magnesium oxide, and anhydrous citric acid",Ferring Pharmaceuticals,,,Switzerland,Europe,,Gastroenterology (non inflammatory bowel disease),General,Colon Cleansing/Laxatives,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/28/17,,,,,,04/11/17,,,,01/09/17,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
318,244,588,851,Cleviprex,clevidipine butyrate,Chiesi Farmaceutici S.p.A.,,,Italy,Europe,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,01/01/2012 - 01/01/2012,,08/04/08,,,,,07/02/07,11/15/03,,,,02/11/04,08/07/03,,80%,8.8,N/A,N/A,N/A,$     0.0,$     4.4,N/A,N/A,$     0.0,Q1 2016,"AstraZeneca PLC, Emerge Health Pty Ltd."
23789,240,32768,59,Climara Pro,estradiol and levonorgestrel,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),N,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha),Non-NME,No,Transdermal,N,N,N,N,N,N,,,,11/21/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
23789,242,32769,59,Climara Pro,estradiol and levonorgestrel,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,N,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha),Non-NME,No,Transdermal,N,N,N,N,N,N,,,,01/04/06,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
22708,77,30911,3822,Clindesse,clindamycin phosphate,Perrigo Company PLC,PRGO,Michigan,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial and Antifungal - Miscellaneous Vaccines and Treatments,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Intravaginal,N,N,N,N,N,N,,,,11/30/04,,,,,10/30/03,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
34282,155,47343,587,Clobex,clobetasol propionate,Galderma S.A.,,,Switzerland,Europe,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,07/24/03,,03/30/17,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Maruho Co., Ltd."
455,199,762,51,Clolar,clofarabine,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ DNA synthesis^ Mitochondria,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,Y,N,N,N,,,,12/29/04,05/29/06,,,,10/22/03,,,,,02/05/02,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
39083,531,54651,4681,Clorotekal,chloroprocaine hydrochloride,B. Braun Melsungen AG,,,Germany,Europe,,Neurology,Pain,Anesthesia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Subarachnoid space,Non-NME,No,Intrathecal,N,N,N,N,N,N,,,,09/26/17,,,,,08/26/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Sintetica SA
26233,3593,36593,4169,Coagadex,,Bio Products Laboratory Ltd.,,,United Kingdom,Europe,,Hematology,Factor Augmentation,Factor X (Stuart-Prower Factor) Deficiency,N,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,10/20/15,03/16/16,,,,07/10/13,03/15/10,,,,03/15/10,09/14/07,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
14962,467,18988,289,Coartem,artemether/lumefantrine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Malaria,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Mitochondrial Electron Transport Chain^ Reactive Oxygen Species/Free Radicals,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,10/01/2016 - 06/30/2017,04/07/09,11/30/99,,,,06/27/08,,,,,,,01/28/99,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3012,321,5138,470,Colazal,balsalazide disodium,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,07/18/00,05/06/98,,,,,,,,,09/25/96,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2007,"Takeda Pharmaceutical Company Ltd, The Menarini Group"
17338,539,22536,826,Colcrys,colchicine,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Arthritis,Gout,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/30/09,,,,,09/29/08,03/26/07,,,,03/26/07,,,N/A,,$   373.1,$   359.9,$   272.4,N/A,$   373.1,$   360.7,$   272.4,N/A,Q4 2018,N/A
17338,422,22539,826,Colcrys,colchicine,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,General,Inflammatory Disorders,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/29/09,,,,,07/20/08,,,,,,,,N/A,,$   373.1,$   359.9,$   272.4,N/A,$   373.1,$   360.7,$   272.4,N/A,Q4 2018,N/A
8656,278,10760,395,Combigan,brimonidine tartrate/timolol,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor^ Beta Adrenergic Receptors,Non-NME,No,Topical,N,N,N,,N,N,,,,10/31/07,02/07/05,,,,09/18/01,,,,,,,,N/A,,N/A,$   377.3,$   375.4,$   174.6,N/A,$   552.4,$   551.4,$   253.1,Q2 2019,N/A
3233,3127,5549,395,Combunox,ibuprofen and oxycodone hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,Pain,Acute Pain,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)^ Opioid receptors",Non-NME,No,Oral (PO),N,N,N,,N,N,,,,11/26/04,,,,,12/19/01,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,BTG plc
15552,78,19799,179,Complera,,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,,N,N,,,01/01/2016 - 01/01/2016,08/10/11,11/28/11,,,,02/10/11,,,,,07/21/08,,,67%,1227.7,$   821.0,$   406.0,$   276.0,$    86.0,"$  1,457.0",$   966.0,$   653.0,$   238.0,Q2 2019,"Japan Tobacco Inc., Johnson &amp; Johnson"
1904,246,3071,223,Concerta,methylphenidate hydrochloride,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/01/00,06/30/11,10/26/07,,,,,,,,,,,N/A,,$   468.0,$   384.0,$   229.0,$   112.0,$   863.0,$   791.0,$   663.0,$   351.0,Q2 2019,N/A
26794,244,37432,8916,Consensi,celecoxib/amlodipine,"Coeptis Pharmaceuticals, LLC",,Pennsylvania,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel^ Cyclooxygenase 2 (COX2) / Prostaglandin-Endoperoxide Synthase 2 (PTGS2),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/31/18,,,,,07/31/17,06/24/14,,,,04/01/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Hebei Changshan Biochemical Pharmaceutical Co. Ltd, Kitov Pharmaceuticals Holdings Ltd., Kuhnil Pharmaceutical, Co. Ltd."
26794,249,37435,8916,Consensi,celecoxib/amlodipine,"Coeptis Pharmaceuticals, LLC",,Pennsylvania,United States,North America,,Rheumatology (non autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel^ Cyclooxygenase 2 (COX2) / Prostaglandin-Endoperoxide Synthase 2 (PTGS2),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/31/18,,,,,07/31/17,06/23/14,,,,04/01/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Hebei Changshan Biochemical Pharmaceutical Co. Ltd, Kitov Pharmaceuticals Holdings Ltd., Kuhnil Pharmaceutical, Co. Ltd."
2875,135,4915,8356,Contrave,bupropion and naltrexone,"Nalpropion Pharmaceuticals, Inc.",,New Jersey,United States,North America,,Metabolic,Obesity,Obesity,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Opioid receptors,Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,09/10/14,03/26/15,,,,03/31/10,04/01/07,,,,04/03/07,06/10/06,,N/A,,$     5.3,$    53.3,N/A,N/A,$     5.3,$    61.4,N/A,N/A,Q3 2017,"Bausch Health Companies Inc., Biologix FZCo, Bruno Farmaceutici SpA, Cheplapharm Arzneimittel GmbH, Consilient Health Ltd., Currax Pharmaceuticals LLC, Kwangdong Pharmaceutical Co., Ltd., Laboratorios Farmacéuticos Rovi, S.A., Merck KGaA"
8156,3128,10072,4104,ConZip,tramadol hydrochloride,Osmotica Pharmaceutical Corp,OSMT,North Carolina,United States,North America,,Neurology,Pain,Chronic Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,05/07/10,,,,,06/29/06,,,,,05/20/04,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q2 2014,"Cipher Pharmaceuticals Inc., Nuvo Pharmaceuticals, Inc., Tecnofarma International Ltd."
1916,176,3088,149,Copegus,ribavirin,Roche Holding AG,RHHBY,,Switzerland,Europe,,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,IMPDH I (Inosine Monophosphate Dehydrogenase 1)^ RNA synthesis,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,12/03/02,11/14/04,01/26/07,,,,,,,,,,,90%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2007,"Bausch Health Companies Inc., Chugai Pharmaceutical Co., Ltd."
18679,200,27613,3547,Copiktra,duvelisib,"Verastem, Inc.",VSTM,Massachusetts,United States,North America,98074422,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,p110 delta/PIK3CD^ p110 gamma/PIK3CG^ PI3K/AKT pathway,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,09/24/18,,,,,02/02/18,11/13/13,,10/31/11,08/09/11,11/13/13,08/08/13,10/31/11,N/A,,N/A,N/A,$     1.7,$     4.7,N/A,N/A,$     1.7,$     4.7,Q2 2019,"CSPC Pharmaceutical Group Co., Ltd., HealthCare Royalty Partners, Infinity Pharmaceuticals, Inc., Sanofi, Yakult Honsha Co. Ltd."
18679,3093,27614,3547,Copiktra,duvelisib,"Verastem, Inc.",VSTM,Massachusetts,United States,North America,98074422,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,p110 delta/PIK3CD^ p110 gamma/PIK3CG^ PI3K/AKT pathway,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,09/24/18,,,,,02/05/18,09/08/14,06/03/13,,,09/08/14,06/03/13,08/09/11,N/A,,N/A,N/A,$     1.7,$     4.7,N/A,N/A,$     1.7,$     4.7,Q2 2019,"CSPC Pharmaceutical Group Co., Ltd., HealthCare Royalty Partners, Infinity Pharmaceuticals, Inc., Sanofi, Yakult Honsha Co. Ltd."
2606,244,4426,180,Coreg CR,carvedilol phosphate controlled-release,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/20/06,,,,,12/21/05,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Avadel Pharmaceuticals plc
2606,264,4899,180,Coreg CR,carvedilol phosphate controlled-release,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/20/06,,,,,12/21/05,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Avadel Pharmaceuticals plc
18001,2976,23514,870,Corifact,,CSL Limited,CSL:AU,,Australia,Oceania,,Hematology,Factor Augmentation,Factor XIII Deficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrin (Coagulation Factor Ia),Biologic,No,Intravenous (IV),N,N,Y,,N,N,,,,02/15/11,,,,,08/18/10,,,,,,05/26/09,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
17290,264,22447,30,Corlanor,ivabradine hydrochloride,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Potassium channels,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,09/01/2019 - 03/31/2020,04/15/15,02/09/12,,,,07/29/14,,,,,12/13/11,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Les Laboratoires Servier, Ono Pharmaceutical Company, Ltd."
14715,155,18645,289,Cosentyx,secukinumab,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-17 (Interleukin 17),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,01/21/15,01/15/15,12/26/14,,,10/31/13,07/19/11,,,,07/19/11,04/29/08,,N/A,,$   765.0,"$  1,275.0","$  1,674.0","$  1,008.0","$  1,128.0","$  2,071.0","$  2,837.0","$  1,649.0",Q2 2019,N/A
14715,336,18646,289,Cosentyx,secukinumab,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-17 (Interleukin 17),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,01/15/16,11/23/15,12/26/14,,,03/18/15,09/23/11,,,,09/23/11,12/16/08,,N/A,,$   765.0,"$  1,275.0","$  1,674.0","$  1,008.0","$  1,128.0","$  2,071.0","$  2,837.0","$  1,649.0",Q2 2019,N/A
14715,252,18647,289,Cosentyx,secukinumab,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-17 (Interleukin 17),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,01/01/2019 - 09/30/2019,01/15/16,11/19/15,,,,03/23/15,10/20/11,,,,10/20/11,12/16/08,,N/A,,$   765.0,"$  1,275.0","$  1,674.0","$  1,008.0","$  1,128.0","$  2,071.0","$  2,837.0","$  1,649.0",Q2 2019,N/A
5747,221,28350,149,Cotellic,cobimetinib,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Mitogen-activated ERK kinase (MEK, MAPKK, MAP2K)",New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,11/10/15,11/20/15,,,,12/11/14,09/29/12,,04/14/11,,09/28/12,,04/14/11,65%,,$    14.3,$    16.5,$    26.4,$     6.0,$    45.8,$    62.1,$   107.6,$    30.1,Q2 2019,"Exelixis, Inc."
23866,246,32895,4638,Cotempla XR-ODT,methylphenidate,"Neos Therapeutics, Inc.",NEOS,Texas,United States,North America,50746479,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/19/17,,,,,12/20/16,08/08/13,,,,08/08/13,,,N/A,,N/A,N/A,$    18.9,$     5.8,N/A,N/A,$    18.9,$     5.8,Q1 2019,N/A
1905,149,3079,254,Cozaar,losartan,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/19/02,,,,,,,,,,,,,N/A,,N/A,N/A,$    22.0,$    10.0,N/A,N/A,$   453.0,$   212.0,Q2 2019,E. I. du Pont de Nemours and Company
18251,705,23875,5,Creon,pancrelipase,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Gastroenterology (non inflammatory bowel disease),Other,Exocrine Pancreatic Insufficiency,Y,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide","Protein, fat, and/or carbohydrate absorption",Biologic,No,Oral (PO),N,N,N,,N,N,,,,04/30/09,,04/22/11,,,,,,,,,,,N/A,,$   730.0,$   831.0,$   928.0,$   484.0,N/A,$   831.0,$   928.0,$   484.0,Q2 2019,"Abbott Laboratories, Eisai Co., Ltd., Mylan N.V."
1971,3116,3179,814,Cresemba,isavuconazonium sulfate,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,Y,N,N,Y,,,,03/06/15,10/15/15,,,,,12/07/06,01/04/05,,,12/07/06,05/02/06,02/24/04,N/A,,N/A,N/A,N/A,N/A,$    54.0,$    87.0,$   122.4,$    30.0,Q1 2019,"Asahi Kasei Corporation, Avir Pharma, Inc., Basilea Pharmaceutica AG, Biotoscana International, Hikma Pharmaceuticals plc, Pfizer Inc."
1784,506,2845,45,Crestor,rosuvastatin calcium,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,HMG CoA Reductase (HMGR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,08/12/03,11/07/02,01/19/05,,,06/27/01,,,,,,,,85%,3461.4,"$  1,223.0",$   373.0,$   170.0,$    54.0,"$  3,401.0","$  2,365.0","$  1,576.5",$   705.1,Q2 2019,"AbbVie Inc., Shionogi &amp; Co. Ltd., Simcere Pharmaceutical Group"
23862,192,32889,534,CroFab,,BTG plc,BTG:LN,,United Kingdom,Europe,,Neurology,General,Neurology - Other,N,Approved,Approved,100% (Same As Avg.),Protein,Snake venom,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,10/02/00,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$   130.7,N/A,N/A,Q4 2017,N/A
19515,3112,25741,3444,Crysvita,burosumab-twza,Ultragenyx Pharmaceutical Inc.,RARE,California,United States,North America,3093449498,Metabolic,Inborn Errors Of Metabolism,X-Linked Hypophosphatemia (XLH),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Fibroblast Growth Factor (FGF),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,Y,Y,N,N,,,09/01/2019 - 09/30/2019,04/17/18,02/19/18,,,,08/24/17,12/03/15,04/27/11,01/27/09,,12/03/15,04/27/11,01/27/09,50%,,N/A,N/A,$     0.7,$     1.7,N/A,N/A,$    73.4,$   123.5,Q2 2019,"Kyowa Hakko Kirin Co., Ltd."
519,440,1475,254,Cubicin,daptomycin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cell Membrane,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,09/12/03,01/19/06,07/01/11,,,12/20/02,03/01/99,,,,03/01/99,,,85%,397.7,$   905.0,$   188.0,$   191.0,$    64.0,"$  1,088.0",$   382.0,$   367.0,$   155.0,Q2 2019,"AstraZeneca PLC, DRI Capital Inc., Eli Lilly &amp; Company, Novartis AG, Royalty Pharma AG"
519,3110,2380,254,Cubicin,daptomycin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Septicemia or Bacteremia (Antibacterial, including Endocarditis)",N,Approved,Approved,100% (Same As Avg.),Small Molecule,Cell Membrane,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,05/25/06,09/05/07,,,,09/26/05,03/07/02,03/01/99,,,03/07/02,03/01/99,,85%,197.3,$   905.0,$   188.0,$   191.0,$    64.0,"$  1,088.0",$   382.0,$   367.0,$   155.0,Q2 2019,"AstraZeneca PLC, DRI Capital Inc., Eli Lilly &amp; Company, Novartis AG, Royalty Pharma AG"
40475,423,56675,2684,Cutaquig,,Octapharma AG,,,Switzerland,Europe,,Autoimmune/immunology,Other,Primary Immunodeficiencies,N,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/12/18,,,,,,03/31/14,,,,03/31/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
17073,192,22149,256,Cuvposa,glycopyrrolate,Merz Pharmaceuticals GmbH,,,Germany,Europe,,Neurology,General,Neurology - Other,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,Non-NME,No,Oral (PO),N,N,Y,,N,N,,,,07/28/10,,,,,09/26/09,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Medexus Pharmaceuticals, Inc., Shionogi &amp; Co. Ltd."
16288,137,20978,470,Cycloset,bromocriptine mesylate,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/05/09,,,,,08/22/97,,,,,11/20/98,,,N/A,,N/A,$     9.0,$    14.0,$     3.0,N/A,$     9.0,$    14.0,$     3.0,Q1 2019,"S2 Therapeutics, Inc., VeroScience, LLC"
22429,154,30433,70,Cyltezo,adalimumab-adbm,Boehringer Ingelheim GmbH,,,Germany,Europe,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/25/17,11/10/17,,,,10/27/16,08/06/14,,,,08/06/14,,01/06/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22429,155,42294,70,Cyltezo,adalimumab-adbm,Boehringer Ingelheim GmbH,,,Germany,Europe,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/25/17,11/10/17,,,,10/27/16,,,,,07/31/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22429,156,42810,70,Cyltezo,adalimumab-adbm,Boehringer Ingelheim GmbH,,,Germany,Europe,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/25/17,11/10/17,,,,10/27/16,,,,,08/15/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22429,365,49882,70,Cyltezo,adalimumab-adbm,Boehringer Ingelheim GmbH,,,Germany,Europe,,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/25/17,11/10/17,,,,10/27/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22429,336,49883,70,Cyltezo,adalimumab-adbm,Boehringer Ingelheim GmbH,,,Germany,Europe,,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/25/17,11/10/17,,,,10/27/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22429,252,49884,70,Cyltezo,adalimumab-adbm,Boehringer Ingelheim GmbH,,,Germany,Europe,,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/25/17,11/10/17,,,,10/27/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22429,321,49885,70,Cyltezo,adalimumab-adbm,Boehringer Ingelheim GmbH,,,Germany,Europe,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/25/17,11/10/17,,,,10/27/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1669,167,2684,136,Cymbalta,duloxetine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/03/04,12/17/04,01/20/10,,,11/12/01,,,,,,,,100%,,$   269.3,$   114.9,$    54.4,$    10.3,$   930.5,$   757.0,$   924.1,$   214.1,Q1 2019,Shionogi &amp; Co. Ltd.
1669,588,2716,136,Cymbalta,duloxetine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Neurology,Pain,Fibromyalgia,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/13/08,,05/26/15,,,08/14/07,,,,,10/18/04,,,100%,,$   269.3,$   114.9,$    54.4,$    10.3,$   930.5,$   757.0,$   924.1,$   214.1,Q1 2019,Shionogi &amp; Co. Ltd.
1669,671,3304,136,Cymbalta,duloxetine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Neurology,Pain,Diabetic Peripheral Neuropathy (DPN),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/03/04,07/04/05,02/22/12,,,03/03/04,,,,,,,,100%,,$   269.3,$   114.9,$    54.4,$    10.3,$   930.5,$   757.0,$   924.1,$   214.1,Q1 2019,Shionogi &amp; Co. Ltd.
1669,169,3565,136,Cymbalta,duloxetine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Anxiety,Generalized Anxiety Disorder (GAD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/23/07,08/22/08,,,,04/27/06,,,,,02/15/06,,,100%,,$   269.3,$   114.9,$    54.4,$    10.3,$   930.5,$   757.0,$   924.1,$   214.1,Q1 2019,Shionogi &amp; Co. Ltd.
1669,3629,11944,136,Cymbalta,duloxetine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Neurology,Pain,Chronic Low Back Pain (CLBP),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/04/10,,,,,06/03/09,,,,,04/16/07,,,100%,,$   269.3,$   114.9,$    54.4,$    10.3,$   930.5,$   757.0,$   924.1,$   214.1,Q1 2019,Shionogi &amp; Co. Ltd.
1858,297,12518,136,Cyramza,ramucirumab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF Receptor (VEGFR),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,06/28/2019 - 09/02/2019,,05/10/19,,06/18/19,,,07/24/18,08/26/10,02/22/08,,,08/26/10,02/22/08,01/08/08,95%,,$   270.1,$   278.8,$   291.5,$   164.9,$   614.1,$   758.3,$   821.4,$   440.1,Q2 2019,"AstraZeneca PLC, Les Laboratoires Servier"
1858,213,12519,136,Cyramza,ramucirumab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Colorectal Cancer (CRC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF Receptor (VEGFR),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,04/24/15,01/28/16,05/23/16,,,02/18/15,12/14/10,07/01/09,,,12/14/10,07/01/09,01/08/08,95%,,$   270.1,$   278.8,$   291.5,$   164.9,$   614.1,$   758.3,$   821.4,$   440.1,Q2 2019,"AstraZeneca PLC, Les Laboratoires Servier"
1858,211,12521,136,Cyramza,ramucirumab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF Receptor (VEGFR),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,12/12/14,01/28/16,06/20/16,,,06/26/14,12/14/10,10/27/08,,,12/14/10,10/27/08,01/08/08,95%,,$   270.1,$   278.8,$   291.5,$   164.9,$   614.1,$   758.3,$   821.4,$   440.1,Q2 2019,"AstraZeneca PLC, Les Laboratoires Servier"
1858,223,15360,136,Cyramza,ramucirumab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Gastric Cancer,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF Receptor (VEGFR),Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,04/21/14,12/19/14,03/26/15,,,04/24/13,07/27/09,,,,07/27/09,,07/24/08,95%,,$   270.1,$   278.8,$   291.5,$   164.9,$   614.1,$   758.3,$   821.4,$   440.1,Q2 2019,"AstraZeneca PLC, Les Laboratoires Servier"
8427,1560,10470,357,Cystaran,cysteamine hydrochloride,Alfasigma S.p.A.,,,Italy,Europe,,Metabolic,Inborn Errors Of Metabolism,Cystinosis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Lysosomal Cysteine Transporter,Non-NME,No,Topical,N,N,Y,,N,N,,,,10/02/12,,,,,03/04/10,,,,,02/02/01,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
814,206,1922,636,Dacogen,decitabine,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Oncology,Hematologic,Myelodysplastic Syndrome (MDS),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA Methyltransferase (DNMT),New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,N,N,N,,,,05/02/06,,,,,04/22/04,,,,,03/17/03,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2013,"Eisai Co., Ltd., Johnson &amp; Johnson"
13008,176,16396,73,Daklinza,daclatasvir,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Non-structural 5A protein (NS5A),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,07/24/15,08/22/14,07/07/14,,,04/07/14,09/16/11,09/04/08,,,09/16/11,09/04/08,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
1792,73,2856,45,Daliresp,roflumilast,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 4 (PDE4),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,01/01/2015 - 01/01/2015,02/28/11,07/05/10,,,,07/20/09,,,,,10/28/04,,,70%,201.6,$    91.0,$   167.0,$   155.0,$    89.0,N/A,$   198.0,$   189.0,$   104.0,Q2 2019,Allergan plc
621,440,2529,395,Dalvance,dalbavancin hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Cell wall synthesis,New Molecular Entity (NME),No,Intravenous (IV),Y,Y,N,N,N,Y,,,,05/23/14,02/19/15,,,,09/26/13,12/17/02,,,,05/11/04,,,N/A,,$    39.3,$    53.9,$    56.1,$    32.3,N/A,$    55.1,$    58.4,$    34.5,Q2 2019,"ACRAF SpA (Gruppo Angelini), Cipher Pharmaceuticals Inc., Correvio Pharma Corp., RaQualia Pharma Inc., Tzamal Medical Ltd."
2340,3197,3942,51,Daptacel,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Diphtheria, pertussis, and tetanus (DT, Td, DTaP and Tdap) Vaccines",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,05/15/02,,,,,,,,,,,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
38008,440,53050,266,Daptomycin TPM,daptomycin,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cell Membrane,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,06/06/18,,,,,,,,,,02/16/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Phosphagenics Limited
9620,207,11984,223,Darzalex,daratumumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Oncology,Hematologic,Multiple Myeloma (MM),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 38 (CD38),Biologic,No,Intravenous (IV),Y,N,Y,Y,N,N,,,,11/16/15,05/23/16,09/27/17,,,07/09/15,03/14/14,12/07/07,,,03/05/14,12/07/07,,N/A,,$   471.0,$   884.0,"$  1,203.0",$   721.0,$   572.0,"$  1,242.0","$  2,025.0","$  1,403.0",Q2 2019,Genmab A/S
21214,3186,28558,28,DaTscan,ioflupane I 123,General Electric,GE,Massachusetts,United States,North America,81327375250,Neurology,Neurodegenerative,Parkinson's Disease - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Transporter (DAT),New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,,N,N,,,,01/14/11,07/27/00,,,,03/09/09,,,,,07/27/00,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
19013,97,25027,312,Daurismo,glasdegib maleate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Hedgehog Signaling Pathway,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,11/21/18,,,,,06/27/18,04/13/18,02/28/14,02/16/10,,04/13/18,02/28/14,02/16/10,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2402,246,4066,2672,Daytrana,methylphenidate,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Topical,N,N,N,,N,N,,,,04/06/06,,,,,06/27/02,,,,,04/28/03,,,N/A,,N/A,N/A,$    23.0,$     6.0,N/A,N/A,$    23.0,$     6.0,Q1 2019,N/A
2300,3197,3852,51,Decavac,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Diphtheria, pertussis, and tetanus (DT, Td, DTaP and Tdap) Vaccines",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Clostridium tetani^ Corynebacterium diptheriae^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,03/24/04,,,,,,,,,,,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3005,725,5128,508,Defitelio,defibrotide sodium,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Hematology,Other,Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease / VOD),Y,Approved,Approved,100% (Same As Avg.),Other Nucleic Acid,Eicosanoids,New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,N,N,N,,,,03/30/16,10/18/13,06/18/19,,,07/31/15,01/20/06,,,,01/20/06,05/21/03,,N/A,,$     9.7,$    11.6,N/A,N/A,$   108.9,$   133.3,$   149.4,$    41.5,Q1 2019,"Alfasigma S.p.A., Bausch Health Companies Inc., Biologix FZCo, Crinos S.p.A., Gen Ilac A.C., Medison Pharma Ltd., Nippon Shinyaku Co., Ltd., Swedish Orphan Biovitrum"
38930,78,54426,254,Delstrigo,"doravirine, lamivudine, tenofovir disoproxil fumarate","Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/30/18,11/22/18,,,,10/23/17,06/05/15,,,,06/05/15,03/26/15,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
21826,321,29483,395,Delzicol,mesalamine,Allergan plc,AGN,,Ireland,Europe,53945515162,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/01/13,,,,,08/01/12,,,,,,,,N/A,,$   360.8,$   195.5,$   130.8,N/A,$   414.5,$   245.7,$   189.5,N/A,Q4 2018,N/A
767,3490,897,51,Dengvaxia,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,Antiviral,Dengue Fever - Vaccines and Treatments,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Dengue virus^ Immune system,Vaccine,No,Subcutaneous (SQ),Y,N,N,N,N,N,,,,05/01/19,12/12/18,,,,12/31/16,11/04/10,,,,11/04/10,03/10/06,11/25/02,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    69.7,N/A,Q3 2018,N/A
35954,239,49981,312,Depo-subQ Provera 104,medroxyprogesterone acetate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Contraception,Contraception,N,Approved,Approved,100% (Same As Avg.),Steroid,Progesterone Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/17/04,,,,,06/30/03,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
35954,349,49982,312,Depo-subQ Provera 104,medroxyprogesterone acetate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Obstetrics/Gynecology,Gynecology,Endometriosis,N,Approved,Approved,100% (Same As Avg.),Steroid,Progesterone Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,03/29/05,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
17567,3130,22886,851,DepoDur,morphine sulfate,Chiesi Farmaceutici S.p.A.,,,Italy,Europe,,Neurology,Pain,Postsurgical Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule with Liposomal Delivery System,Opioid receptors,Non-NME,No,Percutaneous Catheter/Injection,N,N,N,,N,N,,,,05/18/04,04/28/06,,,,07/18/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Flynn Pharma Limited, Pacira BioSciences, Inc."
25406,78,35363,179,Descovy,emtricitabine/tenofovir alafenamide,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,04/04/16,04/21/16,12/09/16,,,04/07/15,05/12/14,,,,01/30/13,,,N/A,,$   226.0,$   958.0,"$  1,217.0",$   479.0,$   298.0,"$  1,218.0","$  1,581.0",$   700.0,Q2 2019,N/A
21225,653,28575,582,Desmopressin Acetate Tablets,desmopressin acetate,Ferring Pharmaceuticals,,,Switzerland,Europe,,Urology,Other,Urinary Incontinence,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Vasopressin receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/08/08,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
21225,3315,30470,582,Desmopressin Acetate Tablets,desmopressin acetate,Ferring Pharmaceuticals,,,Switzerland,Europe,,Endocrine,Other,Central Diabetes Insipidus (CDI),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Vasopressin receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/08/08,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
23741,385,54001,589,Desonate,desonide gel 0.05%,LEO Pharma A/S,,,Denmark,Europe,,Allergy,General,Atopic Dermatitis (Eczema),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,10/20/06,,,,,12/19/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22013,167,29778,4146,Desvenlafaxine Base Extended Release,,Alembic Pharmaceuticals Limited,ALPM:IN,,India,Asia,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/04/13,,,,,02/29/12,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Sun Pharmaceutical Industries Ltd.
2278,543,3820,312,Detrol LA,tolterodine tartrate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Urology,Other,Overactive Bladder (OAB),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,12/22/00,,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,UCB SA
2401,644,4065,826,Dexilant,dexlansoprazole,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Gastroenterology (non inflammatory bowel disease),General,Gastroesophageal Reflux Disease (GERD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Proton pump,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/30/09,09/06/13,,,,01/03/08,12/01/05,,,,08/30/05,,,N/A,,$   436.9,$   443.2,$   452.2,N/A,$   551.1,$   588.8,$   628.3,N/A,Q4 2018,AbbVie Inc.
27486,644,38491,826,Dexilant SoluTab,dexlansoprazole,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Gastroenterology (non inflammatory bowel disease),General,Gastroesophageal Reflux Disease (GERD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Proton pump,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/26/16,,,,,03/26/15,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
21791,554,29431,3910,Dextenza,,"Ocular Therapeutix, Inc.",OCUL,Massachusetts,United States,North America,185340127,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR),Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,11/30/18,,,,,09/24/15,01/09/14,02/25/13,,,01/09/14,08/15/12,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
20300,554,27040,2749,Dexycu,dexamethasone,"EyePoint Pharmaceuticals, Inc.",EYPT,Massachusetts,United States,North America,,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,02/09/18,,,,,04/12/17,01/05/10,,,,01/05/10,,,N/A,,N/A,N/A,N/A,$     0.7,N/A,N/A,N/A,$     0.7,Q1 2019,N/A
20919,3447,28030,3912,Diacomit,stiripentol,Laboratoires Biocodex,,,France,Europe,,Neurology,Seizure Disorders (Epilepsy),Dravet Syndrome (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450^ GABA-A Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,08/20/18,01/04/07,09/28/12,,,12/20/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Meiji Seika Pharma Co., Ltd"
22272,594,30160,4232,Diclegis,doxylamine succinate/pyridoxine hydrochloride,Duchesnay Inc.,,Quebec,Canada,North America,,Not Specified,Other,Emesis,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/08/13,07/06/18,,,,12/17/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Alliance Pharma plc
2468,487,4185,254,Dificid,fidaxomicin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,RNA polymerase,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,05/27/11,12/05/11,07/02/18,,,09/21/10,,,,,02/07/06,12/19/05,,95%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q3 2014,"Astellas Pharma, Inc., AstraZeneca PLC, Endo International plc, OBI Pharma, Inc., Specialised Therapeutics Australia Pty, Ltd."
19195,726,25281,534,DigiFab,digoxin,BTG plc,BTG:LN,,United Kingdom,Europe,,Not Specified,Other,Drug Toxicity,Y,Approved,Approved,100% (Same As Avg.),Polyclonal Antibody,Digoxin,Biologic,No,,N,N,N,,N,N,,,,08/31/01,02/04/10,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    67.4,N/A,N/A,Q4 2017,"Beacon Pharmaceuticals, Ltd., Proreo Pharma Innovation AG"
2256,264,3794,289,Diovan,valsartan,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/14/02,,,,,04/30/01,,,,,,,,N/A,,$   147.0,$    87.0,$    84.0,$    45.0,"$  1,073.0",$   957.0,"$  1,023.0",$   544.0,Q2 2019,UCB SA
2256,181,3990,289,Diovan,valsartan,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Cardiovascular,General,Cardiovascular Disease,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/03/05,,,,,12/17/03,,,,,,,,N/A,,$   147.0,$    87.0,$    84.0,$    45.0,"$  1,073.0",$   957.0,"$  1,023.0",$   544.0,Q2 2019,UCB SA
35833,240,49803,4104,Divigel,estradiol,Osmotica Pharmaceutical Corp,OSMT,North Carolina,United States,North America,,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Topical,N,N,N,N,N,N,,,,06/04/07,,,,,05/01/06,,,,,,,,N/A,,N/A,N/A,$    23.4,$     5.5,N/A,N/A,$    23.4,$     5.5,Q1 2019,N/A
18287,214,23933,3285,Docefrez,docetaxel,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,05/03/11,05/10/10,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
18287,211,23934,3285,Docefrez,docetaxel,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,05/03/11,05/10/10,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
18287,215,23935,3285,Docefrez,docetaxel,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Prostate Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,05/03/11,05/10/10,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
27208,214,38058,2403,Docetaxel Injection,,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,12/22/15,,,,,02/26/15,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Teikoku Seiyaku
27208,211,38059,2403,Docetaxel Injection,,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,12/22/15,,,,,02/26/15,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Teikoku Seiyaku
27208,215,38060,2403,Docetaxel Injection,,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Solid,Prostate Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,12/22/15,,,,,02/26/15,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Teikoku Seiyaku
27208,223,38061,2403,Docetaxel Injection,,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Solid,Gastric Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,12/22/15,,,,,02/26/15,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Teikoku Seiyaku
27208,230,38062,2403,Docetaxel Injection,,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Solid,Head and Neck Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,12/22/15,,,,,02/26/15,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Teikoku Seiyaku
37409,78,52181,266,Dolutegravir/Emtricitabine/Tenofovir (Mylan),"Dolutegravir, Emtricitabine and Tenofovir Alafenamide",Mylan N.V.,MYL,Pennsylvania,United States,North America,,Infectious disease,Antiviral,HIV / AIDS,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ HIV Integrase^ Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/09/18,,,,,08/11/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
8373,188,10400,5899,Doptelet,avatrombopag maleate,"Dova Pharmaceuticals, Inc.",DOVA,North Carolina,United States,North America,455496182,Hematology,Marrow Or Peripheral Blood Stimulator,Thrombocytopenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Thrombopoietin Receptor (TPO-R, c-Mpl, CD110)",New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/21/18,06/20/19,,,,09/22/17,10/29/13,10/31/09,,,10/29/13,06/04/09,12/11/06,N/A,,N/A,N/A,$     7.7,$     4.0,N/A,N/A,$     7.7,$     4.0,Q1 2019,"Bausch Health Companies Inc., Eisai Co., Ltd., Shanghai Fosun Pharmaceutical Group Co., Ltd."
8373,649,10414,5899,Doptelet,avatrombopag maleate,"Dova Pharmaceuticals, Inc.",DOVA,North Carolina,United States,North America,455496182,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Thrombopoietin Receptor (TPO-R, c-Mpl, CD110)",New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,06/26/19,,,,,08/30/18,01/24/12,,,,01/24/12,02/27/07,12/11/06,N/A,,N/A,N/A,$     7.7,$     4.0,N/A,N/A,$     7.7,$     4.0,Q1 2019,"Bausch Health Companies Inc., Eisai Co., Ltd., Shanghai Fosun Pharmaceutical Group Co., Ltd."
2169,534,3603,223,Doribax,doripenem,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,10/12/07,07/25/08,07/25/05,,,12/13/06,12/23/03,,,,12/23/03,09/03/03,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Shionogi &amp; Co. Ltd.
2169,536,3604,223,Doribax,doripenem,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Intra-Abdominal Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,10/12/07,07/25/08,07/25/05,,,12/13/06,03/30/04,,,,03/30/04,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Shionogi &amp; Co. Ltd.
21864,3242,29537,4108,Dotarem,Gadoterate meglumine injection,Guerbet Group,GBT:FP,,France,Europe,,Neurology,General,Neurology - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,03/20/13,,,,,09/20/12,,,,,11/01/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
30867,78,42680,180,Dovato,dolutegravir and lamivudine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV Gag protein^ HIV-1 protease (HIV PR),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/08/19,07/03/19,,,,10/18/18,08/16/16,,06/07/16,,08/16/16,,06/07/16,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Shionogi &amp; Co. Ltd.
1859,207,4675,223,Doxil,doxorubicin hydrochloride,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Oncology,Hematologic,Multiple Myeloma (MM),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule with Liposomal Delivery System,DNA^ DNA synthesis^ Topoisomerase II (DNA gyrase),Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,01/01/2010 - 01/01/2010,05/17/07,12/31/07,,,,11/22/06,,,,,11/01/04,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2012,N/A
18738,3134,24624,2969,Dsuvia,sufentanil,"AcelRx Pharmaceuticals, Inc.",ACRX,California,United States,North America,140529507,Neurology,Pain,Moderate to Severe Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,11/02/18,06/27/18,,,,12/12/16,03/16/15,05/31/11,,,03/16/15,05/31/11,,N/A,,N/A,N/A,$     0.8,$     0.1,N/A,N/A,$     0.8,$     0.1,Q2 2019,N/A
22051,603,29840,180,Duac,clindamycin and benzoyl peroxide,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Dermatology,General,Acne,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacteria-miscellaneous^ Bacterial ribosome^ Protein synthesis,Non-NME,No,Topical,N,N,N,N,N,N,,,,08/26/02,,03/26/15,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2013,N/A
16240,73,20901,3266,Duaklir Pressair,aclidinium and formoterol,Circassia Ltd.,CIR:LN,,United Kingdom,Europe,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Muscarinic acetylcholine receptor,Non-NME,No,Inhaled,N,N,N,N,N,N,,,10/01/2019 - 03/31/2020,03/29/19,11/24/14,,,,06/01/18,09/27/11,,,,09/26/11,02/28/08,,95%,1393.8,N/A,N/A,N/A,N/A,$    27.0,$    79.0,$    95.0,$    37.0,Q2 2019,"Allergan plc, AstraZeneca PLC, Daewoong Pharmaceutical Company Ltd., Kyorin Pharmaceutical Co., Ltd., The Menarini Group"
105,240,78,312,Duavee,bazedoxifene and estrogens (conjugated),Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/03/13,12/16/14,,,,10/03/12,06/21/01,,,,06/21/01,,,95%,796.4,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Ligand Pharmaceuticals, Inc., Royalty Pharma AG"
105,242,31506,312,Duavee,bazedoxifene and estrogens (conjugated),Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,N,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/03/13,,,,,,,,,,09/25/08,,,95%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Ligand Pharmaceuticals, Inc., Royalty Pharma AG"
2774,137,4722,826,Duetact,glimepiride and pioglitazone,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,PPAR/Sulonylurea Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/28/06,01/08/07,01/21/11,,,06/29/05,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
16970,1929,22006,2878,Duexis,ibuprofen/famotidine,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Neurology,Pain,Arthritis Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)^ Histamine H2 Receptor (HRH2)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/23/11,03/07/13,,,,05/26/10,03/27/07,,,,01/08/07,,,N/A,,N/A,N/A,$   114.6,$    29.5,N/A,N/A,$   114.6,$    29.5,Q1 2019,"Grünenthal GmbH, Mallinckrodt plc"
2390,72,4042,254,Dulera,formoterol fumarate; mometasone furoate,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Steroid,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,,N,N,,,01/01/2015 - 01/01/2015,06/22/10,,,,,05/22/09,,,,,09/26/06,01/01/06,,75%,290.9,$   413.0,$   260.0,$   186.0,N/A,$   436.0,$   287.0,$   214.0,N/A,Q4 2018,"Astellas Pharma, Inc., Novartis AG"
19870,155,26345,470,Duobrii,halobetasol propionate/tazarotene,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR)^ Retinoic acid receptor (RARs),Non-NME,No,Topical,N,N,N,N,N,N,,,,04/25/19,,,,,08/18/17,04/29/15,02/29/12,11/05/10,,04/29/15,02/29/12,11/05/10,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2436,73,4127,255,DuoNeb,albuterol sulfate/ipratropium bromide,Merck KGaA,MKGAY,,Germany,Europe,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Muscarinic acetylcholine receptor,Non-NME,No,Inhaled,N,N,N,,N,N,,,,03/23/01,,,,,,,,,,,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2006,N/A
18418,194,24128,5,Duopa,levodopa/carbidopa,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Aromatic L-amino acid decarboxylase (AADC)^ Dopamine Receptor - Unspecified,Non-NME,No,Surgical Implantation,Y,N,Y,N,N,N,,,,01/09/15,01/21/04,,,,05/28/13,,,,,01/18/00,,,N/A,,$    37.0,$    61.0,$    80.0,$    46.0,$   293.0,$   355.0,$   430.0,$   226.0,Q2 2019,N/A
16792,385,22034,51,Dupixent,dupilumab,Sanofi,SNY,,France,Europe,1.05588E+11,Allergy,General,Atopic Dermatitis (Eczema),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-4 Receptor (IL-4R),Biologic,No,Subcutaneous (SQ),N,N,N,Y,N,N,,,,03/28/17,09/27/17,01/22/18,,,07/29/16,02/12/14,01/05/12,,,02/12/14,01/05/12,04/29/10,50%,,N/A,$   259.1,$   730.6,$   755.8,N/A,$   262.7,$   872.2,$   931.0,Q2 2019,"Regeneron Pharmaceuticals, Inc."
16792,72,23510,51,Dupixent,dupilumab,Sanofi,SNY,,France,Europe,1.05588E+11,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-4 Receptor (IL-4R),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,05/06/2019 - 05/10/2019,,10/19/18,05/07/19,03/26/19,,,12/20/17,04/30/15,03/09/11,,,06/10/14,03/09/11,04/29/10,50%,,N/A,$   259.1,$   730.6,$   755.8,N/A,$   262.7,$   872.2,$   931.0,Q2 2019,"Regeneron Pharmaceuticals, Inc."
16792,3159,31027,51,Dupixent,dupilumab,Sanofi,SNY,,France,Europe,1.05588E+11,Allergy,General,Nasal Polyposis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-4 Receptor (IL-4R),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,06/26/19,,,,,12/24/18,11/30/16,,,,11/30/16,08/09/13,,50%,,N/A,$   259.1,$   730.6,$   755.8,N/A,$   262.7,$   872.2,$   931.0,Q2 2019,"Regeneron Pharmaceuticals, Inc."
11194,554,14048,289,Durezol,difluprednate ophthalmic emulsion,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,06/23/08,,,,,12/26/07,01/22/07,,,,01/22/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Senju Pharmaceutical Co., Ltd."
11194,307,14051,289,Durezol,difluprednate ophthalmic emulsion,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Uveitis,Uveitis (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,06/13/12,,,,,12/16/11,,,,,05/09/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Senju Pharmaceutical Co., Ltd."
21320,181,28720,6255,Durlaza,,"Espero Biopharma, Inc.",,Florida,United States,North America,,Cardiovascular,General,Cardiovascular Disease,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/08/15,,,,,09/05/14,,,,,10/29/12,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
19890,244,26375,45,Dutoprol,metoprolol succinate/hydrochlorothiazide,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/28/06,,,,,10/28/05,,,,,,,,N/A,,N/A,N/A,$    39.0,$    26.0,N/A,N/A,$   712.0,$   393.0,Q2 2019,N/A
24032,78,33191,254,Dutrebis,lamivudine and raltegravir,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ HIV Integrase^ Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/06/15,03/26/15,,,,04/08/14,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
23629,539,32517,916,Duzallo,lesinurad/allopurinol,"Ironwood Pharmaceuticals, Inc.",IRWD,Massachusetts,United States,North America,1322377638,Autoimmune/immunology,Arthritis,Gout,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"URAT1 (urate trans-porter 1, SLC22A12/Solute carrier family 22, member 12)^ Xanthine oxidase",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/18/17,08/28/18,,,,10/20/16,,,12/02/15,,12/31/13,,12/02/15,N/A,,N/A,N/A,$     3.4,N/A,N/A,N/A,$     3.4,N/A,Q4 2018,"AstraZeneca PLC, Grünenthal GmbH"
26113,246,36399,579,Dyanavel XR,,Tris Pharma,,New Jersey,United States,North America,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/19/15,,,,,12/18/14,,,,,03/10/14,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
8081,3134,9968,312,Dyloject,diclofenac sodium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Moderate to Severe Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,12/30/14,,,,,12/02/09,,,,,07/12/05,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Celgene Corporation, Therabel Pharma N.V."
18131,236,23700,266,Dymista,azelastine hydrochloride and fluticasone propionate,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Histamine H1 Receptor (HRH1),New Molecular Entity (NME),No,Intranasal,N,N,N,,N,N,,,,05/01/12,01/24/13,,,,04/04/11,,,,,03/02/09,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q1 2015,N/A
11833,257,14908,587,Dysport,abobotulinumtoxinA,Galderma S.A.,,,Switzerland,Europe,,Neurology,"movement disorders, all",Cervical Dystonia,Y,Approved,Approved,100% (Same As Avg.),Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Subcutaneous (SQ), Intradermal",N,N,Y,,N,N,,,,04/29/09,,,,,12/06/07,,,,,02/25/05,,,N/A,,N/A,N/A,N/A,N/A,$   315.0,$   376.6,$   429.6,$   127.1,Q1 2019,"Ipsen SA, Saol Therapeutics"
11833,1508,14970,587,Dysport,abobotulinumtoxinA,Galderma S.A.,,,Switzerland,Europe,,Dermatology,General,Wrinkles,Y,Approved,Approved,100% (Same As Avg.),Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Subcutaneous (SQ), Intradermal",N,N,N,,N,N,,,,04/29/09,02/02/09,,,,12/05/07,,,,,03/13/06,,,N/A,,N/A,N/A,N/A,N/A,$   315.0,$   376.6,$   429.6,$   127.1,Q1 2019,"Ipsen SA, Saol Therapeutics"
11833,701,21262,587,Dysport,abobotulinumtoxinA,Galderma S.A.,,,Switzerland,Europe,,Neurology,"movement disorders, all",Neuromuscular Spasm and Spasticity,N,Approved,Approved,100% (Same As Avg.),Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,"Intramuscular (IM), Subcutaneous (SQ), Intradermal",N,N,N,N,N,N,,,,07/15/15,,,,,09/15/14,,,,,03/01/10,04/30/07,,N/A,,N/A,N/A,N/A,N/A,$   315.0,$   376.6,$   429.6,$   127.1,Q1 2019,"Ipsen SA, Saol Therapeutics"
2725,244,4652,4042,Edarbi,azilsartan medoxomil,"Arbor Pharmaceuticals, LLC",,Georgia,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,03/01/2013 - 03/01/2013,02/25/11,12/09/11,,,,04/27/10,07/19/07,07/11/06,,,07/19/07,07/11/06,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Takeda Pharmaceutical Company Ltd
18012,244,23527,4042,Edarbyclor,azilsartan medoxomil and chlorthalidone,"Arbor Pharmaceuticals, LLC",,Georgia,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1)^ Na/Cl transporter - Thiazide-sensitive,Non-NME,No,Oral (PO),N,N,N,N,N,N,,04/01/2014 - 03/31/2015,,12/20/11,,,,,02/23/11,,,,,01/01/09,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Takeda Pharmaceutical Company Ltd
7630,291,9365,266,Edluar,zolpidem tartrate,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Neurology,Insomnia,Insomnia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,03/13/09,06/15/12,,,,05/14/08,,,,,06/26/06,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Bausch Health Companies Inc., Orexo AB"
2131,78,3538,223,Edurant,rilpivirine,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,01/01/2013 - 01/01/2013,05/20/11,11/28/11,,,,07/23/10,,,,,07/21/08,02/25/05,,N/A,,$    52.0,$    58.0,$    58.0,$    24.0,$   573.0,$   714.0,$   816.0,$   421.0,Q2 2019,N/A
1721,635,5607,312,Effexor XR,venlafaxine XR,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Psychiatry,Other,Social Anxiety Disorder (SAD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,02/11/03,,,,,,,,,,,,,N/A,,$    86.0,$    83.0,$    72.0,$    36.0,$   277.0,$   297.0,$   311.0,$   163.0,Q2 2019,N/A
1721,634,5608,312,Effexor XR,venlafaxine XR,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Psychiatry,Anxiety,Panic Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,11/18/05,,,,,09/29/04,,,,,,,,N/A,,$    86.0,$    83.0,$    72.0,$    36.0,$   277.0,$   297.0,$   311.0,$   163.0,Q2 2019,N/A
1684,179,2706,136,Effient,prasugrel hydrochloride,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Adenosine Diphosphate P2Y12 Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,03/01/2014 - 09/30/2014,07/10/09,02/23/09,03/24/14,,,12/24/07,10/25/04,,,,10/25/04,08/29/04,12/20/00,50%,,$   465.6,$   340.0,$    68.0,N/A,$   535.2,$   506.0,$   197.5,N/A,Q4 2018,"Daiichi Sankyo Co., Ltd."
40134,81,56135,289,Egaten,triclabendazole,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Parasite Tubulin^ Protein synthesis,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,02/13/19,,,,,06/14/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1413,583,2480,459,Egrifta,tesamorelin,Theratechnologies Inc.,THERF,,Canada,North America,256232330,Metabolic,Other,HIV Lipodystrophy,Y,Approved,Approved,100% (Same As Avg.),Protein,Growth Hormone Releasing Hormone (GHRH) Receptor,Biologic,No,Subcutaneous (SQ),N,Y,N,,N,N,,,,11/10/10,,,,,05/29/09,06/30/05,,,,07/05/05,05/25/03,,N/A,,N/A,N/A,$    35.4,$     8.5,N/A,N/A,$    35.4,$     8.5,Q1 2019,"Bachem, Merck KGaA"
325,396,611,826,Elaprase,idursulfase,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Metabolic,Inborn Errors Of Metabolism,Mucopolysaccharidosis II (MPS II; Hunter Syndrome),Y,Approved,Approved,100% (Same As Avg.),Protein,Sulfated alpha-L-iduronic acid,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,07/24/06,01/08/07,10/04/07,,,11/28/05,09/15/03,,04/15/01,01/02/01,10/08/03,,,100%,239.1,$   150.7,$   162.5,$   126.5,N/A,$   589.0,$   615.7,$   634.4,$   305.0,Q1 2019,Sanofi
40519,2944,56761,8538,Elcys,cysteine hydrochloride,"Exela Pharma Sciences, LLC",,North Carolina,United States,North America,,Gastroenterology (non inflammatory bowel disease),General,Gastroenterologic Disorders,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutathione (GSH) synthesis^ Reactive Oxygen Species/Free Radicals,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,04/16/19,,,,,07/27/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
40519,2866,56770,8538,Elcys,cysteine hydrochloride,"Exela Pharma Sciences, LLC",,North Carolina,United States,North America,,Gastroenterology (non inflammatory bowel disease),Other,Liver Failure / Cirrhosis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutathione (GSH) synthesis^ Reactive Oxygen Species/Free Radicals,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,04/16/19,,,,,07/27/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
8095,277,9987,312,Elelyso,taliglucerase alfa,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Metabolic,Inborn Errors Of Metabolism,Gaucher's Disease,Y,Approved,Approved,100% (Same As Avg.),Protein,Glucocerebroside (glucosylceramide),Biologic,No,Intravenous (IV),Y,Y,Y,,N,N,,,,05/01/12,07/13/10,,,,10/15/09,08/27/07,,,,08/27/07,07/13/07,,60%,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q2 2013,"Protalix BioTherapeutics, Inc."
25562,3009,35597,3285,Elepsia XR,levetiracetam,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,SV2A synaptic vesicle protein,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/20/18,,,,,05/29/12,,,,,,,06/30/11,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Sun Pharma Advanced Research Company Ltd.
17593,711,22916,395,Elestat (ophthalmic),epinastine,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,General,Allergic Conjunctivitis (Ophthalmology),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1)^ Mast Cell,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,10/16/03,04/28/03,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Boehringer Ingelheim GmbH, Merck &amp; Co., Inc."
1022,240,1148,523,Elestrin,estradiol,"ANI Pharmaceuticals, Inc.",ANIP,Minnesota,United States,North America,853557256,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Transdermal,N,N,N,,N,N,,,,12/15/06,,,,,02/16/06,10/07/03,,,,10/07/03,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Antares Pharma, Inc., Mylan N.V."
2905,385,4950,470,Elidel,pimecrolimus,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Allergy,General,Atopic Dermatitis (Eczema),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcineurin phosphatase,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,12/13/01,08/06/02,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$    70.0,$    84.0,$    83.0,$     8.0,Q1 2019,Mylan N.V.
1819,215,2903,667,Eligard,leuprolide acetate,Mundipharma International Limited,,,United Kingdom,Europe,,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Peptide,Gonadotropin-Releasing Hormone (GnRH) Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,,N,N,,,,01/23/02,12/21/04,,,,03/23/01,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   141.3,$   150.7,$   143.3,$    30.0,Q1 2019,"Astellas Pharma, Inc., MediGene AG, Sanofi, Sosei Co., Ltd"
2962,346,5038,73,Eliquis,apixaban,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Hematology,Antithrombotic,Venous Thromboembolism (VTE),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/14/14,05/18/11,02/19/15,,,05/15/13,10/26/06,,,,10/26/06,03/04/05,,N/A,,"$  1,759.0","$  2,887.0","$  3,760.0","$  2,475.0","$  3,343.0","$  4,872.0","$  6,438.0","$  3,967.0",Q2 2019,Pfizer Inc.
2962,2965,5039,73,Eliquis,apixaban,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Hematology,Antithrombotic,Stroke Prevention in Atrial Fibrillation (SPAF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,12/28/12,11/20/12,12/26/12,,,10/26/10,12/18/06,,,,12/18/06,,,N/A,,"$  1,759.0","$  2,887.0","$  3,760.0","$  2,475.0","$  3,343.0","$  4,872.0","$  6,438.0","$  3,967.0",Q2 2019,Pfizer Inc.
10749,563,13458,51,Elitek,rasburicase,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Hematologic,Tumor Lysis Syndrome (TLS),Y,Approved,Approved,100% (Same As Avg.),Protein,Uric Acid,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,07/12/02,02/23/01,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
11665,239,17797,395,Ella,ulipristal acetate,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Contraception,Contraception,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Progesterone Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/13/10,05/15/09,,,,10/14/09,,,,,11/01/06,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Gedeon Richter Plc, HRA Pharma, Shin Poong Pharmaceutical Co., Ltd."
16194,511,20816,51,Eloctate,efmoroctocog alfa,Sanofi,SNY,,France,Europe,1.05588E+11,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,06/06/14,11/18/15,12/31/14,,,03/12/13,12/06/10,12/15/09,,,12/06/10,12/15/09,,N/A,,$   445.2,N/A,$   567.7,$   307.3,$   514.0,$    48.4,"$  1,045.8",$   617.0,Q2 2019,"Swedish Orphan Biovitrum, UCB SA"
1815,213,2893,51,Eloxatin,oxaliplatin,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Solid,Colorectal Cancer (CRC),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,08/09/02,,03/31/05,,,,,,,,,,,N/A,,N/A,$     1.2,N/A,N/A,$    39.8,$   205.3,$   221.4,$    61.3,Q1 2019,"Debiopharm S.A., Yakult Honsha Co. Ltd."
18100,3580,35151,3220,Elzonris,tagraxofusp-erzs,"Stemline Therapeutics, Inc.",STML,New York,United States,North America,491956736,Oncology,Hematologic,Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),Y,Approved,Approved,100% (Same As Avg.),Protein,IL-3 (Interleukin-3) Receptor/CD123,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,12/01/2019 - 06/30/2020,,12/21/18,,,,,06/25/18,,,,,,04/03/12,12/06/10,N/A,,N/A,N/A,N/A,$    18.0,N/A,N/A,N/A,$    18.0,Q2 2019,N/A
2827,3128,4824,312,Embeda,morphine sulfate/naltrexone hydrochloride,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Chronic Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,Y,N,,N,N,,,,08/13/09,,,,,06/30/08,,,,,09/28/06,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2009,N/A
3143,767,5376,254,Emend (IV),fosaprepitant dimeglumine,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Neurokinin Receptor,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,01/25/08,01/11/08,09/26/11,,,04/03/06,,,,,,11/10/04,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Ono Pharmaceutical Company, Ltd."
2497,594,4242,254,Emend (Oral),aprepitant,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Not Specified,Other,Emesis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Neurokinin Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/30/06,,10/16/09,,,08/29/05,,,,,,,,N/A,,$   356.0,$   342.0,$   312.0,$   130.0,$   550.0,$   556.0,$   522.0,$   238.0,Q2 2019,"Ono Pharmaceutical Company, Ltd., Perrigo Company PLC"
2497,767,5801,254,Emend (Oral),aprepitant,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Neurokinin Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/26/03,11/11/03,10/16/09,,,09/27/02,,,,,,,,N/A,,$   356.0,$   342.0,$   312.0,$   130.0,$   550.0,$   556.0,$   522.0,$   238.0,Q2 2019,"Ono Pharmaceutical Company, Ltd., Perrigo Company PLC"
25823,3620,35956,815,Emflaza,deflazacort,"PTC Therapeutics, Inc.",PTCT,New Jersey,United States,North America,2341104297,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Duchenne Muscular Dystrophy (DMD),N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,02/09/17,,,,,06/09/16,,,11/09/14,,04/15/15,,11/09/14,N/A,,N/A,$    28.9,$    91.9,$    17.8,N/A,$    28.9,$    91.9,$    17.8,Q1 2019,N/A
21254,288,28616,136,Emgality,galcanezumab-gnlm,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Calcitonin Gene-Related Peptide (CGRP) / Receptor,Biologic,No,Subcutaneous (SQ),Y,N,N,Y,N,N,,,,09/27/18,11/20/18,,,,09/27/17,05/06/15,07/03/12,,,05/06/15,07/03/12,10/19/11,N/A,,N/A,N/A,$     4.9,$    46.0,N/A,N/A,$     4.9,$    48.5,Q2 2019,Royalty Pharma AG
3222,207,5515,73,Empliciti,elotuzumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Hematologic,Multiple Myeloma (MM),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,CS1/SLAMF7^ Immune system,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,01/01/2017 - 12/31/2017,11/30/15,05/11/16,,,,06/29/15,04/20/11,10/14/09,02/21/07,,04/20/11,10/14/09,02/21/07,75%,,N/A,$   151.0,$   164.0,$   121.0,N/A,$   231.0,$   247.0,$   174.0,Q2 2019,AbbVie Inc.
2530,167,4293,266,EMSAM,selegiline,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Monoamine oxidase B (MAO-B),Non-NME,No,Transdermal,N,N,N,,N,N,,,,02/27/06,,,,,05/25/01,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
333,78,624,179,Emtriva,emtricitabine,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,07/02/03,10/24/03,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2014,Royalty Pharma AG
1901,543,3064,395,Enablex,darifenacin,Allergan plc,AGN,,Ireland,Europe,53945515162,Urology,Other,Overactive Bladder (OAB),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/22/04,10/22/04,,,,12/03/02,,,,,,,,N/A,,$    17.1,$     3.6,$     0.8,N/A,N/A,$     3.6,$     0.8,N/A,Q1 2018,"Norgine B.V., Novartis AG, Searchlight Pharma Inc."
220,155,280,30,Enbrel,etanercept,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/30/04,09/30/04,,,,07/01/03,07/03/02,,,,07/03/02,07/29/00,,89%,543.2,"$  4,137.0","$  5,206.0","$  4,807.0","$  1,106.0","$  6,817.4","$  7,885.0","$  5,014.0","$  1,602.0",Q1 2019,"DRI Capital Inc., GlaxoSmithKline plc, Pfizer Inc."
220,252,281,30,Enbrel,etanercept,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,07/24/03,01/21/04,,,,01/22/03,11/01/01,,,,11/15/01,08/16/01,,89%,340.2,"$  4,137.0","$  5,206.0","$  4,807.0","$  1,106.0","$  6,817.4","$  7,885.0","$  5,014.0","$  1,602.0",Q1 2019,"DRI Capital Inc., GlaxoSmithKline plc, Pfizer Inc."
220,336,282,30,Enbrel,etanercept,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,01/22/02,12/17/02,01/01/05,,,07/16/01,,,,,03/22/01,08/16/99,,89%,143.6,"$  4,137.0","$  5,206.0","$  4,807.0","$  1,106.0","$  6,817.4","$  7,885.0","$  5,014.0","$  1,602.0",Q1 2019,"DRI Capital Inc., GlaxoSmithKline plc, Pfizer Inc."
17040,576,22104,2891,Endari,,"Emmaus Life Sciences, Inc.",EMMA,California,United States,North America,,Hematology,Other,Sickle Cell Anemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Nicotinamide Adenine Dinucleotide (NAD+/NADH),Non-NME,No,Oral (PO),Y,N,Y,N,N,N,,,,07/07/17,,,,,09/07/16,07/20/10,,,,07/20/10,08/01/05,08/01/01,100%,441,N/A,N/A,$    15.2,$     5.8,N/A,N/A,$    15.2,$     5.8,Q1 2019,taiba Healthcare
17040,581,35996,2891,Endari,,"Emmaus Life Sciences, Inc.",EMMA,California,United States,North America,,Gastroenterology (non inflammatory bowel disease),Other,Short Bowel Syndrome (SBS),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Nicotinamide Adenine Dinucleotide (NAD+/NADH),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/10/04,,,,,08/08/03,,,,,,,,100%,,N/A,N/A,$    15.2,$     5.8,N/A,N/A,$    15.2,$     5.8,Q1 2019,taiba Healthcare
21234,241,28585,582,Endometrin,,Ferring Pharmaceuticals,,,Switzerland,Europe,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,N,Approved,Approved,100% (Same As Avg.),Steroid,Luteinizing Hormone Receptor (LHR)^ Progesterone Receptor,Non-NME,No,Intravaginal,N,N,N,,N,N,,,,06/21/07,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18394,240,24092,375,Enjuvia,"synthetic conjugated estrogens, B",Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/10/04,,,,,03/22/02,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
20214,155,26903,589,Enstilar,calcipotriol hydrate; betamethasone dipropionate,LEO Pharma A/S,,,Denmark,Europe,,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Vitamin D receptor,Non-NME,No,Topical,N,N,N,N,N,N,,,,10/19/15,03/18/16,,,,12/31/14,,,,,07/09/13,05/16/12,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
749,555,1192,254,Entereg,alvimopan,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Gastroenterology (non inflammatory bowel disease),General,Postoperative Ileus,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,New Molecular Entity (NME),No,Oral (PO),Y,N,N,,N,N,,,,05/20/08,,,,,06/28/04,,,,,09/23/03,,,N/A,54.7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q2 2014,"Eli Lilly &amp; Company, Takeda Pharmaceutical Company Ltd"
21815,156,29467,3822,Entocort EC,,Perrigo Company PLC,PRGO,Michigan,United States,North America,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/02/01,,09/28/16,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Zeria Pharmaceutical Co., Ltd."
11089,264,19804,289,Entresto,valsartan/sacubitril,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1)^ Neutral Endopeptidase/Neprilysin (NEP),New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,09/01/2016 - 12/31/2016,07/07/15,11/19/15,,,,12/17/14,12/17/09,06/03/09,,,12/09/09,06/03/09,,N/A,,N/A,$   174.0,$   556.0,$   420.0,$   170.0,$   507.0,"$  1,042.8",$   788.8,Q2 2019,"Laboratorios Farmacéuticos Rovi, S.A., Les Laboratoires Servier"
78,156,166,826,Entyvio,vedolizumab,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Integrin Alpha-4 beta-7/LPAM,Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,05/20/14,05/22/14,05/22/19,,,06/21/13,02/03/09,02/24/00,05/30/98,,02/03/09,02/24/00,05/13/98,95%,525.2,N/A,"$  1,195.7","$  1,656.0",N/A,N/A,"$  1,803.0","$  2,444.0",N/A,Q4 2018,Roche Holding AG
78,321,167,826,Entyvio,vedolizumab,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Integrin Alpha-4 beta-7/LPAM,Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,05/20/14,05/22/14,07/02/18,,,06/21/13,02/03/09,02/08/01,04/30/98,,02/03/09,02/24/00,05/13/98,95%,1069.5,N/A,"$  1,195.7","$  1,656.0",N/A,N/A,"$  1,803.0","$  2,444.0",N/A,Q4 2018,Roche Holding AG
17456,380,22715,2922,Envarsus XR,tacrolimus,Veloxis Pharmaceuticals A/S,VELO:DC,,Denmark,Europe,,Autoimmune/immunology,Transplant Rejection,Kidney Transplant Rejection,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcineurin phosphatase,Non-NME,No,Oral (PO),N,Y,Y,N,N,N,,,,07/10/15,07/18/14,,,,12/30/13,12/29/08,07/01/07,,,12/29/08,06/21/07,11/28/06,N/A,,N/A,N/A,$    33.7,$    12.3,N/A,N/A,$    33.7,$    12.3,Q1 2019,"Chiesi Farmaceutici S.p.A., Endo International plc, taiba Healthcare"
37987,3384,53015,59,Eovist,gadoxetate disodium,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,07/03/08,,10/19/07,,,06/29/07,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23059,244,31486,8134,Epaned Kit,,Azurity Pharmaceuticals,,Massachusetts,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin Converting Enzyme (ACE),Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,08/13/13,,,,,08/09/12,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23059,264,40603,8134,Epaned Kit,,Azurity Pharmaceuticals,,Massachusetts,United States,North America,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin Converting Enzyme (ACE),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/04/14,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
21499,176,28974,179,Epclusa,,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,HCV Polymerase - Nucleoside Binding Site^ Non-structural 5A protein (NS5A),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,06/28/16,07/06/16,01/08/19,,,10/28/15,07/23/14,05/20/13,12/03/12,,07/23/14,05/20/13,12/03/12,N/A,,"$  1,591.0","$  2,404.0",$   934.0,$   449.0,"$  1,752.0","$  3,510.0","$  1,966.0",$   984.0,Q2 2019,Biotoscana International
33913,3577,46850,583,"Ephedrine Sulfate Injection, USP",Ephedrine Sulfate,Akorn Inc.,AKRX,Illinois,United States,North America,352633568,Cardiovascular,Other,Hypotension/Shock,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Beta Adrenergic Receptors^ Norepinephrine (Noradrenaline),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,03/01/17,,,,,09/15/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23288,3447,31892,2079,Epidiolex,cannabidiol,GW Pharmaceuticals plc,GWPH,,United Kingdom,Europe,4635161809,Neurology,Seizure Disorders (Epilepsy),Dravet Syndrome (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cannabinoid reuptake/Endocannabinoid system^ Cannabinoid-1 (CB1) receptor^ Cannabinoid-2 (CB2) receptor^ GPR55^ Serotonin 5-HT1A receptor,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,08/01/2019 - 09/30/2019,,06/25/18,,,,,10/27/17,10/30/14,,,05/07/14,10/30/14,,,N/A,,N/A,N/A,N/A,$    33.5,N/A,N/A,N/A,$    34.7,Q1 2019,N/A
23288,3008,32822,2079,Epidiolex,cannabidiol,GW Pharmaceuticals plc,GWPH,,United Kingdom,Europe,4635161809,Neurology,Seizure Disorders (Epilepsy),Lennox-Gastaut Syndrome (LGS; Epilepsy),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Cannabinoid reuptake/Endocannabinoid system^ Cannabinoid-1 (CB1) receptor^ Cannabinoid-2 (CB2) receptor^ GPR55^ Serotonin 5-HT1A receptor,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,08/01/2019 - 09/30/2019,,06/25/18,,,,,10/27/17,03/24/15,,,,03/24/15,,,N/A,,N/A,N/A,N/A,$    33.5,N/A,N/A,N/A,$    34.7,Q1 2019,N/A
25688,603,35767,587,Epiduo Forte,adapalene and benzoyl peroxide,Galderma S.A.,,,Switzerland,Europe,,Dermatology,General,Acne,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Retinoic acid receptor (RARs),Non-NME,No,Topical,N,N,N,N,N,N,,,,07/15/15,,,,,09/19/14,08/08/13,,,,08/08/13,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
20736,603,27740,587,Epiduo Gel,adapalene and benzoyl peroxide,Galderma S.A.,,,Switzerland,Europe,,Dermatology,General,Acne,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Retinoic acid receptor (RARs),Non-NME,No,Topical,N,N,N,N,N,N,,,,12/08/08,09/27/16,07/05/16,,,02/08/08,,,,,,,,100%,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Maruho Co., Ltd."
2119,78,3525,180,Epzicom,abacavir and lamivudine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/02/04,12/17/04,,,,10/07/03,,,,,,,,N/A,,$   265.0,$    35.0,$     9.0,$     2.3,$   772.0,$   304.0,$   153.0,$    53.0,Q2 2019,"Pfizer Inc., Takeda Pharmaceutical Company Ltd"
8402,168,10430,1380,Equetro,carbamazepine,Validus Pharmaceuticals LLC,,New Jersey,United States,North America,,Psychiatry,Bipolar,Bipolar Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Unknown,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,12/10/04,,,,,02/13/04,12/01/99,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
620,3116,1244,312,Eraxis,anidulafungin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,Y,Approved,Approved,100% (Same As Avg.),Bacterial Product,"Beta (1,3)-D-Glucan",New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,02/21/06,09/20/07,,,,04/29/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,RaQualia Pharma Inc.
33,213,54,136,Erbitux,cetuximab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Colorectal Cancer (CRC),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,EGFR (Epidermal Growth Factor Receptor),Biologic,No,Intravenous (IV),Y,N,N,Y,N,N,,,,02/12/04,06/30/04,07/16/08,,,08/14/03,05/15/02,10/15/99,,,05/28/02,02/15/01,,40.5%,518.3,N/A,$   541.7,$   531.5,$   113.3,"$  1,662.7",$   645.9,"$  1,576.9",$   344.4,Q1 2019,"Bristol-Myers Squibb Company, Merck KGaA, Sanofi, Yeda R&amp;D Company"
33,230,61,136,Erbitux,cetuximab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Head and Neck Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,EGFR (Epidermal Growth Factor Receptor),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,03/01/06,04/03/06,12/21/12,,,08/30/05,03/12/99,02/07/96,,,05/15/01,,,40.5%,329.4,N/A,$   541.7,$   531.5,$   113.3,"$  1,662.7",$   645.9,"$  1,576.9",$   344.4,Q1 2019,"Bristol-Myers Squibb Company, Merck KGaA, Sanofi, Yeda R&amp;D Company"
24029,155,33179,289,Erelzi,etanercept-szzs,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/30/16,06/27/17,,,,07/30/15,07/02/13,,,,07/02/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
24029,154,37690,289,Erelzi,etanercept-szzs,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/30/16,06/27/17,,,,07/30/15,,,,,07/21/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
24029,252,37691,289,Erelzi,etanercept-szzs,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/30/16,06/27/17,,,,07/30/15,,,,,07/21/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
24029,336,37692,289,Erelzi,etanercept-szzs,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/30/16,06/27/17,,,,07/30/15,,,,,07/21/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
24029,365,41649,289,Erelzi,etanercept-szzs,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/30/16,06/27/17,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
10934,360,13717,149,Erivedge,vismodegib,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Skin Cancer - Basal Cell Carcinoma (BCC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Hedgehog Signaling Pathway,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/30/12,07/12/13,,,,09/12/11,,02/12/09,,,,02/12/09,01/31/07,N/A,271.5,$   136.9,$   162.9,$   163.5,$    84.0,$   207.3,$   252.2,$   263.7,$   127.0,Q2 2019,"Chugai Pharmaceutical Co., Ltd., Curis, Inc., Oberland Capital Management, LLC"
18455,215,24181,223,Erleada,apalutamide,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Androgen receptors,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/14/18,01/16/19,03/26/19,,,10/10/17,10/15/13,11/30/11,08/09/10,,10/15/13,08/09/10,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Nippon Shinyaku Co., Ltd."
17643,199,22983,508,Erwinaze,asparaginase Erwinia chrysanthemi,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Y,Approved,Approved,100% (Same As Avg.),Natural Protein,Asparagine,Biologic,No,"Intramuscular (IM), Intravenous (IV)",Y,N,Y,N,N,N,,,,11/18/11,02/02/15,12/19/16,,,11/09/10,,,,,02/27/08,,,N/A,,$   195.3,$   100.4,N/A,N/A,$   195.3,$   197.4,$   175.1,$    60.9,Q1 2019,"Ohara Pharmaceutical Co., Ltd."
1399,387,2125,149,Esbriet,pirfenidone,Roche Holding AG,RHHBY,,Switzerland,Europe,,Respiratory,Other,Idiopathic Pulmonary Fibrosis (IPF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,p38 MAP kinase (MAPK),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,,,10/15/14,02/28/11,10/16/08,,,11/04/09,04/27/06,,,,04/27/06,04/15/99,,100%,718.7,$   581.0,$   653.1,$   765.7,$   174.6,$   784.2,$   887.1,"$  1,089.7",$   261.7,Q1 2019,"Ildong Pharmaceutical Co., Ltd., KDL GmbH, Marnac, Inc., Shionogi &amp; Co. Ltd."
23330,3555,31972,4532,Eskata,hydrogen peroxide,"Aclaris Therapeutics, Inc.",ACRS,Pennsylvania,United States,North America,33882885,Dermatology,General,Benign Pigmented Lesions,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cell Membrane,Non-NME,No,Topical,N,N,N,N,N,N,,,,12/15/17,02/28/19,,,,02/28/17,01/19/16,11/06/13,,,01/19/16,11/06/13,,N/A,,N/A,N/A,$     2.8,$     0.1,N/A,N/A,$     2.8,$     0.1,Q1 2019,Cipher Pharmaceuticals Inc.
23058,644,31482,3379,Esomeprazole Strontium Delayed-Release,esomeprazole strontium,"Hanmi Pharmaceutical Co., Ltd.",128940:KS,,Korea (South),Asia,,Gastroenterology (non inflammatory bowel disease),General,Gastroesophageal Reflux Disease (GERD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Proton pump,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/06/13,,,,,10/15/10,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    19.5,$    22.9,$    12.8,Q2 2019,"Amneal Pharmaceuticals, Inc., Strides Pharma Science Limited"
23058,3120,31483,3379,Esomeprazole Strontium Delayed-Release,esomeprazole strontium,"Hanmi Pharmaceutical Co., Ltd.",128940:KS,,Korea (South),Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",H. pylori Infection,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Proton pump,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/06/13,,,,,10/15/10,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    19.5,$    22.9,$    12.8,Q2 2019,"Amneal Pharmaceuticals, Inc., Strides Pharma Science Limited"
23058,147,31484,3379,Esomeprazole Strontium Delayed-Release,esomeprazole strontium,"Hanmi Pharmaceutical Co., Ltd.",128940:KS,,Korea (South),Asia,,Gastroenterology (non inflammatory bowel disease),"Acid-Peptic (Gastritis Peptic Ulcer, Etc.)",Ulcers and other acid-peptic gastrointestinal disorders,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Proton pump,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/06/13,,,,,10/15/10,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    19.5,$    22.9,$    12.8,Q2 2019,"Amneal Pharmaceuticals, Inc., Strides Pharma Science Limited"
23058,655,31485,3379,Esomeprazole Strontium Delayed-Release,esomeprazole strontium,"Hanmi Pharmaceutical Co., Ltd.",128940:KS,,Korea (South),Asia,,Oncology,Solid,Zollinger-Ellison Syndrome,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Proton pump,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/06/13,,,,,10/15/10,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    19.5,$    22.9,$    12.8,Q2 2019,"Amneal Pharmaceuticals, Inc., Strides Pharma Science Limited"
17543,511,22852,292,Esperoct,turoctocog alfa pegol,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor VIII^ Coagulation Factor X,Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,10/01/2019 - 12/31/2019,02/19/19,06/20/19,,,,02/27/18,02/01/12,,09/29/10,,02/01/12,,09/29/10,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
26019,240,36266,2949,Estrogel,estradiol,Besins Healthcare SA,,,Thailand,Asia,,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Transdermal,N,N,N,N,N,N,,,,02/09/04,,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Aeterna Zentaris, Inc."
23779,3384,33069,4108,Ethiodol,,Guerbet Group,GBT:FP,,France,Europe,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) - Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Thyroid Hormones (triiodothyronine and thyroxine),New Molecular Entity (NME),No,Intramuscular (IM),N,N,Y,N,N,N,,,,04/10/14,,09/13/13,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Shanghai Pharma Group
25296,154,35206,4607,Eticovo,etanercept-ykro,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/25/19,01/14/16,,,,05/25/17,07/09/13,,,,06/30/13,,02/20/13,N/A,,N/A,N/A,N/A,N/A,$   100.7,$   370.8,$   485.2,$   244.3,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
25296,336,37264,4607,Eticovo,etanercept-ykro,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/25/19,01/16/16,,,,05/25/17,,,,,01/21/15,,,N/A,,N/A,N/A,N/A,N/A,$   100.7,$   370.8,$   485.2,$   244.3,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
25296,252,37265,4607,Eticovo,etanercept-ykro,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/25/19,01/16/16,,,,05/25/17,,,,,01/21/15,,,N/A,,N/A,N/A,N/A,N/A,$   100.7,$   370.8,$   485.2,$   244.3,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
25296,155,37266,4607,Eticovo,etanercept-ykro,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/25/19,01/16/16,,,,05/25/17,,,,,01/21/15,,,N/A,,N/A,N/A,N/A,N/A,$   100.7,$   370.8,$   485.2,$   244.3,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
25296,365,45222,4607,Eticovo,etanercept-ykro,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Protein,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/25/19,01/27/17,,,,05/25/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   100.7,$   370.8,$   485.2,$   244.3,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
10242,385,22493,312,Eucrisa,crisaborole,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Allergy,General,Atopic Dermatitis (Eczema),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 4 (PDE4),New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,12/14/16,,,,,01/07/16,03/31/14,05/17/11,,,03/31/14,09/10/10,,N/A,,N/A,$    67.0,$   148.0,$    48.0,N/A,$    67.0,$   148.0,$    50.0,Q2 2019,N/A
2471,240,4192,3822,Evamist,estradiol,Perrigo Company PLC,PRGO,Michigan,United States,North America,,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Transdermal,N,Y,N,,N,N,,,,07/27/07,05/27/11,,,,09/29/06,12/21/04,,,,12/16/04,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q1 2012,"Acrux, Aspen Pharmacare Holdings Limited, Gedeon Richter Plc, Vivus, Inc."
2991,672,5097,223,Evarrest,,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Hematology,Other,Hemostasis,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrinogen (Coagulation Factor I)^ Thrombin (Coagulation Factor IIa),Biologic,No,Topical,N,N,N,N,N,N,,,,12/05/12,09/25/13,,,,11/18/10,,03/27/08,,,,03/27/08,12/07/06,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
8026,242,9877,30,Evenity,romosozumab-aqqg,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Sclerostin,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/09/19,,01/08/19,,,07/22/16,04/04/12,09/24/09,,,04/04/12,09/24/09,07/26/07,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,$     5.5,Q1 2019,"Astellas Pharma, Inc., UCB SA"
27475,672,38477,223,Evicel,human fibrinogen / human thrombin,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Hematology,Other,Hemostasis,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrinogen (Coagulation Factor I)^ Thrombin (Coagulation Factor IIa),Biologic,No,Topical,N,N,N,N,N,N,,,,03/21/03,10/06/08,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
1771,214,3566,136,Evista,raloxifene hydrochloride,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Breast Cancer,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Endothelin Receptor Type B (EDNRB)^ Estrogen Receptor Alpha (ER1 or ER alpha),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/13/07,,,,,12/14/06,,,,,12/01/04,,,97.7%,,$    50.4,$     7.0,N/A,N/A,$   172.4,$   107.5,N/A,N/A,Q4 2017,"Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Company Ltd"
2707,672,4627,223,Evithrom,"Thrombin, Topical (Human)",Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Hematology,Other,Hemostasis,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrinogen (Coagulation Factor I),Biologic,No,Topical,N,N,N,,N,N,,,,08/27/07,,,,,11/06/06,,,,,06/26/06,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
17900,207,23382,9097,Evomela,melphalan,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Hematologic,Multiple Myeloma (MM),N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA,Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,03/11/16,,,,,12/26/14,,01/28/10,,,,07/27/09,,N/A,,$    16.2,$    35.2,$    28.3,N/A,$    16.2,$    35.2,$    28.3,N/A,Q4 2018,"CASI Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc."
18956,78,24944,73,Evotaz,atazanavir sulfate and cobicistat,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450^ HIV-1 protease (HIV PR),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/29/15,07/13/15,,,,04/04/14,05/31/11,,,,04/20/10,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Gilead Sciences, Inc."
31062,670,42975,343,Evoxac,Cevimeline hydrochloride,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Autoimmune/immunology,Arthritis,Sjogren's Syndrome,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Muscarinic M1 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/11/00,,,,,08/26/98,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
23925,726,33008,4661,Evzio,naloxone hydrochloride,Kaléo Pharmaceutical Inc.,,Virginia,United States,North America,,Not Specified,Other,Drug Toxicity,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,"Intramuscular (IM), Subcutaneous (SQ)",Y,N,N,N,N,N,,,,04/03/14,,,,,12/20/13,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
8397,3629,10417,556,Exalgo,hydromorphone hydrochloride,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Neurology,Pain,Chronic Low Back Pain (CLBP),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,03/01/10,05/15/06,,,,12/28/99,,,,,07/13/04,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q2 2015,"EPIRUS Biopharmaceuticals, Inc., Johnson &amp; Johnson"
2003,141,3259,289,Exelon,rivastigmine tartrate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cholinesterases,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,04/21/00,05/12/98,10/01/00,,,04/07/97,,,,,,,,100%,0,$    90.0,$    18.0,N/A,N/A,$   444.0,$   381.0,N/A,N/A,Q4 2017,N/A
2003,194,4400,289,Exelon,rivastigmine tartrate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Neurodegenerative,Parkinson's Disease (PD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cholinesterases,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,06/27/06,03/08/06,,,,01/19/06,,,,,12/09/04,,,100%,,$    90.0,$    18.0,N/A,N/A,$   444.0,$   381.0,N/A,N/A,Q4 2017,N/A
2740,141,4677,289,Exelon Patch,rivastigmine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cholinesterases,Non-NME,No,Transdermal,N,N,N,N,N,N,,,,07/06/07,09/24/07,04/22/11,,,09/08/06,,,,,01/30/04,10/07/01,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2013,"Ono Pharmaceutical Company, Ltd."
2740,194,24360,289,Exelon Patch,rivastigmine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Neurodegenerative,Parkinson's Disease (PD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cholinesterases,Non-NME,No,Transdermal,N,N,N,N,N,N,,,,07/06/07,,,,,09/08/06,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2013,"Ono Pharmaceutical Company, Ltd."
2360,244,3977,289,Exforge,amlodipine besylate/valsartan,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/20/07,01/17/07,01/20/10,,,02/22/06,,,,,09/20/05,,,N/A,,$    10.0,$    28.0,$    19.0,$     7.0,$   926.0,$   960.0,"$  1,002.0",$   531.0,Q2 2019,UCB SA
8625,244,10713,289,Exforge HCT Combo,amlodipine besylate/valsartan/hydrochlorothiazide,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1)^ Na/Cl transporter - Thiazide-sensitive,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/30/09,10/16/09,,,,06/30/08,,,,,,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,UCB SA
1876,636,3028,289,Exjade,deferasirox,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Hematology,Other,Iron Overload,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,11/02/05,08/28/06,04/16/08,,,05/03/05,05/01/03,,,,12/06/04,12/09/02,,N/A,,$   447.0,$   515.0,$   521.0,$   231.0,$   956.0,"$  1,059.0","$  1,099.0",$   491.0,Q2 2019,N/A
9788,3620,12186,52,Exondys 51,eteplirsen,"Sarepta Therapeutics, Inc.",SRPT,Massachusetts,United States,North America,8429800167,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Duchenne Muscular Dystrophy (DMD),Y,Approved,Approved,100% (Same As Avg.),Antisense,Dystrophin gene (DMD),New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,N,N,N,,,,09/19/16,,,,,06/26/15,10/01/14,12/24/08,,,10/01/14,12/24/08,12/21/07,N/A,,N/A,$   154.6,$   301.0,$    87.0,N/A,$   154.6,$   301.0,$    87.0,Q1 2019,"BioMarin Pharmaceutical Inc., University of Western Australia"
17561,3130,22876,2965,Exparel,bupivacaine,"Pacira BioSciences, Inc.",PCRX,New Jersey,United States,North America,1650324670,Neurology,Pain,Postsurgical Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,New Molecular Entity (NME),No,Intramuscular (IM),N,N,N,N,N,N,,05/01/2020 - 11/30/2020,,10/28/11,,,,,09/30/10,,,,,12/06/08,,,N/A,,$   265.8,$   282.9,$   331.1,$    90.6,$   265.8,$   282.9,$   331.1,$    90.6,Q1 2019,"Nuance Biotech, Inc., Vectura Group plc"
17561,531,27959,2965,Exparel,bupivacaine,"Pacira BioSciences, Inc.",PCRX,New Jersey,United States,North America,1650324670,Neurology,Pain,Anesthesia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,New Molecular Entity (NME),No,Intramuscular (IM),N,N,N,N,N,N,,,,04/06/18,,,,,05/05/14,09/25/12,,,,08/09/12,,,N/A,,$   265.8,$   282.9,$   331.1,$    90.6,$   265.8,$   282.9,$   331.1,$    90.6,Q1 2019,"Nuance Biotech, Inc., Vectura Group plc"
15551,153,19798,289,Extavia,interferon beta-1b,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Protein,Interferon Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,08/14/09,05/20/08,,,,05/06/08,,,,,03/24/08,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,N/A
14847,176,18833,5,Exviera,dasabuvir,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HCV Polymerase (NS5B) - Allosteric binding sites (Non-nucleosides),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,12/19/14,01/16/15,,,,04/21/14,10/10/12,09/09/08,,,10/10/12,09/09/08,,N/A,,$   342.0,$    64.0,N/A,$     0.0,"$  1,522.0",$   488.0,N/A,$     0.0,Q2 2017,"Enanta Pharmaceuticals, Inc."
2855,162,4874,330,Eylea,aflibercept,"Regeneron Pharmaceuticals, Inc.",REGN,New York,United States,North America,32413693800,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Protein,Placental growth factor (PlGF)^ VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,11/18/11,11/22/12,09/28/12,,,02/22/11,08/03/07,05/01/06,03/09/04,,08/03/07,05/01/06,03/09/04,100%,1091.8,"$  2,465.9","$  3,702.2","$  4,076.7","$  1,074.1","$  4,139.2","$  8,085.8","$  9,728.6","$  2,517.8",Q1 2019,"Bayer AG, DRI Capital Inc., Roche Holding AG, Santen Pharmaceutical Co., Ltd."
2855,476,8279,330,Eylea,aflibercept,"Regeneron Pharmaceuticals, Inc.",REGN,New York,United States,North America,32413693800,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Protein,Placental growth factor (PlGF)^ VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,07/30/14,08/11/14,11/18/14,,,11/05/13,04/08/11,12/08/08,,,04/08/11,02/26/09,10/18/06,100%,244.9,"$  2,465.9","$  3,702.2","$  4,076.7","$  1,074.1","$  4,139.2","$  8,085.8","$  9,728.6","$  2,517.8",Q1 2019,"Bayer AG, DRI Capital Inc., Roche Holding AG, Santen Pharmaceutical Co., Ltd."
2855,623,19130,330,Eylea,aflibercept,"Regeneron Pharmaceuticals, Inc.",REGN,New York,United States,North America,32413693800,Ophthalmology,Retinopathy,Macular Edema from Retinal Vein Occlusion (RVO) (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Protein,Placental growth factor (PlGF)^ VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,09/21/12,08/29/13,11/22/13,,,12/31/11,07/23/09,,,,04/30/09,,,100%,,"$  2,465.9","$  3,702.2","$  4,076.7","$  1,074.1","$  4,139.2","$  8,085.8","$  9,728.6","$  2,517.8",Q1 2019,"Bayer AG, DRI Capital Inc., Roche Holding AG, Santen Pharmaceutical Co., Ltd."
2855,364,34217,330,Eylea,aflibercept,"Regeneron Pharmaceuticals, Inc.",REGN,New York,United States,North America,32413693800,Ophthalmology,Retinopathy,Diabetic Retinopathy (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Protein,Placental growth factor (PlGF)^ VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,Y,N,N,,,,03/25/15,,,,,09/30/14,,,,,09/16/14,,,100%,,"$  2,465.9","$  3,702.2","$  4,076.7","$  1,074.1","$  4,139.2","$  8,085.8","$  9,728.6","$  2,517.8",Q1 2019,"Bayer AG, DRI Capital Inc., Roche Holding AG, Santen Pharmaceutical Co., Ltd."
40659,506,57005,3285,Ezallor Sprinkle,rosuvastatin,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,HMG CoA Reductase (HMGR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/18/18,,,,,08/28/15,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
167,274,221,51,Fabrazyme,agalsidase beta,Sanofi,SNY,,France,Europe,1.05588E+11,Metabolic,Inborn Errors Of Metabolism,Fabry's Disease,Y,Approved,Approved,100% (Same As Avg.),Protein,Globotriaosylceramide glycolipid,Biologic,No,Intravenous (IV),N,N,Y,,N,N,,,,04/24/03,08/03/01,01/29/04,,,,,,,,,,,N/A,,$   383.1,$   422.9,$   441.0,$   224.7,$   748.3,$   827.9,$   869.7,$   447.2,Q2 2019,N/A
1670,643,2685,3612,Factive,gemifloxacin mesylate,Vansen Pharma Inc.,VNSN,,Canada,North America,2574000,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Respiratory Tract Infections (Excluding Pneumonia) (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,04/04/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2012,"LG Chem, Ltd., The Menarini Group"
1670,488,3423,3612,Factive,gemifloxacin mesylate,Vansen Pharma Inc.,VNSN,,Canada,North America,2574000,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,04/04/03,,,,,12/15/99,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2012,"LG Chem, Ltd., The Menarini Group"
1153,170,2109,734,Fanapt,iloperidone,"Vanda Pharmaceuticals, Inc.",VNDA,,United States,North America,789370694,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Dopamine 4 (D4) Receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor^ Serotonin 5-HT6 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/06/09,,,,,09/27/07,01/15/99,,,,08/18/98,,,87%,0,N/A,$    75.2,$    77.3,$    40.0,N/A,$    75.2,$    77.3,$    40.0,Q2 2019,"Apotex Inc., Biotoscana International, MegaPharm Ltd., Sanofi, Taro Pharmaceutical Industries Ltd., Titan Pharmaceuticals, Inc."
3046,137,5190,45,Farxiga,dapagliflozin,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/08/14,11/12/12,03/24/14,,,12/27/10,09/24/07,,,,09/24/07,11/15/06,,90%,914.8,$   457.0,$   489.0,$   591.0,$   131.0,$   835.0,"$  1,074.0","$  1,391.0",$   349.0,Q1 2019,"Bristol-Myers Squibb Company, Ono Pharmaceutical Company, Ltd., Sun Pharmaceutical Industries Ltd."
2362,207,5063,9278,Farydak,panobinostat lactate,"Secura Bio, Inc.",,Nevada,United States,North America,,Oncology,Hematologic,Multiple Myeloma (MM),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histone Deacetylase (HDAC),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,02/23/15,08/28/15,07/03/15,,,03/24/14,,,,,07/31/07,05/28/08,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Midatech Pharma PLC
3006,72,5129,45,Fasenra,benralizumab,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-5 (Interleukin-5) and IL-5 Receptor (IL-5R),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,11/14/17,01/10/18,01/19/18,,,11/16/16,10/07/13,12/04/08,,,07/31/13,12/04/08,10/30/06,N/A,,N/A,N/A,$   218.0,$   208.0,N/A,N/A,$   297.0,$   296.0,Q2 2019,"Kyowa Hakko Kirin Co., Ltd."
2457,214,4168,45,Faslodex,fulvestrant,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),New Molecular Entity (NME),No,Intramuscular (IM),N,N,N,N,N,N,,,,04/25/02,03/09/04,09/26/11,,,,,,,,,,,N/A,,$   448.0,$   492.0,$   537.0,$   251.0,$   830.0,$   941.0,"$  1,028.0",$   521.0,Q2 2019,N/A
3090,170,5296,508,FazaClo,clozapine,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Muscarinic M1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor^ Serotonin 5-HT2C receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/09/04,,,,,01/20/03,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2012,"Otsuka Holdings Co., Ltd., Teva Pharmaceutical Industries Ltd."
21655,329,29210,826,FEIBA NF,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Hematology,Factor Augmentation,Hemophilia A and B - General Clotting Products,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor VIII,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,03/18/10,,,,,,,,,,04/25/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    87.2,N/A,Q4 2018,N/A
17340,506,22541,470,Fenoglide,fenofibrate,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,PPAR alpha,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/10/07,,,,,09/29/06,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
1811,3125,2887,375,Fentora,fentanyl citrate,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Pain,Cancer Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,09/25/06,04/04/08,,,,09/06/05,,,,,08/09/04,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2010,N/A
19640,375,25930,3598,Feraccru,ferric maltol,Shield Therapeutics plc,LSE:STX,,United Kingdom,Europe,,Hematology,Marrow Or Peripheral Blood Stimulator,Anemia,Y,Approved,Approved,101% (1% Above Avg.),Small Molecule,Iron,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/26/19,02/18/16,,,,10/01/18,10/12/11,,,,10/12/11,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"AOP Orphan Pharmaceuticals AG, Ewopharma AG, Norgine B.V."
1154,371,2066,512,Feraheme,ferumoxytol,"AMAG Pharmaceuticals, Inc.",AMAG,Massachusetts,United States,North America,414082551,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Independent",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,06/30/09,06/22/12,,,,12/19/07,06/16/04,,,,04/27/04,11/17/03,,100%,,$    70.8,$   106.1,$   135.0,$    40.0,$    70.8,$   106.1,$   135.0,$    40.0,Q1 2019,N/A
1154,187,5520,512,Feraheme,ferumoxytol,"AMAG Pharmaceuticals, Inc.",AMAG,Massachusetts,United States,North America,414082551,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Dependent",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,06/30/09,06/22/12,,,,12/19/07,06/16/04,,,,06/16/04,,,100%,,$    70.8,$   106.1,$   135.0,$    40.0,$    70.8,$   106.1,$   135.0,$    40.0,Q1 2019,N/A
1154,375,12489,512,Feraheme,ferumoxytol,"AMAG Pharmaceuticals, Inc.",AMAG,Massachusetts,United States,North America,414082551,Hematology,Marrow Or Peripheral Blood Stimulator,Anemia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,02/05/18,,,,,08/03/17,06/29/10,,,,06/29/10,03/01/10,01/08/08,100%,,$    70.8,$   106.1,$   135.0,$    40.0,$    70.8,$   106.1,$   135.0,$    40.0,Q1 2019,N/A
18599,636,24413,3371,Ferriprox,deferiprone,Apotex Inc.,,,Canada,North America,,Hematology,Other,Iron Overload,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/14/11,08/25/99,,,,02/02/09,09/13/07,,,,09/13/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
14152,167,17915,395,Fetzima,,Allergan plc,AGN,,Ireland,Europe,53945515162,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/26/13,,,,,09/27/12,10/20/09,,,,10/20/09,12/22/08,,N/A,,N/A,$   333.2,$   342.4,$   192.8,N/A,$   336.3,$   349.6,$   197.6,Q2 2019,Pierre Fabre Medicament S.A.
17163,137,22267,292,FIAsp,,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,01/01/2017 - 01/01/2018,09/29/17,01/09/17,,,,12/09/15,09/16/13,,05/11/10,,09/16/13,,05/11/10,100%,710.9,N/A,N/A,N/A,$    13.8,N/A,$    15.2,$    87.7,$    35.1,Q1 2019,N/A
17163,157,22269,292,FIAsp,,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",N,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,01/01/2017 - 01/01/2018,09/29/17,01/10/17,,,,12/09/15,,,05/11/10,,08/26/13,,05/11/10,100%,277.6,N/A,N/A,N/A,$    13.8,N/A,$    15.2,$    87.7,$    35.1,Q1 2019,N/A
17470,506,22732,2795,Fibricor,fenofibric acid,"Nuvo Pharmaceuticals, Inc.",TSX:NRI,,Canada,North America,0,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,PPAR alpha,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/14/09,,,,,08/15/08,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23215,672,31779,2858,Fibrin Sealant,,"Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Hematology,Other,Hemostasis,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrinogen (Coagulation Factor I)^ Thrombin (Coagulation Factor IIa),Biologic,No,Topical,N,N,N,N,N,N,,,,11/01/17,11/17/17,,,,12/31/16,05/20/08,,,,05/20/08,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
19886,672,26367,2684,Fibryga,fibrinogen (human),Octapharma AG,,,Switzerland,Europe,,Hematology,Other,Hemostasis,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrinogen (Coagulation Factor I),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,06/07/17,,,,,06/09/16,10/16/14,07/10/13,,,10/16/14,04/10/12,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
26526,584,37003,589,Finacea (Foam),azelaic acid,LEO Pharma A/S,,,Denmark,Europe,,Dermatology,General,Rosacea,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,steroid 5a-reductase,Non-NME,No,Topical,N,N,N,N,N,N,,,,07/29/15,,,,,09/30/14,,,,,10/17/12,,03/02/11,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Foamix Pharmaceuticals Ltd.
17862,584,23328,589,Finacea (Gel),Azelaic Acid,LEO Pharma A/S,,,Denmark,Europe,,Dermatology,General,Rosacea,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,steroid 5a-reductase,Non-NME,No,Topical,N,N,N,N,N,N,,,,12/24/02,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2419,556,4096,826,Firazyr,icatibant,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Bradykinin B2 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),Y,Y,Y,N,N,N,,,,08/25/11,07/11/08,09/21/18,,,10/08/07,,,,,02/17/03,,,88%,,$   510.9,$   229.7,$   481.0,N/A,$   578.5,$   265.9,$   615.1,N/A,Q3 2018,Sanofi
16014,2886,20527,1336,Firdapse,amifampridine phosphate,Catalyst Pharmaceuticals Inc.,CPRX,Florida,United States,North America,544518062,Autoimmune/immunology,Other,Lambert-Eaton Myasthenic Syndrome (LEMS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Potassium channels,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,11/28/18,01/05/10,,,,12/17/15,08/02/10,,,,08/02/10,,,N/A,,N/A,N/A,N/A,$    12.4,$    12.7,$    18.8,$    21.7,$    17.5,Q1 2019,"BioMarin Pharmaceutical Inc., Jazz Pharmaceuticals plc"
10595,215,13273,582,Firmagon,degarelix acetate,Ferring Pharmaceuticals,,,Switzerland,Europe,,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Peptide,Gonadotropin-Releasing Hormone (GnRH) Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/24/08,02/17/09,06/29/12,,,02/14/08,04/07/06,,,,04/07/06,10/05/04,,N/A,,N/A,N/A,N/A,N/A,$    40.5,$    43.8,$    46.0,$    10.0,Q1 2019,"Astellas Pharma, Inc."
37212,487,51908,8134,Firvanq,vancomycin hydrochloride,Azurity Pharmaceuticals,,Massachusetts,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI),N,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Cell wall synthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/26/18,,,,,07/28/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23221,423,31792,2858,Flebogamma DIF,,"Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Autoimmune/immunology,Other,Primary Immunodeficiencies,N,Approved,Approved,100% (Same As Avg.),Protein,Immunoglobulin E (IgE),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,12/15/03,07/23/07,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23221,649,43359,2858,Flebogamma DIF,,"Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),N,Approved,Approved,100% (Same As Avg.),Protein,Immunoglobulin E (IgE),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,06/28/2019 - 09/02/2019,,01/08/16,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22736,3127,30962,312,Flector Patch 1.3%,diclofenac hydroxyethylpyrrolidine,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Acute Pain,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Immune system,Non-NME,No,Topical,N,N,N,N,N,N,,,,01/31/07,05/28/03,,,,,,,,,10/18/01,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Institut Biochimique SA
8642,3300,10735,870,Fluad,,CSL Limited,CSL:AU,,Australia,Oceania,,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,11/24/15,05/24/00,,,,,,,,,05/24/00,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Valneva SE
2075,3300,3398,180,Fluarix,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,08/31/05,,,,,05/25/05,,,,,12/09/04,,,N/A,,N/A,N/A,$   524.9,N/A,N/A,N/A,$   709.3,$    20.3,Q1 2019,N/A
18898,3300,24860,180,Fluarix Quadrivalent,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,12/14/12,04/03/13,,,,03/05/12,,,,,06/17/11,02/19/10,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18829,3300,24749,51,FluBlok,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,N,N,N,,,,01/16/13,,,,,,,,,,10/28/04,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"UMN Pharma, Inc."
1322,3300,1596,870,Flucelvax,,CSL Limited,CSL:AU,,Australia,Oceania,,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,10/31/12,06/01/07,,,,12/31/11,,,,,07/15/10,10/25/05,10/20/04,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
39395,3300,55097,870,Flucelvax Quadrivalent,,CSL Limited,CSL:AU,,Australia,Oceania,,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,05/23/16,12/12/18,,,,04/23/15,,,,,11/18/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2108,3300,3482,180,FluLaval,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,"Intramuscular (IM), Subcutaneous (SQ)",Y,N,N,N,N,N,,,,10/05/06,,,,,03/23/06,,,,,03/15/05,,,N/A,,N/A,N/A,$   524.9,N/A,N/A,N/A,$   709.3,$    20.3,Q1 2019,N/A
344,3300,653,45,FluMist - Refrigerated Formulation,,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intranasal,N,N,N,N,N,N,,,,01/08/07,02/01/11,,,,09/19/05,,,,,10/13/03,,,N/A,,N/A,N/A,$    15.0,N/A,N/A,$    78.0,$   110.0,N/A,Q3 2018,Pfizer Inc.
15887,3300,20337,45,FluMist Quadrivalent,,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intranasal,N,N,N,N,N,N,,,03/01/2017 - 09/30/2017,02/29/12,12/06/13,,,,,03/31/09,,,,03/10/09,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Daiichi Sankyo Co., Ltd., DRI Capital Inc."
18907,167,24871,3449,Fluoxetine Tablets,fluoxetine,"Edgemont Pharmaceuticals, LLC",,Texas,United States,North America,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/06/11,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18907,2051,24872,3449,Fluoxetine Tablets,fluoxetine,"Edgemont Pharmaceuticals, LLC",,Texas,United States,North America,,Psychiatry,Other,Obsessive-Compulsive Disorder (OCD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/06/11,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18907,2951,24873,3449,Fluoxetine Tablets,fluoxetine,"Edgemont Pharmaceuticals, LLC",,Texas,United States,North America,,Psychiatry,Other,Eating Disorders,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/06/11,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18907,634,24874,3449,Fluoxetine Tablets,fluoxetine,"Edgemont Pharmaceuticals, LLC",,Texas,United States,North America,,Psychiatry,Anxiety,Panic Disorder,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/06/11,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
381,3300,1579,870,Fluvirin,,CSL Limited,CSL:AU,,Australia,Oceania,,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,N,N,N,,,,10/18/01,,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
2357,3300,3968,51,Fluzone,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,"Intramuscular (IM), Intradermal",N,N,N,N,N,N,,,,09/14/02,02/24/09,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
13544,3300,17103,51,Fluzone High Dose,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,12/23/09,,,,,03/02/09,,,,,10/26/08,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
17518,3300,22821,51,Fluzone Quadrivalent,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,Antiviral,Seasonal Influenza Vaccines,N,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,"Intramuscular (IM), Intradermal",N,N,N,N,N,N,,,,06/10/13,,,,,10/18/12,10/08/10,,,,10/08/10,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
415,246,709,289,Focalin,,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,11/13/01,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Celgene Corporation, Johnson Matthey Plc"
818,246,738,289,Focalin XR,,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/26/05,,,,,07/08/04,07/02/03,,,,07/02/03,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Alkermes plc, Celgene Corporation"
1079,205,2451,9097,Folotyn,pralatrexate,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Hematologic,Non-Hodgkin's Lymphoma (NHL),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR),New Molecular Entity (NME),No,Intravenous (IV),Y,Y,Y,,N,N,,,,09/24/09,,,,,,,,,,,,,100%,57.7,$    46.3,$    43.1,$    47.9,N/A,$    46.3,$    43.1,$    47.9,N/A,Q4 2018,"Clinigen Group plc, Mundipharma International Limited"
1079,3097,28235,9097,Folotyn,pralatrexate,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Hematologic,Peripheral T-Cell Lymphoma (PTCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR),New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,N,N,N,,,,09/24/09,,07/03/17,,,,,08/01/06,,,,07/01/05,,100%,,$    46.3,$    43.1,$    47.9,N/A,$    46.3,$    43.1,$    47.9,N/A,Q4 2018,"Clinigen Group plc, Mundipharma International Limited"
1266,72,1621,254,Foradil Aerolizer,formoterol fumarate,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,New Molecular Entity (NME),No,Inhaled,N,N,N,,N,N,,,,02/16/01,,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,"Astellas Pharma, Inc., Novartis AG"
1266,73,3065,254,Foradil Aerolizer,formoterol fumarate,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,New Molecular Entity (NME),No,Inhaled,N,N,N,,N,N,,,,09/25/01,03/08/04,,,,,,,,,05/08/00,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,"Astellas Pharma, Inc., Novartis AG"
18340,167,24010,3449,Forfivo,bupropion hydrochloride,"Edgemont Pharmaceuticals, LLC",,Texas,United States,North America,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,11/10/11,,,,,04/07/09,,,,,,04/07/08,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Cary Pharmaceuticals, IntelGenx Technologies Corp., SWK Holdings Corporation"
271,242,433,136,Forteo,teriparatide recombinant human,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,Y,Approved,Approved,100% (Same As Avg.),Protein,Parathyroid Hormone Receptor (PTHR),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,12/01/02,06/01/03,,,,,,,,,,,,100%,2556.2,$   770.5,$   965.3,$   757.3,$   298.7,"$  1,500.0","$  1,749.1","$  1,575.6",$   673.7,Q2 2019,Johnson &amp; Johnson
1061,549,2004,410,Fortesta,testosterone,"Kyowa Hakko Kirin Co., Ltd.",4151:JP,,Japan,Asia,,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Transdermal,N,Y,N,,N,N,,,,12/29/10,12/30/04,,,,06/03/02,,,,,08/25/03,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    25.6,$    11.0,Q2 2019,Endo International plc
21683,242,29269,2817,Fortical,,"Sawai Pharmaceutical Co., Ltd.",4555:JP,Minnesota,United States,North America,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Calcitonin Receptor,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,08/12/05,,,,,,,,,,11/01/02,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Unigene Laboratories, Inc."
1789,3179,2853,826,Fosrenol,lanthanum carbonate,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Renal,Chronic Renal Failure,Hyperphosphatemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Phosphate,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/27/04,03/31/04,10/01/08,,,04/30/02,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$    62.8,N/A,N/A,N/A,Q3 2016,"Bayer AG, Sanofi"
1082,288,2092,142,Frova,frovatriptan succinate,Endo International plc,ENDP,,Ireland,Europe,554131557,Neurology,Headache,Migraine and Other Headaches,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT1 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/08/01,01/24/02,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2014,"Ligand Pharmaceuticals, Inc., The Menarini Group"
19865,91,26339,266,Fulphila,pegfilgrastim-jmdb,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Hematology,Marrow Or Peripheral Blood Stimulator,Neutropenia / Leukopenia,Y,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,06/04/18,11/20/18,,,,12/09/16,,,,,05/07/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Biocon, Ltd."
3017,684,5149,9097,Fusilev,levoleucovorin calcium,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Solid,Bone Cancer,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,03/07/08,06/01/98,10/01/99,,,12/18/90,,,,,01/03/92,,,100%,,$    34.9,$     7.4,$     2.4,N/A,N/A,$     7.4,$     2.4,N/A,Q4 2018,"Pfizer Inc., Sanofi"
3017,213,5571,9097,Fusilev,levoleucovorin calcium,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Solid,Colorectal Cancer (CRC),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,04/29/11,06/01/98,10/01/99,,,10/31/08,,,,,03/02/05,,,100%,,$    34.9,$     7.4,$     2.4,N/A,N/A,$     7.4,$     2.4,N/A,Q4 2018,"Pfizer Inc., Sanofi"
575,78,1222,21,Fuzeon,enfuvirtide,"Alexion Pharmaceuticals, Inc.",ALXN,Connecticut,United States,North America,24868581569,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Peptide,gp41,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,,N,N,,,,10/15/04,05/27/03,,,,09/13/02,,,,,,,,49.25%,14.9,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q1 2015,"Novartis AG, Roche Holding AG"
2066,3009,5333,134,Fycompa,perampanel,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMPA-type glutamate receptor,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,10/22/12,07/27/12,03/28/16,,,12/22/11,05/14/08,,,,05/14/08,02/02/07,,N/A,,$    49.0,$    63.7,$    82.4,N/A,$    95.0,$   133.8,$   176.5,N/A,Q4 2018,"Biotoscana International, Hikma Pharmaceuticals plc"
17864,701,23330,3645,Gablofen,baclofen,"Piramal Healthcare, Ltd.",PIHC:IN,,India,Asia,,Neurology,"movement disorders, all",Neuromuscular Spasm and Spasticity,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA Receptors,Non-NME,No,Intrathecal,N,N,N,,N,N,,,,11/19/10,,,,,03/30/09,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
40665,3502,57011,59,Gadavist,gadobutrol,Bayer AG,BAYRY,,Germany,Europe,,Cardiovascular,Coronary Artery Disease (General),Coronary Artery Disease  Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Blood plasma,Non-NME,Yes,Intravenous (IV),N,N,N,N,N,N,,,,07/12/19,,,,,,,,,,,,,N/A,,N/A,N/A,$   124.0,N/A,N/A,N/A,$   405.1,$   216.9,Q2 2019,N/A
40665,3242,57012,59,Gadavist,gadobutrol,Bayer AG,BAYRY,,Germany,Europe,,Neurology,General,Neurology - Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Blood plasma,Non-NME,Yes,Intravenous (IV),N,N,N,N,N,N,,,,03/14/11,,,,,05/13/10,,,,,,,,N/A,,N/A,N/A,$   124.0,N/A,N/A,N/A,$   405.1,$   216.9,Q2 2019,N/A
40665,800,57013,59,Gadavist,gadobutrol,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Solid,Breast Cancer - Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Blood plasma,Non-NME,Yes,Intravenous (IV),N,N,N,N,N,N,,,,06/11/14,,,,,12/10/13,,,,,,,,N/A,,N/A,N/A,$   124.0,N/A,N/A,N/A,$   405.1,$   216.9,Q2 2019,N/A
6669,274,6933,1259,Galafold,migalastat hydrochloride,"Amicus Therapeutics, Inc.",FOLD,New Jersey,United States,North America,,Metabolic,Inborn Errors Of Metabolism,Fabry's Disease,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha-galactosidase,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,08/10/18,05/26/16,03/22/18,,,12/14/17,06/22/09,08/31/05,08/05/04,,06/22/09,09/08/05,08/05/04,N/A,,N/A,N/A,N/A,$     9.1,N/A,N/A,$    91.3,$    34.0,Q1 2019,GlaxoSmithKline plc
24699,422,34324,465,Gamifant,emapalumab-lzsg,Swedish Orphan Biovitrum,SOBI:SS,,Sweden,Europe,,Autoimmune/immunology,General,Inflammatory Disorders,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Interferon-gamma (IFN-g)/Type II Interferon,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,07/01/2019 - 01/31/2020,,11/20/18,,,,,03/20/18,,,,,,03/25/13,10/24/11,N/A,,N/A,N/A,N/A,$    31.4,N/A,N/A,N/A,$    31.4,Q2 2019,N/A
8394,3161,16936,826,Gammagard,"Immune Globulin Intravenous (Human), 10% Solution",Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Neurology,Neurodegenerative,Multifocal Motor Neuropathy (MMN),N,Approved,Approved,100% (Same As Avg.),Protein,Amyloid Beta/Amyloid Plaques^ Immune system,Biologic,No,Intravenous (IV),N,N,Y,,N,N,,,,06/25/12,07/27/11,,,,01/09/12,07/01/08,,,,10/16/08,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
14279,423,18075,826,Gammagard (Subcutaneous),,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/22/11,06/10/16,,,,07/22/10,,,,,03/16/08,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22097,423,29901,4169,Gammaplex,,Bio Products Laboratory Ltd.,,,United Kingdom,Europe,,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,09/17/09,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
22097,649,29902,4169,Gammaplex,,Bio Products Laboratory Ltd.,,,United Kingdom,Europe,,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),N,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,03/08/13,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
15904,3160,20371,2858,Gamunex (IV),"Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified","Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Neurology,Other,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),N,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,Y,,N,N,,,,09/12/08,07/02/09,,,,,,,,,02/07/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2010,Kedrion S.p.A.
15904,423,20372,2858,Gamunex (IV),"Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified","Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,08/27/03,06/08/06,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2010,Kedrion S.p.A.
15904,649,20373,2858,Gamunex (IV),"Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified","Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,08/27/03,06/08/06,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2010,Kedrion S.p.A.
15920,423,20396,2858,Gamunex-C (SQ),"Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified","Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,10/13/10,,,,,,,,,,07/23/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Kedrion S.p.A.
21420,3023,28863,4008,Garamycin Ophthalmic Ointment (generic),Garamycin,Fera Pharmaceuticals,,New York,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Topical,N,N,N,,N,N,,,,07/30/04,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
21421,3023,28864,4008,Garamycin Ophthalmic Solution USP 0.3% (generic),Garamycin,Fera Pharmaceuticals,,New York,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Topical,N,N,N,,N,N,,,,01/30/04,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
1912,3080,3083,254,Gardasil,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,"Human papillomavirus (HPV) Prevention (Antiviral, Vaccines)",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Human Papillomavirus (HPV)^ Immune system,Vaccine,No,Intramuscular (IM),Y,N,N,N,N,N,,,,06/08/06,09/20/06,07/01/11,,,12/01/05,,,,,02/02/05,01/25/05,,75%,,"$  1,506.0","$  1,564.0","$  1,872.0",$   818.0,"$  2,173.0","$  2,309.0","$  3,151.0","$  1,724.0",Q2 2019,"AstraZeneca PLC, CSL Limited, GlaxoSmithKline plc"
14245,3080,18036,254,Gardasil 9,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,"Human papillomavirus (HPV) Prevention (Antiviral, Vaccines)",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Human Papillomavirus (HPV)^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,12/10/14,06/10/15,,,,12/10/13,,,,,12/09/08,09/20/06,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
698,581,2331,826,Gattex,teduglutide,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Gastroenterology (non inflammatory bowel disease),Other,Short Bowel Syndrome (SBS),Y,Approved,Approved,100% (Same As Avg.),Peptide,GLP-2 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,Y,,N,N,,,01/01/2015 - 01/01/2015,12/21/12,08/30/12,,,,11/30/11,04/06/04,,,,04/06/04,,06/29/00,100%,347.2,$   189.6,$   287.5,$   280.1,N/A,$   219.4,$   335.5,$   443.2,N/A,Q3 2018,N/A
11082,200,19851,149,Gazyva,obinutuzumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,11/01/13,07/23/14,,,,04/20/13,12/16/09,,,,12/16/09,12/09/08,,62%,381.1,$   118.5,$   163.5,$   198.1,$   110.1,$   200.2,$   287.8,$   396.0,$   241.1,Q2 2019,"Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., PDL BioPharma, Inc."
11082,3093,27849,149,Gazyva,obinutuzumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,02/26/16,06/13/16,07/02/18,,,08/31/15,03/17/10,,,,03/17/10,06/17/08,,62%,,$   118.5,$   163.5,$   198.1,$   110.1,$   200.2,$   287.8,$   396.0,$   241.1,Q2 2019,"Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., PDL BioPharma, Inc."
8161,543,10078,395,Gelnique,oxybutynin chloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Urology,Other,Overactive Bladder (OAB),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel^ Muscarinic acetylcholine receptor,Non-NME,No,"Topical, Transdermal",N,N,N,,N,N,,,,01/27/09,09/27/11,,,,03/27/08,,,,,01/07/08,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1825,214,2920,136,Gemzar,gemcitabine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Breast Cancer,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,05/19/04,06/22/03,,,,12/18/03,,,,,12/12/02,05/12/01,,100%,,$     -2.1,$     3.6,N/A,N/A,$   111.1,$   111.0,N/A,N/A,Q4 2017,N/A
1825,224,2921,136,Gemzar,gemcitabine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Ovarian Cancer,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,07/14/06,07/29/04,,,,06/17/05,,,,,06/06/04,,,100%,,$     -2.1,$     3.6,N/A,N/A,$   111.1,$   111.0,N/A,N/A,Q4 2017,N/A
17789,239,23207,395,Generess Fe,estradiol/norethindrone acetate/ferrous fumarate,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/22/10,,,,,11/25/09,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
3063,608,5237,5,Gengraf,cyclosporine,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Transplant Rejection,Heart Transplant Rejection,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Calcineurin phosphatase,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/12/00,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3063,380,5238,5,Gengraf,cyclosporine,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Transplant Rejection,Kidney Transplant Rejection,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Calcineurin phosphatase,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/12/00,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3063,727,5239,5,Gengraf,cyclosporine,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Transplant Rejection,Liver Transplant Rejection,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Calcineurin phosphatase,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/12/00,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3063,154,5240,5,Gengraf,cyclosporine,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Calcineurin phosphatase,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/12/00,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3063,155,5241,5,Gengraf,cyclosporine,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,Calcineurin phosphatase,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/12/00,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2845,306,4861,312,Genotropin,somatropin recombinant,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Short Stature,Turner Syndrome,N,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,04/27/06,,,,,06/28/05,,,,,,,,N/A,,$   141.0,$    98.0,$   129.0,$    34.0,$   578.0,$   532.0,$   557.0,$   232.0,Q2 2019,N/A
2845,708,4862,312,Genotropin,somatropin recombinant,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Other,Prader-Willi Syndrome,N,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,06/20/00,,,,,,,,,,,,,N/A,,$   141.0,$    98.0,$   129.0,$    34.0,$   578.0,$   532.0,$   557.0,$   232.0,Q2 2019,N/A
19497,78,25714,179,Genvoya,emtricitabine; cobicistat; elvitegravir; tenofovir alafenamide,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ HIV Integrase^ Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/05/15,11/19/15,06/17/16,,,11/05/14,01/24/13,12/23/11,10/19/10,,01/24/13,12/23/11,10/19/10,N/A,,"$  1,301.0","$  3,033.0","$  3,631.0","$  1,461.0","$  1,484.0","$  3,674.0","$  4,624.0","$  1,995.0",Q2 2019,N/A
1892,170,3048,312,Geodon  (Oral and IM),ziprasidone hydrochloride (oral) or mesylate (IM),Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,,N,N,,,,02/05/01,07/01/98,,,,,,,,,,,,100%,0,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2013,"Ligand Pharmaceuticals, Inc., Meiji Seika Pharma Co., Ltd, RaQualia Pharma Inc."
1892,168,3052,312,Geodon  (Oral and IM),ziprasidone hydrochloride (oral) or mesylate (IM),Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Psychiatry,Bipolar,Bipolar Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,,N,N,,,,08/19/04,10/31/05,,,,10/21/03,,,,,04/01/03,,,100%,0,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2013,"Ligand Pharmaceuticals, Inc., Meiji Seika Pharma Co., Ltd, RaQualia Pharma Inc."
22551,3577,33726,453,Giapreza,angiotensin II,La Jolla Pharmaceutical Company,LJPC,California,United States,North America,243448095,Cardiovascular,Other,Hypotension/Shock,Y,Approved,Approved,100% (Same As Avg.),Peptide,Angiotensin II Receptor Type 1 (AT1)^ Angiotensin II Receptor Type 2 (AT2),New Molecular Entity (NME),No,Intravenous (IV),N,Y,N,N,N,N,,06/27/2019 - 09/02/2019,,12/21/17,,,,,08/28/17,,,,,01/13/15,,07/23/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    10.1,$     4.4,Q1 2019,HealthCare Royalty Partners
7783,321,9575,470,Giazo,,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/03/12,,,,,07/17/07,,,,,01/11/06,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Takeda Pharmaceutical Company Ltd, The Menarini Group"
1814,153,3045,289,Gilenya,fingolimod hydrochloride,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Sphingosine 1-Phosphate Receptor (S1P-R),New Molecular Entity (NME),No,Oral (PO),Y,N,N,Y,N,N,,,,09/21/10,03/17/11,09/26/11,,,12/18/09,01/19/06,,,,01/19/06,01/30/04,,95%,1340.5,"$  1,683.0","$  1,709.0","$  1,765.0",$   392.0,"$  3,109.0","$  3,185.0","$  3,381.9",$   774.2,Q1 2019,Mitsubishi Tanabe Pharma Corporation
8414,211,10454,70,Gilotrif,afatinib,Boehringer Ingelheim GmbH,,,Germany,Europe,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor)^ ErbB3/HER3^ ErbB4/HER4^ HER2/neu or ErbB-2,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,07/12/13,09/25/13,01/07/14,,,11/15/12,04/04/08,,,,04/04/08,09/03/07,,N/A,743.6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16947,533,21981,826,Glassia (IV),alpha 1 proteinase inhibitor,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Respiratory,Other,Emphysema,Y,Approved,Approved,100% (Same As Avg.),Protein,Alpha-1-antitrypsin (A1AT)^ Protease,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,07/01/10,,,,,05/29/09,,,,,10/16/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q3 2013,"Chiesi Farmaceutici S.p.A., Kamada Ltd."
8661,153,10767,945,Glatopa,glatiramer acetate,"Momenta Pharmaceuticals, Inc.",MNTA,Massachusetts,United States,North America,932506725,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Peptide,T lymphocytes,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/16/15,,,,,12/27/07,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
1461,198,2950,289,Gleevec,imatinib mesylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Chronic Myelogenous Leukemia (CML),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,05/10/01,11/07/01,,,,,,,,,,,,N/A,,"$  1,214.0",$   627.0,$   440.0,$   175.0,"$  3,323.0","$  1,943.0","$  1,561.0",$   630.0,Q2 2019,N/A
1461,626,2970,289,Gleevec,imatinib mesylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Gastrointestinal Stromal Tumor (GIST),N,Approved,Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,,N,N,,,,02/01/02,05/31/02,07/17/07,,,,,,,,,,,N/A,,"$  1,214.0",$   627.0,$   440.0,$   175.0,"$  3,323.0","$  1,943.0","$  1,561.0",$   630.0,Q2 2019,N/A
1461,199,3981,289,Gleevec,imatinib mesylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/19/06,09/19/06,01/31/07,,,12/21/05,,,,,09/20/05,05/24/02,,N/A,,"$  1,214.0",$   627.0,$   440.0,$   175.0,"$  3,323.0","$  1,943.0","$  1,561.0",$   630.0,Q2 2019,N/A
1461,686,4472,289,Gleevec,imatinib mesylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Hypereosinophilic Syndrome (HES),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/19/06,11/28/06,,,,03/29/06,,,,,,03/27/03,,N/A,,"$  1,214.0",$   627.0,$   440.0,$   175.0,"$  3,323.0","$  1,943.0","$  1,561.0",$   630.0,Q2 2019,N/A
1461,663,4473,289,Gleevec,imatinib mesylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Other,Mastocytosis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/19/06,,,,,03/01/06,,,,,,,,N/A,,"$  1,214.0",$   627.0,$   440.0,$   175.0,"$  3,323.0","$  1,943.0","$  1,561.0",$   630.0,Q2 2019,N/A
1461,695,4474,289,Gleevec,imatinib mesylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Dermatofibrosarcoma protuberans (DFSP),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/19/06,09/19/06,,,,12/19/05,,,,,08/26/05,,,N/A,,"$  1,214.0",$   627.0,$   440.0,$   175.0,"$  3,323.0","$  1,943.0","$  1,561.0",$   630.0,Q2 2019,N/A
1461,206,4892,289,Gleevec,imatinib mesylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Myelodysplastic Syndrome (MDS),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/19/06,11/28/06,,,,12/19/05,,,,,,,,N/A,,"$  1,214.0",$   627.0,$   440.0,$   175.0,"$  3,323.0","$  1,943.0","$  1,561.0",$   630.0,Q2 2019,N/A
1461,2744,18597,289,Gleevec,imatinib mesylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Myeloproliferative Disorders (MPD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/20/06,11/28/06,,,,12/19/05,,,,,,,,N/A,,"$  1,214.0",$   627.0,$   440.0,$   175.0,"$  3,323.0","$  1,943.0","$  1,561.0",$   630.0,Q2 2019,N/A
25381,3203,37365,7446,Gleolan,aminolevulinic acid hydrochloride,photonamic GmbH and Co. KG,,,Germany,Europe,,Oncology,Solid,Brain Cancer - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reactive Oxygen Species/Free Radicals,Non-NME,Yes,"Oral (PO), Topical",N,N,Y,N,N,N,,,,06/06/17,09/07/07,03/13/13,,,12/06/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Chugai Pharmaceutical Co., Ltd., medac GmbH, SBI Pharmaceuticals Co. Ltd., Specialised Therapeutics Australia Pty, Ltd."
40694,539,57054,9250,Gloperba,colchicine,"ROMEG Therapeutics, LLC",,Massachusetts,United States,North America,,Autoimmune/immunology,Arthritis,Gout,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/30/19,,,,,03/30/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Avion Pharmaceuticals, LLC"
2985,137,5088,470,Glumetza,metformin (modified release),Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/03/05,,,,,04/27/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$   133.0,$   113.0,$    38.0,Q1 2019,"LG Chem, Ltd., PDL BioPharma, Inc."
38548,147,53820,8538,Glyrx-PF,glycopyrrolate,"Exela Pharma Sciences, LLC",,North Carolina,United States,North America,,Gastroenterology (non inflammatory bowel disease),"Acid-Peptic (Gastritis Peptic Ulcer, Etc.)",Ulcers and other acid-peptic gastrointestinal disorders,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,Non-NME,No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,07/11/18,,,,,09/05/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38548,531,53839,8538,Glyrx-PF,glycopyrrolate,"Exela Pharma Sciences, LLC",,North Carolina,United States,North America,,Neurology,Pain,Anesthesia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,Non-NME,No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,07/11/18,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18861,137,24799,70,Glyxambi,empagliflozin and linagliptin,Boehringer Ingelheim GmbH,,,Germany,Europe,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl peptidase IV (DPP-IV)^ SGLT,Non-NME,No,Oral (PO),N,N,N,N,N,N,,09/16/2016 - 11/21/2016,,01/30/15,,11/20/18,,,01/29/14,09/21/11,,,,01/11/11,,,50%,718.7,N/A,$   114.5,N/A,N/A,N/A,$   177.2,N/A,N/A,Q2 2017,Eli Lilly &amp; Company
18613,3245,24436,2838,Gocovri,amantadine HCl extended release,"Adamas Pharmaceuticals, Inc.",ADMS,California,United States,North America,170027015,Neurology,"movement disorders, all",Levodopa-Induced Dyskinesia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine^ NMDA Glutamate Receptor^ Norepinephrine (Noradrenaline),Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,08/24/17,,,,,10/24/16,07/18/11,,,,07/18/11,,,N/A,,N/A,N/A,$    34.1,$    11.7,N/A,N/A,$    34.1,$    11.7,Q1 2019,N/A
29687,446,41180,6255,GoNitro,nitroglycerin,"Espero Biopharma, Inc.",,Florida,United States,North America,,Cardiovascular,Other,Angina,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Guanylate Cyclase (sGC),Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,06/08/16,,,,,08/10/15,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,G Pohl Boskamp GmbH &amp; Co.
1315,3157,1686,120,Gralise,,"Assertio Therapeutics, Inc.",ASRT,Illinois,United States,North America,,Neurology,Pain,Postherpetic Neuralgia (PHN),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,Non-NME,No,Oral (PO),N,N,Y,,N,N,,,,01/28/11,,,,,03/30/10,05/10/06,02/14/05,,,05/10/06,02/14/05,,N/A,,N/A,N/A,$    58.0,$    13.3,N/A,N/A,$    58.0,$    13.3,Q1 2019,N/A
19415,767,25596,3556,Granisol,Granisetron HCl,"OncBioMune Pharmaceuticals, Inc.",OTCQB:OBMP,Louisiana,United States,North America,,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT3 receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,02/28/08,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
16144,91,20730,375,Granix,"Tbo-filgrastim, granulocyte colony-stimulating factor",Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Hematology,Marrow Or Peripheral Blood Stimulator,Neutropenia / Leukopenia,Y,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,,N,N,,,,08/29/12,09/16/08,,,,11/30/09,,,,,02/21/08,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
3087,236,5292,254,Grastek,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Natural Protein,Immune system,Biologic,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,04/11/14,09/25/06,,,,01/25/13,,,,,12/11/06,,05/23/06,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   102.2,$    38.9,Q1 2019,"ALK-Abello A/S, CSL Limited, The Menarini Group"
16222,3007,20873,556,H.P. Acthar Gel,corticotropin,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Neurology,Seizure Disorders (Epilepsy),Infantile Spasms (West Syndrome; Epilepsy),N,Approved,Approved,100% (Same As Avg.),Peptide,Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),Non-NME,No,"Intramuscular (IM), Oral (PO), Subcutaneous (SQ)",N,N,Y,,N,N,,,,10/15/10,,,,,06/23/06,,,,,07/31/01,,,N/A,,"$  1,160.4","$  1,195.1","$  1,110.1",$   490.3,"$  1,160.4","$  1,195.1","$  1,110.1",$   490.3,Q2 2019,N/A
2588,3301,4395,51,H5N1 Vaccine (SNY),"Influenza Virus Vaccine, H5N1",Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,Antiviral,Pandemic Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,04/17/07,,,,,,,,,,,,03/23/05,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
24040,154,33202,4607,Hadlima,adalimumab-bwwd,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/23/19,08/24/17,,,,07/23/18,04/08/14,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    16.7,$    83.0,Q2 2019,"Merck &amp; Co., Inc."
24040,252,41835,4607,Hadlima,adalimumab-bwwd,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/23/19,08/24/17,,,,07/23/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    16.7,$    83.0,Q2 2019,"Merck &amp; Co., Inc."
24040,155,41836,4607,Hadlima,adalimumab-bwwd,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/23/19,08/24/17,,,,07/23/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    16.7,$    83.0,Q2 2019,"Merck &amp; Co., Inc."
24040,336,41837,4607,Hadlima,adalimumab-bwwd,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/23/19,08/24/17,,,,07/23/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    16.7,$    83.0,Q2 2019,"Merck &amp; Co., Inc."
24040,156,41838,4607,Hadlima,adalimumab-bwwd,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/23/19,08/24/17,,,,07/23/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    16.7,$    83.0,Q2 2019,"Merck &amp; Co., Inc."
24040,321,41839,4607,Hadlima,adalimumab-bwwd,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/23/19,08/24/17,,,,07/23/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    16.7,$    83.0,Q2 2019,"Merck &amp; Co., Inc."
24040,365,49093,4607,Hadlima,adalimumab-bwwd,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/23/19,08/24/17,,,,07/23/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    16.7,$    83.0,Q2 2019,"Merck &amp; Co., Inc."
19907,556,26401,870,Haegarda,C1 esterase inhibitor (human),CSL Limited,CSL:AU,,Australia,Oceania,,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Y,Approved,Approved,100% (Same As Avg.),Protein,Complement Pathway,Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,06/22/17,,,,,06/30/16,,,,,02/20/14,04/10/12,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
3041,214,5180,134,Halaven,eribulin mesylate,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,N,,,,11/15/10,03/17/11,04/22/11,,,03/30/10,10/01/06,,,,06/01/06,12/08/05,,N/A,,$   122.8,$   146.4,$   147.9,N/A,$   266.4,$   362.8,$   376.6,N/A,Q4 2018,"Bausch Health Companies Inc., Biotoscana International, Ewopharma AG, IQVIA Holdings Inc., NewBridge Pharmaceuticals"
3041,610,5332,134,Halaven,eribulin mesylate,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Oncology,Solid,Sarcoma,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),New Molecular Entity (NME),No,Intravenous (IV),N,N,Y,N,N,N,,,,01/28/16,05/02/16,02/29/16,,,07/29/15,03/31/11,,,,03/31/11,02/02/07,,N/A,,$   122.8,$   146.4,$   147.9,N/A,$   266.4,$   362.8,$   376.6,N/A,Q4 2018,"Bausch Health Companies Inc., Biotoscana International, Ewopharma AG, IQVIA Holdings Inc., NewBridge Pharmaceuticals"
20728,176,27723,179,Harvoni,sofosbuvir/ledipasvir,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,HCV Polymerase - Nucleoside Binding Site^ Non-structural 5A protein (NS5A),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,10/10/14,11/17/14,07/03/15,,,02/10/14,10/04/12,,,,05/07/12,,,100%,7154.9,"$  4,941.0","$  3,053.0",$   802.0,$   203.0,"$  9,081.0","$  4,370.0","$  1,222.0",$   418.0,Q2 2019,Biotoscana International
21739,3241,29350,906,Hemangeol,propranolol hydrochloride,Pierre Fabre Medicament S.A.,,,France,Europe,,Dermatology,General,Hemangioma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,03/17/14,04/23/14,,,,05/17/13,,,,,03/03/10,09/05/08,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Maruho Co., Ltd."
21209,511,28544,149,Hemlibra,emicizumab-kxwh,Roche Holding AG,RHHBY,,Switzerland,Europe,,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor IX^ Coagulation Factor X,Biologic,No,Subcutaneous (SQ),N,N,Y,Y,N,N,,,,11/16/17,02/27/18,03/23/18,,,06/23/17,12/02/15,09/30/14,,,12/02/15,09/30/14,01/10/14,N/A,,N/A,$     3.1,$   235.6,$   380.9,N/A,$     3.1,$   342.2,$   534.9,Q2 2019,"Chugai Pharmaceutical Co., Ltd., JW Pharmaceutical Corporation"
2538,1328,4316,7775,HepaGam B,Hepatitis B Immune Globulin Intravenous (Human),Saol Therapeutics,,Georgia,United States,North America,,Infectious disease,Antiviral,"Hepatitis B Prevention (Vaccines, Antiviral)",Y,Approved,Approved,100% (Same As Avg.),Polyclonal Antibody,Hepatitis B/HBV,Biologic,No,Intravenous (IV),N,N,Y,,N,N,,,,01/30/06,03/17/10,,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
1688,1328,2712,133,Heplisav-B,,Dynavax Technologies Corporation,DVAX,California,United States,North America,220047087,Infectious disease,Antiviral,"Hepatitis B Prevention (Vaccines, Antiviral)",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Toll-like receptor 9 (TLR9),Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,02/01/2020 - 08/31/2020,,11/09/17,,,,,04/26/12,,,,,09/02/04,,,N/A,,N/A,N/A,$     6.9,$     5.6,N/A,N/A,$     6.9,$     5.6,Q1 2019,Pfizer Inc.
329,319,619,179,Hepsera,Adefovir,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/20/02,03/06/03,12/01/04,,,,,,,,03/17/99,09/16/96,,100%,10.8,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q1 2014,GlaxoSmithKline plc
62,223,4102,149,Herceptin,trastuzumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Gastric Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,10/20/10,01/28/10,03/10/11,,,04/19/10,,,,,10/19/05,,,97.88%,55,"$  2,562.6","$  2,739.2","$  2,973.8","$  1,509.6","$  6,899.9","$  7,125.3","$  7,141.0","$  3,265.1",Q2 2019,"Chugai Pharmaceutical Co., Ltd., PDL BioPharma, Inc."
14195,214,17974,149,Herceptin Hylecta,trastuzumab and hyaluronidase-oysk,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,02/28/19,09/02/13,,,,05/01/18,10/22/09,,,,10/22/09,,12/08/08,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Halozyme Therapeutics, Inc., PDL BioPharma, Inc."
19641,214,25932,375,Herzuma,trastuzumab-pkrb,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/14/18,02/09/18,03/31/18,,,05/30/17,,,,,,,01/27/16,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Celltrion, Inc., Mundipharma International Limited, Vcell Healthcare Limited"
2672,3387,4561,734,Hetlioz,tasimelteon,"Vanda Pharmaceuticals, Inc.",VNDA,,United States,North America,789370694,Neurology,Other,Non-24 Hour Sleep Wake Disorder (Non-24),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Melatonin Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,01/31/14,07/03/15,,,,05/31/13,02/03/06,,,,05/18/06,12/29/05,,100%,179.1,$    71.7,$    90.0,$   115.7,$    66.8,$    71.7,$    90.0,$   115.7,$    66.8,Q2 2019,Bristol-Myers Squibb Company
20948,3198,28094,180,Hiberix,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Hib vaccines (Haemophilus influenzae b),Y,Approved,Approved,100% (Same As Avg.),Vaccine,Haemophilus influenzae^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,08/19/09,,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
15067,423,19139,870,Hizentra,Immune Globulin Subcutaneous (Human),CSL Limited,CSL:AU,,Australia,Oceania,,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,03/04/10,04/14/11,09/27/13,,,04/30/09,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
15067,3160,26105,870,Hizentra,Immune Globulin Subcutaneous (Human),CSL Limited,CSL:AU,,Australia,Oceania,,Neurology,Other,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),N,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,03/16/18,03/05/18,03/26/19,,,,03/12/12,,,,03/12/12,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3116,579,5340,4042,Horizant,gabapentin enacarbil,"Arbor Pharmaceuticals, LLC",,Georgia,United States,North America,,Neurology,"movement disorders, all",Restless Leg Syndrome (RLS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,01/01/2015 - 01/01/2015,,04/06/11,,01/18/12,,,01/09/09,03/14/06,07/14/04,,,03/14/06,07/14/04,11/10/03,100%,138,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q2 2015,"Astellas Pharma, Inc."
3116,3157,5342,4042,Horizant,gabapentin enacarbil,"Arbor Pharmaceuticals, LLC",,Georgia,United States,North America,,Neurology,Pain,Postherpetic Neuralgia (PHN),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,New Molecular Entity (NME),No,Oral (PO),N,N,Y,,N,N,,,,06/06/12,,,,,08/09/11,,,,,,07/14/04,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q2 2015,"Astellas Pharma, Inc."
242,154,342,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,12/31/02,09/08/03,04/16/08,,,04/15/02,02/04/00,,,,02/04/00,,,97.3%,8185.8,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
242,365,343,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,02/21/08,09/12/08,07/01/11,,,04/26/07,,,,,09/09/02,,,97.3%,147.5,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
242,156,344,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,02/27/07,06/07/07,10/29/10,,,09/07/06,09/29/03,,,,09/30/03,09/09/02,,97.3%,1462.6,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
242,336,474,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,10/03/05,08/15/05,01/20/10,,,12/16/04,03/03/03,,,,03/03/03,02/04/03,,97.3%,89.6,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
242,155,475,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,01/18/08,12/20/07,01/20/10,,,03/23/07,12/01/04,,,,10/14/04,02/04/03,,97.3%,1227.9,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
242,252,2182,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,07/31/06,06/07/06,10/29/10,,,10/04/05,02/05/04,,,,02/05/04,,,97.3%,439.3,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
242,321,4064,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,09/28/12,04/11/12,06/14/13,,,01/26/11,12/05/06,,,,12/05/06,10/19/05,,97.3%,,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
242,307,21872,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Ophthalmology,Uveitis,Uveitis (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,06/30/16,06/24/16,09/28/16,,,09/03/15,,,,,06/04/10,,,97.3%,,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
242,3332,25132,5,Humira,adalimumab,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Dermatology,General,Hidradenitis Suppurativa,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,09/09/15,07/30/15,02/21/19,,,11/10/14,11/07/11,,,,11/07/11,03/02/11,,97.3%,,"$ 10,432.0","$ 12,361.0","$ 13,685.0","$  3,215.0","$ 16,078.0","$ 18,427.0","$ 20,467.8","$  4,562.2",Q1 2019,"Eisai Co., Ltd., Royalty Pharma AG"
2093,255,3488,289,Hycamtin,topotecan hydrochloride,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Cervical Cancer,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Topoisomerase I (Topo-I),New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,06/14/06,12/01/06,,,,12/15/05,,,,,02/09/04,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2011,N/A
2626,545,4487,583,Hydase,,Akorn Inc.,AKRX,Illinois,United States,North America,352633568,Ophthalmology,Other,Spreading Agent,Y,Approved,Approved,100% (Same As Avg.),Protein,Hyaluronic acid,New Molecular Entity (NME),No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,,N,N,,,,10/25/05,,,,,10/20/03,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Primapharm, Inc."
37943,706,52951,8373,Hydrocodone Bitartrate and Guaifenesin,,"ECI Pharmaceuticals, LLC",,Florida,United States,North America,,Infectious disease,Antiviral,Viral Rhinitis (Common Cold),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/24/18,,,,,04/13/16,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2115,545,3521,789,Hylenex,hyaluronidase (human recombinant),"Halozyme Therapeutics, Inc.",HALO,California,United States,North America,2344723347,Ophthalmology,Other,Spreading Agent,Y,Approved,Approved,100% (Same As Avg.),Protein,Hyaluronic acid,Biologic,No,"Subcutaneous (SQ), Intradermal",N,N,N,N,N,N,,,,12/02/05,,,,,03/28/05,,,,,,,,100%,11.1,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
11081,423,13923,826,HyQvia,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/12/14,05/16/13,,,,06/30/11,01/05/09,,,,01/05/09,09/10/07,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Halozyme Therapeutics, Inc."
23452,155,32198,289,Hyrimoz,adalimumab-adaz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/30/18,07/27/18,,,,10/30/17,12/19/13,,,,12/19/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23452,154,40410,289,Hyrimoz,adalimumab-adaz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/30/18,07/27/18,,,,10/30/17,03/31/16,,,,03/31/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23452,365,48685,289,Hyrimoz,adalimumab-adaz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/30/18,07/27/18,,,,10/30/17,,,,,05/31/17,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23452,156,48686,289,Hyrimoz,adalimumab-adaz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/30/18,07/27/18,,,,10/30/17,,,,,05/31/17,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23452,336,48687,289,Hyrimoz,adalimumab-adaz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/30/18,07/27/18,,,,10/30/17,,,,,05/31/17,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23452,252,48688,289,Hyrimoz,adalimumab-adaz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/30/18,07/27/18,,,,10/30/17,,,,,05/31/17,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23452,321,48689,289,Hyrimoz,adalimumab-adaz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,10/30/18,07/27/18,,,,10/30/17,,,,,05/31/17,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22501,3629,30560,325,Hysingla ER,"hydrocodone bitartrate extended release, abuse-deterrent hydrocodone",Purdue Pharma L.P.,,Connecticut,United States,North America,,Neurology,Pain,Chronic Low Back Pain (CLBP),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/20/14,,,,,04/28/14,07/21/11,,,,07/21/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
16321,214,21045,312,Ibrance,palbociclib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cyclin Dependent Kinase (CDK),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,02/03/15,11/09/16,09/27/17,,,08/13/14,02/25/13,10/08/08,09/20/04,,02/25/13,10/08/08,09/20/04,92%,1661.9,"$  2,068.0","$  2,825.0","$  2,921.0","$  1,572.0","$  2,135.0","$  3,126.0","$  4,118.0","$  2,394.0",Q2 2019,"Amgen, Inc."
10582,198,17562,826,Iclusig,ponatinib,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Oncology,Hematologic,Chronic Myelogenous Leukemia (CML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ Fibroblast Growth Factor Receptor (FGFR)^ FMS-like tyrosine kinase 3 (FLT-3)^ RET^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,12/14/12,07/01/13,09/28/16,,,09/27/12,07/27/12,09/13/10,,,07/27/12,09/13/10,02/07/08,95%,151.1,N/A,$   172.0,$   236.0,$    56.3,N/A,$   238.9,$   344.6,$    85.1,Q1 2019,"ACRAF SpA (Gruppo Angelini), Biologix FZCo, Endo International plc, Gen Ilac A.C., Incyte Corporation, Medison Pharma Ltd., Otsuka Holdings Co., Ltd., PDL BioPharma, Inc., Pint Pharma International S.A.,, Specialised Therapeutics Australia Pty, Ltd."
10582,199,22463,826,Iclusig,ponatinib,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),N,Approved,Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ Fibroblast Growth Factor Receptor (FGFR)^ FMS-like tyrosine kinase 3 (FLT-3)^ RET^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,12/14/12,07/01/13,09/28/16,,,09/27/12,,09/13/10,,,,09/13/10,02/07/08,95%,75.5,N/A,$   172.0,$   236.0,$    56.3,N/A,$   238.9,$   344.6,$    85.1,Q1 2019,"ACRAF SpA (Gruppo Angelini), Biologix FZCo, Endo International plc, Gen Ilac A.C., Incyte Corporation, Medison Pharma Ltd., Otsuka Holdings Co., Ltd., PDL BioPharma, Inc., Pint Pharma International S.A.,, Specialised Therapeutics Australia Pty, Ltd."
17741,512,23131,870,Idelvion,albutrepenonacog alfa,CSL Limited,CSL:AU,,Australia,Oceania,,Hematology,Factor Augmentation,Hemophilia B,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor IX,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,03/04/16,05/11/16,09/29/16,,,12/05/14,01/12/12,07/21/11,10/01/10,,01/12/12,07/21/11,10/01/10,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
22255,97,30136,82,Idhifa,enasidenib,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Isocitrate Dehydrogenase (IDH),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,05/31/2019 - 11/30/2019,,08/01/17,,,,,12/31/16,,,08/09/13,,10/16/15,,08/09/13,N/A,,N/A,$    20.0,$    68.0,$    44.0,N/A,$    20.0,$    72.0,$    50.0,Q2 2019,"Agios Pharmaceuticals, Inc."
1882,365,4206,289,Ilaris,canakinumab,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-1 (Interleukin-1),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,Y,N,N,N,,,,05/10/13,09/03/13,,,,11/30/12,07/16/09,,,,07/16/09,07/17/07,01/31/07,N/A,,N/A,N/A,$   262.0,$   142.0,$   283.0,$   402.0,$   554.0,$   316.0,Q2 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Regeneron Pharmaceuticals, Inc., XOMA Corporation"
1882,656,13868,289,Ilaris,canakinumab,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Other,Cryopyrin (CIAS1)-Associated Periodic Syndromes (CAPS),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-1 (Interleukin-1),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,06/17/09,10/23/09,09/27/11,,,12/17/08,,,,,07/18/07,06/02/05,,N/A,,N/A,N/A,$   262.0,$   142.0,$   283.0,$   402.0,$   554.0,$   316.0,Q2 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Regeneron Pharmaceuticals, Inc., XOMA Corporation"
1882,3176,27100,289,Ilaris,canakinumab,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Other,Tumor Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-1 (Interleukin-1),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,Y,N,N,,,,09/23/16,02/23/17,12/31/16,,,03/23/16,07/09/14,,,,09/04/12,11/16/10,,N/A,,N/A,N/A,$   262.0,$   142.0,$   283.0,$   402.0,$   554.0,$   316.0,Q2 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Regeneron Pharmaceuticals, Inc., XOMA Corporation"
1882,422,28805,289,Ilaris,canakinumab,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,General,Inflammatory Disorders,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-1 (Interleukin-1),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,Y,N,N,,,,09/23/16,02/23/17,12/31/16,,,03/23/16,07/09/14,,,,07/09/14,02/14/11,,N/A,,N/A,N/A,$   262.0,$   142.0,$   283.0,$   402.0,$   554.0,$   316.0,Q2 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Regeneron Pharmaceuticals, Inc., XOMA Corporation"
18145,554,23735,289,Ilevro Suspension,nepafenac,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Topical,N,N,N,N,N,N,,,,10/16/12,05/03/13,,,,12/16/11,10/25/10,,,,10/25/10,03/16/10,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
16021,155,20534,3285,Ilumya,tildrakizumab-asmn,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-23 (Interleukin-23),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,05/01/2020 - 11/30/2020,03/20/18,09/18/18,,,,03/23/17,12/21/12,11/22/10,11/24/08,,12/21/12,11/22/10,11/24/08,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$     3.4,$     9.0,Q2 2019,"Almirall Prodesfarma, S.A., China Medical System Holdings Limited, Merck &amp; Co., Inc."
16220,476,20868,2750,Iluvien,fluocinolone acetonide,"Alimera Sciences, Inc.",ALIM,Georgia,United States,North America,39944960,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,09/26/14,04/24/12,,,,06/29/10,,,,,02/28/05,,,80%,,N/A,N/A,$    32.4,$    14.1,N/A,N/A,$    46.9,$    23.8,Q2 2019,"EyePoint Pharmaceuticals, Inc., Knight Therapeutics Inc., Ocumension Therapeutics, Societa Industria Farmaceutica Italiana S.p.A., Specialised Therapeutics Australia Pty, Ltd."
16220,307,24691,2750,Iluvien,fluocinolone acetonide,"Alimera Sciences, Inc.",ALIM,Georgia,United States,North America,39944960,Ophthalmology,Uveitis,Uveitis (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,Y,N,N,N,,,,10/12/18,03/25/19,,,,01/05/18,06/28/12,,,09/12/11,06/28/12,,,80%,,N/A,N/A,$    32.4,$    14.1,N/A,N/A,$    46.9,$    23.8,Q2 2019,"EyePoint Pharmaceuticals, Inc., Knight Therapeutics Inc., Ocumension Therapeutics, Societa Industria Farmaceutica Italiana S.p.A., Specialised Therapeutics Australia Pty, Ltd."
14596,3094,18484,5,Imbruvica,ibrutinib,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Oncology,Hematologic,Mantle Cell Lymphoma - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bruton's Tyrosine Kinase (BTK)^ Interleukin-2-inducible T-cell kinase (ITK),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,,,11/13/13,10/17/14,12/02/16,,,06/28/13,11/07/12,02/28/11,02/20/09,,11/07/12,02/28/11,02/13/09,45%,,"$  1,146.0","$  2,985.0","$  4,097.0","$  2,431.0","$  1,596.0","$  4,037.0","$  5,583.0","$  3,330.0",Q2 2019,"Johnson &amp; Johnson, Royalty Pharma AG"
14596,200,21157,5,Imbruvica,ibrutinib,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bruton's Tyrosine Kinase (BTK)^ Interleukin-2-inducible T-cell kinase (ITK),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,,,02/12/14,10/17/14,03/28/16,,,06/28/13,,,,,04/11/12,12/05/10,12/07/09,45%,3996.1,"$  1,146.0","$  2,985.0","$  4,097.0","$  2,431.0","$  1,596.0","$  4,037.0","$  5,583.0","$  3,330.0",Q2 2019,"Johnson &amp; Johnson, Royalty Pharma AG"
14596,208,29575,5,Imbruvica,ibrutinib,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Oncology,Hematologic,Waldenstrom Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bruton's Tyrosine Kinase (BTK)^ Interleukin-2-inducible T-cell kinase (ITK),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,01/29/15,07/10/15,,,,10/20/14,,,,,11/29/12,07/27/12,05/20/10,45%,,"$  1,146.0","$  2,985.0","$  4,097.0","$  2,431.0","$  1,596.0","$  4,037.0","$  5,583.0","$  3,330.0",Q2 2019,"Johnson &amp; Johnson, Royalty Pharma AG"
14596,3327,32814,5,Imbruvica,ibrutinib,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Oncology,Hematologic,Marginal Zone Lymphoma - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bruton's Tyrosine Kinase (BTK)^ Interleukin-2-inducible T-cell kinase (ITK),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,01/19/17,,,,,09/26/16,,,,,03/05/14,12/12/13,,45%,,"$  1,146.0","$  2,985.0","$  4,097.0","$  2,431.0","$  1,596.0","$  4,037.0","$  5,583.0","$  3,330.0",Q2 2019,"Johnson &amp; Johnson, Royalty Pharma AG"
14596,250,33285,5,Imbruvica,ibrutinib,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Transplant Rejection,Graft vs. Host Disease (GVHD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bruton's Tyrosine Kinase (BTK)^ Interleukin-2-inducible T-cell kinase (ITK),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,08/02/17,,,,,02/02/17,12/08/16,07/18/14,,,12/08/16,07/18/14,,45%,,"$  1,146.0","$  2,985.0","$  4,097.0","$  2,431.0","$  1,596.0","$  4,037.0","$  5,583.0","$  3,330.0",Q2 2019,"Johnson &amp; Johnson, Royalty Pharma AG"
21140,211,32365,45,Imfinzi,durvalumab,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),Y,N,N,Y,N,N,,,,02/16/18,09/21/18,07/02/18,,,08/16/17,04/24/14,03/25/14,11/27/13,,04/22/14,03/25/14,09/25/12,N/A,,N/A,$    19.0,$   564.0,$   473.0,N/A,$    19.0,$   633.0,$   633.0,Q2 2019,"Celgene Corporation, Eli Lilly &amp; Company"
21140,217,37042,45,Imfinzi,durvalumab,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Solid,Bladder Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,05/01/17,,,,,10/13/16,,,,,08/04/15,,09/25/12,N/A,,N/A,$    19.0,$   564.0,$   473.0,N/A,$    19.0,$   633.0,$   633.0,Q2 2019,"Celgene Corporation, Eli Lilly &amp; Company"
2698,221,4611,30,Imlygic,talimogene laherparepvec,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Viral,Granulocyte Macrophage Colony-Stimulating Factor Receptor (GM-CSFR)/CD116^ Immune system^ Oncolytic Virus Therapy,Biologic,No,Intratumoral,N,Y,N,N,N,N,,,,10/27/15,12/16/15,,,,06/30/14,04/14/09,02/14/06,,,04/14/09,02/14/06,01/06/03,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
988,458,925,4641,Impavido,miltefosine,Knight Therapeutics Inc.,GUD:CN,Quebec,Canada,North America,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Leishmaniasis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphatidylcholine,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,03/19/14,12/06/04,,,,04/19/13,,,,,05/31/10,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
26090,155,36363,7731,Impoyz,clobetasol propionate,"Encore Dermatology, Inc.",,Pennsylvania,United States,North America,,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,11/28/17,,,,,,12/09/15,05/05/14,,,12/09/15,05/05/14,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Dr. Reddy's Laboratories
22510,648,30572,4309,Imvexxy,estradiol,"TherapeuticsMD, Inc.",TXMD,Florida,United States,North America,711264755,Endocrine,Menopause (Including Specific HRT),Vaginal Atrophy,Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Intravaginal,N,N,N,N,N,N,,,,05/30/18,,,,,07/07/16,09/29/14,,08/12/13,,09/29/14,,08/12/13,N/A,,N/A,N/A,$     1.1,$     2.0,N/A,N/A,$     1.1,$     2.0,Q1 2019,"CVC Capital Partners SICAV-FIS S.A., Knight Therapeutics Inc."
19275,194,25398,8,Inbrija,levodopa,"Acorda Therapeutics, Inc.",ACOR,New York,United States,North America,129834265,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Receptor - Unspecified,Non-NME,No,Inhaled,N,N,N,N,N,N,,08/01/2019 - 09/30/2019,,12/21/18,,,,,12/05/17,09/14/14,05/07/12,,,09/14/14,05/07/12,01/06/12,N/A,,N/A,N/A,N/A,$     4.3,N/A,N/A,N/A,$     4.3,Q2 2019,N/A
1624,553,2605,220,Increlex,mecasermin recombinant,Ipsen SA,IPSEY,,France,Europe,,Endocrine,Short Stature,Growth Hormone Insensitivity Syndrome (GHIS),Y,Approved,Approved,100% (Same As Avg.),Protein,IGF-1R (Insulin-like Growth Factor-1 Receptor)^ Insulin Receptor,Biologic,No,Subcutaneous (SQ),N,N,Y,,N,N,,,,08/31/05,08/08/07,,,,02/28/05,10/28/04,,,,06/16/04,,,N/A,,N/A,N/A,N/A,N/A,$    26.2,$    26.4,$    27.8,$    12.6,Q2 2019,N/A
17104,73,22188,180,Incruse Ellipta,umeclidinium bromide,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,"Inhaled, Topical",N,N,N,N,N,N,,,,04/30/14,04/28/14,03/26/15,,,04/30/13,,,,,02/03/11,08/10/07,05/18/07,N/A,,$   117.0,$   174.0,$   247.0,$    97.0,$   155.0,$   261.0,$   378.0,$   161.0,Q2 2019,"Innoviva, Inc., Vectura Group plc"
19637,154,25923,3597,Inflectra,infliximab-dyyb,"Celltrion, Inc.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/05/16,09/10/13,07/04/14,,,08/08/14,,,,,,,,N/A,,N/A,$   118.0,$   259.0,$   131.0,N/A,$   419.0,$   642.0,$   291.0,Q2 2019,"Les Laboratoires Servier, Mundipharma International Limited, Nippon Kayaku Co., Ltd., Pfizer Inc., Vcell Healthcare Limited"
19637,252,27162,3597,Inflectra,infliximab-dyyb,"Celltrion, Inc.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/05/16,09/10/13,07/04/14,,,08/08/14,,,,,,,,N/A,,N/A,$   118.0,$   259.0,$   131.0,N/A,$   419.0,$   642.0,$   291.0,Q2 2019,"Les Laboratoires Servier, Mundipharma International Limited, Nippon Kayaku Co., Ltd., Pfizer Inc., Vcell Healthcare Limited"
19637,321,27681,3597,Inflectra,infliximab-dyyb,"Celltrion, Inc.",,,Korea (South),Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/05/16,09/10/13,07/04/14,,,08/08/14,,,,,,,,N/A,,N/A,$   118.0,$   259.0,$   131.0,N/A,$   419.0,$   642.0,$   291.0,Q2 2019,"Les Laboratoires Servier, Mundipharma International Limited, Nippon Kayaku Co., Ltd., Pfizer Inc., Vcell Healthcare Limited"
19637,156,27682,3597,Inflectra,infliximab-dyyb,"Celltrion, Inc.",,,Korea (South),Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,04/01/2016 - 04/30/2016,,,04/05/16,09/10/13,07/04/14,,,08/08/14,,,,,,,,N/A,,N/A,$   118.0,$   259.0,$   131.0,N/A,$   419.0,$   642.0,$   291.0,Q2 2019,"Les Laboratoires Servier, Mundipharma International Limited, Nippon Kayaku Co., Ltd., Pfizer Inc., Vcell Healthcare Limited"
19637,155,27683,3597,Inflectra,infliximab-dyyb,"Celltrion, Inc.",,,Korea (South),Asia,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/05/16,09/10/13,07/04/14,,,08/08/14,,,,,,,,N/A,,N/A,$   118.0,$   259.0,$   131.0,N/A,$   419.0,$   642.0,$   291.0,Q2 2019,"Les Laboratoires Servier, Mundipharma International Limited, Nippon Kayaku Co., Ltd., Pfizer Inc., Vcell Healthcare Limited"
19637,336,30668,3597,Inflectra,infliximab-dyyb,"Celltrion, Inc.",,,Korea (South),Asia,,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/05/16,09/10/13,07/04/14,,,08/08/14,,,,,,,,N/A,,N/A,$   118.0,$   259.0,$   131.0,N/A,$   419.0,$   642.0,$   291.0,Q2 2019,"Les Laboratoires Servier, Mundipharma International Limited, Nippon Kayaku Co., Ltd., Pfizer Inc., Vcell Healthcare Limited"
38545,211,53814,3285,Infugem,gemcitabine,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,07/16/18,,,,,03/29/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38545,214,53834,3285,Infugem,gemcitabine,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,07/16/18,,,,,03/29/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38545,220,53835,3285,Infugem,gemcitabine,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Pancreatic Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,07/16/18,,,,,03/29/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38545,224,53836,3285,Infugem,gemcitabine,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Ovarian Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,07/16/18,,,,,03/29/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16210,3244,20847,276,Ingrezza,valbenazine,"Neurocrine Biosciences, Inc.",NBIX,California,United States,North America,8597577675,Neurology,"movement disorders, all",Tardive Dyskinesia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Vesicular monamine transporters (VMATs),New Molecular Entity (NME),No,Oral (PO),Y,N,N,Y,N,N,,,,04/11/17,,,,,08/11/16,10/20/14,09/19/11,,07/15/11,10/20/14,09/19/11,,N/A,,N/A,$   116.6,$   409.6,$   316.9,N/A,$   116.6,$   409.6,$   316.9,Q2 2019,Mitsubishi Tanabe Pharma Corporation
7954,375,9772,343,Injectafer,ferric carboxymaltose,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Hematology,Marrow Or Peripheral Blood Stimulator,Anemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,07/25/13,06/26/07,,,,10/13/11,,,,,01/18/05,,,N/A,,N/A,$   309.0,$    96.0,N/A,N/A,$   309.0,$    96.0,N/A,Q4 2018,"Fresenius SE &amp; Co. KGaA, Vifor Pharma Group, Zeria Pharmaceutical Co., Ltd."
7954,371,20522,343,Injectafer,ferric carboxymaltose,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Independent",N,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,07/25/13,,,,,09/30/11,03/30/10,,,,10/13/09,,,N/A,,N/A,$   309.0,$    96.0,N/A,N/A,$   309.0,$    96.0,N/A,Q4 2018,"Fresenius SE &amp; Co. KGaA, Vifor Pharma Group, Zeria Pharmaceutical Co., Ltd."
2195,216,3677,312,Inlyta,axitinib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Renal Cell Cancer (RCC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Platelet-derived growth factor receptor (PDGFR)^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,01/27/12,09/04/12,06/29/12,,,04/14/11,10/17/08,,,,10/17/08,05/14/05,,N/A,182.8,$   161.0,$   125.0,$   119.0,$    93.0,$   401.0,$   340.0,$   298.0,$   177.0,Q2 2019,"SFJ Pharmaceuticals, Inc."
878,346,948,82,Innohep,tinzaparin,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Hematology,Antithrombotic,Venous Thromboembolism (VTE),Y,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Coagulation Factor X^ Thrombin (Coagulation Factor IIa),New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,,N,N,,,,07/14/00,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,LEO Pharma A/S
2613,264,4449,312,Inspra,eplerenone,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Mineralocorticoid Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/07/03,03/23/04,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,N/A
2613,244,4450,312,Inspra,eplerenone,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Mineralocorticoid Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,09/27/02,,07/31/07,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,N/A
2124,78,3530,223,Intelence,etravirine,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),Y,N,N,,N,N,,,,01/18/08,08/28/08,12/25/08,,,07/17/07,,,,,11/01/05,12/18/01,,100%,211.5,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2013,N/A
6466,291,6729,325,Intermezzo,zolpidem tartrate,Purdue Pharma L.P.,,Connecticut,United States,North America,,Neurology,Insomnia,Insomnia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,11/23/11,,,,,10/01/08,,,,,04/01/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2013,"Paratek Pharmaceuticals, Inc."
18476,648,24216,512,Intrarosa,dehydroepiandrosterone,"AMAG Pharmaceuticals, Inc.",AMAG,Massachusetts,United States,North America,414082551,Endocrine,Menopause (Including Specific HRT),Vaginal Atrophy,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Androgen receptors^ Estrogen,Non-NME,No,Intravaginal,N,N,N,N,N,N,,,,11/16/16,01/08/18,,,,10/16/15,,,,,05/05/10,,,80%,394.3,N/A,$     1.9,$    16.2,$     4.4,N/A,$     1.9,$    16.2,$     4.4,Q1 2019,"Bayer AG, EndoCeutics Inc., Mundipharma International Limited"
2795,246,4762,826,Intuniv Extended Release,guanfacine hydrochloride,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/03/09,09/21/15,03/30/17,,,08/24/06,,,,,05/10/05,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    59.9,N/A,Q4 2018,Shionogi &amp; Co. Ltd.
1990,440,3214,254,Invanz,ertapenem,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,11/21/01,04/18/02,,,,,,,,,,,,N/A,,$   329.0,$   361.0,$   253.0,$    32.0,$   561.0,$   602.0,$   496.0,$   150.0,Q2 2019,N/A
1990,536,3324,254,Invanz,ertapenem,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Intra-Abdominal Infections (Antibacterial),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,11/21/01,10/09/06,,,,,,,,,,,,N/A,,$   329.0,$   361.0,$   253.0,$    32.0,$   561.0,$   602.0,$   496.0,$   150.0,Q2 2019,N/A
1990,488,25966,254,Invanz,ertapenem,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,11/21/01,,,,,,,,,,,,,N/A,,$   329.0,$   361.0,$   253.0,$    32.0,$   561.0,$   602.0,$   496.0,$   150.0,Q2 2019,N/A
1990,534,25967,254,Invanz,ertapenem,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,"Intramuscular (IM), Intravenous (IV)",N,N,N,N,N,N,,,,11/21/01,,,,,,,,,,,,,N/A,,$   329.0,$   361.0,$   253.0,$    32.0,$   561.0,$   602.0,$   496.0,$   150.0,Q2 2019,N/A
1932,170,3120,223,Invega,paliperidone,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/20/06,06/25/07,01/25/11,,,11/30/05,01/12/05,,,,,,,100%,82.9,$    70.0,N/A,N/A,$     0.0,$   311.0,N/A,N/A,$     0.0,Q4 2016,N/A
2353,170,3964,223,Invega Sustenna,paliperidone palmitate,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,07/31/09,03/04/11,09/20/13,,,10/29/07,,,,,01/12/05,,,92.5%,553.6,"$  1,343.0","$  1,590.0","$  1,791.0",$   989.0,"$  2,214.0","$  2,569.0","$  2,928.0","$  1,608.0",Q2 2019,Alkermes plc
18566,170,24368,223,Invega Trinza,paliperidone palmitate,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,05/18/15,05/31/16,,,,11/19/14,01/17/12,,07/18/11,,01/17/12,,05/09/11,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Alkermes plc
23044,554,31452,4447,Inveltys,loteprednol etabonate,"Kala Pharmaceuticals, Inc.",KALA,Massachusetts,United States,North America,155460017,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,08/22/18,,,,,10/24/17,06/19/14,,,01/06/14,06/19/14,,,N/A,,N/A,N/A,N/A,$     1.4,N/A,N/A,N/A,$     1.4,Q1 2019,N/A
17166,137,22272,223,Invokamet,canagliflozin / immediate release metformin,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ SGLT,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/11/14,04/25/14,,,,12/12/12,10/18/11,,,,10/18/11,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Mitsubishi Tanabe Pharma Corporation, Mundipharma International Limited"
17166,181,50408,223,Invokamet,canagliflozin / immediate release metformin,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,General,Cardiovascular Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ SGLT,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/30/18,08/27/18,,,,,,,,,12/14/09,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Mitsubishi Tanabe Pharma Corporation, Mundipharma International Limited"
21769,137,29396,223,Invokamet XR,canagliflozin / extended release metformin,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ SGLT,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/20/16,,,,,11/20/15,,,,,01/22/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Mitsubishi Tanabe Pharma Corporation, PDL BioPharma, Inc."
21769,181,50411,223,Invokamet XR,canagliflozin / extended release metformin,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,General,Cardiovascular Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ SGLT,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/30/18,,,,,,,,,,12/14/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Mitsubishi Tanabe Pharma Corporation, PDL BioPharma, Inc."
13681,137,17285,223,Invokana,canagliflozin,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/29/13,11/19/13,07/04/14,,,05/31/12,09/28/09,,,,09/28/09,03/24/08,,87%,4208.6,"$  1,273.0",$   944.0,$   711.0,$   154.0,"$  1,407.0","$  1,111.0",$   938.2,$   219.3,Q1 2019,"Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Mundipharma International Limited, PDL BioPharma, Inc."
13681,181,49481,223,Invokana,canagliflozin,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,General,Cardiovascular Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/30/18,09/04/18,,,,10/02/17,,,,,12/14/09,,,87%,,"$  1,273.0",$   944.0,$   711.0,$   154.0,"$  1,407.0","$  1,111.0",$   938.2,$   219.3,Q1 2019,"Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Mundipharma International Limited, PDL BioPharma, Inc."
20812,346,27853,470,Iprivask,desiruden recombinant,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Hematology,Antithrombotic,Venous Thromboembolism (VTE),Y,Approved,Approved,100% (Same As Avg.),Protein,Thrombin (Coagulation Factor IIa),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/04/03,07/09/97,,,,06/28/00,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
215,211,258,45,Iressa,gefitinib,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,07/13/15,06/24/09,07/16/02,,,12/02/14,,,,,,05/24/00,,100%,,$    23.0,$    39.0,$    26.0,$     8.0,$   513.0,$   528.0,$   518.0,$   252.0,Q2 2019,N/A
2427,78,4112,254,Isentress,raltegravir,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV Integrase,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,10/12/07,12/20/07,06/30/08,,,04/13/07,,,,,02/21/06,11/18/05,,100%,691.4,$   721.0,$   565.0,$   513.0,$   202.0,"$  1,387.0","$  1,205.0","$  1,140.0",$   502.0,Q2 2019,Cipla Limited
23524,78,32318,254,Isentress (oral suspension),raltegravir,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV Integrase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/20/13,,,,,06/26/13,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
1106,278,2075,470,Istalol,timolol maleate,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Topical,N,N,N,,N,N,,,,06/07/04,,,,,07/28/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2012,"Senju Pharmaceutical Co., Ltd."
3003,417,5120,82,Istodax,romidepsin,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Cutaneous T-Cell Lymphoma (CTCL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histone Deacetylase (HDAC),New Molecular Entity (NME),No,Intravenous (IV),Y,Y,Y,,N,N,,07/01/2014 - 07/01/2014,,11/05/09,,,,,01/12/09,,,,,,04/30/02,,N/A,,$    71.6,$    67.0,$    48.0,$    14.0,$    79.3,$    76.0,$    63.0,$    23.0,Q2 2019,"Astellas Pharma, Inc."
3003,3097,5121,82,Istodax,romidepsin,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Peripheral T-Cell Lymphoma (PTCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Histone Deacetylase (HDAC),New Molecular Entity (NME),No,Intravenous (IV),N,N,Y,N,N,N,,,,06/16/11,,,,,12/17/10,,,,,,09/30/04,,N/A,,$    71.6,$    67.0,$    48.0,$    14.0,$    79.3,$    76.0,$    63.0,$    23.0,Q2 2019,"Astellas Pharma, Inc."
1449,214,2168,4264,Ixempra,ixabepilone,R-PHARM JSC,,,Russia,Europe,,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,12/01/2009 - 12/01/2009,12/01/2010 - 12/01/2010,10/16/07,,,,,04/16/07,09/01/03,,,,01/22/04,06/01/03,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2010,"Oncology Venture A/S, Otsuka Holdings Co., Ltd."
2731,704,4665,914,Ixiaro,,Valneva SE,VLA:FP,,France,Europe,,Infectious disease,Antiviral,Japanese Encephalitis,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Japanese Encephalitis Virus,Vaccine,No,Intramuscular (IM),N,N,Y,N,N,N,,,08/20/2010 - 08/20/2010,03/30/09,03/31/09,,,,12/20/07,09/19/05,,,,09/19/05,05/21/03,,N/A,,N/A,N/A,N/A,N/A,N/A,$    68.2,$    79.1,$    50.9,Q2 2019,"Adimmune Corp., Biological E. Limited"
22783,154,31022,312,Ixifi,infliximab-qbtx,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/13/17,05/18/18,07/02/18,,,02/13/17,09/30/14,,05/15/13,,09/30/14,,05/05/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
22783,156,48692,312,Ixifi,infliximab-qbtx,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/13/17,05/18/18,07/02/18,,,02/13/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
22783,155,48693,312,Ixifi,infliximab-qbtx,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/13/17,05/18/18,07/02/18,,,02/13/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
22783,321,48694,312,Ixifi,infliximab-qbtx,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/13/17,05/18/18,07/02/18,,,02/13/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
22783,336,48695,312,Ixifi,infliximab-qbtx,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/13/17,05/18/18,07/02/18,,,02/13/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
22783,252,48696,312,Ixifi,infliximab-qbtx,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/13/17,05/18/18,07/02/18,,,02/13/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
16285,512,20974,6381,Ixinity,trenonacog alfa,Aptevo Therapeutics Inc.,APVO,Washington,United States,North America,16789011,Hematology,Factor Augmentation,Hemophilia B,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,04/29/15,,,,,04/17/12,03/12/10,,03/12/09,,03/01/10,07/14/09,03/12/09,N/A,,N/A,N/A,$    23.1,$     7.0,N/A,N/A,$    23.1,$     7.0,Q1 2019,Ipsen SA
19995,278,26549,289,Izba,travoprost,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostaglandin F receptor (FP)/PGF2 alpha receptor,Non-NME,No,Topical,N,N,N,N,N,N,,,01/01/2015 - 01/01/2015,05/15/14,02/20/14,,,,07/15/13,,,,,11/29/11,10/23/08,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
8505,3052,23705,208,Jakafi,ruxolitinib phosphate,Incyte Corporation,INCY,Delaware,United States,North America,17639667387,Oncology,Hematologic,Myelofibrosis (MF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,JAK/STAT,New Molecular Entity (NME),No,Oral (PO),Y,Y,Y,N,N,N,,,,11/16/11,08/28/12,07/08/14,,,06/03/11,07/06/09,,,,07/06/09,09/25/07,,100%,482,$   852.5,"$  1,133.1","$  1,387.3",$   785.1,"$  1,433.5","$  1,910.1","$  2,364.3","$  1,327.1",Q2 2019,"Eli Lilly &amp; Company, Novartis AG"
8505,3053,23706,208,Jakafi,ruxolitinib phosphate,Incyte Corporation,INCY,Delaware,United States,North America,17639667387,Oncology,Hematologic,Polycythemia Vera (PV),N,Approved,Approved,100% (Same As Avg.),Small Molecule,JAK/STAT,New Molecular Entity (NME),No,Oral (PO),Y,Y,Y,N,N,N,,,,12/04/14,03/17/15,09/30/15,,,06/30/14,11/02/10,,,,11/02/10,01/08/08,,100%,857.5,$   852.5,"$  1,133.1","$  1,387.3",$   785.1,"$  1,433.5","$  1,910.1","$  2,364.3","$  1,327.1",Q2 2019,"Eli Lilly &amp; Company, Novartis AG"
8505,250,39823,208,Jakafi,ruxolitinib phosphate,Incyte Corporation,INCY,Delaware,United States,North America,17639667387,Autoimmune/immunology,Transplant Rejection,Graft vs. Host Disease (GVHD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,JAK/STAT,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,05/24/19,,,,,08/31/18,02/14/17,12/30/16,,,02/14/17,04/21/16,,100%,,$   852.5,"$  1,133.1","$  1,387.3",$   785.1,"$  1,433.5","$  1,910.1","$  2,364.3","$  1,327.1",Q2 2019,"Eli Lilly &amp; Company, Novartis AG"
2460,137,4172,254,Janumet,sitagliptin with metformin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ Dipeptidyl peptidase IV (DPP-IV),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/30/07,07/16/08,,,,05/31/06,,,,,12/15/05,11/10/04,,97.5%,,$   984.0,$   863.0,$   811.0,$   333.0,"$  2,200.0","$  2,158.0","$  2,227.0","$  1,076.5",Q2 2019,"Ono Pharmaceutical Company, Ltd., Otsuka Holdings Co., Ltd., Royalty Pharma AG"
15574,137,19833,254,Janumet XR,sitagliptin/metformin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ Dipeptidyl peptidase IV (DPP-IV),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,02/02/12,,,,,10/31/10,,,,,,,12/09/08,95%,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Ono Pharmaceutical Company, Ltd., Otsuka Holdings Co., Ltd., PDL BioPharma, Inc., Royalty Pharma AG"
1694,137,2719,254,Januvia,sitagliptin phosphate hydrate,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl peptidase IV (DPP-IV),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/16/06,03/21/07,10/16/09,,,12/16/06,,,,,07/21/04,,,97.5%,3711.4,"$  2,306.0","$  2,154.0","$  1,969.0",$   855.0,"$  3,908.0","$  3,737.0","$  3,686.0","$  1,745.5",Q2 2019,"Ono Pharmaceutical Company, Ltd., Otsuka Holdings Co., Ltd., Royalty Pharma AG"
12058,137,15202,70,Jardiance,empagliflozin,Boehringer Ingelheim GmbH,,,Germany,Europe,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/01/14,05/22/14,12/26/14,,,03/25/13,07/28/10,09/08/08,,,07/28/10,09/08/08,06/12/08,50%,1154.8,$   288.8,$   290.4,N/A,N/A,$   403.8,"$  1,222.6","$  1,617.2",N/A,Q4 2018,"Eli Lilly &amp; Company, Lupin Limited"
12058,181,49479,70,Jardiance,empagliflozin,Boehringer Ingelheim GmbH,,,Germany,Europe,,Cardiovascular,General,Cardiovascular Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/02/16,,,,,11/04/15,,,,,08/20/15,,,50%,,$   288.8,$   290.4,N/A,N/A,$   403.8,"$  1,222.6","$  1,617.2",N/A,Q4 2018,"Eli Lilly &amp; Company, Lupin Limited"
17376,549,22603,2929,Jatenzo,testosterone undecanoate,Clarus Therapeutics Inc.,,Illinois,United States,North America,,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/27/19,,,,,06/26/17,07/25/11,,,,07/25/11,04/30/08,11/27/07,100%,131,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
17965,137,23465,70,Jentadueto,linagliptin and metformin,Boehringer Ingelheim GmbH,,,Germany,Europe,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ Dipeptidyl peptidase IV (DPP-IV),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/30/12,07/20/12,,,,01/19/11,,,,,02/05/09,,,N/A,,N/A,$   213.2,N/A,N/A,N/A,"$  2,154.7","$  1,546.4",N/A,Q4 2018,"Eli Lilly &amp; Company, PDL BioPharma, Inc."
16059,2892,20588,2293,Jetrea,ocriplasmin,Oxurion NV,OXUR:BB,,Belgium,Europe,,Ophthalmology,Other,Vitreomacular Adhesion (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrin (Coagulation Factor Ia),Biologic,No,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV)",N,N,Y,N,N,N,,,01/01/2018 - 12/31/2018,10/17/12,03/13/13,,,,04/17/12,01/09/09,01/18/05,,,01/09/09,01/18/05,03/16/04,N/A,,$     4.9,$     5.1,$     5.8,N/A,$     4.9,$     5.1,$     5.8,N/A,Q4 2018,"Novartis AG, NuVue Technologies"
24644,1508,34241,4844,Jeuveau,prabotulinumtoxinA-xvfs,"Evolus, Inc.",EOLS,California,United States,North America,,Dermatology,General,Wrinkles,Y,Approved,Approved,100% (Same As Avg.),Natural Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biosimilar,No,Intramuscular (IM),N,N,N,N,N,N,,06/10/2019 - 07/31/2019,,02/01/19,,,,,05/15/17,02/05/15,,,,02/05/15,07/08/14,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Daewoong Pharmaceutical Company Ltd.
10758,215,13471,51,Jevtana,cabazitaxel,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,N,,,,06/17/10,03/17/11,07/31/14,,,03/31/10,12/28/06,,,,12/28/06,,,100%,107.6,$   126.4,$   182.3,$   206.1,$   114.1,$   277.3,$   442.5,$   486.4,$   267.6,Q2 2019,N/A
17656,511,23000,59,Jivi,damoctocog alfa pegol,Bayer AG,BAYRY,,Germany,Europe,,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,08/30/18,11/22/18,09/21/18,,,08/31/17,,,,,05/24/12,,09/30/10,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23069,246,31505,4456,Jornay PM,methylphenidate,Highland Therapeutics Inc.,,,Canada,North America,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/08/18,,,,,09/30/16,04/28/14,,,,04/28/14,10/03/13,06/25/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18703,3117,24559,470,Jublia,efinaconazole,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,01/31/2014 - 06/30/2014,06/06/14,,,,,07/31/12,02/02/10,,,,02/02/10,05/26/09,,N/A,,$   113.0,N/A,N/A,N/A,$   113.0,$    66.0,$    55.0,$    11.0,Q1 2019,"Kaken Pharmaceutical Company, Ltd, Mitsubishi Tanabe Pharma Corporation, TIPR-HUYA Advancing Innovative Medicines"
24231,78,33538,180,Juluca,rilpivirine; dolutegravir,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,HIV / AIDS,N,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV Integrase^ Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/21/17,05/21/18,11/26/18,,,06/01/17,05/03/15,,03/08/15,,05/03/15,,03/08/15,N/A,,N/A,N/A,$   165.0,$   169.0,N/A,N/A,$   177.0,$   199.0,Q2 2019,Johnson &amp; Johnson
2796,506,4763,326,Juxtapid,lomitapide medylate,Novelion Therapeutics Inc.,NVLN,British Columbia,Canada,North America,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Microsomal Triglyceride Transfer Protein (MTP),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,12/21/12,07/31/13,09/28/16,,,03/05/12,,,,,01/18/08,06/14/06,,90%,359.6,N/A,$    46.5,$    35.4,$     9.1,$   110.3,$    72.1,$    59.1,$    14.2,Q1 2019,"Amryt Pharma plc, Bristol-Myers Squibb Company, Recordati SpA, University of Pennsylvania"
38056,334,53119,636,Jynarque,tolvaptan,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Renal,Polycystic Kidney Disease,Polycystic Kidney Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Vasopressin receptors,Non-NME,No,Oral (PO),Y,N,Y,N,N,N,,,,04/23/18,,,,,03/01/13,,,,,02/01/07,02/23/06,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
547,214,4553,149,Kadcyla,ado-trastuzumab emtansine,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ HER2/neu or ErbB-2^ Microtubules (Tubulin),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,02/22/13,11/15/13,09/20/13,,,08/27/12,03/02/09,07/31/07,05/18/06,,10/14/08,07/31/07,05/18/06,92%,527.1,$   322.7,$   349.8,$   364.5,$   278.0,$   848.6,$   932.8,$   994.1,$   636.0,Q2 2019,"Chugai Pharmaceutical Co., Ltd., Endo International plc, PDL BioPharma, Inc."
196,556,520,826,Kalbitor,ecallantide,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Y,Approved,Approved,100% (Same As Avg.),Protein,Kinin-Kallikrein System,Biologic,No,Subcutaneous (SQ),Y,Y,Y,N,N,N,,01/01/2014 - 01/01/2014,07/01/2015 - 07/01/2015,11/27/09,,,,,09/23/08,12/08/05,,,,12/08/05,02/03/03,,100%,,N/A,$    66.9,$    52.0,N/A,$    52.2,$    66.9,$    62.9,N/A,Q3 2018,"Lee's Pharmaceutical Holdings Limited, Novellus Biopharma AG, taiba-ME"
1766,78,2807,5,Kaletra,lopinavir and ritonavir,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Infectious disease,Antiviral,HIV / AIDS,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,HIV-1 protease (HIV PR),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/15/00,03/20/01,01/01/02,,,,,,,,,,,100%,130.4,$   116.0,$    71.0,$    55.0,$    23.0,$   695.0,$   423.0,$   336.0,$   155.0,Q2 2019,N/A
2643,74,4513,389,Kalydeco,ivacaftor,Vertex Pharmaceuticals Incorporated,VRTX,Massachusetts,United States,North America,46999678216,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,CF transmembrane conductance regulator (CFTR),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,,,01/31/12,07/23/12,,,,10/19/11,05/27/09,06/12/07,05/17/06,,05/27/09,06/12/07,05/17/06,N/A,,$   198.2,N/A,"$  1,008.0",$   506.0,$   703.7,$   845.0,"$  1,008.0",$   506.0,Q2 2019,Royalty Pharma AG
21922,214,29633,30,Kanjinti,trastuzumab-anns,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,06/13/19,05/16/18,09/21/18,,,07/31/17,07/16/13,,,,07/16/13,,03/22/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Allergan plc, Daiichi Sankyo Co., Ltd., Simcere Pharmaceutical Group, Synthon Biopharmaceuticals, Inc."
21922,223,53344,30,Kanjinti,trastuzumab-anns,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Gastric Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,06/13/19,05/16/18,09/21/18,,,07/31/17,,,,,02/18/15,,03/22/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    34.0,$   137.0,Q2 2019,"Allergan plc, Daiichi Sankyo Co., Ltd., Simcere Pharmaceutical Group, Synthon Biopharmaceuticals, Inc."
18161,3056,23758,21,Kanuma,sebelipase alfa,"Alexion Pharmaceuticals, Inc.",ALXN,Connecticut,United States,North America,24868581569,Metabolic,Inborn Errors Of Metabolism,Lysosomal Acid Lipase Deficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,Cholesterol/Cholesteryl Ester^ Triglycerides,Biologic,No,Intravenous (IV),Y,N,Y,Y,N,N,,,,12/08/15,08/28/15,03/28/16,,,10/21/14,02/11/13,,,,07/12/12,09/28/11,,N/A,,$    20.4,$    42.4,$    51.3,$    29.1,$    29.1,$    65.6,$    92.0,$    49.7,Q2 2019,N/A
38717,244,54055,3285,Kapspargo Sprinkle,metoprolol succinate,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/26/18,,,,,03/30/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38717,446,54059,3285,Kapspargo Sprinkle,metoprolol succinate,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Cardiovascular,Other,Angina,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/26/18,,,,,03/30/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38717,264,54060,3285,Kapspargo Sprinkle,metoprolol succinate,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/26/18,,,,,03/30/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
8370,244,10380,2647,Kapvay/Jenloga,clonidine hydrochloride,ADVANZ PHARMA Corp.,ADVZ:CN,Ontario,Canada,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,09/29/09,,,,,02/20/08,,,,,07/12/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Shionogi &amp; Co. Ltd.
8370,246,10381,2647,Kapvay/Jenloga,clonidine hydrochloride,ADVANZ PHARMA Corp.,ADVZ:CN,Ontario,Canada,North America,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/28/10,,,,,10/01/09,,,,,10/30/07,07/12/07,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Shionogi &amp; Co. Ltd.
22240,236,30104,579,Karbinal ER,carbinoxamine maleate,Tris Pharma,,New Jersey,United States,North America,,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/28/13,,,,,12/07/10,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Cerecor Inc.
40653,244,56992,8134,Katerzia,amlodipine benzoate,Azurity Pharmaceuticals,,Massachusetts,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/08/19,,,,,09/14/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
40653,267,56993,8134,Katerzia,amlodipine benzoate,Azurity Pharmaceuticals,,Massachusetts,United States,North America,,Cardiovascular,Coronary Artery Disease (General),Coronary Artery Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/08/19,,,,,09/14/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
19098,137,25149,826,Kazano,alogliptin and metformin,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ Dipeptidyl peptidase IV (DPP-IV),Non-NME,No,Oral (PO),N,N,N,N,N,N,,07/25/2013 - 09/30/2013,06/01/2016 - 12/31/2016,01/25/13,09/19/13,,,,11/23/11,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Royalty Pharma AG
20115,672,26746,870,Kcentra,"Prothrombin Complex Concentrate, Human",CSL Limited,CSL:AU,,Australia,Oceania,,Hematology,Other,Hemostasis,Y,Approved,Approved,100% (Same As Avg.),Peptide,Coagulation Factor IX^ Coagulation Factor VII^ Coagulation Factor X^ Protein C^ Protein S^ Thrombin (Coagulation Factor IIa),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,04/29/13,01/11/08,03/30/17,,,03/30/12,07/01/08,,,,09/13/05,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
23168,574,31695,912,Kedbumin,,Kedrion S.p.A.,,,Italy,Europe,,Cardiovascular,Other,Hypovolemia,N,Approved,Approved,100% (Same As Avg.),Protein,Osmosis/Osmotic Pressure,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,06/03/11,,,,,08/03/10,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
21998,190,29760,2874,Kedrab,,Kamada Ltd.,KMDA,,Israel,Asia,221445504,Infectious disease,Antiviral,Antiviral - Miscellaneous Vaccines,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system^ Rabies virus,Biologic,No,Intramuscular (IM),N,N,N,N,N,N,,,,08/23/17,,,,,08/26/16,05/06/13,,,,05/06/13,,07/19/11,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Kedrion S.p.A.
11212,701,14071,88,Kemstro,,UCB SA,UCB:BB,,Belgium,Europe,,Neurology,"movement disorders, all",Neuromuscular Spasm and Spasticity,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA Receptors^ GABA-B Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/30/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Jazz Pharmaceuticals plc
1136,179,1390,851,Kengreal,cangrelor tetrasodium,Chiesi Farmaceutici S.p.A.,,,Italy,Europe,,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Adenosine Diphosphate P2Y12 Receptor,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,01/01/2016 - 01/01/2016,06/22/15,03/25/15,,,,04/30/13,04/04/06,12/31/03,,,04/04/06,12/31/03,,90%,116,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,AstraZeneca PLC
32,348,3262,465,Kepivance,palifermin,Swedish Orphan Biovitrum,SOBI:SS,,Sweden,Europe,,Autoimmune/immunology,Other,Mucositis,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibroblast Growth Factor Receptor-2,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,12/15/04,10/25/05,,,,06/24/04,04/26/01,,03/30/96,,04/26/01,,04/17/96,100%,2.6,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2013,"Amgen, Inc."
2940,272,22775,88,Keppra IR,levetiracetam,UCB SA,UCB:BB,,Belgium,Europe,,Neurology,Seizure Disorders (Epilepsy),Seizure Disorders (Epilepsy),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,SV2A synaptic vesicle protein,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,08/23/06,05/15/06,,,,10/27/05,,,,,11/30/01,,,N/A,,N/A,$   281.4,N/A,N/A,N/A,"$  1,253.8",$   365.9,$    90.8,Q1 2019,"Otsuka Holdings Co., Ltd."
8168,3009,10088,88,Keppra XR,levetiracetam,UCB SA,UCB:BB,,Belgium,Europe,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,SV2A synaptic vesicle protein,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,09/12/08,09/02/09,,,,11/14/07,,,,,07/26/06,,,N/A,,$   239.0,$   117.9,N/A,$     0.0,$   803.0,$   445.8,N/A,$     0.0,Q2 2017,N/A
8098,3117,9990,312,Kerydin,tavaborole,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Leucyl-tRNA synthetase (bacterial or fungal),New Molecular Entity (NME),No,Topical,N,Y,N,N,N,N,,,,07/08/14,,,,,07/26/13,12/16/10,,,,12/16/10,04/19/06,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q2 2015,Novartis AG
9547,154,11884,330,Kevzara,sarilumab,"Regeneron Pharmaceuticals, Inc.",REGN,New York,United States,North America,32413693800,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-6 Receptor (IL-6R),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,05/22/17,06/27/17,09/27/17,,,10/30/15,02/18/10,,,,02/18/10,,11/29/07,N/A,,N/A,$    12.0,$    73.0,$    20.7,N/A,$    13.2,$    94.6,$    33.7,Q1 2019,"Asahi Kasei Corporation, Sanofi"
19200,221,25288,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,09/04/14,07/17/15,09/28/16,,,01/13/14,09/11/13,12/04/12,04/01/11,12/09/10,09/11/13,12/04/12,04/01/11,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,211,29567,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,10/02/15,08/02/16,12/19/16,,,04/02/15,08/14/13,,04/18/12,12/09/10,08/14/13,,04/18/12,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,197,30396,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Solid Tumors,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,05/23/17,,12/21/18,,,11/28/16,,07/24/14,05/09/13,,,07/24/14,05/09/13,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,204,30492,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Hematologic,Hodgkin's Lymphoma,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,03/14/17,05/02/17,11/30/17,,,09/15/16,06/02/16,06/17/15,06/02/13,,06/02/16,06/17/15,06/02/13,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,213,31694,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Colorectal Cancer (CRC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,05/23/17,,,,,11/28/16,02/04/16,09/02/15,,,02/04/16,09/02/15,02/28/14,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,216,32154,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Renal Cell Cancer (RCC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,08/01/2019 - 09/30/2019,11/01/2019 - 05/31/2020,04/19/19,,,,,12/20/18,09/26/16,12/18/13,,,09/26/16,12/18/13,,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,230,33463,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Head and Neck Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,08/05/16,09/04/18,,,,02/09/16,12/01/14,07/24/14,05/09/13,,12/01/14,07/24/14,05/09/13,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,223,34287,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Gastric Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,09/22/17,,,,,03/22/17,02/23/15,02/17/15,09/16/13,,02/23/15,02/17/15,09/16/13,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,217,34288,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Bladder Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,05/17/17,08/24/17,01/02/18,,,02/03/17,11/17/14,,05/09/13,,11/17/14,07/24/14,05/09/13,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,111,36444,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Small Cell Lung Cancer (SCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,06/17/19,,,,,12/16/18,05/08/17,01/04/16,02/28/14,,05/08/17,01/04/16,02/28/14,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,3585,37377,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Merkel Cell Carcinoma,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,12/19/18,,,,,,,,,,,12/03/14,,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,273,37427,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Esophageal Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,07/30/19,,,,,01/30/19,12/16/15,,,,12/16/15,09/23/15,,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,3095,37964,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Hematologic,Diffuse Large B-Cell Lymphoma (DLBCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,06/13/18,,,,,10/03/17,,12/23/15,,,,12/23/15,,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,297,38947,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,11/09/18,,,,,05/09/18,,,,,03/03/16,,,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
19200,255,41088,254,Keytruda,pembrolizumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Cervical Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,06/12/18,,,,,12/28/17,,01/04/16,,,,01/04/16,,N/A,,$   792.0,"$  2,308.0","$  4,149.0","$  2,782.0","$  1,402.0","$  3,809.0","$  7,171.0","$  4,903.0",Q2 2019,"DRI Capital Inc., Otsuka Holdings Co., Ltd."
39362,684,55053,9097,Khapzory,levoleucovorin,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Solid,Bone Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,10/19/18,,,,,12/22/17,,,,,,,,N/A,,N/A,N/A,$     0.9,N/A,N/A,N/A,$     0.9,N/A,Q4 2018,N/A
39362,213,55054,9097,Khapzory,levoleucovorin,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Solid,Colorectal Cancer (CRC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,10/19/18,,,,,12/22/17,,,,,,,,N/A,,N/A,N/A,$     0.9,N/A,N/A,N/A,$     0.9,N/A,Q4 2018,N/A
23056,167,31480,4140,Khedezla ER,desvenlafaxine,Currax Pharmaceuticals LLC,,New Jersey,United States,North America,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/10/13,,,,,09/13/12,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Endo International plc, Osmotica Pharmaceutical Corp"
28,154,42,465,Kineret,anakinra,Swedish Orphan Biovitrum,SOBI:SS,,Sweden,Europe,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Protein,IL-1 Receptor (IL-1R),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,11/15/01,03/18/02,,,,,,,,,12/15/00,,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,$   143.9,$    82.0,Q2 2019,"Amgen, Inc., Horizon Pharma plc"
28,656,22353,465,Kineret,anakinra,Swedish Orphan Biovitrum,SOBI:SS,,Sweden,Europe,,Autoimmune/immunology,Other,Cryopyrin (CIAS1)-Associated Periodic Syndromes (CAPS),N,Approved,Approved,100% (Same As Avg.),Protein,IL-1 Receptor (IL-1R),Biologic,No,Subcutaneous (SQ),N,N,Y,,N,N,,,,12/21/12,,,,,07/06/12,,,,,08/26/10,,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,$   143.9,$    82.0,Q2 2019,"Amgen, Inc., Horizon Pharma plc"
23363,3197,32028,180,Kinrix,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Diphtheria, pertussis, and tetanus (DT, Td, DTaP and Tdap) Vaccines",N,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Immune system^ Polio virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,06/24/08,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18444,214,30902,289,Kisqali,ribociclib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Cyclin Dependent Kinase (CDK),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,03/13/17,08/24/17,,,,08/29/16,10/07/13,,,,10/07/13,06/06/13,,N/A,,N/A,$    61.0,$   235.0,$   202.0,N/A,$    61.0,$   235.0,$   202.0,Q2 2019,"Otsuka Holdings Co., Ltd."
34849,214,48280,289,Kisqali Femara Co-Pack,ribociclib/letrozole,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Aromatase^ Cyclin Dependent Kinase (CDK),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/04/17,,,,,01/30/17,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
3118,511,5343,59,Kogenate FS,octocog alfa,Bayer AG,BAYRY,,Germany,Europe,,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,06/28/00,08/04/00,,,,,,,,,,,,N/A,,$   436.7,$   365.5,$   367.6,N/A,"$  1,293.3","$  1,100.3","$  1,004.5",$   490.2,Q2 2019,N/A
10483,137,13114,45,Kombiglyze XR,saxagliptin and metformin,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ Dipeptidyl peptidase IV (DPP-IV),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/05/10,11/24/11,,,,12/29/09,,,,,08/22/05,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2013,"Bristol-Myers Squibb Company, Otsuka Holdings Co., Ltd., Royalty Pharma AG"
1683,637,10497,720,Korlym,mifepristone,Corcept Therapeutics Inc.,CORT,California,United States,North America,1496514502,Endocrine,Other,Cushing's Syndrome,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Androgen receptors^ Glucocorticoid Receptor (GR)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,10/01/2014 - 04/30/2015,,02/17/12,,,,,04/15/11,12/19/07,,,,12/19/07,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q2 2015,N/A
17655,511,22999,59,Kovaltry,,Bayer AG,BAYRY,,Germany,Europe,,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,03/16/16,02/18/16,03/29/16,,,12/16/14,,,,,01/04/10,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22062,467,29853,180,Krintafel,tafenoquine succinate,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Malaria,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis^ Plasmodium,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,07/20/18,,,,,11/22/17,04/28/14,,,,04/28/14,01/15/13,07/01/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
873,539,1952,2878,Krystexxa,pegloticase,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Autoimmune/immunology,Arthritis,Gout,Y,Approved,Approved,100% (Same As Avg.),Protein,Uric Acid,Biologic,No,Intravenous (IV),N,Y,Y,,N,N,,,,09/14/10,01/08/13,,,,10/31/08,05/17/06,04/07/04,,,05/17/06,04/07/04,07/08/03,N/A,,N/A,N/A,$   258.8,$    52.3,N/A,N/A,$   258.8,$    52.3,Q1 2019,"Mountain View Pharmaceuticals, Inc."
789,191,1291,65,Kuvan,sapropterin dihydrochloride,BioMarin Pharmaceutical Inc.,BMRN,California,United States,North America,13080442306,Metabolic,Inborn Errors Of Metabolism,Phenylketonuria (PKU),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,phenylalanine hydroxylase,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,12/13/07,12/02/08,03/01/92,,,05/24/07,04/07/05,12/23/04,,,04/07/05,11/04/04,01/29/04,89%,465.8,N/A,N/A,N/A,N/A,N/A,$   407.2,$   433.6,$   220.2,Q2 2019,"Daiichi Sankyo Co., Ltd., Merck KGaA"
17959,3556,23457,395,Kybella,sodium deoxycholate,Allergan plc,AGN,,Ireland,Europe,53945515162,Dermatology,Surgical and Other Invasive Procedures,Fat Removal,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cell Membrane,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,07/18/2016 - 01/18/2017,,04/29/15,,,,,05/13/14,08/30/11,08/28/07,,,08/30/11,08/28/07,,N/A,,$    50.2,$    49.5,$    31.8,$    15.8,$    52.5,$    56.3,$    38.1,$    18.0,Q2 2019,Bayer AG
21276,239,28652,59,Kyleena,,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Contraception,Contraception,N,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Intrauterine,N,N,N,N,N,N,,,,09/16/16,10/03/16,,,,11/18/15,,,,,03/01/12,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
20776,199,30033,289,Kymriah,tisagenlecleucel-t,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),N,Approved,Approved,100% (Same As Avg.),Cellular,Autologous Chimeric Antigen Receptor T-cells (CAR-T)^ Cluster of Differentiation 19 (CD19)^ Immune system^ Stem Cells/Other Cell Therapies^ T lymphocytes,Biologic,No,Intravenous (IV),Y,N,Y,Y,N,N,,,01/01/2019 - 07/31/2019,08/30/17,08/27/18,03/26/19,,,02/02/17,,06/18/14,06/21/12,,,06/18/14,03/25/13,N/A,,N/A,N/A,$    76.0,$   103.0,N/A,N/A,$    76.0,$   103.0,Q2 2019,"bluebird bio, Celyad, Oxford BioMedica plc, Talaris Therapeutics, Inc., Thermo Fisher Scientific, University of Pennsylvania"
20776,3095,33487,289,Kymriah,tisagenlecleucel-t,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Diffuse Large B-Cell Lymphoma (DLBCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Cellular,Autologous Chimeric Antigen Receptor T-cells (CAR-T)^ Cluster of Differentiation 19 (CD19)^ Immune system^ Stem Cells/Other Cell Therapies^ T lymphocytes,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,01/01/2019 - 07/31/2019,05/01/18,08/27/18,03/26/19,,,10/31/17,,,,,,10/28/14,,N/A,,N/A,N/A,$    76.0,$   103.0,N/A,N/A,$    76.0,$   103.0,Q2 2019,"bluebird bio, Celyad, Oxford BioMedica plc, Talaris Therapeutics, Inc., Thermo Fisher Scientific, University of Pennsylvania"
9588,207,11938,30,Kyprolis,carfilzomib,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Hematologic,Multiple Myeloma (MM),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Proteasome,New Molecular Entity (NME),No,Intravenous (IV),Y,Y,Y,N,N,N,,,,07/20/12,11/19/15,07/04/16,,,09/28/11,02/20/10,08/15/07,,,02/02/10,08/15/07,,98%,468.5,$   554.0,$   562.0,$   583.0,$   154.0,$   692.0,$   835.0,$   968.0,$   245.0,Q1 2019,"Dr. Reddy's Laboratories, Ligand Pharmaceuticals, Inc., Ono Pharmaceutical Company, Ltd."
2194,168,3673,180,Lamictal,lamotrigine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Psychiatry,Bipolar,Bipolar Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Sodium and Calcium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/20/03,03/01/03,07/01/11,,,08/29/02,,,,,02/01/99,,,100%,,$   426.0,$   432.0,$   413.0,$   177.0,$   835.0,$   845.0,$   821.0,$   353.0,Q2 2019,"Allergan plc, Aspen Pharmacare Holdings Limited"
2194,272,4810,180,Lamictal,lamotrigine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Neurology,Seizure Disorders (Epilepsy),Seizure Disorders (Epilepsy),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Sodium and Calcium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,09/22/06,,10/16/08,,,02/07/05,,,,,,,,100%,,$   426.0,$   432.0,$   413.0,$   177.0,$   835.0,$   845.0,$   821.0,$   353.0,Q2 2019,"Allergan plc, Aspen Pharmacare Holdings Limited"
8495,3009,10560,180,Lamictal XR,lamotrigine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Sodium and Calcium Channels,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/29/09,,,,,11/22/06,,,,,,,,100%,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
8495,272,22788,180,Lamictal XR,lamotrigine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Neurology,Seizure Disorders (Epilepsy),Seizure Disorders (Epilepsy),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Sodium and Calcium Channels,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/29/10,,,,,03/31/09,,,,,,,,100%,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
2291,157,3841,51,Lantus,insulin glargine,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/20/00,06/09/00,,,,,,,,,,,,100%,873.9,"$  3,917.5","$  2,905.9","$  1,864.7",$   641.6,"$  6,345.0","$  5,288.4","$  4,118.8","$  1,730.6",Q2 2019,N/A
2291,137,3842,51,Lantus,insulin glargine,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/20/00,06/09/00,,,,,,,,,,,,100%,4681.3,"$  3,917.5","$  2,905.9","$  1,864.7",$   641.6,"$  6,345.0","$  5,288.4","$  4,118.8","$  1,730.6",Q2 2019,N/A
17125,711,22214,395,Lastacaft,alcaftadine,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,General,Allergic Conjunctivitis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,07/28/10,,,,,09/28/09,,,,,01/06/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Johnson &amp; Johnson
18414,2569,24123,395,Latisse,bimatoprost,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,Other,Other Ophthalmological Indications (Ophthalmology),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Prostaglandin F receptor (FP)/PGF2 alpha receptor,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,12/24/08,01/07/10,,,,06/30/08,,,,,,,,N/A,,$    77.9,$    56.4,$    41.6,$    77.3,$    86.4,$    64.7,$    45.8,$    83.7,Q2 2019,"Senju Pharmaceutical Co., Ltd."
2244,170,3768,686,Latuda,lurasidone hydrochloride,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT7 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,04/01/2020 - 10/31/2020,10/28/10,03/21/14,,,,12/30/09,,,,,07/31/08,07/05/05,,100%,362.8,N/A,N/A,N/A,N/A,"$  1,254.0","$  1,611.0","$  1,657.0",$   852.0,Q2 2019,"ACRAF SpA (Gruppo Angelini), Bukwang Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., DiethelmKellerSiberHegner, Les Laboratoires Servier, NewBridge Pharmaceuticals, Standard Chemical &amp; Pharmaceutical Company, Ltd."
2244,168,15555,686,Latuda,lurasidone hydrochloride,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Psychiatry,Bipolar,Bipolar Disorder,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT7 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,11/01/2016 - 03/31/2018,04/01/2020 - 10/31/2020,06/28/13,,,,,09/06/12,02/03/09,,,12/17/08,02/03/09,07/31/08,,100%,531.1,N/A,N/A,N/A,N/A,"$  1,254.0","$  1,611.0","$  1,657.0",$   852.0,Q2 2019,"ACRAF SpA (Gruppo Angelini), Bukwang Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., DiethelmKellerSiberHegner, Les Laboratoires Servier, NewBridge Pharmaceuticals, Standard Chemical &amp; Pharmaceutical Company, Ltd."
18118,1508,23677,1358,laViv,,"Fibrocell Science, Inc.",FCSC,Pennsylvania,United States,North America,16673817,Dermatology,General,Wrinkles,Y,Approved,Approved,100% (Same As Avg.),Cellular,Fibroblasts,Biologic,No,Intradermal,N,Y,N,,N,N,,,,06/21/11,,,,,03/09/09,,,,,08/05/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
15674,3125,19997,7966,Lazanda,fentanyl pectin citrate,Slán Medicinal Holdings Limited,,,Ireland,Europe,,Neurology,Pain,Cancer Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Intranasal,N,N,N,N,N,N,,,,06/30/11,08/31/10,,,,08/31/09,,,,,01/29/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    40.0,$    18.2,Q2 2019,"Kyowa Hakko Kirin Co., Ltd."
18546,153,24331,51,Lemtrada,alemtuzumab,Sanofi,SNY,,France,Europe,1.05588E+11,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 52 (CD52),Biologic,No,Intravenous (IV),Y,N,N,N,N,N,,,,11/14/14,09/12/13,,,,11/27/12,09/26/07,01/07/03,,,09/26/07,04/02/03,,74%,900,$   257.4,$   281.3,$   218.1,$    93.8,$   451.9,$   542.3,$   464.9,$   187.7,Q2 2019,"Bayer AG, BTG plc, Takeda Pharmaceutical Company Ltd"
7833,532,9625,134,Lenvima,lenvatinib,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Oncology,Solid,Thyroid Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Fibroblast Growth Factor Receptor (FGFR)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Tyrosine Kinases^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,02/13/15,05/28/15,03/26/15,,,,03/22/11,,,,03/22/11,10/31/08,07/15/05,N/A,,$   139.0,$   198.3,$   339.8,N/A,$   198.0,$   290.2,$   571.7,N/A,Q4 2018,"Biotoscana International, IQVIA Holdings Inc., Merck &amp; Co., Inc., SFJ Pharmaceuticals, Inc."
7833,297,20742,134,Lenvima,lenvatinib,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Fibroblast Growth Factor Receptor (FGFR)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Tyrosine Kinases^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,08/15/18,08/23/18,03/23/18,,,07/24/17,02/01/13,,,,02/01/13,,,N/A,,$   139.0,$   198.3,$   339.8,N/A,$   198.0,$   290.2,$   571.7,N/A,Q4 2018,"Biotoscana International, IQVIA Holdings Inc., Merck &amp; Co., Inc., SFJ Pharmaceuticals, Inc."
7833,216,21789,134,Lenvima,lenvatinib,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Oncology,Solid,Renal Cell Cancer (RCC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Fibroblast Growth Factor Receptor (FGFR)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Tyrosine Kinases^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,05/13/16,08/25/16,,,,11/16/15,,,,,,02/01/11,05/21/10,N/A,,$   139.0,$   198.3,$   339.8,N/A,$   198.0,$   290.2,$   571.7,N/A,Q4 2018,"Biotoscana International, IQVIA Holdings Inc., Merck &amp; Co., Inc., SFJ Pharmaceuticals, Inc."
732,245,672,179,Letairis,ambrisentan,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Endothelin Receptor Type A (EDNRA),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,06/15/07,04/21/08,,,,12/18/06,01/08/04,10/15/02,,,01/12/04,,,87.5%,381.6,$   819.0,$   887.0,$   943.0,$   401.0,N/A,N/A,$   943.0,$   401.0,Q2 2019,"AbbVie Inc., GlaxoSmithKline plc"
2185,666,43799,8599,Leukine,sargramostim,"Partner Therapeutics, Inc.",,Massachusetts,United States,North America,,Not Specified,Other,Acute Radiation Syndrome (ARS),N,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte Macrophage Colony-Stimulating Factor Receptor (GM-CSFR)/CD116,Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,03/29/18,,,,,09/29/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1929,440,3183,223,Levaquin,levofloxacin hydrate,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,Non-NME,No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,09/14/00,,10/01/93,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2012,"Daiichi Sankyo Co., Ltd., Sanofi"
1929,673,19031,223,Levaquin,levofloxacin hydrate,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,Non-NME,No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,11/05/02,,10/01/93,,,01/04/02,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2012,"Daiichi Sankyo Co., Ltd., Sanofi"
1706,137,2735,292,Levemir,insulin detemir,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,06/16/05,06/04/04,10/22/07,,,12/06/02,,,,,,,,100%,1265.2,N/A,"$  1,406.9","$  1,077.8",$   229.7,"$  2,564.6","$  2,131.0","$  1,753.7",$   398.6,Q1 2019,N/A
1706,157,3256,292,Levemir,insulin detemir,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,06/25/2015 - 08/31/2015,,06/17/05,06/01/04,10/22/07,,,12/06/02,,,,,,,,100%,457.7,N/A,"$  1,406.9","$  1,077.8",$   229.7,"$  2,564.6","$  2,131.0","$  1,753.7",$   398.6,Q1 2019,N/A
1922,160,3095,59,Levitra,vardenafil hydrochloride,Bayer AG,BAYRY,,Germany,Europe,,Urology,Male Sexual Dysfunction,Erectile Dysfunction (ED),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 5 (PDE5),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/19/03,03/06/03,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q4 2015,"GlaxoSmithKline plc, Merck &amp; Co., Inc."
18519,139,24284,882,Levothyroxine Sodium for Injection,levothyroxine sodium,Fresenius SE & Co. KGaA,FSNUY,,Germany,Europe,0,Endocrine,Thyroid,Hypothyroidism,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Thyroid hormone receptors (TRs),Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,06/24/11,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2982,139,5085,312,Levoxyl,levothyroxine sodium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Thyroid,Hypothyroidism,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Thyroid hormone receptors (TRs),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/25/01,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2009,N/A
1609,167,2572,395,Lexapro,escitalopram oxalate,Allergan plc,AGN,,Ireland,Europe,53945515162,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/15/02,,04/22/11,,,03/23/01,08/27/99,,,,08/27/99,,,N/A,,N/A,$    51.8,$    64.9,$     5.5,N/A,$   402.0,$   514.3,$   125.0,Q1 2019,"Abbott Laboratories, Almirall Prodesfarma, S.A., H. Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd."
1609,169,3024,395,Lexapro,escitalopram oxalate,Allergan plc,AGN,,Ireland,Europe,53945515162,Psychiatry,Anxiety,Generalized Anxiety Disorder (GAD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,12/18/03,,,,,,,,,,01/07/02,,,N/A,,N/A,$    51.8,$    64.9,$     5.5,N/A,$   402.0,$   514.3,$   125.0,Q1 2019,"Abbott Laboratories, Almirall Prodesfarma, S.A., H. Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd."
40130,155,56129,8963,Lexette,halobetasol propionate,Mayne Pharma Group Limited,MYX: ASX,,Australia,Oceania,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,05/24/18,,,,,07/28/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
8179,1468,10109,814,Lexiscan,,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Cardiovascular,Coronary Artery Disease (General),Myocardial Perfusion Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Adenosine A2a Receptor,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,04/10/08,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   660.0,$   663.0,N/A,N/A,Q4 2017,"General Electric, Gilead Sciences, Inc., Rapidscan Pharma Solutions, Inc."
30,78,43,180,Lexiva,fosamprenavir,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV-1 protease (HIV PR),Non-NME,No,Oral (PO),Y,N,N,,N,N,,,,10/20/03,07/12/04,,,,12/20/02,,,,,,,,N/A,,$    39.0,N/A,N/A,$     0.0,$    69.0,N/A,N/A,$     0.0,Q4 2016,"Kissei Pharmaceutical Co., Ltd, Pfizer Inc."
2475,321,4198,826,Lialda,mesalamine,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/16/07,01/19/07,09/28/16,,,12/21/05,,,,,11/01/05,,,N/A,,$   714.3,$   473.1,$   194.8,N/A,$   792.1,$   569.4,$   359.6,N/A,Q3 2018,"Cosmo Pharmaceuticals N.V., Mochida Pharmaceutical Co., Ltd., Nogra Pharma Ltd."
25212,3165,40621,330,Libtayo,cemiplimab-rwlc,"Regeneron Pharmaceuticals, Inc.",REGN,New York,United States,North America,32413693800,Oncology,Solid,Skin Cancer - Squamous Cell Carcinoma (SCC),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,09/28/18,07/01/19,,,,02/28/18,,03/31/16,,,,03/31/16,03/08/15,N/A,,N/A,N/A,$    14.8,$    26.8,N/A,N/A,$    14.8,$    26.8,Q1 2019,Sanofi
6712,450,7562,1219,LidoSite,Lidocaine HCl / Epinephrine topical iontophoretic,"Vyteris, Inc.",VYTRQ,New Jersey,United States,North America,,Neurology,Pain,Pain Indications,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Sodium Channels,Non-NME,No,Topical,N,N,N,N,N,N,,,,05/06/04,,,,,09/25/02,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
25173,239,35018,395,Liletta,levonorgestrel,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Contraception,Contraception,Y,Approved,Approved,100% (Same As Avg.),Steroid,Progesterone Receptor,Non-NME,No,Intrauterine,N,N,N,N,N,N,,,,02/26/15,12/28/12,,,,,,,,,01/05/10,,,N/A,,$    23.3,$    37.6,$    50.9,$    36.7,N/A,$    37.6,$    50.9,$    36.7,Q2 2019,Medicines360
8466,435,10522,916,Linzess,linaclotide acetate,"Ironwood Pharmaceuticals, Inc.",IRWD,Massachusetts,United States,North America,1322377638,Gastroenterology (non inflammatory bowel disease),Other,Irritable Bowel Syndrome (IBS),Y,Approved,Approved,100% (Same As Avg.),Peptide,Guanylyl cyclase c Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/30/12,11/26/12,12/19/16,,,08/09/11,01/14/09,,,,01/14/09,04/13/07,05/23/06,50%,,$   625.6,$   701.1,$   761.3,$   357.3,$   642.9,$   723.0,$   815.8,$   390.3,Q2 2019,"Allergan plc, Astellas Pharma, Inc., AstraZeneca PLC"
8466,661,10524,916,Linzess,linaclotide acetate,"Ironwood Pharmaceuticals, Inc.",IRWD,Massachusetts,United States,North America,1322377638,Gastroenterology (non inflammatory bowel disease),Other,Chronic Idiopathic Constipation,Y,Approved,Approved,100% (Same As Avg.),Peptide,Guanylyl cyclase c Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/30/12,,08/21/18,,,08/09/11,,,,,09/16/08,10/24/06,05/23/06,50%,,$   625.6,$   701.1,$   761.3,$   357.3,$   642.9,$   723.0,$   815.8,$   390.3,Q2 2019,"Allergan plc, Astellas Pharma, Inc., AstraZeneca PLC"
2732,506,4666,672,Lipofen,fenofibrate,"Kowa Company, Ltd.",,,Japan,Asia,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,PPAR alpha,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/11/06,,,,,02/26/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q2 2014,Cipher Pharmaceuticals Inc.
10892,246,13662,1800,Liquadd,dextroamphetamine sulfate,"Auriga Laboratories, Inc.",ARGA,Georgia,United States,North America,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine^ Norepinephrine (Noradrenaline),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/29/08,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Outlook Pharmaceuticals, Inc."
1274,506,4671,672,Livalo,pitavastatin calcium,"Kowa Company, Ltd.",,,Japan,Asia,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,HMG CoA Reductase (HMGR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/03/09,07/15/10,07/13/03,,,10/03/08,,,,,07/31/03,,,N/A,,N/A,$     1.4,N/A,N/A,N/A,$    26.7,$    52.7,$    30.3,Q2 2019,"Esteve, S.A., Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Recordati SpA"
16410,239,21162,395,Lo Loestrin FE,norethindrone acetate/ethinyl estradiol,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/21/10,,,,,03/26/09,,,,,11/30/06,,,N/A,,$   403.5,$   459.3,$   527.7,$   271.3,$   403.5,$   459.3,$   527.7,$   271.3,Q2 2019,N/A
22400,239,30379,395,Lo Minastrin Fe,Norethindrone Acetate; Ethinyl Estradiol; Ferrous Fumarate,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/24/13,,,,,09/27/12,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23129,2981,31629,45,Lokelma,sodium zirconium cyclosilicate,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Other,Hyperkalemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Potassium,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/18/18,03/22/18,,,,05/26/15,11/28/12,12/14/11,,,11/28/12,12/14/11,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18864,73,24804,686,Lonhala Magnair,glycopyrrolate bromide,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,12/05/17,,,,,07/29/16,10/14/14,08/29/11,,,10/14/14,09/26/11,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    12.6,$     6.4,Q1 2019,N/A
18579,213,24385,636,LONSURF,trifluridine/tipiracil,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Oncology,Solid,Colorectal Cancer (CRC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis^ Thymidine Phosphorylase^ Thymidylate Synthase,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,09/22/15,04/25/16,03/24/14,,,10/21/14,05/29/12,,05/11/12,,05/29/12,,05/11/12,N/A,,$   216.0,$   200.6,$   181.1,$    51.8,$   277.3,$   290.5,$   275.6,$    74.5,Q1 2019,"Les Laboratoires Servier, TTY Biopharm Company Limited"
18579,223,40924,636,LONSURF,trifluridine/tipiracil,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Oncology,Solid,Gastric Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis^ Thymidine Phosphorylase^ Thymidylate Synthase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,07/25/2019 - 09/30/2019,05/01/2019 - 11/30/2019,02/22/19,,,,,,01/04/16,,,,01/04/16,,,N/A,,$   216.0,$   200.6,$   181.1,$    51.8,$   277.3,$   290.5,$   275.6,$    74.5,Q1 2019,"Les Laboratoires Servier, TTY Biopharm Company Limited"
23831,211,32832,312,Lorbrena,lorlatinib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Anaplastic lymphoma kinase (ALK)^ ROS kinase,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,05/06/2019 - 05/10/2019,,11/02/18,05/07/19,09/21/18,,,,04/27/17,,,,04/27/17,01/24/14,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18393,239,24091,375,LoSeasonique,ethinyl estradiol and levonorgestrel,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/24/08,,,,,12/26/07,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
24673,554,34281,470,Lotemax SM,loteprednol etabonate,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,02/25/19,,,,,,01/09/14,,,,01/09/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
3098,435,5309,7245,Lotronex,alosetron hydrochloride,"Sebela Pharmaceuticals, Inc.",,Georgia,United States,North America,,Gastroenterology (non inflammatory bowel disease),Other,Irritable Bowel Syndrome (IBS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT3 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,02/09/00,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,GlaxoSmithKline plc
9507,506,11828,180,Lovaza,omega-3-acid ethyl esters,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Diglycerol Acyltransferase (DGAT)^ Lipoprotein lipase^ PPAR gamma,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,10/01/2012 - 10/01/2012,11/10/04,,09/28/12,,,01/09/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   241.8,$   288.9,$   280.5,N/A,Q4 2018,"Alfasigma S.p.A., BASF AG, Grupo Ferrer Internacional, S.A., Kuhnil Pharmaceutical, Co. Ltd., Mylan N.V., Societa Prodotti Antibiotici S.p.A., Takeda Pharmaceutical Company Ltd"
25000,560,34749,991,Lucemyra,lofexidine hydrochloride,"US WorldMeds, LLC",,Kentucky,United States,North America,,Psychiatry,Other,Substance Use Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor,Non-NME,No,Oral (PO),Y,N,N,N,N,N,,,,05/16/18,,,,,11/21/17,,,,,06/27/06,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Bausch Health Companies Inc., STADA Arzneimittel AG"
80,162,183,149,Lucentis,ranibizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,,N,N,,,,06/30/06,01/24/07,01/21/09,,,12/30/05,03/15/03,,,,06/24/03,03/25/02,,97%,840.1,"$  1,435.6","$  1,441.3","$  1,684.6",$   928.3,"$  3,270.6","$  3,329.3","$  3,731.6","$  1,997.3",Q2 2019,"ForSight VISION4, Inc., Novartis AG, PDL BioPharma, Inc., XOMA Corporation"
80,476,4479,149,Lucentis,ranibizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,08/10/12,01/07/11,02/21/14,,,10/13/11,,,,,07/11/07,04/12/06,,97%,230.3,"$  1,435.6","$  1,441.3","$  1,684.6",$   928.3,"$  3,270.6","$  3,329.3","$  3,731.6","$  1,997.3",Q2 2019,"ForSight VISION4, Inc., Novartis AG, PDL BioPharma, Inc., XOMA Corporation"
80,623,5210,149,Lucentis,ranibizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Ophthalmology,Retinopathy,Macular Edema from Retinal Vein Occlusion (RVO) (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,06/22/10,06/06/11,08/31/13,,,12/22/09,,,,,07/11/07,,,97%,,"$  1,435.6","$  1,441.3","$  1,684.6",$   928.3,"$  3,270.6","$  3,329.3","$  3,731.6","$  1,997.3",Q2 2019,"ForSight VISION4, Inc., Novartis AG, PDL BioPharma, Inc., XOMA Corporation"
80,364,20872,149,Lucentis,ranibizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Ophthalmology,Retinopathy,Diabetic Retinopathy (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,Y,N,N,,05/01/2019 - 12/31/2019,,02/06/15,,,,,,,,,,03/06/07,,,97%,,"$  1,435.6","$  1,441.3","$  1,684.6",$   928.3,"$  3,270.6","$  3,329.3","$  3,731.6","$  1,997.3",Q2 2019,"ForSight VISION4, Inc., Novartis AG, PDL BioPharma, Inc., XOMA Corporation"
80,3607,38662,149,Lucentis,ranibizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Ophthalmology,Other,Choroidal Neovascularization (CNV),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,01/05/17,11/14/16,,,,07/11/16,09/24/13,,,,10/07/10,,,97%,,"$  1,435.6","$  1,441.3","$  1,684.6",$   928.3,"$  3,270.6","$  3,329.3","$  3,731.6","$  1,997.3",Q2 2019,"ForSight VISION4, Inc., Novartis AG, PDL BioPharma, Inc., XOMA Corporation"
35880,3502,49867,3523,Lumason,sulfur hexafluoride,Bracco S.p.A.,,,Italy,Europe,,Cardiovascular,Coronary Artery Disease (General),Coronary Artery Disease  Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Blood plasma,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,10/10/14,03/26/01,,,,,,,,,03/26/01,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
35880,3384,49868,3523,Lumason,sulfur hexafluoride,Bracco S.p.A.,,,Italy,Europe,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) - Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Blood plasma,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,04/04/16,03/26/01,,,,06/04/15,,,,,03/26/01,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
35880,3635,53449,3523,Lumason,sulfur hexafluoride,Bracco S.p.A.,,,Italy,Europe,,Urology,Other,Vesicoureteral Reflux (VUR) - Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Blood plasma,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,12/22/16,,,,,06/29/16,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
1665,278,2678,395,Lumigan,bimatoprost,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostaglandin F receptor (FP)/PGF2 alpha receptor,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,03/16/01,03/08/02,07/08/09,,,,,,,,,,,N/A,,$   326.4,$   317.5,$   291.8,$   119.8,$   688.1,$   689.0,$   684.4,$   295.3,Q2 2019,"Senju Pharmaceutical Co., Ltd."
16117,328,20685,1364,Lumoxiti,moxetumomab pasudotox-tdfk,Innate Pharma S.A.,IPH:FP,,France,Europe,,Oncology,Hematologic,Hairy Cell Leukemia,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 22 (CD22)^ Mitochondria^ RNA translation,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,09/13/18,,,,,01/29/18,05/16/13,,04/17/07,,05/16/13,,04/17/07,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,AstraZeneca PLC
337,291,612,686,Lunesta,eszopiclone,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Neurology,Insomnia,Insomnia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/16/04,,01/18/12,,,01/31/03,,,,,,,,95%,,N/A,N/A,N/A,N/A,$    73.4,$    92.8,$   102.6,N/A,Q4 2018,"Eisai Co., Ltd., Sanofi"
930,531,2008,134,Lusedra,fospropofol disodium,"Eisai Co., Ltd.",ESALY,,Japan,Asia,,Neurology,Pain,Anesthesia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,01/01/2011 - 01/01/2011,12/12/08,,,,,09/27/07,09/20/04,,,,05/10/04,11/06/03,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,ProQuest Pharmaceuticals Inc.
19928,347,26432,289,Lutathera,lutetium Lu 177 dotatate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Neuroendocrine Tumors (NET),Y,Approved,Approved,100% (Same As Avg.),Peptide,Radiopharmaceutical^ Somatostatin Receptors,New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,N,N,N,,,,01/26/18,09/29/17,,,,04/28/16,09/30/12,01/31/08,,,09/30/12,01/31/08,,N/A,,N/A,N/A,$   167.0,$   215.0,N/A,N/A,$   167.0,$   215.0,Q2 2019,Fujifilm Holdings Corp.
8362,2051,12267,508,Luvox CR,fluvoxamine maleate,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Psychiatry,Other,Obsessive-Compulsive Disorder (OCD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/28/08,,,,,05/01/06,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2012,"AbbVie Inc., Alkermes plc"
23612,3342,32487,4589,Luxturna,voretigene neparvovec-rzyl,"Spark Therapeutics, Inc.",ONCE,Pennsylvania,United States,North America,3733944813,Ophthalmology,Congenital Blindness,Leber's Congenital Amaurosis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Viral Gene Therapy,RPE65 (Retinal pigment epithelium-specific 65 kDa protein),Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,Y,Y,N,N,,,,12/19/17,11/22/18,,,,05/18/17,10/26/12,12/01/10,08/14/07,,10/26/12,12/01/10,08/14/07,N/A,,N/A,N/A,$    27.0,$     9.8,N/A,N/A,$    27.0,$     9.8,Q1 2019,Novartis AG
24638,3117,34233,470,Luzu,luliconazole 1%,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Ergosterol biosynthesis,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,11/14/13,,04/11/05,,,12/11/12,,03/30/09,,,,03/30/09,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Topica Pharmaceuticals, Inc."
2305,239,3861,312,Lybrel,ethinyl estradiol and levonorgestrel,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/22/07,,,,,05/27/05,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
8015,800,9856,600,Lymphoseek,technetium Tc 99m tilmanocept,Cardinal Health Inc.,CAH,Ohio,United States,North America,13309039032,Oncology,Solid,Breast Cancer - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Macrophages^ Mannose^ Radiopharmaceutical,New Molecular Entity (NME),Yes,"Intravenous (IV), Subcutaneous (SQ), Intradermal",N,N,N,N,N,N,,,,03/13/13,11/20/14,,,,08/10/11,,,,,08/25/09,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,Q2 2015,"Navidea Biopharmaceuticals, Inc., Norgine B.V., Sinotau Pharmaceuticals Group, SpePharm B.V."
8015,1326,10757,600,Lymphoseek,technetium Tc 99m tilmanocept,Cardinal Health Inc.,CAH,Ohio,United States,North America,13309039032,Oncology,Solid,Melanoma - Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Macrophages^ Mannose^ Radiopharmaceutical,New Molecular Entity (NME),Yes,"Intravenous (IV), Subcutaneous (SQ), Intradermal",N,N,N,N,N,N,,,09/06/2014 - 03/08/2015,03/13/13,11/20/14,,,,08/10/11,,,,,08/25/09,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,Q2 2015,"Navidea Biopharmaceuticals, Inc., Norgine B.V., Sinotau Pharmaceuticals Group, SpePharm B.V."
8015,2334,13742,600,Lymphoseek,technetium Tc 99m tilmanocept,Cardinal Health Inc.,CAH,Ohio,United States,North America,13309039032,Oncology,Solid,Head and Neck Cancer - Imaging,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Macrophages^ Mannose^ Radiopharmaceutical,New Molecular Entity (NME),Yes,"Intravenous (IV), Subcutaneous (SQ), Intradermal",Y,N,Y,N,N,N,,,,06/13/14,11/20/14,,,,12/17/13,,,,,06/16/09,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,Q2 2015,"Navidea Biopharmaceuticals, Inc., Norgine B.V., Sinotau Pharmaceuticals Group, SpePharm B.V."
5962,214,6452,45,Lynparza,olaparib,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Poly ADP-Ribose Polymerase (PARP),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/12/18,04/08/19,07/02/18,,,08/18/17,04/18/14,,,,04/18/14,06/19/07,06/03/07,N/A,,$   127.0,$   141.0,$   345.0,$   262.0,$   218.0,$   297.0,$   647.0,$   520.0,Q2 2019,"Cancer Research UK, Merck &amp; Co., Inc."
5962,224,14131,45,Lynparza,olaparib,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Solid,Ovarian Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Poly ADP-Ribose Polymerase (PARP),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,12/19/14,12/18/14,01/19/18,,,02/03/14,09/04/13,,,,05/16/13,06/27/07,06/03/07,N/A,,$   127.0,$   141.0,$   345.0,$   262.0,$   218.0,$   297.0,$   647.0,$   520.0,Q2 2019,"Cancer Research UK, Merck &amp; Co., Inc."
1723,362,2896,312,Lyrica,pregabalin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Neuropathic Pain,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,12/30/04,07/06/04,04/16/10,,,12/19/11,,,,,,,,95%,5386.4,"$  3,138.0","$  3,464.0","$  3,594.0",$   889.0,"$  4,787.0","$  5,064.0","$  4,970.0","$  1,246.0",Q1 2019,"Amneal Pharmaceuticals, Inc., Eisai Co., Ltd., Royalty Pharma AG"
1723,3009,2897,312,Lyrica,pregabalin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/10/05,07/06/04,,,,10/30/03,,,,,,,,95%,54.8,"$  3,138.0","$  3,464.0","$  3,594.0",$   889.0,"$  4,787.0","$  5,064.0","$  4,970.0","$  1,246.0",Q1 2019,"Amneal Pharmaceuticals, Inc., Eisai Co., Ltd., Royalty Pharma AG"
1723,588,3307,312,Lyrica,pregabalin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Fibromyalgia,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/21/07,,06/22/12,,,12/20/06,,,,,11/16/06,10/25/02,,95%,942.5,"$  3,138.0","$  3,464.0","$  3,594.0",$   889.0,"$  4,787.0","$  5,064.0","$  4,970.0","$  1,246.0",Q1 2019,"Amneal Pharmaceuticals, Inc., Eisai Co., Ltd., Royalty Pharma AG"
1723,671,19099,312,Lyrica,pregabalin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Diabetic Peripheral Neuropathy (DPN),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/30/04,,,,,10/30/03,,,,,,,,95%,,"$  3,138.0","$  3,464.0","$  3,594.0",$   889.0,"$  4,787.0","$  5,064.0","$  4,970.0","$  1,246.0",Q1 2019,"Amneal Pharmaceuticals, Inc., Eisai Co., Ltd., Royalty Pharma AG"
1723,3157,26740,312,Lyrica,pregabalin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Postherpetic Neuralgia (PHN),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/30/04,,04/16/10,,,,,,,,,,,95%,,"$  3,138.0","$  3,464.0","$  3,594.0",$   889.0,"$  4,787.0","$  5,064.0","$  4,970.0","$  1,246.0",Q1 2019,"Amneal Pharmaceuticals, Inc., Eisai Co., Ltd., Royalty Pharma AG"
22837,3157,31139,312,Lyrica CR,pregabalin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Postherpetic Neuralgia (PHN),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/11/17,,,,,12/15/16,,,,,02/28/11,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
22837,362,50513,312,Lyrica CR,pregabalin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Neuropathic Pain,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/11/17,,,,,12/15/16,,,,,02/28/11,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
22837,671,50514,312,Lyrica CR,pregabalin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Diabetic Peripheral Neuropathy (DPN),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/11/17,,,,,12/15/16,,,,,02/28/11,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
21596,1473,29134,582,Lysteda,tranexamic acid,Ferring Pharmaceuticals,,,Switzerland,Europe,,Endocrine,Other,Dysmenorrhea,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Plasminogen,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,11/13/09,,,,,01/30/09,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18886,179,24842,945,M-Enoxaparin,enoxaparin sodium,"Momenta Pharmaceuticals, Inc.",MNTA,Massachusetts,United States,North America,932506725,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),N,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Coagulation Factor X^ Thrombin (Coagulation Factor IIa),Non-NME,No,Subcutaneous (SQ),N,N,N,,N,N,,,,07/23/10,,,,,08/30/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2015,Novartis AG
18886,346,24843,945,M-Enoxaparin,enoxaparin sodium,"Momenta Pharmaceuticals, Inc.",MNTA,Massachusetts,United States,North America,932506725,Hematology,Antithrombotic,Venous Thromboembolism (VTE),N,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Coagulation Factor X^ Thrombin (Coagulation Factor IIa),Non-NME,No,Subcutaneous (SQ),N,N,N,,N,N,,,,07/23/10,,,,,08/30/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2015,Novartis AG
20298,1577,27038,4,Maci,,Vericel Corporation,VCEL,Massachusetts,United States,North America,746007859,Orthopedics,Bone and Joint Conditions,Cartilage and Joint Repair,Y,Approved,Approved,100% (Same As Avg.),Cellular,Stem Cells/Other Cell Therapies,Biologic,No,Intraarticular,N,N,N,N,N,N,,,,12/13/16,06/27/13,,,,01/04/16,,,,,08/01/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    79.9,N/A,Q4 2018,"Innovative Cellular Therapeutics Co.,Ltd."
12346,285,15562,292,Macrilen,macimorelin acetate,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Short Stature,Short Stature / Growth Hormone Deficiency,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Ghrelin Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/20/17,01/11/19,,,,06/30/17,,,,,10/19/09,,11/13/08,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Aeterna Zentaris, Inc., Besins Healthcare SA, Strongbridge Biopharma plc"
336,162,627,470,Macugen,pegaptanib sodium,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Other Nucleic Acid,VEGF (Vascular endothelial growth factor),New Molecular Entity (NME),No,Intraocular/Subretinal/Subconjunctival,Y,N,N,,N,N,,,,12/17/04,01/31/06,,,,06/17/04,,,,,11/17/03,06/01/01,,86.5%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2006,"DRI Capital Inc., Enzon Pharmaceuticals, Inc., Gilead Sciences, Inc., Ionis Pharmaceuticals, Inc., Nektar Therapeutics, Pfizer Inc."
12704,2546,16049,512,Makena,hydroxyprogesterone caproate,"AMAG Pharmaceuticals, Inc.",AMAG,Massachusetts,United States,North America,414082551,Obstetrics/Gynecology,Obstetrics,Preterm Labor,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Progesterone Receptor,Non-NME,No,"Intramuscular (IM), Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,02/03/11,,,,,05/04/06,,,,,06/12/03,,,N/A,,$   236.8,$   387.2,$   322.3,$    31.3,$   236.8,$   387.2,$   322.3,$    31.3,Q1 2019,N/A
3099,467,5312,180,Malarone,atovaquone and proguanil hydrochloride,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Malaria,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR)^ Mitochondrial Electron Transport Chain,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/14/00,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
1481,199,4480,9097,Marqibo,vincristine sulfate,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Y,Approved,Approved,100% (Same As Avg.),Small Molecule with Liposomal Delivery System,Microtubules (Tubulin),Non-NME,No,Intravenous (IV),Y,Y,Y,,N,N,,07/01/2014 - 07/01/2014,,08/09/12,,,,,07/18/11,,08/17/06,,,,12/14/04,,N/A,30.9,$     7.2,$     6.6,$     5.4,N/A,$     7.2,$     6.6,$     5.4,N/A,Q4 2018,"Arbutus Biopharma Corporation, CASI Pharmaceuticals, Inc."
1863,153,2996,255,Mavenclad,cladribine,Merck KGaA,MKGAY,,Germany,Europe,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Ribonucleotide Reductase (RNR),Non-NME,No,Oral (PO),Y,N,N,N,N,N,,,,03/29/19,08/25/17,,,,09/30/09,01/11/05,,,,02/20/96,,,90%,,N/A,N/A,N/A,N/A,N/A,N/A,$   102.7,$    48.8,Q1 2019,Teva Pharmaceutical Industries Ltd.
22768,176,31002,5,Mavyret,glecaprevir/pibrentasvir,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HCV Protease^ Non-structural 5A protein (NS5A),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,08/03/17,07/28/17,09/27/17,,,12/19/16,01/11/16,11/21/13,08/12/13,,11/15/15,11/21/13,08/12/13,N/A,,N/A,N/A,$   852.0,$   799.0,N/A,N/A,"$  1,658.0","$  1,570.0",Q2 2019,"Enanta Pharmaceuticals, Inc."
14058,153,17801,289,Mayzent,siponimod,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Sphingosine 1-Phosphate Receptor (S1P-R),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,09/01/2019 - 03/31/2020,01/01/2020 - 07/31/2020,03/26/19,,,,,07/26/18,01/16/13,04/09/09,,,01/16/13,04/09/09,01/11/07,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18309,638,23965,142,Megace ES,,Endo International plc,ENDP,,Ireland,Europe,554131557,Metabolic,Other,HIV / AIDS Cachexia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/05/05,,,,,06/29/04,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q2 2012,Alkermes plc
16817,221,21779,289,Mekinist,trametinib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Mitogen-activated ERK kinase (MEK, MAPKK, MAP2K)",New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,05/29/13,06/30/14,03/31/16,,,08/03/12,01/24/11,,,,01/24/11,11/25/09,,90%,312,$   298.0,$   339.0,$   457.0,$   230.0,$   672.0,$   873.0,"$  1,155.0",$   637.0,Q2 2019,Japan Tobacco Inc.
16817,211,29822,289,Mekinist,trametinib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Mitogen-activated ERK kinase (MEK, MAPKK, MAP2K)",New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,09/01/2017 - 03/31/2018,06/22/17,03/27/17,,,,09/22/16,,,,,,07/20/12,,90%,,$   298.0,$   339.0,$   457.0,$   230.0,$   672.0,$   873.0,"$  1,155.0",$   637.0,Q2 2019,Japan Tobacco Inc.
16817,532,48511,289,Mekinist,trametinib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Thyroid Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Mitogen-activated ERK kinase (MEK, MAPKK, MAP2K)",New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,05/04/18,,,,,10/31/17,,,,,,03/28/14,,90%,,$   298.0,$   339.0,$   457.0,$   230.0,$   672.0,$   873.0,"$  1,155.0",$   637.0,Q2 2019,Japan Tobacco Inc.
2858,221,23781,312,Mektovi,binimetinib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Mitogen-activated ERK kinase (MEK, MAPKK, MAP2K)",New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/27/18,09/20/18,01/08/19,,,06/30/17,01/08/13,04/07/11,,,01/08/13,04/07/11,04/19/10,N/A,,N/A,N/A,N/A,$    17.7,N/A,N/A,N/A,$    17.7,Q1 2019,"Ono Pharmaceutical Company, Ltd., Pierre Fabre Medicament S.A."
1734,524,3009,51,Menactra Vaccine,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Meningococcal Vaccines and Other Meningococcus-Specific Agents (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Vaccine,"Immune system^ Neisseria meningitidis - Groups A, C, Y, and W-135",Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,01/17/05,,,,,12/22/03,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   673.0,$   152.8,Q1 2019,N/A
5722,524,5803,180,MenHibrix,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Meningococcal Vaccines and Other Meningococcus-Specific Agents (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Vaccine,"Haemophilus influenzae^ Immune system^ Neisseria meningitidis - Groups A, C, Y, and W-135",Vaccine,No,Intramuscular (IM),Y,N,N,,N,N,,,,06/14/12,,,,,08/31/09,,,,,05/14/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
5722,3198,28072,180,MenHibrix,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Hib vaccines (Haemophilus influenzae b),N,Approved,Approved,100% (Same As Avg.),Vaccine,"Haemophilus influenzae^ Immune system^ Neisseria meningitidis - Groups A, C, Y, and W-135",Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,06/14/12,,,,,08/31/09,,,,,05/28/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
15498,241,19710,582,Menopur,,Ferring Pharmaceuticals,,,Switzerland,Europe,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Follicle-Stimulating Hormone Receptor (FSHR)^ Gonadotropin-Releasing Hormone (GnRH) Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,,N,N,,,,10/29/04,,,,,12/19/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
1318,524,1592,180,Menveo,"Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine",GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Meningococcal Vaccines and Other Meningococcus-Specific Agents (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Vaccine,"Immune system^ Neisseria meningitidis - Groups A, C, Y, and W-135",Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,09/30/2011 - 09/30/2011,02/19/10,03/15/10,,,,08/29/08,04/18/06,,,,07/17/06,,,100%,,$   165.0,$   243.2,$   237.2,$    31.2,$   277.0,$   356.8,$   316.0,$    44.8,Q1 2019,N/A
19615,3115,25881,3444,Mepsevii,vestronidase alfa-vjbk,Ultragenyx Pharmaceutical Inc.,RARE,California,United States,North America,3093449498,Metabolic,Inborn Errors Of Metabolism,Mucopolysaccharidosis VII (MPS VII; Sly Syndrome),Y,Approved,Approved,100% (Same As Avg.),Protein,Beta-glucuronidase,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,11/15/17,08/27/18,,,,05/23/17,12/15/14,,,,12/15/14,05/15/13,,N/A,,N/A,N/A,$     7.9,$     5.9,N/A,N/A,$     7.9,$     5.9,Q2 2019,N/A
1974,440,3187,312,Merrem,meropenem hydrate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cell wall synthesis^ Gram-Negative Bacteria,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,05/25/05,,09/30/95,,,08/02/04,,,,,,,,100%,,N/A,N/A,N/A,N/A,$   141.3,$   187.0,$   264.1,$    66.4,Q1 2019,"Sumitomo Dainippon Pharma Co., Ltd."
649,246,1226,826,Metadate CD CII,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/03/01,05/24/06,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,UCB SA
9466,644,11578,470,Metozolv ODT,metoclopramide hydrochloride,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),General,Gastroesophageal Reflux Disease (GERD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Serotonin 5-HT3 receptor^ Serotonin 5-HT4 receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,09/04/09,,,,,11/05/07,,,,,09/05/07,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Wilmington Pharmaceuticals, LLC"
23114,534,31595,395,Metronidazole 1.3% Vaginal Gel,metronidazole,Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Microbial DNA^ Reactive Oxygen Species/Free Radicals,Non-NME,No,Intravaginal,N,N,N,N,N,N,,,,03/24/14,,,,,05/24/13,,,,,04/23/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Bausch Health Companies Inc.
7980,181,9804,70,Micardis,telmisartan,Boehringer Ingelheim GmbH,,,Germany,Europe,,Cardiovascular,General,Cardiovascular Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/19/09,11/27/09,,,,12/16/08,,,,,03/03/99,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   222.3,$    40.0,Q1 2019,"Astellas Pharma, Inc., Bayer AG, GlaxoSmithKline plc, WKD Holding Oy"
10760,244,13473,70,Micardis HCT,telmisartan and hydrochlorothiazide,Boehringer Ingelheim GmbH,,,Germany,Europe,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1)^ Na/Cl transporter - Thiazide-sensitive,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/17/00,04/22/02,04/22/09,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$    83.7,$    44.6,N/A,N/A,Q4 2017,"Astellas Pharma, Inc., Bayer AG"
23062,239,31492,395,Minastrin 24 Fe,Norethindrone Acetate; Ethinyl Estradiol; Ferrous Fumarate,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/08/13,,,,,07/09/12,,,,,,,,N/A,,$   325.9,$    61.4,$     9.5,N/A,$   327.3,$    61.4,$     9.5,N/A,Q4 2018,N/A
21224,653,28573,582,Minirin Spray,desmopressin acetate,Ferring Pharmaceuticals,,,Switzerland,Europe,,Urology,Other,Urinary Incontinence,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Vasopressin receptors,Non-NME,No,Intranasal,N,N,N,,N,N,,,,09/16/02,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
21224,3315,30471,582,Minirin Spray,desmopressin acetate,Ferring Pharmaceuticals,,,Switzerland,Europe,,Endocrine,Other,Central Diabetes Insipidus (CDI),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Vasopressin receptors,Non-NME,No,Intranasal,N,N,N,N,N,N,,,,09/16/02,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
21469,240,28932,2672,Minivelle,,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Endocrine,Menopause (Including Specific HRT),Menopause (including Hormone Replacement Therapy [HRT]),N,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Transdermal,N,N,N,,N,N,,,,10/29/12,,,,,,,,,,,,,N/A,,N/A,N/A,$    55.3,$     7.4,N/A,N/A,$    55.3,$     7.4,Q1 2019,Novartis AG
23365,440,32038,2685,Minocin IV (reformulation),minocycline hydrochloride,"Melinta Therapeutics, Inc.",MLNT,Connecticut,United States,North America,141731242,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Intravenous (IV),N,N,N,N,N,Y,,,,04/17/15,,,,,02/18/15,,,,,09/07/12,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,The Menarini Group
2201,579,4945,70,Mirapex,pramipexole,Boehringer Ingelheim GmbH,,,Germany,Europe,,Neurology,"movement disorders, all",Restless Leg Syndrome (RLS),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,11/07/06,04/07/06,,,,07/28/05,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2010,Pfizer Inc.
12588,194,15876,70,Mirapex ER,Pramipexole Hydrochloride,Boehringer Ingelheim GmbH,,,Germany,Europe,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/19/10,10/14/09,,,,10/24/08,,,,,04/25/07,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Daiichi Sankyo Co., Ltd."
2336,187,4104,1307,Mircera,methoxy polyethylene glycol-epoetin beta,Vifor Pharma Group,GNHAY,,Switzerland,Europe,,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Dependent",Y,Approved,Approved,100% (Same As Avg.),Protein,Erythropoietin Receptor (EPOR),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,11/15/07,07/20/07,,,,04/20/06,,,,,05/17/04,,,N/A,,N/A,N/A,N/A,N/A,$   522.8,$   515.7,$   540.2,$   282.1,Q2 2019,"Chugai Pharmaceutical Co., Ltd., Roche Holding AG, Royalty Pharma AG"
2336,371,4105,1307,Mircera,methoxy polyethylene glycol-epoetin beta,Vifor Pharma Group,GNHAY,,Switzerland,Europe,,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Independent",Y,Approved,Approved,100% (Same As Avg.),Protein,Erythropoietin Receptor (EPOR),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,11/15/07,07/20/07,,,,04/20/06,,,,,11/12/05,,,N/A,,N/A,N/A,N/A,N/A,$   522.8,$   515.7,$   540.2,$   282.1,Q2 2019,"Chugai Pharmaceutical Co., Ltd., Roche Holding AG, Royalty Pharma AG"
18522,239,28647,59,Mirena,levonorgestrel,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Contraception,Contraception,N,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Intrauterine,N,N,N,,N,N,,,,12/06/00,05/09/90,,,,,,,,,,,,N/A,,$   777.5,$   850.5,$   883.0,N/A,"$  1,157.8","$  1,284.8","$  1,344.5",$   699.3,Q2 2019,N/A
3031,584,5167,587,Mirvaso,brimonidine tartrate,Galderma S.A.,,,Switzerland,Europe,,Dermatology,General,Rosacea,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor,Non-NME,No,Topical,N,N,N,N,N,N,,,,08/23/13,02/21/14,,,,10/25/12,09/13/12,,,,08/01/11,05/02/07,11/08/06,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Maruho Co., Ltd."
25256,539,35129,4099,Mitigare,colchicine,Hikma Pharmaceuticals plc,HKMPY,,United Kingdom,Europe,,Autoimmune/immunology,Arthritis,Gout,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/26/14,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
19530,278,25764,3566,Mitosol,mitomycin/mannitol,"Mobius Therapeutics, LLC",,Missouri,United States,North America,,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Topical,N,N,N,N,N,N,,,,02/07/12,,,,,06/21/10,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
15810,1929,20203,70,Mobic,meloxicam,Boehringer Ingelheim GmbH,,,Germany,Europe,,Neurology,Pain,Arthritis Pain,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,04/13/00,02/21/96,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,AbbVie Inc.
15810,249,37258,70,Mobic,meloxicam,Boehringer Ingelheim GmbH,,,Germany,Europe,,Rheumatology (non autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,04/30/00,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,AbbVie Inc.
25408,3128,35366,343,MorphaBond ER,morphine,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Neurology,Pain,Chronic Pain,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/02/15,,,,,11/21/14,,,,,,,09/04/14,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Inspirion Delivery Technologies, LLC"
36785,3128,51250,8015,Morphine Sulfate 100mg/5mL,morphine sulfate,"Lannett Company, Inc.",LCI,Pennsylvania,United States,North America,,Neurology,Pain,Chronic Pain,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/23/11,,,,,02/26/10,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
17094,661,22175,826,Motegrity,prucalopride,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Gastroenterology (non inflammatory bowel disease),Other,Chronic Idiopathic Constipation,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT4 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/14/18,10/15/09,,,,,08/03/11,,,,01/10/12,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Johnson &amp; Johnson
6019,551,6457,343,Movantik,naloxegol,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Gastroenterology (non inflammatory bowel disease),Other,Opioid Induced Constipation (OIC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/16/14,12/09/14,,,,09/16/13,03/15/11,01/08/08,,,03/15/11,01/08/08,04/09/07,56%,361.2,$    91.0,$   122.0,$   108.0,$    45.0,$    91.0,$   170.1,$   159.8,$    72.4,Q2 2019,"AstraZeneca PLC, Knight Therapeutics Inc., Kyowa Hakko Kirin Co., Ltd., Nektar Therapeutics"
22772,3359,31007,470,MoviPrep,"polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid",Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),General,Colon Cleansing/Laxatives,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Osmosis/Osmotic Pressure,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/02/06,03/06/06,,,,06/07/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    20.0,$    25.0,$     5.0,Q1 2019,"EA Pharma Co., Ltd., Norgine B.V., Takeda Pharmaceutical Company Ltd"
8094,643,9986,235,Moxatag,amoxicillin,"Ligand Pharmaceuticals, Inc.",LGND,California,United States,North America,1998912930,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Respiratory Tract Infections (Excluding Pneumonia) (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Penicillin Binding Proteins (PBP),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/23/08,,,,,03/23/07,,,,,03/02/04,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2010,N/A
16306,81,21025,5497,Moxidectin,moxidectin,Medicines Development for Global Health,,,Australia,Oceania,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutamate-gated chloride ion channels (invertebrates),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,06/13/18,,,,,10/13/17,,,,,06/03/09,05/04/04,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
2422,300,4508,51,Mozobil,plerixafor,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,"Surgical, Interventional Radiological, and Other Invasive Procedures",Bone Marrow Transplant and Stem Cell Transplant,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Chemokine (C-X-C motif) Receptor 4 (CXCR4),New Molecular Entity (NME),No,Subcutaneous (SQ),N,Y,Y,N,N,N,,,10/01/2011 - 10/01/2011,12/15/08,07/31/09,,,,06/16/08,01/25/05,,,,01/25/05,,,100%,91.7,$   179.5,$   110.0,$   110.6,$    61.0,$   275.2,$   187.3,$   197.1,$   105.1,Q2 2019,N/A
16124,188,20697,618,Mulpleta,lusutrombopag,Shionogi & Co. Ltd.,4507:JP,,Japan,Asia,,Hematology,Marrow Or Peripheral Blood Stimulator,Thrombocytopenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Thrombopoietin Receptor (TPO-R, c-Mpl, CD110)",New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,07/31/18,02/18/19,09/28/15,,,12/31/17,11/01/13,02/04/10,,,09/04/15,02/04/10,11/20/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$     1.8,N/A,Q4 2018,Eddingpharm
2428,3548,4113,51,Multaq,dronedarone hydrochloride,Sanofi,SNY,,France,Europe,1.05588E+11,Cardiovascular,Dysrythmia (Arrythmia),Atrial Fibrillation/Flutter,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Beta Adrenergic Receptors^ Calcium Channel^ Potassium channels^ Sodium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,03/01/2011 - 03/01/2011,07/01/09,11/26/09,,,,06/30/08,,,,,01/17/03,,,100%,,$   331.8,$   326.5,$   340.6,$   152.4,$   385.2,$   387.2,$   402.9,$   181.8,Q2 2019,N/A
23155,211,31666,30,Mvasi,bevacizumab-awwb,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,09/14/17,01/18/18,,,,11/14/16,11/06/13,,,,11/06/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Daiichi Sankyo Co., Ltd."
23155,213,50124,30,Mvasi,bevacizumab-awwb,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Colorectal Cancer (CRC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,09/14/17,01/18/18,,,,11/14/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Daiichi Sankyo Co., Ltd."
23155,228,50125,30,Mvasi,bevacizumab-awwb,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,09/14/17,,,,,11/14/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Daiichi Sankyo Co., Ltd."
23155,216,50126,30,Mvasi,bevacizumab-awwb,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Renal Cell Cancer (RCC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,09/14/17,01/18/18,,,,11/14/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Daiichi Sankyo Co., Ltd."
23155,255,50127,30,Mvasi,bevacizumab-awwb,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Cervical Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,09/14/17,01/18/18,,,,11/14/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Daiichi Sankyo Co., Ltd."
16497,2936,21299,326,Myalept,metreleptin,Novelion Therapeutics Inc.,NVLN,British Columbia,Canada,North America,,Metabolic,Other,Lipodystrophy,Y,Approved,Approved,100% (Same As Avg.),Protein,Leptin Receptor (LepR),Biologic,No,Subcutaneous (SQ),Y,N,Y,N,N,N,,,,02/24/14,07/31/18,03/25/13,,,04/03/12,07/16/09,,,,07/16/09,,,N/A,,N/A,$    51.0,$    48.0,$    11.4,N/A,$    66.4,$    71.4,$    18.0,Q1 2019,"Amgen, Inc., Bristol-Myers Squibb Company, Shionogi &amp; Co. Ltd."
3245,3116,5570,814,Mycamine,micafungin sodium,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,Y,Approved,Approved,100% (Same As Avg.),Peptide,"Beta (1,3)-D-Glucan",New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,03/16/05,05/07/08,,,,04/29/02,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   353.7,$   374.5,$   323.4,$    70.8,Q1 2019,N/A
3245,3117,25909,814,Mycamine,micafungin sodium,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,N,Approved,Approved,100% (Same As Avg.),Peptide,"Beta (1,3)-D-Glucan",New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,03/16/05,05/07/08,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   353.7,$   374.5,$   323.4,$    70.8,Q1 2019,N/A
2754,246,4692,826,Mydayis,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine^ Norepinephrine (Noradrenaline),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/20/17,,,,,07/21/06,,,,,10/09/14,,,N/A,,N/A,$    21.6,$    62.9,N/A,N/A,$    21.6,$    62.9,N/A,Q4 2018,"Supernus Pharmaceuticals, Inc."
1686,380,2709,289,Myfortic,mycophenolic acid,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Transplant Rejection,Kidney Transplant Rejection,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,IMPDH II (Inosine Monophosphate Dehydrogenase 2),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,03/01/04,,,,,04/30/03,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   383.0,$   378.0,N/A,N/A,Q4 2017,N/A
646,97,1223,312,Mylotarg,gemtuzumab ozogamicin for injection,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ Cluster of Differentiation 33 (CD33)^ DNA,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,09/01/17,04/23/18,07/25/05,,,11/02/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2010,"PDL BioPharma, Inc., UCB SA"
1395,257,1812,991,Myobloc,rimabotulinumtoxinB,"US WorldMeds, LLC",,Kentucky,United States,North America,,Neurology,"movement disorders, all",Cervical Dystonia,Y,Approved,Approved,100% (Same As Avg.),Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,Intramuscular (IM),N,N,N,,N,N,,,,12/08/00,01/22/01,01/21/11,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Eisai Co., Ltd., Perrigo Company PLC"
441,335,906,51,Myozyme/Lumizyme,alglucosidase alfa,Sanofi,SNY,,France,Europe,1.05588E+11,Metabolic,Inborn Errors Of Metabolism,Pompe Disease,Y,Approved,Approved,100% (Same As Avg.),Protein,Glycogen,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,04/28/06,03/29/06,,,,07/29/05,05/29/03,04/15/03,,,09/10/03,,,N/A,,$   266.4,$   300.1,$   327.1,$   183.0,$   691.9,$   905.8,$   968.4,$   512.7,Q2 2019,DRI Capital Inc.
8309,543,10299,814,Myrbetriq,mirabegron,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Urology,Other,Overactive Bladder (OAB),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-3 adrenergic receptor (ß3 adrenoceptor),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/28/12,12/20/12,07/01/11,,,08/26/11,,,,,05/14/08,02/01/08,,N/A,,N/A,N/A,N/A,N/A,$   844.1,"$  1,148.8","$  1,356.9",$   338.7,Q1 2019,N/A
17570,2944,22891,470,Mytesi,crofelemer,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),General,Gastroenterologic Disorders,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium-activated Chloride Channels (CaCC)^ CF transmembrane conductance regulator (CFTR),New Molecular Entity (NME),No,Oral (PO),Y,Y,N,,N,N,,,,12/31/12,,,,,12/14/11,,,,,03/14/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Jaguar Health, Inc., RedHill Biopharma Ltd."
40703,157,57065,58,Myxredlin,insulin,Baxter International Inc.,BAX,Illinois,United States,North America,46924193203,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",N,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,06/20/19,,,,,08/22/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Celerity Pharmaceuticals, LLC"
40703,137,57066,58,Myxredlin,insulin,Baxter International Inc.,BAX,Illinois,United States,North America,46924193203,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",N,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,06/20/19,,,,,08/22/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Celerity Pharmaceuticals, LLC"
786,493,1140,65,Naglazyme,,BioMarin Pharmaceutical Inc.,BMRN,California,United States,North America,13080442306,Metabolic,Inborn Errors Of Metabolism,Mucopolysaccharidosis VI (MPS VI),Y,Approved,Approved,100% (Same As Avg.),Protein,N-Acetylgalactosamine 4-sulfatase,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,05/31/05,01/24/06,03/28/08,,,11/29/04,10/15/03,,10/15/00,,12/30/03,,,100%,207.6,N/A,N/A,N/A,N/A,$   296.7,$   332.6,$   345.9,$   185.1,Q2 2019,"AnGes, Inc."
23770,141,32737,395,Namenda (oral solution),,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,NMDA Glutamate Receptor^ Serotonin 5-HT3 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,04/18/05,,,,,05/01/03,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   459.3,N/A,Q4 2018,"Daiichi Sankyo Co., Ltd., H. Lundbeck A/S, Merz Pharmaceuticals GmbH"
210,141,250,395,Namenda (tablets),memantine hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,NMDA Glutamate Receptor^ Serotonin 5-HT3 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/16/03,05/15/02,01/21/11,,,07/31/02,,,,,04/14/99,,,95%,513,$   627.6,$   452.8,$    71.0,$     9.5,$   627.6,$   894.7,$   599.0,$   130.2,Q1 2019,"Daiichi Sankyo Co., Ltd., H. Lundbeck A/S, Merz Pharmaceuticals GmbH"
16973,141,22010,395,Namenda XR,memantine hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,NMDA Glutamate Receptor^ Serotonin 5-HT3 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/21/10,,,,,08/21/09,,,,,01/16/07,,,95%,383.3,$   627.6,$   452.8,$    71.0,$     9.5,$   627.6,$   894.7,$   599.0,$   130.2,Q1 2019,"Adamas Pharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., H. Lundbeck A/S, Merz Pharmaceuticals GmbH"
18614,141,24437,395,Namzaric,memantine hydrochloride extended-release and donepezil hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cholinesterases^ NMDA Glutamate Receptor^ Serotonin 5-HT3 receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/24/14,,,,,03/04/14,,,,,06/04/12,05/15/12,07/18/11,N/A,,$    57.5,$   130.8,$   115.8,$    46.0,N/A,$   130.8,$   115.8,$    46.0,Q2 2019,"Adamas Pharmaceuticals, Inc."
18716,726,31317,1298,Narcan,naloxone,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Not Specified,Other,Drug Toxicity,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Intranasal,Y,N,N,N,N,N,,,,11/18/15,03/23/18,,,,07/17/15,,,08/21/13,,,,08/21/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    41.7,$   138.5,Q2 2019,"Opiant Pharmaceuticals, Inc., SWK Holdings Corporation"
18948,236,24934,266,Nasacort HFA,triamcinolone acetonide,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Allergy,General,Allergic Rhinitis,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intranasal,N,N,N,N,N,N,,,,04/07/04,,,,,12/17/96,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Sanofi
20818,3070,27864,142,Nascobal,cyanocobalamin,Endo International plc,ENDP,,Ireland,Europe,554131557,Metabolic,Other,Vitamin B12 Deficiency,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Coenzyme B12-dependent enzymes,Non-NME,No,Intranasal,N,N,N,N,N,N,,,,01/31/05,,,,,12/26/03,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
1917,3159,36662,254,Nasonex,mometasone furoate monohydrate,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Allergy,General,Nasal Polyposis,N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intranasal,N,N,N,N,N,N,,,,12/15/04,,,,,,,,,,,,,N/A,,$   184.0,$    53.0,$    23.0,N/A,$   536.0,$   386.0,$   376.0,$   170.0,Q2 2019,"Kyorin Pharmaceutical Co., Ltd."
16751,239,21669,59,Natazia,estradiol valerate/dienogest,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/06/10,10/11/10,,,,07/06/09,,,,,05/15/09,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18918,549,24887,5817,Natesto,testosterone,"Aytu BioScience, Inc.",AYTU,Colorado,United States,North America,12001401,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Intranasal,N,N,N,N,N,N,,08/01/2019 - 02/29/2020,,05/28/14,,,,,04/29/13,10/03/11,,,,10/03/11,08/06/10,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Acerus Pharmaceuticals Corporation, Carnot Laboratorios, Eu Hwa Pte, Hyundai Pharmaceuticals Co., Ltd, M et P Pharma AG, medac GmbH, Therios Healthcare"
272,2557,5506,826,Natpara,parathyroid hormone 1-84,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Endocrine,Other,Hypoparathyroidism,Y,Approved,Approved,100% (Same As Avg.),Protein,Parathyroid Hormone Receptor (PTHR),Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,01/23/15,04/24/17,,,,10/24/13,12/22/08,,,,06/27/08,03/14/07,,100%,695.6,N/A,$   146.1,$   153.4,N/A,$    84.3,$   147.4,$   225.3,N/A,Q3 2018,DRI Capital Inc.
192,575,3072,223,Natrecor,nesiritide,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Y,Approved,Approved,100% (Same As Avg.),Peptide,Natriuretic Peptide Receptors,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,08/10/01,,,,,04/27/98,,,,,11/07/96,01/12/94,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Pharma Services Holding, Inc."
21207,81,28540,3974,Natroba,spinosad,"ParaPRO, LLC",,Indiana,United States,North America,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutamate-gated chloride ion channels (invertebrates)^ Nicotinic Acetylcholine Receptors (invertebrates),New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,01/18/11,,,,,01/21/09,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
15047,272,19108,88,Nayzilam,midazolam,UCB SA,UCB:BB,,Belgium,Europe,,Neurology,Seizure Disorders (Epilepsy),Seizure Disorders (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Intranasal,Y,Y,Y,N,N,N,,,,05/17/19,,,,,05/27/18,07/18/11,,,,07/18/11,12/08/08,07/25/06,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
21751,181,29371,1008,NeoProfen,,Recordati SpA,REC:IM,,Italy,Europe,,Cardiovascular,General,Cardiovascular Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",New Molecular Entity (NME),No,Intravenous (IV),N,N,Y,,N,N,,,,04/13/06,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
25250,531,35123,882,Neostigmine Methylsulfate Injection,Neostigmine Methylsulfate,Fresenius SE & Co. KGaA,FSNUY,,Germany,Europe,0,Neurology,Pain,Anesthesia,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Not Specified,Cholinesterases,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,01/08/15,,,,,12/28/11,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2697,214,4606,3443,Nerlynx,neratinib maleate,"Puma Biotechnology, Inc.",PBYI,California,United States,North America,422535733,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor)^ ErbB4/HER4^ HER2/neu or ErbB-2,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,Y,N,N,N,N,,,,07/17/17,09/04/18,,,,07/19/16,01/16/09,03/07/06,,,01/16/09,03/07/06,,85%,,N/A,$    26.2,$   200.5,$    45.6,N/A,$    26.2,$   200.5,$    45.6,Q1 2019,"CANbridge Life Sciences Ltd., Knight Therapeutics Inc., Medison Pharma Ltd., Pfizer Inc., Pierre Fabre Medicament S.A., Pint Pharma International S.A.,, Specialised Therapeutics Asia Pte Ltd"
2687,137,4587,826,Nesina,alogliptin,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl peptidase IV (DPP-IV),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,07/25/2013 - 09/30/2013,,01/25/13,09/19/13,04/16/10,,,12/27/07,01/20/06,,,,03/02/06,,,95%,575,$    45.8,$    52.8,$    49.9,N/A,$   421.6,$   480.6,$   497.5,N/A,Q4 2018,"Royalty Pharma AG, Sanofi"
23835,3418,32838,289,Netspot,,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Diagnostics,Neuroendocrine Tumors (NET) - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,New Molecular Entity (NME),Yes,,N,N,Y,N,N,N,,,,06/01/16,12/08/16,,,,07/01/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
27,91,41,30,Neulasta,pegfilgrastim,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Hematology,Marrow Or Peripheral Blood Stimulator,Neutropenia / Leukopenia,Y,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,01/31/02,08/29/02,09/30/14,,,03/20/01,10/01/99,,,,10/01/99,,,100%,4002.1,"$  3,925.0","$  3,931.0","$  3,866.0","$  1,612.0","$  4,648.0","$  4,534.0","$  4,475.0","$  1,987.9",Q2 2019,"DRI Capital Inc., Kyowa Hakko Kirin Co., Ltd., Nektar Therapeutics, Roche Holding AG"
26,666,36026,30,Neupogen,filgrastim,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Not Specified,Other,Acute Radiation Syndrome (ARS),N,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,03/30/15,,,,,09/30/14,,,,,,,,100%,,$   534.0,$   369.0,$   223.0,$   105.0,$   765.0,$   549.0,$   365.0,$   148.0,Q2 2019,"DRI Capital Inc., Kyowa Hakko Kirin Co., Ltd., Roche Holding AG"
2203,194,3688,88,Neupro,rotigotine,UCB SA,UCB:BB,,Belgium,Europe,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor,New Molecular Entity (NME),No,Transdermal,N,N,N,N,N,N,,,,05/10/07,02/15/06,12/25/12,,,01/28/05,,,,,11/10/02,07/28/01,,N/A,,$    92.0,$   116.4,$   111.7,N/A,$   335.0,$   491.8,$   355.3,N/A,Q4 2018,"NewBridge Pharmaceuticals, Otsuka Holdings Co., Ltd."
2203,579,3699,88,Neupro,rotigotine,UCB SA,UCB:BB,,Belgium,Europe,,Neurology,"movement disorders, all",Restless Leg Syndrome (RLS),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor,New Molecular Entity (NME),No,Transdermal,N,N,N,,N,N,,,,04/02/12,08/29/08,12/25/12,,,,,,,,02/22/05,07/12/04,,N/A,,$    92.0,$   116.4,$   111.7,N/A,$   335.0,$   491.8,$   355.3,N/A,Q4 2018,"NewBridge Pharmaceuticals, Otsuka Holdings Co., Ltd."
20857,1329,27920,3645,Neuraceq,,"Piramal Healthcare, Ltd.",PIHC:IN,,India,Asia,,Neurology,Neurodegenerative,Alzheimer's Disease - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Amyloid Beta/Amyloid Plaques^ Radiopharmaceutical,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,03/20/14,02/20/14,,,,,,,,,11/30/09,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Bayer AG, Ci-Co Healthcare Co., Ltd., PET Pharm Biotech Co. Ltd"
1854,3157,2975,312,Neurontin,gabapentin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Pain,Postherpetic Neuralgia (PHN),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Voltage-gated calcium channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/28/02,,,,,,,,,,,,,N/A,,$    48.0,N/A,N/A,N/A,$   182.0,N/A,N/A,N/A,Q4 2016,"Fuji Pharma Co., Ltd."
2164,554,3595,289,Nevanac,nepafenac,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,08/19/05,12/11/07,11/08/10,,,02/28/05,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
55,297,68,30,Nexavar,sorafenib tosylate,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),N,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Raf kinase^ RET^ Tyrosine Kinases^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,Y,Y,,N,N,,,,11/16/07,10/29/07,05/20/09,,,06/27/07,11/05/04,09/04/02,,,11/05/04,08/18/03,,50%,278.7,$   346.0,$   335.0,$   253.3,N/A,$   964.9,$   952.6,$   836.2,$   407.8,Q2 2019,Bayer AG
55,216,591,30,Nexavar,sorafenib tosylate,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Renal Cell Cancer (RCC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Raf kinase^ RET^ Tyrosine Kinases^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,Y,Y,N,N,N,,,,12/20/05,07/19/06,01/28/08,,,07/11/05,10/25/03,,,,10/27/03,08/18/03,,50%,60.5,$   346.0,$   335.0,$   253.3,N/A,$   964.9,$   952.6,$   836.2,$   407.8,Q2 2019,Bayer AG
55,532,3704,30,Nexavar,sorafenib tosylate,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Thyroid Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Raf kinase^ RET^ Tyrosine Kinases^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,11/22/13,05/30/14,06/20/14,,,06/24/13,10/16/09,,,,10/16/09,11/05/04,,50%,84.1,$   346.0,$   335.0,$   253.3,N/A,$   964.9,$   952.6,$   836.2,$   407.8,Q2 2019,Bayer AG
1936,644,3124,45,Nexium,esomeprazole magnesium,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Gastroenterology (non inflammatory bowel disease),General,Gastroesophageal Reflux Disease (GERD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Proton pump,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,02/20/01,07/12/00,07/01/11,,,,,,,,,,,N/A,,$   554.0,$   499.0,$   306.0,$    66.0,"$  2,806.3","$  2,749.3","$  2,423.8",$   520.1,Q1 2019,"Daiichi Sankyo Co., Ltd., Grünenthal GmbH, Pfizer Inc."
1936,147,4433,45,Nexium,esomeprazole magnesium,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Gastroenterology (non inflammatory bowel disease),"Acid-Peptic (Gastritis Peptic Ulcer, Etc.)",Ulcers and other acid-peptic gastrointestinal disorders,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Proton pump,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,11/24/04,05/12/09,07/01/11,,,01/28/04,,,,,,,,N/A,,$   554.0,$   499.0,$   306.0,$    66.0,"$  2,806.3","$  2,749.3","$  2,423.8",$   520.1,Q1 2019,"Daiichi Sankyo Co., Ltd., Grünenthal GmbH, Pfizer Inc."
1936,655,4556,45,Nexium,esomeprazole magnesium,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Solid,Zollinger-Ellison Syndrome,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Proton pump,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,10/12/06,,07/01/11,,,12/15/05,,,,,,,,N/A,,$   554.0,$   499.0,$   306.0,$    66.0,"$  2,806.3","$  2,749.3","$  2,423.8",$   520.1,Q1 2019,"Daiichi Sankyo Co., Ltd., Grünenthal GmbH, Pfizer Inc."
17895,3581,23376,58,Nexterone,amiodarone hydrochloride,Baxter International Inc.,BAX,Illinois,United States,North America,46924193203,Cardiovascular,Dysrythmia (Arrythmia),Ventricular Tachycardia or Fibrillation,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Beta Adrenergic Receptors^ Calcium Channel^ Potassium channels^ Sodium Channels,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,12/24/08,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Ligand Pharmaceuticals, Inc."
14992,207,20026,826,Ninlaro,ixazomib citrate,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Oncology,Hematologic,Multiple Myeloma (MM),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Proteasome,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,Y,N,N,N,,,,11/20/15,11/21/16,03/29/17,,,07/10/15,06/19/12,11/22/10,05/05/09,,06/19/12,11/22/10,05/05/09,N/A,,$   225.0,$   352.0,$   424.0,N/A,$   227.6,$   415.5,$   564.7,N/A,Q4 2018,N/A
40520,244,56762,8538,Nipride RTU,sodium nitroprusside,"Exela Pharma Sciences, LLC",,North Carolina,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Reactive Oxygen Species/Free Radicals,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,03/08/17,,,,,05/06/16,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
35691,3001,49613,7691,Nityr,nitisinone,Cycle Pharmaceuticals Ltd.,,,United Kingdom,Europe,,Metabolic,Inborn Errors Of Metabolism,Tyrosinemia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"4-hydroxyphenyl-pyruvate dioxygenase (HPPD; a-ketoisocaproate dioxygenase, KIC dioxygenase)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/26/17,07/26/18,,,,09/26/16,,,,,,,10/31/15,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
29439,91,40827,312,Nivestym,filgrastim-aafi,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Hematology,Marrow Or Peripheral Blood Stimulator,Neutropenia / Leukopenia,Y,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,07/20/18,,,,,09/21/17,,,05/06/16,,,,05/06/16,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
21226,2291,30473,582,Nocdurna,desmopressin acetate,Ferring Pharmaceuticals,,,Switzerland,Europe,,Urology,Other,"Urinary Symptoms (e.g. Nocturia, Polyuria)",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Vasopressin receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,06/21/18,,06/18/19,,,06/19/09,,,,,06/09/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Kissei Pharmaceutical Co., Ltd"
16127,2291,20703,831,Noctiva,desmopressin acetate,Avadel Pharmaceuticals plc,AVDL,,Ireland,Europe,75874628,Urology,Other,"Urinary Symptoms (e.g. Nocturia, Polyuria)",Y,Approved,Approved,100% (Same As Avg.),Peptide,Vasopressin receptors,Non-NME,No,Intranasal,N,N,N,N,N,N,,,,03/03/17,,,,,02/04/16,,,,,07/10/09,11/17/08,11/06/08,N/A,,N/A,N/A,$     2.1,$     0.6,N/A,N/A,$     2.1,$     0.6,Q1 2019,"CPEX Pharmaceuticals, Inc., Serenity Pharmaceuticals, Inc."
3070,731,5252,240,Northera,droxidopa,H. Lundbeck A/S,HLUKF,,Denmark,Europe,,Cardiovascular,Other,Orthostatic Hypotension,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors,New Molecular Entity (NME),No,Oral (PO),Y,Y,Y,N,N,N,,,,02/18/14,,,,,09/28/11,02/07/08,,,,09/24/07,07/13/01,,N/A,,$   160.6,N/A,$   190.7,N/A,$   160.6,$   255.4,$   268.6,$    66.2,Q1 2019,"Sumitomo Dainippon Pharma Co., Ltd."
234,153,314,255,Novantrone,mitoxantrone,Merck KGaA,MKGAY,,Germany,Europe,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA^ DNA synthesis^ Topoisomerase II (DNA gyrase),New Molecular Entity (NME),No,Intravenous (IV),N,N,Y,,N,N,,,,10/13/00,,,,,06/04/99,,,,,02/01/97,,,65%,0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2006,"Astellas Pharma, Inc., Pfizer Inc."
17188,511,22299,292,NovoEight,turoctocog alfa,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,01/01/2014 - 01/01/2014,10/15/13,11/13/13,,,,10/16/12,04/14/09,,,,04/14/09,,03/12/09,N/A,,N/A,$    47.3,$    45.5,$    13.1,N/A,$   182.8,$   211.8,$    59.8,Q1 2019,N/A
1707,137,2910,292,NovoLog,insulin aspart,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,06/07/00,09/07/99,10/29/09,,,,,,,,,,,100%,1522.9,N/A,"$  1,595.8","$  1,475.4",$   331.5,"$  2,990.1","$  3,028.2","$  2,938.0",$   722.0,Q1 2019,N/A
1707,157,3257,292,NovoLog,insulin aspart,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,06/08/00,09/07/99,10/29/09,,,,,,,,,,,100%,738.7,N/A,"$  1,595.8","$  1,475.4",$   331.5,"$  2,990.1","$  3,028.2","$  2,938.0",$   722.0,Q1 2019,N/A
18073,157,23605,292,NovoLog Mix,insulin aspart,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",N,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,11/01/01,08/01/00,08/28/03,,,,,,,,,,,100%,69.8,N/A,$   262.4,$   202.8,$    42.7,"$  1,573.4","$  1,550.4","$  1,485.1",$   387.1,Q1 2019,N/A
18073,137,23606,292,NovoLog Mix,insulin aspart,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",N,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,11/01/01,08/01/00,08/28/03,,,,,,,,,,,100%,1018.5,N/A,$   262.4,$   202.8,$    42.7,"$  1,573.4","$  1,550.4","$  1,485.1",$   387.1,Q1 2019,N/A
734,378,5132,292,NovoSeven,eptacog alfa,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Autoimmune/immunology,Acquired Hemophilia,Acquired Hemophilia,N,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor IX^ Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,10/13/06,,,,,12/30/05,,,,,,,,N/A,,N/A,$   673.8,$   512.9,$   119.4,"$  1,051.1","$  1,393.9","$  1,233.9",$   306.1,Q1 2019,Bristol-Myers Squibb Company
1919,3116,3091,254,Noxafil,posaconazole,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Ergosterol biosynthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,Y,N,N,N,,,,09/18/06,10/25/05,,,,05/01/04,,,,,07/22/03,,,N/A,,$   244.0,$   309.0,$   353.0,$   191.0,$   596.0,$   637.0,$   743.0,$   383.0,Q2 2019,N/A
1919,3117,33589,254,Noxafil,posaconazole,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Ergosterol biosynthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,10/20/06,11/09/06,,,,,,,,,,,,N/A,,$   244.0,$   309.0,$   353.0,$   191.0,$   596.0,$   637.0,$   743.0,$   383.0,Q2 2019,N/A
1846,649,2954,30,Nplate,romiplostim,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),Y,Approved,Approved,100% (Same As Avg.),Protein,"Thrombopoietin Receptor (TPO-R, c-Mpl, CD110)",Biologic,No,Subcutaneous (SQ),Y,N,Y,N,N,N,,,01/01/2012 - 01/01/2012,08/22/08,02/04/09,01/01/11,,,10/24/07,04/21/05,,,,04/21/05,12/06/04,,100%,314.7,$   350.0,$   392.0,$   438.0,$   236.0,$   584.0,$   642.0,$   717.0,$   398.2,Q2 2019,"Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Company Ltd"
18690,215,24544,59,Nubeqa,darolutamide,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Androgen receptors,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,02/01/2020 - 08/31/2020,12/01/2019 - 06/30/2020,07/30/19,,,,,02/26/19,,,,,07/30/14,03/16/11,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Endo International plc, Orion Corporation"
40544,72,56811,180,Nucala Liquid Formulation,mepolizumab,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,Asthma,Asthma,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-5 (Interleukin-5) and IL-5 Receptor (IL-5R),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,06/06/19,08/01/19,,,,08/07/18,,,,,12/15/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"PDL BioPharma, Inc."
40544,629,56814,180,Nucala Liquid Formulation,mepolizumab,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Autoimmune/immunology,Vasculitis,Antineutrophil Cytoplasmic Antibodies (ANCA) Associated Vasculitis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-5 (Interleukin-5) and IL-5 Receptor (IL-5R),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,06/06/19,,,,,08/07/19,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"PDL BioPharma, Inc."
2476,72,4199,180,Nucala Lyophilized Powder Formulation,mepolizumab,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-5 (Interleukin-5) and IL-5 Receptor (IL-5R),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,11/04/15,12/01/15,03/29/16,,,11/05/14,10/29/12,,,,01/26/12,12/23/00,,N/A,,$    97.0,$   307.0,$   454.0,$   261.0,$   139.0,$   447.0,$   749.0,$   448.0,Q2 2019,"PDL BioPharma, Inc."
2476,629,30140,180,Nucala Lyophilized Powder Formulation,mepolizumab,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Autoimmune/immunology,Vasculitis,Antineutrophil Cytoplasmic Antibodies (ANCA) Associated Vasculitis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-5 (Interleukin-5) and IL-5 Receptor (IL-5R),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,12/12/17,,05/31/18,,,06/28/17,,,,,02/14/14,,12/25/13,N/A,,$    97.0,$   307.0,$   454.0,$   261.0,$   139.0,$   447.0,$   749.0,$   448.0,Q2 2019,"PDL BioPharma, Inc."
7721,3127,9478,3447,Nucynta,tapentadol immediate release (IR),"Collegium Pharmaceutical, Inc.",COLL,Massachusetts,United States,North America,392985272,Neurology,Pain,Acute Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Opioid receptors,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,11/20/08,08/10/10,,,,01/23/08,,,,,04/28/06,,,N/A,,N/A,N/A,$   212.1,$    49.4,N/A,N/A,$   212.1,$    49.4,Q1 2019,"Assertio Therapeutics, Inc., Grünenthal GmbH, Takeda Pharmaceutical Company Ltd"
7726,3629,9491,3447,Nucynta ER,tapentadol extended release (ER),"Collegium Pharmaceutical, Inc.",COLL,Massachusetts,United States,North America,392985272,Neurology,Pain,Chronic Low Back Pain (CLBP),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/25/11,08/10/10,,,,12/01/09,,,,,04/28/06,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Assertio Therapeutics, Inc., Grünenthal GmbH, Takeda Pharmaceutical Company Ltd"
7726,671,22386,3447,Nucynta ER,tapentadol extended release (ER),"Collegium Pharmaceutical, Inc.",COLL,Massachusetts,United States,North America,392985272,Neurology,Pain,Diabetic Peripheral Neuropathy (DPN),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Opioid receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/28/12,,,,,10/31/11,,,,,04/01/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Assertio Therapeutics, Inc., Grünenthal GmbH, Takeda Pharmaceutical Company Ltd"
1138,552,2094,636,Nuedexta,dextromethorphan hydrobromide and quinidine sulfate,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Neurology,Other,Pseudobulbar Affect (PBA),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450^ NMDA Glutamate Receptor^ Sigma-1 Receptor,Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,10/29/10,06/24/13,,,,01/27/06,,,,,12/20/00,,,N/A,,N/A,N/A,N/A,N/A,N/A,$   234.9,$   261.0,$    58.1,Q1 2019,N/A
2331,380,3931,73,Nulojix,belatacept,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Autoimmune/immunology,Transplant Rejection,Kidney Transplant Rejection,Y,Approved,Approved,100% (Same As Avg.),Protein,Cluster of Differentiation 80 (CD80)^ Cluster of Differentiation 86 (CD86),Biologic,No,Intravenous (IV),Y,Y,Y,N,N,N,,,,06/15/11,06/17/11,,,,06/30/10,07/28/05,,,,01/26/05,05/17/04,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2013,N/A
2207,194,3692,7,Nuplazid,pimavanserin,"Acadia Pharmaceuticals, Inc.",ACAD,California,United States,North America,3683445703,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT2A receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,04/29/16,,,,,09/01/15,06/11/07,,,,06/11/07,06/23/04,,100%,515.5,$     5.4,$   125.0,$   223.9,$   146.2,$     5.4,$   125.0,$   223.9,$   146.2,Q2 2019,N/A
32172,239,44439,254,NuvaRing,ethinyl estradiol and etonogestrel,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Endocrine,Contraception,Contraception,Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Progesterone Receptor,New Molecular Entity (NME),No,Intravaginal,N,N,N,N,N,N,,,,10/03/01,06/12/01,,,,12/28/99,,,,,,,,N/A,,N/A,$   565.0,$   722.0,$   391.0,N/A,$   761.0,$   902.0,$   459.0,Q2 2019,Grünenthal GmbH
1812,433,2888,375,Nuvigil,armodafinil,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Other,Narcolepsy,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Unknown,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/15/07,,,,,03/31/05,,,,,11/04/04,,,100%,,$   200.0,$    31.0,N/A,$     0.0,$   200.0,$    31.0,N/A,$     0.0,Q2 2017,N/A
1812,578,2889,375,Nuvigil,armodafinil,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Other,Sleep Apnea,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Unknown,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/15/07,,,,,03/31/05,,,,,11/04/04,,,100%,,$   200.0,$    31.0,N/A,$     0.0,$   200.0,$    31.0,N/A,$     0.0,Q2 2017,N/A
1812,618,2890,375,Nuvigil,armodafinil,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Other,Shift Work Sleep Disorder (SWSD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Unknown,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/15/07,,,,,03/31/05,,,,,11/04/04,,,100%,,$   200.0,$    31.0,N/A,$     0.0,$   200.0,$    31.0,N/A,$     0.0,Q2 2017,N/A
21319,511,28718,2684,Nuwiq,simoctocog alfa,Octapharma AG,,,Switzerland,Europe,,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,09/04/15,07/24/14,,,,06/04/14,,,,,05/17/10,05/04/10,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Kedrion S.p.A.
3132,440,5364,879,Nuzyra,omadacycline,"Paratek Pharmaceuticals, Inc.",PRTK,Massachusetts,United States,North America,143348757,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Gram-Negative Bacteria^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,N,N,N,Y,,09/01/2019 - 03/31/2020,,10/02/18,,,,,02/02/18,03/18/09,,,,03/18/09,10/25/07,12/12/06,N/A,,N/A,N/A,N/A,$     1.3,N/A,N/A,N/A,$     1.3,Q1 2019,"Zai Laboratory, Inc."
3132,488,23433,879,Nuzyra,omadacycline,"Paratek Pharmaceuticals, Inc.",PRTK,Massachusetts,United States,North America,143348757,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Gram-Negative Bacteria^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,N,N,N,Y,,09/01/2019 - 03/31/2020,,10/02/18,,,,,02/02/18,11/09/15,,,,01/27/11,,,N/A,,N/A,N/A,N/A,$     1.3,N/A,N/A,N/A,$     1.3,Q1 2019,"Zai Laboratory, Inc."
22418,3337,30414,4042,Nymalize,nimodipine,"Arbor Pharmaceuticals, LLC",,Georgia,United States,North America,,Neurology,Stroke,Subarachnoid Hemorrhage,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel,Non-NME,No,Oral (PO),Y,N,Y,N,N,N,,,,05/10/13,,,,,11/20/12,,,,,09/16/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
10852,378,13605,826,Obizur,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Acquired Hemophilia,Acquired Hemophilia,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,10/24/14,11/11/15,,,,,11/16/10,,,,11/16/10,,09/04/03,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Ipsen SA
15236,1565,19358,2651,Ocaliva,obeticholic acid,"Intercept Pharmaceuticals, Inc.",ICPT,New York,United States,North America,1958084522,Autoimmune/immunology,Other,Primary Biliary Cholangitis (PBC) and Hepatic Fibrosis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Farnesoid X receptor (FXR)/NR1H4,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,05/27/16,12/12/16,,,,06/29/15,01/06/12,10/29/07,,,01/06/12,10/29/07,05/16/06,100%,,$    18.2,$   115.9,$   140.8,$    38.0,$    18.2,$   129.2,$   177.9,$    51.8,Q1 2019,"Sumitomo Dainippon Pharma Co., Ltd."
2157,153,5196,149,Ocrevus,ocrelizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,Intravenous (IV),Y,N,N,Y,N,N,,,,03/28/17,01/08/18,,,,04/28/16,04/14/11,06/26/08,,,08/28/10,06/26/08,10/11/06,66%,1132.8,N/A,$   886.4,"$  2,111.9","$  1,456.4",N/A,$   895.7,"$  2,389.2","$  1,735.4",Q2 2019,"Biogen, Inc., Chugai Pharmaceutical Co., Ltd., PDL BioPharma, Inc."
15701,423,20036,2684,Octagam,,Octapharma AG,,,Switzerland,Europe,,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,05/21/04,02/01/95,,,,08/14/02,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
15701,649,33765,2684,Octagam,,Octapharma AG,,,Switzerland,Europe,,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),N,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,07/11/14,,,,,,,,,,10/01/10,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
21747,329,29364,2684,Octaplas,,Octapharma AG,,,Switzerland,Europe,,Hematology,Factor Augmentation,Hemophilia A and B - General Clotting Products,Y,Approved,Approved,100% (Same As Avg.),Protein,,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,01/17/13,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
16771,236,21709,994,Odactra,,ALK-Abello A/S,ALKB:DC,,Denmark,Europe,,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Natural Protein,Immune system,Biologic,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,03/01/17,08/30/15,09/28/15,,,02/09/16,10/10/12,,,,10/10/12,05/11/10,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Abbott Laboratories, Torii Pharmaceutical Co., Ltd."
25111,78,34908,179,Odefsey,"tenofovir alafenamide, emtricitabine, and rilpivirine","Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/01/16,06/21/16,,,,07/01/15,01/19/15,,,,12/29/14,,,N/A,,$   313.0,$   964.0,"$  1,242.0",$   548.0,$   340.0,"$  1,106.0","$  1,598.0",$   784.0,Q2 2019,Johnson &amp; Johnson
16686,360,21571,3285,Odomzo,sonidegib,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Skin Cancer - Basal Cell Carcinoma (BCC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Hedgehog Signaling Pathway,New Molecular Entity (NME),No,"Oral (PO), Topical",N,N,N,N,N,N,,,,07/24/15,08/14/15,,,,09/26/14,,08/18/09,04/11/09,,,08/18/09,04/11/09,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
8415,387,10453,70,Ofev,nintedanib,Boehringer Ingelheim GmbH,,,Germany,Europe,,Respiratory,Other,Idiopathic Pulmonary Fibrosis (IPF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Fibroblast Growth Factor Receptor (FGFR)^ Platelet-derived growth factor receptor (PDGFR)^ Src Kinase Family^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,,,10/15/14,01/15/15,07/03/15,,,,05/09/11,,,,05/09/11,08/09/07,,N/A,609.4,N/A,N/A,N/A,N/A,$   279.0,N/A,"$  1,217.6",N/A,Q4 2018,N/A
3004,3130,5126,556,Ofirmev,acetaminophen (intravenous),Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Neurology,Pain,Postsurgical Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cannabinoid reuptake/Endocannabinoid system^ Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,11/02/10,,,,,05/12/09,,,,,04/01/05,,,N/A,,N/A,N/A,$   341.9,$   186.1,N/A,N/A,$   341.9,$   186.1,Q2 2019,Bristol-Myers Squibb Company
3004,2128,12591,556,Ofirmev,acetaminophen (intravenous),Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Not Specified,Other,Fever,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cannabinoid reuptake/Endocannabinoid system^ Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,11/02/10,,,,,05/12/09,,,,,04/01/07,,,N/A,,N/A,N/A,$   341.9,$   186.1,N/A,N/A,$   341.9,$   186.1,Q2 2019,Bristol-Myers Squibb Company
19864,214,26337,266,Ogivri,trastuzumab-dkst,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/01/17,12/19/18,,,,11/08/16,03/01/13,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Biocon, Ltd."
19864,223,51255,266,Ogivri,trastuzumab-dkst,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Oncology,Solid,Gastric Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,12/01/17,12/19/18,,,,11/08/16,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Biocon, Ltd."
10549,167,13210,2065,Oleptro,trazodone hydrochloride,ACRAF SpA (Gruppo Angelini),,,Italy,Europe,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT2A receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,02/02/10,,,,,09/18/08,06/07/07,,,,06/07/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2011,"Endo International plc, Lee's Pharmaceutical Holdings Limited"
12314,154,15521,136,Olumiant,baricitinib,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,JAK/STAT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/31/18,02/13/17,07/03/17,,,01/15/16,11/02/12,05/07/09,,,11/02/12,05/07/09,07/29/08,80%,4072.8,N/A,N/A,$     6.7,$    17.1,N/A,$    45.9,$   202.6,$   184.5,Q2 2019,Incyte Corporation
8537,176,10607,223,Olysio,simeprevir,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HCV Protease,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,11/22/13,05/14/14,09/27/13,,,03/28/13,02/03/11,02/20/08,,,02/03/11,02/20/08,02/08/07,90%,,$    55.0,N/A,N/A,$     0.0,$   106.0,N/A,N/A,$     0.0,Q4 2016,Medivir AB
18244,176,23865,5,Ombitasvir,ombitasvir,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Non-structural 5A protein (NS5A),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,12/19/14,01/15/15,09/28/15,,,,10/10/12,04/20/11,08/12/10,,10/10/12,04/20/11,08/12/10,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    66.0,$    46.0,Q1 2019,"Enanta Pharmaceuticals, Inc."
23987,3120,33105,3014,Omeclamox-Pak,"amoxicillin, clarithromycin, omeprazole",Cumberland Pharmaceuticals Inc.,CPIX,Tennessee,United States,North America,89128556,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",H. pylori Infection,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Penicillin Binding Proteins (PBP)^ Protein synthesis^ Proton pump,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/08/11,,,,,,,,,,,,,N/A,,$     2.6,$     1.9,$     0.6,$     0.2,$     2.6,$     1.9,$     0.6,$     0.2,Q1 2019,N/A
15939,554,20424,2716,Omidria,phenylephrine/ketorolac,Omeros Corporation,OMER,Washington,United States,North America,940488658,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Alpha 1 Adrenergic Receptor^ Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Topical,N,N,N,N,N,N,,,,05/30/14,07/28/15,,,,07/30/13,05/19/11,09/09/08,,,05/19/11,09/09/08,,N/A,,$    28.7,$    65.0,$    29.9,$    21.8,$    28.7,$    65.0,$    29.9,$    21.8,Q1 2019,N/A
2596,236,4412,8484,Omnaris,ciclesonide,Covis Pharma B.V.,,,Switzerland,Europe,,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Intranasal,N,N,N,,N,N,,,,10/20/06,,,,,12/22/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2015,N/A
2723,285,4650,289,Omnitrope,somatropin,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Endocrine,Short Stature,Short Stature / Growth Hormone Deficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),Biosimilar,No,Subcutaneous (SQ),N,N,N,,N,N,,,,05/30/06,04/18/06,06/25/09,,,07/31/03,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
19633,506,25916,3595,Omtryg,,Aker ASA,AKER:NO,,Norway,Europe,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Diglycerol Acyltransferase (DGAT)^ Lipoprotein lipase^ PPAR gamma,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/23/14,,,,,01/31/13,,,,,11/23/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
24965,603,34702,470,Onexton Gel,clindamycin and benzoyl peroxide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Dermatology,General,Acne,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacteria-miscellaneous^ Bacterial ribosome^ Protein synthesis,Non-NME,No,Topical,N,N,N,N,N,N,,,,11/24/14,,,,,01/30/14,,,,,,,,N/A,,N/A,$    29.0,$    38.0,$    12.0,N/A,$    29.0,$    38.0,$    12.0,Q1 2019,N/A
11696,3008,14737,240,Onfi,clobazam,H. Lundbeck A/S,HLUKF,,Denmark,Europe,,Neurology,Seizure Disorders (Epilepsy),Lennox-Gastaut Syndrome (LGS; Epilepsy),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,10/21/11,,03/15/00,,,,09/04/07,,,,09/04/07,11/13/06,04/05/04,N/A,,$   355.2,N/A,N/A,N/A,$   355.2,$   467.1,$   481.5,$    49.4,Q1 2019,"Alfresa Pharma Corporation, Daiichi Sankyo Co., Ltd."
1698,137,2723,45,Onglyza,saxagliptin hydrate,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl peptidase IV (DPP-IV),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,04/01/2013 - 04/01/2013,07/31/09,10/01/09,03/25/13,,,06/30/08,10/28/05,,,,10/28/05,09/12/05,,82.5%,535,$   376.0,$   320.0,$   223.0,$   120.0,$   720.0,$   611.0,$   543.0,$   287.2,Q2 2019,"Bristol-Myers Squibb Company, Kyowa Hakko Kirin Co., Ltd., Otsuka Holdings Co., Ltd., Royalty Pharma AG"
18209,220,23818,220,Onivyde,irinotecan sucrosofate,Ipsen SA,IPSEY,,France,Europe,,Oncology,Solid,Pancreatic Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule with Liposomal Delivery System,Topoisomerase I (Topo-I),Non-NME,No,"Intravenous (IV), Intratumoral",Y,N,Y,N,N,N,,,,10/22/15,10/18/16,,,,04/27/15,12/14/11,03/09/09,,12/03/08,12/14/11,03/09/09,,N/A,,$    37.4,N/A,N/A,N/A,$    37.4,$    86.1,$   136.4,$    46.9,Q1 2019,"Les Laboratoires Servier, PharmaEngine, Inc."
11148,3117,13996,180,Onmel,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Ergosterol biosynthesis,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,04/28/10,,,,,03/31/09,02/17/04,,,,02/17/04,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
19085,3092,25125,428,Onpattro,patisiran,"Alnylam Pharmaceuticals, Inc.",ALNY,Massachusetts,United States,North America,8082428640,Metabolic,Other,Hereditary Transthyretin (hATTR) Amyloidosis With Polyneuropathy (Familial Amyloid Polyneuropathy),Y,Approved,Approved,100% (Same As Avg.),siRNA/RNAi,Transthyretin (TTR),New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,Y,N,N,,,,08/10/18,08/27/18,06/18/19,,,12/12/17,11/10/13,06/07/12,,,08/09/13,06/07/12,01/06/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    12.6,$    26.3,Q1 2019,"Arbutus Biopharma Corporation, GENESIS Pharma, Ionis Pharmaceuticals, Inc., Medison Pharma Ltd., Sanofi"
3268,3125,5641,1020,Onsolis,,"BioDelivery Sciences International, Inc.",BDSI,North Carolina,United States,North America,311043119,Neurology,Pain,Cancer Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,07/16/09,10/20/10,,,,10/31/07,,,,,02/16/06,,04/01/02,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Mylan N.V.
24207,214,33505,4607,Ontruzant,trastuzumab-dttb,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,01/18/19,11/15/17,,,,10/20/17,05/26/14,,02/28/14,,05/26/14,,02/20/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Merck &amp; Co., Inc."
24207,223,54323,4607,Ontruzant,trastuzumab-dttb,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Oncology,Solid,Gastric Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,01/18/19,11/15/17,,,,10/20/17,,,,,08/31/16,,02/20/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Merck &amp; Co., Inc."
22579,288,30693,4325,Onzetra Xsail,Sumatriptan,"OptiNose, Inc.",OPTN,Pennsylvania,United States,North America,258084337,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT1 receptor,Non-NME,No,Intranasal,N,N,N,N,N,N,,,,01/27/16,,,,,01/27/14,01/06/12,,,,01/06/12,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2678,3128,4566,142,Opana IR,oxymorphone,Endo International plc,ENDP,,Ireland,Europe,554131557,Neurology,Pain,Chronic Pain,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,Y,N,,N,N,,,,06/22/06,,,,,12/20/02,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2769,216,4715,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Renal Cell Cancer (RCC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),Y,N,N,Y,N,N,,,,11/23/15,04/04/16,08/26/16,,,09/16/15,10/18/12,06/16/11,,,08/16/12,06/16/11,08/01/06,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2769,221,21927,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),Y,N,Y,Y,N,N,,,,12/22/14,06/19/15,07/04/14,,,07/30/14,01/15/13,,,,01/15/13,11/05/12,08/01/06,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2769,211,24962,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),Y,N,N,Y,N,N,,,,03/04/15,07/20/15,12/17/15,,,12/22/14,09/13/12,,01/12/12,,09/13/12,,08/01/06,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2769,297,27873,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,09/22/17,,,,,03/24/17,12/16/15,,,,12/16/15,,08/03/12,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2769,213,30161,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Colorectal Cancer (CRC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,12/01/2019 - 06/30/2020,08/01/17,,,,,02/02/17,,,,,,03/25/14,08/01/06,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2769,204,33317,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Hematologic,Hodgkin's Lymphoma,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,10/14/2016 - 12/19/2016,,05/17/16,11/22/16,12/02/16,,,03/01/16,,07/23/14,,,,07/23/14,05/04/12,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2769,230,34518,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Head and Neck Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,11/10/16,04/28/17,03/24/17,,,05/11/16,05/05/14,,,,05/05/14,,10/30/12,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2769,217,35702,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Bladder Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,02/02/17,06/02/17,,,,09/02/16,02/02/16,02/26/15,,,02/02/16,10/30/13,,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2769,111,36443,73,Opdivo,nivolumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Small Cell Lung Cancer (SCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,08/16/18,,,,,02/16/18,09/03/15,,,,09/03/15,10/30/13,,N/A,,"$  2,664.0","$  3,102.0","$  4,239.0","$  2,236.0","$  4,686.1","$  4,948.0","$  6,735.0","$  3,624.0",Q2 2019,"Ono Pharmaceutical Company, Ltd."
2600,245,4418,223,Opsumit,macitentan,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Endothelin Receptor Type A (EDNRA)^ Endothelin Receptor Type B (EDNRB),New Molecular Entity (NME),No,Oral (PO),N,Y,N,N,N,N,,,,10/18/13,12/20/13,03/26/15,,,10/19/12,,,,,12/11/06,,,80%,380.2,$   533.6,$   320.0,$   700.0,$   375.0,$   846.0,$   573.0,"$  1,215.0",$   654.0,Q2 2019,"Nippon Shinyaku Co., Ltd."
17592,711,22915,266,Optivar,azelastine,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Ophthalmology,General,Allergic Conjunctivitis (Ophthalmology),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,05/22/00,,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
21213,531,28557,3977,Orabloc,articaine hydrochloride; epinephrine bitartrate,Pierrel S.p.A.,PRL:IM,,Italy,Europe,,Neurology,Pain,Anesthesia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Beta Adrenergic Receptors^ Sodium Channels,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,02/26/10,,,,,11/25/08,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
1708,584,2736,587,Oracea,doxycycline,Galderma S.A.,,,Switzerland,Europe,,Dermatology,General,Rosacea,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/30/06,07/29/08,,,,08/01/05,,,,,06/15/04,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,MediGene AG
17235,236,22369,2906,Oralair,,Stallergenes SAS,GENP:FP,,France,Europe,,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Natural Protein,Immune system,Biologic,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,04/01/14,06/24/08,,,,12/18/12,,,,,10/27/08,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Endo International plc, Greer Laboratories, Inc."
1562,72,2503,2647,Orapred ODT,prednisolone sodium phosphate,ADVANZ PHARMA Corp.,ADVZ:CN,Ontario,Canada,North America,,Respiratory,Asthma,Asthma,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/01/06,,,,,08/01/05,,,,,04/21/04,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Shionogi &amp; Co. Ltd.
18099,3117,23642,3464,Oravig,miconazole,Midatech Pharma PLC,MTP,,United Kingdom,Europe,40926371,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Ergosterol biosynthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/16/10,10/13/06,09/21/18,,,,,,,,10/13/06,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2011,"Fujifilm Holdings Corp., Handok Pharmaceuticals, Inc., Mission Pharmacal Company, R-PHARM JSC, Shafayab Gostar, Ltd., Sosei Co., Ltd, SpePharm B.V., Vectans Pharma"
1400,440,2124,2685,Orbactiv,oritavancin,"Melinta Therapeutics, Inc.",MLNT,Connecticut,United States,North America,141731242,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Cell wall synthesis,New Molecular Entity (NME),No,Intravenous (IV),N,Y,N,N,N,Y,,,01/01/2016 - 01/01/2016,08/06/14,03/23/15,,,,12/06/13,,,,,09/20/01,,,100%,142.6,N/A,N/A,N/A,N/A,$    11.5,N/A,N/A,N/A,Q3 2016,The Menarini Group
1774,154,2833,73,Orencia,abatacept,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Protein,Cluster of Differentiation 80 (CD80)^ Cluster of Differentiation 86 (CD86),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,N,N,N,N,,,,12/23/05,05/21/07,07/26/10,,,12/23/04,,,,,11/12/03,,,98%,1661.8,"$  1,532.0","$  1,704.0","$  1,875.0","$  1,015.0","$  2,265.0","$  2,479.0","$  2,710.0","$  1,418.0",Q2 2019,"Ono Pharmaceutical Company, Ltd., Repligen Corp., Simcere Pharmaceutical Group"
1774,365,4990,73,Orencia,abatacept,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Protein,Cluster of Differentiation 80 (CD80)^ Cluster of Differentiation 86 (CD86),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/07/08,01/20/10,02/23/18,,,06/08/07,,,,,11/13/06,,,98%,,"$  1,532.0","$  1,704.0","$  1,875.0","$  1,015.0","$  2,265.0","$  2,479.0","$  2,710.0","$  1,418.0",Q2 2019,"Ono Pharmaceutical Company, Ltd., Repligen Corp., Simcere Pharmaceutical Group"
1774,336,12727,73,Orencia,abatacept,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Protein,Cluster of Differentiation 80 (CD80)^ Cluster of Differentiation 86 (CD86),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,06/30/17,07/26/17,,,,08/31/16,07/11/13,,,,07/11/13,12/05/07,,98%,,"$  1,532.0","$  1,704.0","$  1,875.0","$  1,015.0","$  2,265.0","$  2,479.0","$  2,710.0","$  1,418.0",Q2 2019,"Ono Pharmaceutical Company, Ltd., Repligen Corp., Simcere Pharmaceutical Group"
6616,245,6793,385,Orenitram,treprostinil diolamine,United Therapeutics Corporation,UTHR,Maryland,United States,North America,3493948188,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostacyclin Receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/20/13,,,,,12/27/11,06/07/06,,,01/28/05,06/07/06,,02/25/05,95%,224,$   157.2,$   185.8,$   205.1,$   112.4,$   157.2,$   185.8,$   205.1,$   112.4,Q2 2019,"HealthCare Royalty Partners, Supernus Pharmaceuticals, Inc."
17395,3001,22645,465,Orfadin,nitisinone,Swedish Orphan Biovitrum,SOBI:SS,,Sweden,Europe,,Metabolic,Inborn Errors Of Metabolism,Tyrosinemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"4-hydroxyphenyl-pyruvate dioxygenase (HPPD; a-ketoisocaproate dioxygenase, KIC dioxygenase)",New Molecular Entity (NME),No,Oral (PO),N,N,Y,,N,N,,,,01/18/02,02/21/05,,,,12/27/99,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$    90.1,$   101.0,$   103.6,$    43.4,Q2 2019,"Acorda Therapeutics, Inc., China National Chemical Corporation"
228,349,303,5,Orilissa,elagolix,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Obstetrics/Gynecology,Gynecology,Endometriosis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gonadotropin-Releasing Hormone (GnRH) Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/24/18,,,,,09/06/17,06/05/12,02/10/05,11/27/03,,06/05/12,03/02/05,,N/A,,N/A,N/A,N/A,$    31.0,N/A,N/A,N/A,$    32.0,Q2 2019,"Neurocrine Biosciences, Inc."
9964,74,12444,389,Orkambi,lumacaftor; ivacaftor,Vertex Pharmaceuticals Incorporated,VRTX,Massachusetts,United States,North America,46999678216,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,CF transmembrane conductance regulator (CFTR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,07/02/15,11/18/15,,,,11/05/14,02/26/13,03/25/09,01/07/08,,02/26/13,03/25/09,01/07/08,95%,3065.7,$   444.7,N/A,"$  1,262.0",$   609.0,$   468.6,"$  1,320.0","$  1,262.0",$   609.0,Q2 2019,Royalty Pharma AG
19113,239,25174,223,Ortho Evra,"norelgestromin, ethinyl estradiol",Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Endocrine,Contraception,Contraception,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,New Molecular Entity (NME),No,Transdermal,N,N,N,N,N,N,,,,11/20/01,08/22/02,,,,12/21/00,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
19525,239,25756,223,Ortho Tri-Cyclen Lo,norgestimate/ethinyl estradiol,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/22/02,,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
15291,137,19441,826,Oseni,alogliptin/pioglitazone,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl peptidase IV (DPP-IV)^ PPAR gamma,Non-NME,No,Oral (PO),N,N,N,N,N,N,,07/25/2013 - 09/30/2013,,01/25/13,09/24/13,07/01/11,,,09/24/08,,,,,06/07/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Royalty Pharma AG
21844,3245,29509,4104,Osmolex ER,amantadine hydrochloride extended release,Osmotica Pharmaceutical Corp,OSMT,North Carolina,United States,North America,,Neurology,"movement disorders, all",Levodopa-Induced Dyskinesia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine^ NMDA Glutamate Receptor^ Norepinephrine (Noradrenaline),Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,02/16/18,,,,,01/18/17,03/29/13,12/01/06,,,03/29/13,12/01/06,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22776,3359,31011,470,OsmoPrep,sodium phosphate monobasic monohydrate; sodium phosphate dibasic anhydrous,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),General,Colon Cleansing/Laxatives,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Osmosis/Osmotic Pressure,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/16/06,,,,,04/29/05,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
9870,648,12313,4232,Osphena,ospemifene,Duchesnay Inc.,,Quebec,Canada,North America,,Endocrine,Menopause (Including Specific HRT),Vaginal Atrophy,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/26/13,01/15/15,,,,04/26/12,,,,,02/17/06,,,N/A,182.8,N/A,N/A,N/A,N/A,N/A,N/A,$    27.3,N/A,Q4 2018,"Pharmbio Korea Inc., QuatRx Pharmaceuticals Co., Shionogi &amp; Co. Ltd."
402,155,3113,82,Otezla,apremilast,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 4 (PDE4),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/23/14,01/15/15,12/20/16,,,,,01/27/05,,,08/31/10,01/27/05,,N/A,0,$   904.4,"$  1,058.0","$  1,275.0",$   700.0,"$  1,017.2","$  1,279.0","$  1,608.0",$   882.0,Q2 2019,N/A
402,336,5277,82,Otezla,apremilast,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 4 (PDE4),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/21/14,01/15/15,12/20/16,,,,06/30/10,,,,06/30/10,10/26/06,,N/A,139.7,$   904.4,"$  1,058.0","$  1,275.0",$   700.0,"$  1,017.2","$  1,279.0","$  1,608.0",$   882.0,Q2 2019,N/A
402,389,21441,82,Otezla,apremilast,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Autoimmune/immunology,Vasculitis,Behçet Syndrome,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 4 (PDE4),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,02/01/2020 - 07/31/2020,07/01/2019 - 12/31/2019,07/19/19,,,,,09/21/18,01/13/14,08/28/09,,,01/13/14,08/28/09,,N/A,,$   904.4,"$  1,058.0","$  1,275.0",$   700.0,"$  1,017.2","$  1,279.0","$  1,608.0",$   882.0,Q2 2019,N/A
23093,3124,31559,2907,Otiprio,ciprofloxacin,"Otonomy, Inc.",OTIC,California,United States,North America,71368191,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Topoisomerase II (DNA gyrase) and IV,Non-NME,No,Intratympanic,N,N,N,N,N,N,,,,12/11/15,,,,,02/26/15,,,,,10/08/13,,06/18/13,N/A,,N/A,$     1.3,$     0.7,$     0.4,N/A,$     1.3,$     0.7,$     0.4,Q2 2019,"Glenmark Pharmaceuticals Limited, Mission Pharmacal Company"
24678,3124,34292,3363,Otovel,ciprofloxacin hydrocholride and fluocinolone acetonide,Salvat Biotech,,,Spain,Europe,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Topoisomerase II (DNA gyrase) and IV,Non-NME,No,Topical,N,N,N,N,N,N,,,,04/29/16,,,,,06/30/15,,,,,07/15/11,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Arbor Pharmaceuticals, LLC, Lee's Pharmaceutical Holdings Limited, Medexus Pharmaceuticals, Inc."
17848,154,23308,1003,Otrexup,methotrexate,"Antares Pharma, Inc.",ATRS,New Jersey,United States,North America,497830410,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR),Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,10/01/2014 - 10/01/2014,,10/14/13,,,,,12/14/12,,05/01/12,02/01/11,,,06/26/12,01/12/11,N/A,,N/A,N/A,$    11.9,$     4.8,N/A,N/A,$    11.9,$     4.8,Q1 2019,N/A
17848,365,29399,1003,Otrexup,methotrexate,"Antares Pharma, Inc.",ATRS,New Jersey,United States,North America,497830410,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR),Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,10/14/2013 - 10/14/2013,10/01/2014 - 10/01/2014,,10/14/13,,,,,12/14/12,,,,,,,,N/A,,N/A,N/A,$    11.9,$     4.8,N/A,N/A,$    11.9,$     4.8,Q1 2019,N/A
17848,155,29400,1003,Otrexup,methotrexate,"Antares Pharma, Inc.",ATRS,New Jersey,United States,North America,497830410,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR),Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,10/14/2013 - 10/14/2013,10/01/2014 - 10/01/2014,,10/14/13,,,,,12/14/12,,,,,,,,N/A,,N/A,N/A,$    11.9,$     4.8,N/A,N/A,$    11.9,$     4.8,Q1 2019,N/A
18520,241,24285,255,Ovidrel,choriogonadotropin alfa,Merck KGaA,MKGAY,,Germany,Europe,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Y,Approved,Approved,100% (Same As Avg.),Protein,Luteinizing Hormone Receptor (LHR),Non-NME,No,Subcutaneous (SQ),N,N,N,,N,N,,,,09/20/00,02/02/01,,,,11/24/99,,,,,09/29/99,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
15486,3134,19692,3445,Oxaydo,oxycodone HCl,Zyla Life Sciences,ZCOR,Pennsylvania,United States,North America,,Neurology,Pain,Moderate to Severe Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/17/11,,,,,01/02/09,,,,,05/03/10,,,N/A,,N/A,$     5.6,$     5.8,$     1.1,N/A,$     5.6,$     5.8,$     1.1,Q1 2019,"Acura Pharmaceuticals, Inc."
24332,265,33706,981,Oxervate,,Dompé Farmaceutici S.p.A.,,,Italy,Europe,,Ophthalmology,Other,Ophthalmic Wound Healing (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Protein,Nerve growth factor (NGF)/receptor^ Trk (Tropomyosin Receptor Kinase) Receptors,Biologic,No,Intraocular/Subretinal/Subconjunctival,N,N,Y,N,N,N,,,,08/22/18,07/06/17,,,,,,04/23/15,,,,06/23/14,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
17794,3009,23213,2995,Oxtellar XR,oxcarbazepine,"Supernus Pharmaceuticals, Inc.",SUPN,Maryland,United States,North America,1504479404,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/19/12,,,,,12/31/11,,,,,12/31/05,,,N/A,,$    51.7,$    67.6,$    84.7,$    42.8,$    51.7,$    67.6,$    84.7,$    42.8,Q2 2019,"Aequus Pharmaceuticals, Inc."
18540,3128,24322,325,OxyContin (reformulated),oxycodone hydrochloride,Purdue Pharma L.P.,,Connecticut,United States,North America,,Neurology,Pain,Chronic Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,11/28/2018 - 06/30/2019,04/05/10,,,,,11/29/07,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Mundipharma International Limited, Shionogi &amp; Co. Ltd."
22052,543,29841,395,Oxytrol,oxybutynin,Allergan plc,AGN,,Ireland,Europe,53945515162,Urology,Other,Overactive Bladder (OAB),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Transdermal,N,N,N,N,N,N,,,,02/26/03,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
10488,137,13119,292,Ozempic,semaglutide,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/05/17,02/09/18,03/23/18,,,12/05/16,,,,,06/21/12,06/12/08,01/31/08,N/A,,N/A,N/A,N/A,$   192.0,N/A,N/A,$   267.1,$   216.8,Q1 2019,N/A
16833,623,21810,395,Ozurdex,dexamethasone,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,Retinopathy,Macular Edema from Retinal Vein Occlusion (RVO) (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,06/17/09,07/27/10,,,,12/24/08,,,,,,,,N/A,,$    84.4,$    98.4,$   111.0,$    60.2,$   263.4,$   311.8,$   298.7,$   204.3,Q2 2019,N/A
16833,307,21811,395,Ozurdex,dexamethasone,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,Uveitis,Uveitis (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,N,,N,N,,06/20/2011 - 06/20/2011,,09/24/10,08/03/11,,,,10/29/09,,,,,06/05/06,,,N/A,,$    84.4,$    98.4,$   111.0,$    60.2,$   263.4,$   311.8,$   298.7,$   204.3,Q2 2019,N/A
16833,476,21816,395,Ozurdex,dexamethasone,Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,N,N,N,N,,,,06/30/14,09/02/14,,,,,,,,,09/14/05,,,N/A,,$    84.4,$    98.4,$   111.0,$    60.2,$   263.4,$   311.8,$   298.7,$   204.3,Q2 2019,N/A
9533,191,11865,65,Palynziq,pegvaliase,BioMarin Pharmaceutical Inc.,BMRN,California,United States,North America,13080442306,Metabolic,Inborn Errors Of Metabolism,Phenylketonuria (PKU),Y,Approved,Approved,100% (Same As Avg.),Protein,Phenylalanine,Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,05/24/18,05/03/19,,,,06/30/17,06/05/13,09/09/09,,,06/05/13,09/09/09,05/20/08,N/A,,N/A,N/A,$    12.2,$    31.1,N/A,N/A,$    12.2,$    31.1,Q2 2019,Merck KGaA
16624,705,21476,392,Pancreaze,pancrelipase,"Vivus, Inc.",VVUS,California,United States,North America,36248037,Gastroenterology (non inflammatory bowel disease),Other,Exocrine Pancreatic Insufficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,"Protein, fat, and/or carbohydrate absorption",Biologic,No,Oral (PO),N,N,N,,N,N,,,,04/12/10,,,,,06/23/09,,,,,09/02/08,,,N/A,,N/A,N/A,$    16.3,$     5.1,N/A,N/A,$    16.3,$     5.1,Q1 2019,Nordmark Arzneimittel GmbH &amp; Co. KG
2263,194,3803,508,Parcopa,carbidopa-levodopa,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Aromatic L-amino acid decarboxylase (AADC)^ Dopamine Receptor - Unspecified,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,08/27/04,,,,,03/28/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Teva Pharmaceutical Industries Ltd., UCB SA"
14493,176,18351,5,Paritaprevir,paritaprevir,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HCV Protease,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,08/01/2015 - 02/29/2016,12/19/14,01/15/15,09/28/15,,,,10/10/12,03/02/10,02/18/09,,10/10/12,03/02/10,02/18/09,85%,,N/A,N/A,N/A,N/A,N/A,N/A,$    66.0,$    29.0,Q2 2019,"Enanta Pharmaceuticals, Inc."
18110,367,23661,30,Parsabiv,velcalcetide,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Endocrine,Hyperparathyroidism,Hyperparathyroidism (Secondary),Y,Approved,Approved,100% (Same As Avg.),Peptide,Protein Kinase C (PKC),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,02/07/17,11/11/16,12/19/16,,,08/25/15,02/05/13,03/14/11,,,02/05/13,03/14/11,07/20/10,N/A,,N/A,N/A,$   302.0,$   109.0,N/A,N/A,$   336.0,$   126.0,Q1 2019,"Ono Pharmaceutical Company, Ltd."
18450,711,24176,289,Pataday,olopatadine hydrochloride,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,General,Allergic Conjunctivitis (Ophthalmology),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,12/22/04,,,,,08/14/02,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Kyowa Hakko Kirin Co., Ltd."
2021,236,3298,289,Patanase,olopatadine hydrochloride,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Intranasal,N,N,N,,N,N,,,,04/15/08,,,,,12/27/04,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
1259,169,2151,818,Paxil,paroxetine HCL,Vectura Group plc,VEC:LN,,United Kingdom,Europe,,Psychiatry,Anxiety,Generalized Anxiety Disorder (GAD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,04/16/01,,,,,,,,,,,,,N/A,,$    21.0,N/A,N/A,N/A,$   280.0,$   238.0,$   226.0,$   103.0,Q2 2019,"Aspen Pharmacare Holdings Limited, GlaxoSmithKline plc"
1259,659,3411,818,Paxil,paroxetine HCL,Vectura Group plc,VEC:LN,,United Kingdom,Europe,,Psychiatry,Other,Post-Traumatic Stress Disorder (PTSD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/14/01,,11/22/13,,,,,,,,,,,N/A,,$    21.0,N/A,N/A,N/A,$   280.0,$   238.0,$   226.0,$   103.0,Q2 2019,"Aspen Pharmacare Holdings Limited, GlaxoSmithKline plc"
1259,566,3412,818,Paxil,paroxetine HCL,Vectura Group plc,VEC:LN,,United Kingdom,Europe,,Neurology,Other,Premenstrual Dysphoric Disorder (PMDD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/02/03,,,,,,,,,,,,,N/A,,$    21.0,N/A,N/A,N/A,$   280.0,$   238.0,$   226.0,$   103.0,Q2 2019,"Aspen Pharmacare Holdings Limited, GlaxoSmithKline plc"
1259,635,3413,818,Paxil,paroxetine HCL,Vectura Group plc,VEC:LN,,United Kingdom,Europe,,Psychiatry,Other,Social Anxiety Disorder (SAD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/17/03,,,,,,,,,,,,,N/A,,$    21.0,N/A,N/A,N/A,$   280.0,$   238.0,$   226.0,$   103.0,Q2 2019,"Aspen Pharmacare Holdings Limited, GlaxoSmithKline plc"
19438,711,25628,289,Pazeo,olopatadine hydrochloride,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,General,Allergic Conjunctivitis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Topical,N,N,N,N,N,N,,,,01/30/15,,,,,07/30/14,,,,,09/13/11,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
1782,176,2843,254,Peg-Intron,peginterferon alpha-2b,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Protein,Interferon Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,01/22/01,05/29/00,10/22/04,,,,,,,,,,,97%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2015,"DRI Capital Inc., Enzon Pharmaceuticals, Inc., Nektar Therapeutics"
1782,221,5429,254,Peg-Intron,peginterferon alpha-2b,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Solid,Melanoma,N,Approved,Approved,100% (Same As Avg.),Protein,Interferon Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,03/29/11,,,,,,,,,,09/13/05,,,97%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2015,"DRI Capital Inc., Enzon Pharmaceuticals, Inc., Nektar Therapeutics"
1225,176,1860,149,Pegasys,peginterferon alfa-2a,Roche Holding AG,RHHBY,,Switzerland,Europe,,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Protein,Interferon Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,10/16/02,06/20/02,10/22/03,,,05/22/00,,,,,,,,95%,,$    50.8,$    31.4,$    59.8,N/A,$   261.6,$   180.9,$   257.0,N/A,Q4 2018,"Ascletis Pharma, Inc., Chugai Pharmaceutical Co., Ltd., Nektar Therapeutics"
1225,319,4550,149,Pegasys,peginterferon alfa-2a,Roche Holding AG,RHHBY,,Switzerland,Europe,,Infectious disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),N,Approved,Approved,100% (Same As Avg.),Protein,Interferon Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,05/13/05,02/25/05,09/26/11,,,,,,,,,,,95%,95.9,$    50.8,$    31.4,$    59.8,N/A,$   261.6,$   180.9,$   257.0,N/A,Q4 2018,"Ascletis Pharma, Inc., Chugai Pharmaceutical Co., Ltd., Nektar Therapeutics"
28650,211,39905,2403,Pemfexy,,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR)^ Thymidylate Synthase,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,10/27/17,,,,,12/31/16,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
28650,652,39907,2403,Pemfexy,,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Oncology,Solid,Mesothelioma,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR)^ Thymidylate Synthase,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,10/27/17,,,,,12/31/16,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
16502,249,21305,2795,Pennsaid 1.5%,diclofenac sodium,"Nuvo Pharmaceuticals, Inc.",TSX:NRI,,Canada,North America,0,Rheumatology (non autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,"Topical, Transdermal",N,N,N,N,N,N,,,,11/04/09,,,,,08/07/01,,,,,10/23/98,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Endo International plc, Mallinckrodt plc, NovaMedica LLC"
20699,249,27670,2878,Pennsaid 2%,diclofenac sodium,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Rheumatology (non autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,"Topical, Transdermal",N,N,N,N,N,N,,03/01/2020 - 09/30/2020,,01/17/14,,,,,05/04/12,,,,,,07/14/10,,N/A,,N/A,N/A,$   190.2,$    50.2,N/A,N/A,$   190.2,$    50.2,Q1 2019,"Gebro Holding GmbH, Mallinckrodt plc, NovaMedica LLC, Nuvo Pharmaceuticals, Inc., Sayre Therapeutics Pvt Ltd."
2341,3197,3943,51,Pentacel,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Diphtheria, pertussis, and tetanus (DT, Td, DTaP and Tdap) Vaccines",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Haemophilus influenzae^ Immune system^ Polio virus,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,06/23/08,,,,,07/26/05,,,,,10/29/01,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2011,N/A
2341,3198,28004,51,Pentacel,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Hib vaccines (Haemophilus influenzae b),Y,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Haemophilus influenzae^ Immune system^ Polio virus,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,06/23/08,,,,,07/26/05,,,,,10/29/01,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2011,N/A
2341,3199,28088,51,Pentacel,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,Antiviral,Poliovirus vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Haemophilus influenzae^ Immune system^ Polio virus,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,06/23/08,,,,,,,,,,10/29/01,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2011,N/A
5715,73,5802,266,Perforomist,formoterol fumarate,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,,N,N,,,,05/11/07,,,,,06/29/06,,,,,,,,50%,724.2,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Chiesi Farmaceutici S.p.A.
81,214,184,149,Perjeta,pertuzumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,05/01/2013 - 05/01/2013,06/08/12,03/04/13,06/28/13,,,12/07/11,03/23/07,05/01/06,12/01/01,,03/23/07,06/02/03,12/07/01,97%,1193.1,$   924.2,"$  1,033.4","$  1,345.4",$   788.3,"$  1,885.1","$  2,241.5","$  2,815.7","$  1,755.5",Q2 2019,"Chugai Pharmaceutical Co., Ltd., PDL BioPharma, Inc."
25987,170,36224,2679,Perseris,risperidone,Indivior plc,INDV:LN,,United Kingdom,Europe,541889368,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/27/18,,,,,09/28/17,,,,,09/14/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"DURECT Corporation, HLS Therapeutics, Inc."
22398,705,30376,851,Pertzye,pancrelipase,Chiesi Farmaceutici S.p.A.,,,Italy,Europe,,Gastroenterology (non inflammatory bowel disease),Other,Exocrine Pancreatic Insufficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,"Protein, fat, and/or carbohydrate absorption",Biologic,No,Oral (PO),Y,N,N,N,N,N,,,,05/17/12,,,,,10/27/08,,,,,05/16/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Digestive Care, Inc."
8396,167,10419,2672,Pexeva,paroxetine mesylate,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/03/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
8396,634,10420,2672,Pexeva,paroxetine mesylate,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Psychiatry,Anxiety,Panic Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/03/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
8396,233,10421,2672,Pexeva,paroxetine mesylate,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Psychiatry,General,Psychiatric Disorder or Disease,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/03/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2098,596,3497,3273,Photofrin,porfimer sodium,"Pinnacle Biologics, Inc.",,Illinois,United States,North America,,Gastroenterology (non inflammatory bowel disease),"Acid-Peptic (Gastritis Peptic Ulcer, Etc.)",Dysplasia in Barrett's Esophagus,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Reactive Oxygen Species/Free Radicals,New Molecular Entity (NME),No,Intravenous (IV),N,N,Y,,N,N,,,,08/04/03,,,,,05/30/02,,,,,,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Knight Therapeutics Inc., Pfizer Inc."
25417,2569,35379,5110,Photrexa/KXL System,riboflavin,"Avedro, Inc.",,Massachusetts,United States,North America,,Ophthalmology,Other,Other Ophthalmological Indications (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reactive Oxygen Species/Free Radicals,Non-NME,No,Topical,N,N,Y,N,N,N,,,,04/15/16,,,,,03/08/12,,,,,09/02/11,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
14102,690,17854,589,Picato Gel,ingenol mebutate,LEO Pharma A/S,,,Denmark,Europe,,Dermatology,General,Actinic Keratoses,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Mitochondria^ Protein Kinase C (PKC),New Molecular Entity (NME),No,Topical,N,Y,N,,N,N,,,,01/23/12,11/19/12,,,,03/31/11,09/09/08,03/16/05,08/27/04,03/23/04,09/09/08,03/16/05,08/27/04,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
20582,78,27451,254,Pifeltro,doravirine,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/30/18,11/22/18,,,,10/23/17,12/18/14,10/26/12,,,12/18/14,10/26/12,05/15/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18441,214,30904,289,Piqray,alpelisib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,p110 alpha/PIK3CA^ PI3K/AKT pathway,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,10/01/2019 - 04/30/2020,,05/24/19,,,,,12/18/18,07/21/15,,,,07/21/15,06/06/13,03/19/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18697,239,24550,7818,Plan B One-Step,levonorgestrel,"Foundation Consumer Healthcare, LLC",,Pennsylvania,United States,North America,,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/10/09,,,,,01/24/06,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
2087,179,3427,51,Plavix,clopidogrel bisulfate,Sanofi,SNY,,France,Europe,1.05588E+11,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Adenosine Diphosphate P2Y12 Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,02/28/02,09/07/06,,,,,,,,,,,,N/A,,$     1.1,$     1.2,N/A,N/A,"$  1,319.9","$  1,684.1","$  1,717.2",$   865.5,Q2 2019,Bristol-Myers Squibb Company
14158,153,17922,64,Plegridy,peginterferon beta-1a,"Biogen, Inc.",BIIB,Massachusetts,United States,North America,46991785631,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Protein,Interferon Receptor,Biologic,No,"Intramuscular (IM), Subcutaneous (SQ)",Y,Y,N,N,N,N,,,,08/15/14,07/18/14,,,,05/15/13,05/20/09,,,,05/20/09,,01/13/09,100%,1049.1,$   304.8,$   295.5,$   248.0,$   111.0,$   482.0,$   494.3,$   448.0,$   221.0,Q2 2019,"Eisai Co., Ltd., UCB SA"
24771,3359,34426,470,Plenvu,,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),General,Colon Cleansing/Laxatives,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Osmosis/Osmotic Pressure,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/04/18,10/24/17,,,,04/13/17,,,,,09/30/14,10/25/12,,N/A,,N/A,N/A,$     2.0,$     2.0,N/A,N/A,$     2.0,$     2.0,Q1 2019,"Korea Pharma Co, LTD., Norgine B.V."
8526,531,10595,4239,Pliaglis,lidocaine and tetracaine,Taro Pharmaceutical Industries Ltd.,TARO,,Israel,Asia,3297717354,Neurology,Pain,Anesthesia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,Non-NME,No,Topical,N,N,N,,N,N,,06/01/2012 - 06/01/2012,,06/29/06,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Crescita Therapeutics, Inc."
18218,3095,28436,149,Polivy,polatuzumab vedotin-piiq,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Hematologic,Diffuse Large B-Cell Lymphoma (DLBCL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ CD79b^ Microtubules (Tubulin),Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,11/01/2019 - 05/31/2020,,06/10/19,,,,,12/19/18,11/21/17,10/09/12,,,11/21/17,10/09/12,,N/A,,N/A,N/A,N/A,$     2.0,N/A,N/A,N/A,$     2.0,Q2 2019,"Chugai Pharmaceutical Co., Ltd., Seattle Genetics, Inc."
21418,3023,28861,4008,Polycin (generic),bacitracin zinc and polymyxin b sulfate,Fera Pharmaceuticals,,New York,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cell wall^ Protein synthesis,Non-NME,No,Topical,N,N,N,,N,N,,,,02/27/02,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
399,207,710,82,Pomalyst,pomalidomide,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Multiple Myeloma (MM),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiogenesis^ E3 ubiquitin ligase^ Immune system,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,02/08/13,08/05/13,03/31/15,,,04/10/12,03/17/11,,,,03/17/11,07/08/02,,N/A,,$   777.5,"$  1,008.0","$  1,391.0",$   837.0,"$  1,310.7","$  1,614.0","$  2,040.0","$  1,176.0",Q2 2019,N/A
2302,211,15430,136,Portrazza,necitumumab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,EGFR (Epidermal Growth Factor Receptor),Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,11/24/15,02/15/16,06/18/19,,,12/02/14,11/05/09,,,,11/05/09,07/24/08,,N/A,,$    14.2,$     9.4,N/A,N/A,$    14.3,$    10.3,N/A,N/A,Q4 2017,"AstraZeneca PLC, Les Laboratoires Servier, Nippon Kayaku Co., Ltd."
10467,417,27540,410,Poteligeo,mogamulizumab-kpkc,"Kyowa Hakko Kirin Co., Ltd.",4151:JP,,Japan,Asia,,Oncology,Hematologic,Cutaneous T-Cell Lymphoma (CTCL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Chemokine Receptor 4 (CCR4),Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,08/08/18,11/26/18,03/17/14,,,10/04/17,12/13/12,11/02/10,,,12/13/12,06/09/09,03/06/08,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    16.2,$    57.2,Q2 2019,N/A
2808,346,4787,70,Pradaxa,dabigatran etexilate mesylate,Boehringer Ingelheim GmbH,,,Germany,Europe,,Hematology,Antithrombotic,Venous Thromboembolism (VTE),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Thrombin (Coagulation Factor IIa),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,01/01/2014 - 06/30/2014,,04/07/14,03/27/08,,,,,01/18/06,,,,01/18/06,01/01/05,,N/A,,N/A,N/A,N/A,N/A,$   725.5,"$  1,744.1","$  1,644.9",N/A,Q4 2018,N/A
2808,2965,12759,70,Pradaxa,dabigatran etexilate mesylate,Boehringer Ingelheim GmbH,,,Germany,Europe,,Hematology,Antithrombotic,Stroke Prevention in Atrial Fibrillation (SPAF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Thrombin (Coagulation Factor IIa),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/19/10,08/04/11,01/21/11,,,12/15/09,01/18/06,,,,01/18/06,,,N/A,,N/A,N/A,N/A,N/A,$   725.5,"$  1,744.1","$  1,644.9",N/A,Q4 2018,N/A
16259,506,20931,51,Praluent,alirocumab,Sanofi,SNY,,France,Europe,1.05588E+11,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,07/24/15,09/28/15,07/05/16,,,12/31/15,02/07/12,01/10/11,11/20/09,,02/07/12,01/10/11,11/20/09,50%,5099.5,$    61.5,$   134.0,$   176.2,$    49.9,$    74.9,$   197.6,$   299.4,$   138.1,Q2 2019,"Regeneron Pharmaceuticals, Inc."
10957,137,13755,292,PrandiMet,repaglinide and metformin,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ Potassium channels,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/23/08,,,,,08/15/07,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"AbbVie Inc., Boehringer Ingelheim GmbH, Shionogi &amp; Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd."
22934,726,31275,70,Praxbind,idarucizumab,Boehringer Ingelheim GmbH,,,Germany,Europe,,Not Specified,Other,Drug Toxicity,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Dabigatran,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,10/16/15,11/20/15,,,,02/19/15,05/22/14,,09/25/12,,05/22/14,,09/25/12,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
2614,3301,4452,180,Prepandrix (with AS03 adjuvant),,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,Pandemic Influenza Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Influenza Virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,11/22/13,05/14/08,01/20/10,,,03/05/12,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
27448,3359,38397,582,Prepopik,"sodium picosulphate, magnesium oxide, citric acid",Ferring Pharmaceuticals,,,Switzerland,Europe,,Gastroenterology (non inflammatory bowel disease),General,Colon Cleansing/Laxatives,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/16/12,06/27/16,,,,09/16/11,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Nippon Chemiphar Co Ltd
19730,244,26126,467,Prestalia,perindopril arginine/amlodipine besylate,"Adhera Therapeutics, Inc.",ATRX,North Carolina,United States,North America,1856390,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin Converting Enzyme (ACE)^ Calcium Channel,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/21/15,,,,,03/21/14,,,,,01/17/12,,,N/A,,N/A,N/A,$     0.1,N/A,N/A,N/A,$     0.1,N/A,Q4 2018,"Les Laboratoires Servier, XOMA Corporation"
1950,414,3146,312,Prevnar,,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Streptococcus pneumoniae / Pneumococcus,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,02/17/00,02/02/01,02/28/10,,,,,,,,,,,N/A,,N/A,N/A,"$  3,360.0","$  1,490.0",N/A,N/A,"$  5,802.0","$  2,665.0",Q2 2019,Takeda Pharmaceutical Company Ltd
2863,414,4889,312,Prevnar 13,pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein),Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Streptococcus pneumoniae / Pneumococcus,Vaccine,No,Intramuscular (IM),Y,N,N,N,N,N,,,,02/24/10,12/09/09,06/30/13,,,03/31/09,,,,,10/05/06,,,N/A,,"$  3,645.0","$  3,334.0","$  3,360.0","$  1,490.0","$  5,718.0","$  5,601.0","$  5,802.0","$  2,665.0",Q2 2019,N/A
21185,411,28503,254,Prevymis,letermovir,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,Cytomegalovirus (CMV) Infection (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Human Cytomegalovirus (HCMV),New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,Y,N,N,N,,,,11/08/17,01/08/18,03/23/18,,,03/08/17,06/23/14,,,,06/23/14,04/23/10,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,AiCuris GmbH &amp; Co. KG
36479,244,50808,717,Prexxartan,valsartan,Medicure Inc.,MCUJF,,Canada,North America,47998791,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/19/17,,,,,12/30/16,,,,,04/14/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Carmel Biosciences, Inc."
36479,264,50809,717,Prexxartan,valsartan,Medicure Inc.,MCUJF,,Canada,North America,47998791,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/19/17,,,,,,,,,,04/14/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Carmel Biosciences, Inc."
36479,181,50810,717,Prexxartan,valsartan,Medicure Inc.,MCUJF,,Canada,North America,47998791,Cardiovascular,General,Cardiovascular Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/19/17,,,,,,,,,,04/14/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Carmel Biosciences, Inc."
18497,78,24246,223,Prezcobix,cobicistat/darunavir,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450^ HIV-1 protease (HIV PR),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/29/15,11/19/14,,,,03/31/14,10/13/11,,,,09/23/11,,,N/A,,N/A,N/A,"$  1,169.0",$   659.0,N/A,N/A,"$  1,955.0","$  1,058.0",Q2 2019,"Gilead Sciences, Inc."
2127,78,3534,223,Prezista,darunavir,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV-1 protease (HIV PR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/23/06,02/11/07,11/22/07,,,10/18/05,,,,,,02/14/03,,100%,764,"$  1,143.0","$  1,109.0","$  1,169.0",$   659.0,"$  1,851.0","$  1,821.0","$  1,955.0","$  1,058.0",Q2 2019,N/A
1387,3128,1799,7142,Prialt,ziconotide,TerSera Therapeutics LLC,,Illinois,United States,North America,,Neurology,Pain,Chronic Pain,Y,Approved,Approved,100% (Same As Avg.),Peptide,Calcium Channel,New Molecular Entity (NME),No,Intrathecal,N,N,N,N,N,N,,,,12/28/04,02/21/05,,,,12/29/99,,,,,01/13/98,,,N/A,,$    29.1,$    27.4,$    20.7,N/A,$    29.1,$    27.4,$    20.7,N/A,Q3 2018,Riemser Pharma GmbH
18622,72,24451,888,Primatene Mist,epinephrine,"Amphastar Pharmaceuticals, Inc.",AMPH,California,United States,North America,961153036,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,11/07/18,,,,,07/25/13,05/20/11,,,,05/20/11,,,N/A,,N/A,N/A,$     3.6,$     2.9,N/A,N/A,$     3.6,$     2.9,Q1 2019,N/A
26844,3124,37509,7323,Primsol,trimethoprim hydrochloride,"Allegis Holdings, LLC",,Illinois,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/24/00,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
2307,167,3866,312,Pristiq,desvenlafaxine succinate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/29/08,,,,,12/22/05,,,,,,,,N/A,,$   579.0,$   133.0,$    70.0,N/A,$   731.0,$   304.0,$   206.0,N/A,Q4 2018,"Les Laboratoires Servier, Mochida Pharmaceutical Co., Ltd."
17448,423,22702,870,Privigen,"Immune Globulin Intravenous (Human), 10% Liquid",CSL Limited,CSL:AU,,Australia,Oceania,,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,07/26/07,04/25/08,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
17448,649,22703,870,Privigen,"Immune Globulin Intravenous (Human), 10% Liquid",CSL Limited,CSL:AU,,Australia,Oceania,,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),N,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,07/26/07,04/25/08,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
17448,3160,23127,870,Privigen,"Immune Globulin Intravenous (Human), 10% Liquid",CSL Limited,CSL:AU,,Australia,Oceania,,Neurology,Other,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),N,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,09/14/17,04/04/13,03/26/19,,,11/11/16,,,,,03/12/12,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
39843,72,55724,375,ProAir Digihaler Inhalation Powder,albuterol sulfate,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,12/21/18,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
39843,73,55726,375,ProAir Digihaler Inhalation Powder,albuterol sulfate,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,12/21/18,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2551,72,4334,375,ProAir HFA,albuterol sulfate,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,,N,N,,,,10/29/04,,,,,01/31/03,,,,,,,,N/A,,$   565.0,$   501.0,$   397.0,N/A,$   565.0,$   501.0,$   397.0,$    59.0,Q1 2019,N/A
23820,72,32818,375,ProAir RespiClick,albuterol,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,03/05/15,,,,,,,,,,10/26/12,02/19/10,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
2877,560,4918,380,Probuphine,buprenorphine hydrochloride,"Titan Pharmaceuticals, Inc.",TTNP,California,United States,North America,9487104,Psychiatry,Other,Substance Use Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,05/26/16,06/20/19,,,,10/29/12,10/25/06,,06/19/03,,10/25/06,,06/19/03,N/A,,N/A,N/A,$     0.5,$     0.3,N/A,N/A,$     0.5,$     0.3,Q1 2019,"Knight Therapeutics Inc., Molteni Farmaceutici S.p.A."
15906,1560,20376,2878,Procysbi,cysteamine bitartrate,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Metabolic,Inborn Errors Of Metabolism,Cystinosis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Lysosomal Cysteine Transporter,Non-NME,No,Oral (PO),N,Y,Y,N,N,N,,,,04/30/13,09/06/13,,,,03/30/12,06/28/10,05/20/09,,,06/28/10,06/01/09,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,$   154.8,$    39.6,Q1 2019,Chiesi Farmaceutici S.p.A.
1689,608,5267,814,Prograf,tacrolimus,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Autoimmune/immunology,Transplant Rejection,Heart Transplant Rejection,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcineurin phosphatase,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,03/26/06,05/15/09,,,,06/02/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,"$  1,659.2","$  1,812.2","$  1,821.1",$   414.9,Q1 2019,N/A
15927,533,20412,2858,PROLASTIN-C,Alpha-1 protease inhibitor (human),"Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Respiratory,Other,Emphysema,Y,Approved,Approved,100% (Same As Avg.),Natural Protein,Alpha-1-antitrypsin (A1AT)^ Protease,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,10/19/09,,,,,,06/28/06,,,,06/28/06,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2010,N/A
18912,554,24881,470,Prolensa,bromfenac sodium,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Topical,N,N,N,N,N,N,,,,04/08/13,,,,,06/18/12,05/04/11,,,,01/05/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Senju Pharmaceutical Co., Ltd."
15589,395,24986,30,Prolia,denosumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Bone Complications (including bone metastases),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,RANK Ligand (RANKL),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,09/16/11,05/28/10,,,,12/19/08,01/27/05,,,,01/27/05,,,100%,210.9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Daiichi Sankyo Co., Ltd."
18984,242,19855,30,Prolia (Osteoporosis),denosumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,RANK Ligand (RANKL),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,06/01/10,05/28/10,03/25/13,,,12/19/08,08/10/04,,,,08/10/04,03/24/04,09/09/98,100%,,"$  1,049.0","$  1,272.0","$  1,500.0",$   390.0,"$  1,788.1","$  2,179.1","$  2,534.3",$   650.1,Q1 2019,"Daiichi Sankyo Co., Ltd., GlaxoSmithKline plc"
710,649,1827,289,Promacta,eltrombopag olamine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Thrombopoietin Receptor (TPO-R, c-Mpl, CD110)",New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,11/20/08,03/11/10,10/29/10,,,12/19/07,02/14/06,12/03/04,01/06/03,,02/14/06,12/03/04,01/06/03,92%,195.7,$   310.0,$   446.0,$   581.0,$   318.0,$   635.0,$   867.0,"$  1,174.0",$   656.0,Q2 2019,Royalty Pharma AG
710,188,4258,289,Promacta,eltrombopag olamine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Hematology,Marrow Or Peripheral Blood Stimulator,Thrombocytopenia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Thrombopoietin Receptor (TPO-R, c-Mpl, CD110)",New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,01/01/2015 - 01/01/2015,11/16/12,09/24/13,,,,05/30/12,11/05/07,,,,11/05/07,07/26/06,,92%,,$   310.0,$   446.0,$   581.0,$   318.0,$   635.0,$   867.0,"$  1,174.0",$   656.0,Q2 2019,Royalty Pharma AG
710,3247,29821,289,Promacta,eltrombopag olamine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Hematology,Marrow Or Peripheral Blood Stimulator,Aplastic Anemia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Thrombopoietin Receptor (TPO-R, c-Mpl, CD110)",New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,08/26/14,08/23/15,08/25/17,,,02/28/14,,,,,,10/09/12,,92%,,$   310.0,$   446.0,$   581.0,$   318.0,$   635.0,$   867.0,"$  1,174.0",$   656.0,Q2 2019,Royalty Pharma AG
1923,3200,3096,254,ProQuad,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,"Measles, Mumps and Rubella (MMR) Vaccines",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Measles virus^ Mumps virus^ Rubella Virus^ Varicella Zoster Virus (VSV),Vaccine,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,N,N,N,,,,09/06/05,04/05/06,,,,08/31/04,,,,,,,,N/A,,"$  1,361.0","$  1,374.0","$  1,430.0",$   843.0,"$  1,641.0","$  1,676.0","$  1,798.0","$  1,171.0",Q2 2019,N/A
1923,641,28005,254,ProQuad,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,Chickenpox and Shingles - Vaccines and Treatments,N,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Measles virus^ Mumps virus^ Rubella Virus^ Varicella Zoster Virus (VSV),Vaccine,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,N,N,N,,,,09/06/05,04/05/06,,,,08/31/04,,,,,,,,N/A,,"$  1,361.0","$  1,374.0","$  1,430.0",$   843.0,"$  1,641.0","$  1,676.0","$  1,798.0","$  1,171.0",Q2 2019,N/A
1313,534,1676,120,Proquin XR,ciprofloxacin hydrochloride,"Assertio Therapeutics, Inc.",ASRT,Illinois,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/19/05,07/23/08,,,,07/20/04,06/03/03,10/01/01,,,06/03/03,10/01/01,01/23/01,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Mylan N.V."
1949,644,3145,312,Protonix,pantoprazole sodium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Gastroenterology (non inflammatory bowel disease),General,Gastroesophageal Reflux Disease (GERD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Proton pump,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/02/00,06/12/09,,,,,,,,,,,,N/A,,N/A,$    36.5,$    40.0,N/A,N/A,$   307.0,$   559.4,N/A,Q4 2018,Takeda Pharmaceutical Company Ltd
1949,655,3351,312,Protonix,pantoprazole sodium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Zollinger-Ellison Syndrome,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Proton pump,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,04/19/02,,,,,,,,,,,,,N/A,,N/A,$    36.5,$    40.0,N/A,N/A,$   307.0,$   559.4,N/A,Q4 2018,Takeda Pharmaceutical Company Ltd
1839,385,13162,589,Protopic,tacrolimus,LEO Pharma A/S,,,Denmark,Europe,,Allergy,General,Atopic Dermatitis (Eczema),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcineurin phosphatase,Non-NME,No,Topical,N,N,N,N,N,N,,,,12/08/00,02/28/02,06/30/99,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,$    28.0,N/A,N/A,$     0.0,Q1 2016,"Astellas Pharma, Inc., Maruho Co., Ltd., Roche Holding AG"
834,215,1477,7578,Provenge,sipuleucel-T,"Sanpower Group, Co., Ltd",,,China,Asia,,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Cellular,Immune system^ Prostatic Acid Phosphatase (PAP)^ Stem Cells/Other Cell Therapies,Biologic,No,Intravenous (IV),Y,Y,N,N,N,N,,,,04/29/10,09/06/13,,,,11/13/06,,,,,01/11/02,,,100%,212.5,$   227.0,N/A,N/A,$     0.0,$   227.0,$   164.0,N/A,$     0.0,Q2 2017,N/A
323,578,3880,375,Provigil (Sparlon),modafinil,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Other,Sleep Apnea,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Unknown,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,01/23/04,06/30/92,11/25/11,,,12/23/02,,,,,11/01/01,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2014,"Alfresa Pharma Corporation, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Ltd"
323,618,3881,375,Provigil (Sparlon),modafinil,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Other,Shift Work Sleep Disorder (SWSD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Unknown,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,01/23/04,08/30/05,,,,12/23/02,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2014,"Alfresa Pharma Corporation, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Ltd"
2148,2951,56763,136,Prozac,fluoxetine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Other,Eating Disorders,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/29/02,,,,,,,,,,,,,100%,,$    98.8,$    80.6,$    73.8,$    31.1,$   181.6,$   167.9,$   159.4,$    72.4,Q2 2019,N/A
24031,199,33188,4685,Purixan,mercaptopurine,Nova Laboratories Limited,,,United Kingdom,Europe,,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,04/28/14,03/09/12,,,,,,,10/01/12,,,,10/01/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2661,3120,4544,395,Pylera,"bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride",Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",H. pylori Infection,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Microbial DNA^ Protein synthesis^ Reactive Oxygen Species/Free Radicals,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,09/28/06,12/20/11,,,,10/02/01,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"NewBridge Pharmaceuticals, NovaMedica LLC"
32934,244,45468,8134,Qbrelis,lisinopril,Azurity Pharmaceuticals,,Massachusetts,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin Converting Enzyme (ACE),Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,07/29/16,,,,,06/30/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
24058,151,33231,3855,Qbrexza,glycopyrronium tosylate,Dermira Inc.,DERM,California,United States,North America,359712229,Dermatology,General,Dermatology,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor^ Sweat gland activation,Non-NME,No,Topical,N,N,N,N,N,N,,,,06/29/18,,,,,,08/03/15,12/19/13,,,08/03/15,12/19/13,,N/A,,N/A,N/A,$     2.9,$     2.5,N/A,N/A,$     2.9,$     2.5,Q1 2019,"Maruho Co., Ltd."
2653,135,4531,392,Qsymia,phentermine and topiramate,"Vivus, Inc.",VVUS,California,United States,North America,36248037,Metabolic,Obesity,Obesity,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine^ GABA-A Receptor^ Norepinephrine (Noradrenaline),Non-NME,No,Oral (PO),N,Y,N,N,N,N,,07/01/2017 - 07/01/2017,,07/17/12,,,,,12/29/09,11/01/07,,,,06/21/07,05/10/06,,100%,,$    48.6,$    44.9,$    40.5,$     8.4,$    48.6,$    44.9,$    40.5,$     8.4,Q1 2019,"Alvogen, Inc."
21822,137,29476,45,Qtern,,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl peptidase IV (DPP-IV)^ SGLT,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/27/17,07/19/16,,,,,,,,,01/11/07,,,50%,458.3,N/A,$     4.0,N/A,N/A,N/A,$     5.0,N/A,N/A,Q4 2017,Bristol-Myers Squibb Company
40451,137,56635,45,Qternmet XR,,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl Peptidase (DPP) 4^ SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/02/19,,,,,07/02/18,,,,,07/12/12,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22072,3197,29863,51,Quadracel,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Diphtheria, pertussis, and tetanus (DT, Td, DTaP and Tdap) Vaccines",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Immune system^ Polio virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,03/24/15,,,,,03/24/14,,,,,04/29/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
22072,3199,35801,51,Quadracel,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,Antiviral,Poliovirus vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Bordetella pertussis^ Clostridium tetani^ Corynebacterium diptheriae^ Immune system^ Polio virus,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,03/24/15,,,,,03/24/14,,,,,04/29/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
17473,467,22737,826,Qualaquin,quinine sulfate,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Malaria,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Unknown,Non-NME,No,Oral (PO),N,N,Y,,N,N,,,,08/12/05,,,,,10/14/04,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18688,239,24542,375,Quartette,levonorgestrel and ethinyl estradiol,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Endocrine,Contraception,Contraception,Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/28/13,,,,,05/31/12,10/15/09,10/30/06,,,10/15/09,10/30/06,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
16885,3009,21898,2817,Qudexy XR,topiramate,"Sawai Pharmaceutical Co., Ltd.",4555:JP,Minnesota,United States,North America,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,03/11/14,,,,,,,,,,12/02/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16885,3008,32882,2817,Qudexy XR,topiramate,"Sawai Pharmaceutical Co., Ltd.",4555:JP,Minnesota,United States,North America,,Neurology,Seizure Disorders (Epilepsy),Lennox-Gastaut Syndrome (LGS; Epilepsy),N,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/11/14,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16885,288,41178,2817,Qudexy XR,topiramate,"Sawai Pharmaceutical Co., Ltd.",4555:JP,Minnesota,United States,North America,,Neurology,Headache,Migraine and Other Headaches,N,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/15/16,,,,,06/17/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
18207,246,23816,579,Quillivant XR,methylphenidate hydrochloride,Tris Pharma,,New Jersey,United States,North America,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,09/27/12,,,,,07/29/10,05/19/09,,,,05/19/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23549,3023,32352,564,Quixin,levofloxacin hydrate,"Santen Pharmaceutical Co., Ltd.",4536:JP,,Japan,Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Topoisomerase II (DNA gyrase) and IV,Non-NME,No,Topical,N,N,N,N,N,N,,,,02/28/00,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Daiichi Sankyo Co., Ltd., Johnson &amp; Johnson"
3278,3157,5657,1292,Qutenza,capsaicin,Grünenthal GmbH,,,United Kingdom,Europe,,Neurology,Pain,Postherpetic Neuralgia (PHN),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"TRPV1, transient receptor potential vanilloid receptor 1, VR-1",Non-NME,No,Topical,Y,N,Y,,N,N,,,10/01/2010 - 10/01/2010,11/16/09,05/21/09,,,,10/16/08,,,,,06/15/05,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2015,"Acorda Therapeutics, Inc., NeurogesX, Inc."
2442,236,21697,375,Qvar HFA,beclometasone dipropionate HFA,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Allergy,General,Allergic Rhinitis,N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,"Inhaled, Intranasal",N,N,N,,N,N,,,,03/26/12,,,,,05/24/11,10/29/09,03/02/09,,,10/29/09,03/02/09,,N/A,,N/A,$   349.0,$   182.0,N/A,$   462.0,$   349.0,$   182.0,$    64.0,Q1 2019,N/A
23819,72,32817,375,QVAR RediHaler,,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Respiratory,Asthma,Asthma,N,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,N,N,N,,,,08/03/17,,,,,10/03/16,12/31/13,,,,12/31/13,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
17777,193,24633,262,Radicava,edaravone,Mitsubishi Tanabe Pharma Corporation,4508:JP,,Japan,Asia,,Neurology,Neurodegenerative,Amyotrophic Lateral Sclerosis (ALS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Mitochondria,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,Y,N,N,N,,,,05/05/17,,06/30/01,,,06/16/16,,,,,05/12/15,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   246.0,N/A,Q4 2018,N/A
22578,666,30692,4324,Radiogardase,ferric hexacyanoferrate,Heyltex Corporation,,Texas,United States,North America,,Not Specified,Other,Acute Radiation Syndrome (ARS),N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Metal ions (e.g., Ca2+, Cu2+, Zn2+, and Fe2/3+)",New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,10/02/03,,,,,03/10/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Nanotherapeutics, Inc."
16768,236,21705,254,Ragwitek,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Natural Protein,Immune system,Biologic,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,04/17/14,,,,,03/01/13,,,,,12/03/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,ALK-Abello A/S
481,446,782,179,Ranexa,ranolazine,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Cardiovascular,Other,Angina,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Late Sodium Current,New Molecular Entity (NME),No,Oral (PO),N,Y,N,N,N,N,,,,01/27/06,07/10/08,,,,07/27/05,,,,,07/07/99,,,93%,583.3,N/A,N/A,$   758.0,$   174.0,$   677.0,$   717.0,$   758.0,$   174.0,Q2 2019,"Roche Holding AG, The Menarini Group"
2225,569,3735,395,Rapaflo,silodosin,Allergan plc,AGN,,Ireland,Europe,53945515162,Urology,General,Benign Prostatic Hyperplasia (BPH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/08/08,01/29/10,01/23/06,,,12/13/07,06/13/05,,,,06/13/05,,,N/A,,$   116.6,$   108.1,$    81.9,$    11.8,$   122.4,$   216.4,$   468.4,$    96.5,Q1 2019,"Almirall Prodesfarma, S.A., Daiichi Sankyo Co., Ltd., Kissei Pharmaceutical Co., Ltd, Recordati SpA, Takeda Pharmaceutical Company Ltd, Zambon Company S.p.A."
1690,2719,35470,312,Rapamune,sirolimus,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,General,Tuberous Sclerosis Complex (TSC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,FKBP12,New Molecular Entity (NME),No,"Oral (PO), Topical",N,N,Y,Y,N,N,,,,05/28/15,08/02/18,03/23/18,,,12/23/14,12/31/06,,,,12/31/06,,,N/A,,$    74.0,N/A,N/A,N/A,$   170.0,N/A,N/A,N/A,Q4 2016,"Alkermes plc, Nobelpharma Co., Ltd."
2511,3302,4265,870,Rapivab,peramivir,CSL Limited,CSL:AU,,Australia,Oceania,,Infectious disease,Antiviral,Influenza (excluding vaccines),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Influenza Viral Neuraminidase,New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,N,,,,12/19/14,04/13/18,01/13/10,,,12/19/13,07/17/09,07/24/07,,,07/16/09,07/24/07,01/17/06,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    18.2,N/A,Q4 2018,"BioCryst Pharmaceuticals, Inc., GC Pharma, Merck KGaA, Shionogi &amp; Co. Ltd."
22474,672,30501,556,Raplixa,,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Hematology,Other,Hemostasis,Y,Approved,Approved,100% (Same As Avg.),Protein,,Biologic,No,Topical,N,N,N,N,N,N,,,,04/30/15,03/19/15,,,,,06/06/12,,,,06/12/12,11/15/11,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16393,654,21135,2878,Ravicti,glycerol phenylbutyrate,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Metabolic,Inborn Errors Of Metabolism,Urea Cycle Disorders and Derangements (UCD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutamine,Non-NME,No,Oral (PO),Y,Y,Y,N,N,N,,,,02/01/13,11/27/15,,,,12/23/11,10/27/09,10/23/07,,,07/07/09,08/28/07,,N/A,,$   151.6,$   193.9,$   226.7,$    49.9,$   151.6,$   193.9,$   226.7,$    49.9,Q1 2019,"Bausch Health Companies Inc., Swedish Orphan Biovitrum"
17997,367,23508,1327,Rayaldee,calcifediol,Opko Health,OPK,Florida,United States,North America,1041174050,Endocrine,Hyperparathyroidism,Hyperparathyroidism (Secondary),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Vitamin D,Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,06/17/16,,,,,05/29/15,09/20/12,,,,09/20/12,11/20/07,,N/A,,N/A,N/A,$    20.3,$     5.8,N/A,N/A,$    20.3,$     5.8,Q1 2019,"Fresenius SE &amp; Co. KGaA, Japan Tobacco Inc."
17038,422,22099,2878,Rayos,prednisone,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Autoimmune/immunology,General,Inflammatory Disorders,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/26/12,12/17/08,,,,09/28/11,,,,,12/17/08,,,N/A,,N/A,N/A,$    63.4,$    19.4,N/A,N/A,$    63.4,$    19.4,Q1 2019,"Merck KGaA, Mundipharma International Limited, Vectura Group plc"
1896,141,3055,223,Razadyne - IR and ER,galantamine hydrobromide,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cholinesterases,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,02/28/01,04/01/01,01/21/11,,,,,,,,,,,90%,0,N/A,N/A,N/A,N/A,$   153.0,$   161.1,$   149.0,N/A,Q4 2018,"SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Ltd"
1564,153,2505,255,Rebif,interferon beta-1a,Merck KGaA,MKGAY,,Germany,Europe,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Protein,Interferon Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,03/07/02,05/04/98,,,,,,,,,,,,70%,767.1,N/A,N/A,N/A,N/A,"$  1,929.9","$  1,954.0","$  1,661.3",$   339.5,Q1 2019,Pfizer Inc.
17275,512,22419,292,Rebinyn,nonacog beta pegol,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Hematology,Factor Augmentation,Hemophilia B,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,05/31/17,06/06/17,07/31/18,,,05/16/16,05/05/11,,08/25/09,,04/08/11,,08/25/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
20967,536,28126,254,Recarbrio,relebactam/imipenem/cilastatin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Intra-Abdominal Infections (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,Y,,01/01/2020 - 07/31/2020,,07/17/19,,,,,11/16/18,09/01/15,,,,09/01/15,07/09/12,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
20967,534,28127,254,Recarbrio,relebactam/imipenem/cilastatin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,Y,,01/01/2020 - 07/31/2020,,07/17/19,,,,,11/16/18,09/01/15,,,,09/01/15,06/21/12,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1878,368,3031,289,Reclast,zoledronic acid,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Paget Disease of Bone,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Osteoclast,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,04/17/07,04/15/05,,,,09/21/04,,,,,,,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,$    12.6,N/A,Q4 2018,Asahi Kasei Corporation
1878,242,3032,289,Reclast,zoledronic acid,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Osteoclast,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,08/17/07,10/05/07,09/28/16,,,10/17/06,,,,,01/20/05,,,100%,,N/A,N/A,N/A,N/A,N/A,N/A,$    12.6,N/A,Q4 2018,Asahi Kasei Corporation
738,672,3223,58,Recothrom,,Baxter International Inc.,BAX,Illinois,United States,North America,46924193203,Hematology,Other,Hemostasis,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrinogen (Coagulation Factor I),Biologic,No,Topical,N,N,N,N,N,N,,,,01/17/08,,,,,12/18/06,10/27/05,,,,10/27/05,04/19/04,12/03/03,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q3 2015,"Bayer AG, Bristol-Myers Squibb Company"
17603,321,22930,470,Rectabul,budesonide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,10/08/14,,09/27/17,,,11/30/13,01/26/15,,,,12/31/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Biotoscana International, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, EA Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd"
1062,3128,1476,395,Rectiv,,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,Pain,Chronic Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Guanylate Cyclase (sGC),Non-NME,No,Topical,N,Y,N,,N,N,,,,06/21/11,09/13/04,,,,06/30/04,11/13/03,,,,01/29/04,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$     3.6,N/A,Q1 2018,"Kyowa Hakko Kirin Co., Ltd."
493,511,1080,312,ReFacto Antihemophilic Factor,,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,03/07/00,04/15/99,,,,,,,,,,,,N/A,,$   122.0,$   112.0,$   109.0,$    27.0,$   554.0,$   551.0,$   514.0,$   106.0,Q1 2019,Swedish Orphan Biovitrum
2479,551,4204,470,Relistor (Oral),methylnaltrexone,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),Other,Opioid Induced Constipation (OIC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/19/16,,,,,06/23/15,09/08/10,08/22/06,,,09/08/10,08/22/06,12/23/05,90%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Progenics Pharmaceuticals, Inc."
916,551,1980,470,Relistor SC,methylnaltrexone bromide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),Other,Opioid Induced Constipation (OIC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,01/01/2016 - 01/01/2016,04/24/08,07/02/08,,,,03/30/07,01/20/04,,,,06/15/03,,,90%,139.8,N/A,N/A,N/A,N/A,N/A,$    42.0,$    44.0,N/A,Q2 2018,"Lupin Limited, Progenics Pharmaceuticals, Inc., Swedish Orphan Biovitrum"
2281,288,3824,312,Relpax,eletriptan hydrobromide,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT1 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/26/02,06/12/01,,,,,,,,,06/12/01,,,N/A,256.6,$   225.0,$   143.0,N/A,N/A,$   323.0,$   235.0,N/A,N/A,Q4 2017,N/A
243,155,347,223,Remicade,infliximab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,09/27/06,10/06/05,01/20/10,,,09/02/05,,,,,07/28/05,03/21/03,,100%,166.6,"$  4,842.0","$  4,525.0","$  3,854.0","$  1,713.0","$  7,342.0","$  7,152.0","$  6,447.4","$  2,678.1",Q2 2019,"DRI Capital Inc., Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
243,321,348,223,Remicade,infliximab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,09/15/05,03/09/06,06/18/10,,,,,,,,11/12/03,,,100%,1132.5,"$  4,842.0","$  4,525.0","$  3,854.0","$  1,713.0","$  7,342.0","$  7,152.0","$  6,447.4","$  2,678.1",Q2 2019,"DRI Capital Inc., Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
243,252,406,223,Remicade,infliximab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,12/17/04,05/21/03,04/16/10,,,02/15/04,,,,,,,,100%,624,"$  4,842.0","$  4,525.0","$  3,854.0","$  1,713.0","$  7,342.0","$  7,152.0","$  6,447.4","$  2,678.1",Q2 2019,"DRI Capital Inc., Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
243,336,513,223,Remicade,infliximab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,05/13/05,10/14/04,01/20/10,,,12/01/04,,,,,10/25/02,,,100%,58.5,"$  4,842.0","$  4,525.0","$  3,854.0","$  1,713.0","$  7,342.0","$  7,152.0","$  6,447.4","$  2,678.1",Q2 2019,"DRI Capital Inc., Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
730,245,668,385,Remodulin (injection),treprostinil sodium,United Therapeutics Corporation,UTHR,Maryland,United States,North America,3493948188,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostacyclin Receptors,New Molecular Entity (NME),No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,05/21/02,08/10/05,03/26/14,,,10/16/00,,,,,,,,N/A,333,$   482.0,N/A,N/A,N/A,$   602.0,$   670.9,$   599.0,$   311.3,Q2 2019,"Ascendis Pharma A/S, DEKA Research &amp; Development Corporation, GlaxoSmithKline plc, Lee's Pharmaceutical Holdings Limited, Medtronic plc, Mochida Pharmaceutical Co., Ltd., Pfizer Inc."
23977,154,33090,4607,Renflexis,infliximab-abda,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,04/21/17,05/30/16,,,,03/21/16,09/04/13,,07/31/13,,09/04/13,,02/20/13,N/A,,N/A,$     0.6,N/A,N/A,$     0.1,$     9.0,$    43.3,$    31.5,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
23977,252,37986,4607,Renflexis,infliximab-abda,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,04/21/17,05/30/16,,,,03/21/16,,,07/31/13,,,,02/20/13,N/A,,N/A,$     0.6,N/A,N/A,$     0.1,$     9.0,$    43.3,$    31.5,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
23977,156,37987,4607,Renflexis,infliximab-abda,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,04/21/17,05/30/16,,,,03/21/16,,,07/31/13,,,,02/20/13,N/A,,N/A,$     0.6,N/A,N/A,$     0.1,$     9.0,$    43.3,$    31.5,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
23977,321,37988,4607,Renflexis,infliximab-abda,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,04/21/17,05/30/16,,,,03/21/16,,,07/31/13,,,,02/20/13,N/A,,N/A,$     0.6,N/A,N/A,$     0.1,$     9.0,$    43.3,$    31.5,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
23977,336,37989,4607,Renflexis,infliximab-abda,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,04/21/17,05/30/16,,,,03/21/16,,,07/31/13,,,,02/20/13,N/A,,N/A,$     0.6,N/A,N/A,$     0.1,$     9.0,$    43.3,$    31.5,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
23977,155,37990,4607,Renflexis,infliximab-abda,"Samsung Bioepis Co., Ltd.",,,Korea (South),Asia,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,04/21/17,05/30/16,,,,03/21/16,,,07/31/13,,,,02/20/13,N/A,,N/A,$     0.6,N/A,N/A,$     0.1,$     9.0,$    43.3,$    31.5,Q2 2019,"Biogen, Inc., Ewopharma AG, Merck &amp; Co., Inc."
2581,3179,4384,51,Renvela (Tablet or Powder),sevelamer carbonate,Sanofi,SNY,,France,Europe,1.05588E+11,Renal,Chronic Renal Failure,Hyperphosphatemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Phosphate,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/19/07,06/09/09,,,,12/20/06,,,,,05/04/05,,,N/A,,N/A,N/A,$   280.0,$    66.7,N/A,N/A,$   455.0,$   163.9,Q2 2019,N/A
16091,506,20637,30,Repatha,evolocumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9),Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,08/27/15,07/21/15,01/21/16,,,08/27/14,10/05/12,06/01/11,09/03/09,,10/05/12,06/01/11,09/03/09,100%,4935.1,$   101.0,$   225.0,$   358.0,$    83.0,$   141.0,$   319.0,$   588.2,$   146.4,Q1 2019,"Astellas Pharma, Inc., Dr. Reddy's Laboratories"
1795,579,2862,180,Requip IR,ropinirole hydrochloride,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Neurology,"movement disorders, all",Restless Leg Syndrome (RLS),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/05/05,04/03/06,,,,07/07/03,,,,,05/07/01,,,N/A,,$    18.0,$    15.0,$     7.0,N/A,$   158.0,$   143.0,$   113.8,N/A,Q4 2018,N/A
1267,194,1616,180,Requip XL,ropinirole hydrochloride,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/13/08,04/23/07,,,,02/09/07,06/27/03,,,,06/27/03,06/11/01,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,Q4 2011,Vectura Group plc
15897,278,20354,556,Rescula,unoprostone isopropyl,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Potassium channels,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,08/03/00,02/08/03,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    12.8,N/A,Q4 2018,"Santen Pharmaceutical Co., Ltd."
2499,548,4247,395,Restasis,cyclosporine (opthalmic emulsion),Allergan plc,AGN,,Ireland,Europe,53945515162,Ophthalmology,Other,Dry Eye (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcineurin phosphatase,Non-NME,No,Topical,N,N,N,N,N,N,,09/01/2017 - 06/30/2018,,12/23/02,,,,,,,,,,,,,95%,1201.5,"$  1,419.5","$  1,412.3","$  1,197.0",$   542.6,"$  1,487.5","$  1,473.6","$  1,261.5",$   564.9,Q2 2019,"Merck &amp; Co., Inc."
19299,187,25430,1307,Retacrit,epoetin zeta,Vifor Pharma Group,GNHAY,,Switzerland,Europe,,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Dependent",Y,Approved,Approved,100% (Same As Avg.),Protein,Erythropoietin Receptor (EPOR),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,05/15/18,12/18/07,,,,12/16/14,,,,,01/09/12,,09/06/11,N/A,,N/A,N/A,$    10.2,$    44.0,N/A,N/A,$    42.9,$    82.0,Q2 2019,"NovaQuest Capital Management, Pfizer Inc., STADA Arzneimittel AG"
19299,371,35058,1307,Retacrit,epoetin zeta,Vifor Pharma Group,GNHAY,,Switzerland,Europe,,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Independent",N,Approved,Approved,100% (Same As Avg.),Protein,Erythropoietin Receptor (EPOR),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,05/15/18,12/18/07,,,,,,,,,,,09/06/11,N/A,,N/A,N/A,$    10.2,$    44.0,N/A,N/A,$    42.9,$    82.0,Q2 2019,"NovaQuest Capital Management, Pfizer Inc., STADA Arzneimittel AG"
19299,372,36845,1307,Retacrit,epoetin zeta,Vifor Pharma Group,GNHAY,,Switzerland,Europe,,Hematology,Marrow Or Peripheral Blood Stimulator,Anemia Due to Oncology Treatment,N,Approved,Approved,100% (Same As Avg.),Protein,Erythropoietin Receptor (EPOR),Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,05/15/18,12/18/07,,,,,,,,,,,12/05/13,N/A,,N/A,N/A,$    10.2,$    44.0,N/A,N/A,$    42.9,$    82.0,Q2 2019,"NovaQuest Capital Management, Pfizer Inc., STADA Arzneimittel AG"
23883,307,32923,470,Retisert,fluocinolone acetonide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Uveitis,Uveitis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intraocular/Subretinal/Subconjunctival,Y,N,Y,N,N,N,,,,04/08/05,,,,,10/07/04,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"EyePoint Pharmaceuticals, Inc."
1557,245,2483,312,Revatio,sildenafil citrate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 5 (PDE5),New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,06/06/05,10/28/05,01/01/08,,,12/01/04,,,,,05/03/04,,,100%,28.2,$    98.0,$   120.0,$   138.0,$    62.0,$   285.0,$   252.0,$   227.0,$    98.0,Q2 2019,N/A
25746,423,35835,5411,Revcovi,elapegademase-lvlr,"Leadiant Biosciences, Inc.",,Maryland,United States,North America,,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Adenosine Deaminase (ADA),Non-NME,No,Intramuscular (IM),Y,N,Y,N,N,N,,,,10/05/18,,03/26/19,,,10/24/17,,,,,12/17/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Teijin Pharma Limited
398,207,712,82,Revlimid,lenalidomide,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Multiple Myeloma (MM),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiogenesis^ E3 ubiquitin ligase^ Immune system,New Molecular Entity (NME),No,Oral (PO),Y,Y,Y,N,N,N,,,,06/30/06,06/14/07,06/24/10,,,12/29/05,01/15/03,07/15/03,,,07/22/04,05/08/01,,100%,6919.8,"$  4,416.9","$  5,426.0","$  6,469.0","$  1,686.0","$  6,973.6","$  8,187.0","$  9,685.0","$  2,577.0",Q1 2019,"BeiGene, Ltd."
398,206,729,82,Revlimid,lenalidomide,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Myelodysplastic Syndrome (MDS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiogenesis^ E3 ubiquitin ligase^ Immune system,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,,N,N,,07/01/2012 - 07/01/2012,,12/27/05,11/21/11,08/20/10,,,01/10/05,,,,,,12/10/02,,100%,583.4,"$  4,416.9","$  5,426.0","$  6,469.0","$  1,686.0","$  6,973.6","$  8,187.0","$  9,685.0","$  2,577.0",Q1 2019,"BeiGene, Ltd."
398,3094,27674,82,Revlimid,lenalidomide,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Mantle Cell Lymphoma - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiogenesis^ E3 ubiquitin ligase^ Immune system,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/05/13,07/15/16,,,,12/05/12,12/21/09,,,,12/21/09,05/03/06,,100%,,"$  4,416.9","$  5,426.0","$  6,469.0","$  1,686.0","$  6,973.6","$  8,187.0","$  9,685.0","$  2,577.0",Q1 2019,"BeiGene, Ltd."
398,3093,27677,82,Revlimid,lenalidomide,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiogenesis^ E3 ubiquitin ligase^ Immune system,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,08/01/2019 - 01/31/2020,02/01/2020 - 08/31/2020,05/28/19,,,,,12/27/18,11/18/11,,,,11/18/11,06/19/06,,100%,,"$  4,416.9","$  5,426.0","$  6,469.0","$  1,686.0","$  6,973.6","$  8,187.0","$  9,685.0","$  2,577.0",Q1 2019,"BeiGene, Ltd."
398,3327,36394,82,Revlimid,lenalidomide,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Marginal Zone Lymphoma - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiogenesis^ E3 ubiquitin ligase^ Immune system,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,08/01/2019 - 01/31/2020,,05/28/19,,,,,12/27/18,,,,,09/09/13,,,100%,,"$  4,416.9","$  5,426.0","$  6,469.0","$  1,686.0","$  6,973.6","$  8,187.0","$  9,685.0","$  2,577.0",Q1 2019,"BeiGene, Ltd."
17110,167,22194,636,Rexulti,brexpiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Norepinephrine (Noradrenaline)^ Serotonin 5-HT1A receptor^ Serotonin 5-HT2A receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO), Subcutaneous (SQ)",N,N,N,N,N,N,,,,07/10/15,,,,,07/14/14,07/28/11,01/13/10,,,07/28/11,11/13/09,,N/A,,N/A,N/A,$   627.2,N/A,$   387.2,$   637.2,$   894.3,$   246.6,Q1 2019,H. Lundbeck A/S
17110,170,22195,636,Rexulti,brexpiprazole,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Norepinephrine (Noradrenaline)^ Serotonin 5-HT1A receptor^ Serotonin 5-HT2A receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO), Subcutaneous (SQ)",N,N,N,N,N,N,,,,07/10/15,07/31/18,01/19/18,,,07/14/14,09/20/11,09/10/09,,,09/20/11,09/10/09,,N/A,,N/A,N/A,$   627.2,N/A,$   387.2,$   637.2,$   894.3,$   246.6,Q1 2019,H. Lundbeck A/S
2130,78,3537,73,Reyataz,atazanavir sulfate,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Infectious disease,Antiviral,HIV / AIDS,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,HIV-1 protease (HIV PR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,06/20/03,03/02/04,,,,,,,,,,,,N/A,,$   484.0,$   327.0,$   157.0,N/A,$   912.0,$   698.0,$   427.0,N/A,Q4 2018,"AbbVie Inc., Novartis AG"
17122,584,22211,4532,Rhofade,oxymetazoline hydrochloride,"Aclaris Therapeutics, Inc.",ACRS,Pennsylvania,United States,North America,33882885,Dermatology,General,Rosacea,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors,Non-NME,No,Topical,N,N,N,N,N,N,,,,01/18/17,,,,,03/23/16,06/24/14,08/19/10,,,06/24/14,08/19/10,06/30/10,N/A,,N/A,N/A,N/A,$     3.7,N/A,N/A,N/A,$     3.7,Q1 2019,N/A
3247,649,5575,870,Rhophylac,Rho(D) Immune Globulin Intravenous (Human),CSL Limited,CSL:AU,,Australia,Oceania,,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),Y,Approved,Approved,100% (Same As Avg.),Polyclonal Antibody,Fc receptors,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,04/02/07,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
21336,278,28743,3218,Rhopressa,netarsudil,"Aerie Pharmaceuticals, Inc.",AERI,North Carolina,United States,North America,1108159133,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Rho GTPase/Rho Kinase,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,09/01/2019 - 03/31/2020,,12/18/17,,,,,02/28/17,07/14/14,04/03/12,,,07/14/14,04/03/12,,N/A,,N/A,N/A,$    24.2,$    10.9,N/A,N/A,$    24.2,$    10.9,Q1 2019,N/A
19716,672,26106,870,RiaSTAP,fibrinogen,CSL Limited,CSL:AU,,Australia,Oceania,,Hematology,Other,Hemostasis,N,Approved,Approved,100% (Same As Avg.),Protein,Fibrinogen (Coagulation Factor I),Biologic,No,Intravenous (IV),N,N,Y,,N,N,,,,01/16/09,07/31/10,,,,07/21/08,,,,,,07/03/07,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
20189,137,26874,3285,Riomet,metformin,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,09/11/03,,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Daiichi Sankyo Co., Ltd."
1246,168,3054,223,Risperdal,risperidone,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Psychiatry,Bipolar,Bipolar Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,12/04/03,,,,,,,,,,05/17/00,,,100%,0,N/A,N/A,$   315.0,$   158.0,N/A,N/A,$   737.0,$   361.0,Q2 2019,N/A
1246,619,3681,223,Risperdal,risperidone,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Neurology,Neurodevelopmental Disorders,Autism Spectrum Disorders (Autism),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/06/06,,,,,12/19/03,,,,,05/20/05,,,100%,,N/A,N/A,$   315.0,$   158.0,N/A,N/A,$   737.0,$   361.0,Q2 2019,N/A
2318,170,3901,223,Risperdal Consta,risperidone,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,Non-NME,No,Intramuscular (IM),N,N,N,,N,N,,,,10/29/03,07/31/02,04/27/09,,,,,,,,,,,90%,126.9,$   289.0,$   360.0,$   162.0,N/A,$   683.0,$   805.0,$   384.0,N/A,Q2 2018,Alkermes plc
2318,168,3959,223,Risperdal Consta,risperidone,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Psychiatry,Bipolar,Bipolar Disorder,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Alpha 2 Adrenergic Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,Non-NME,No,Intramuscular (IM),N,N,N,,N,N,,,,05/15/09,,,,,04/14/08,,,,,10/28/04,,,90%,86.9,$   289.0,$   360.0,$   162.0,N/A,$   683.0,$   805.0,$   384.0,N/A,Q2 2018,Alkermes plc
416,246,3017,289,Ritalin LA,methylphenidate hydrochloride,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/06/02,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Alkermes plc, Celgene Corporation"
1,154,241,149,Rituxan,rituximab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,02/28/06,07/11/06,,,,08/31/05,12/08/03,,,,12/08/03,06/24/02,,69%,966.8,"$  3,993.7","$  4,215.2","$  4,356.0","$  2,281.8","$  7,454.3","$  7,533.3","$  6,856.0","$  3,340.1",Q2 2019,"Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd."
1,200,368,149,Rituxan,rituximab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,02/18/10,02/27/09,03/26/19,,,05/19/09,12/08/03,,,,10/06/04,12/04/01,,69%,124.3,"$  3,993.7","$  4,215.2","$  4,356.0","$  2,281.8","$  7,454.3","$  7,533.3","$  6,856.0","$  3,340.1",Q2 2019,"Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd."
1,629,2990,149,Rituxan,rituximab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Vasculitis,Antineutrophil Cytoplasmic Antibodies (ANCA) Associated Vasculitis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,01/01/2014 - 01/01/2014,04/19/11,04/30/13,,,,,,,,,01/10/05,12/21/04,,69%,62.4,"$  3,993.7","$  4,215.2","$  4,356.0","$  2,281.8","$  7,454.3","$  7,533.3","$  6,856.0","$  3,340.1",Q2 2019,"Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd."
1,3095,28243,149,Rituxan,rituximab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Hematologic,Diffuse Large B-Cell Lymphoma (DLBCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,02/10/06,06/02/98,,,,,,,,,12/10/01,12/04/01,,69%,,"$  3,993.7","$  4,215.2","$  4,356.0","$  2,281.8","$  7,454.3","$  7,533.3","$  6,856.0","$  3,340.1",Q2 2019,"Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd."
1,392,35656,149,Rituxan,rituximab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,Other,Pemphigus Vulgaris,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,06/07/18,03/11/19,,,,12/07/17,08/12/09,,,,08/12/09,09/30/03,,69%,,"$  3,993.7","$  4,215.2","$  4,356.0","$  2,281.8","$  7,454.3","$  7,533.3","$  6,856.0","$  3,340.1",Q2 2019,"Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd."
15791,3093,20170,149,Rituxan Hycela,rituximab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,06/22/17,03/28/14,,,,11/03/16,02/16/11,,09/10/09,,,,09/10/09,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Halozyme Therapeutics, Inc."
15791,200,23485,149,Rituxan Hycela,rituximab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,06/22/17,05/31/16,,,,,,,06/06/11,,,,08/22/16,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Halozyme Therapeutics, Inc."
15791,3095,30670,149,Rituxan Hycela,rituximab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Hematologic,Diffuse Large B-Cell Lymphoma (DLBCL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,06/22/17,03/28/14,,,,11/03/16,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Halozyme Therapeutics, Inc."
17522,512,22825,826,Rixubis,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Hematology,Factor Augmentation,Hemophilia B,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,10/24/2014 - 12/30/2014,,06/26/13,12/19/14,12/26/14,,,09/04/12,,,,,10/21/10,,07/22/10,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23003,278,31387,3218,Rocklatan,netarsudil/latanoprost,"Aerie Pharmaceuticals, Inc.",AERI,North Carolina,United States,North America,1108159133,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Prostaglandin F receptor (FP)/PGF2 alpha receptor^ Rho GTPase/Rho Kinase,Non-NME,No,Topical,N,N,N,N,N,N,,,,03/12/19,,,,,05/15/18,09/21/15,09/17/13,,,09/21/15,09/17/13,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
20694,506,27663,395,Rosuvastatin Zinc,rosuvastatin zinc,Allergan plc,AGN,,Ireland,Europe,53945515162,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HMG CoA Reductase (HMGR),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/04/11,,,,,07/15/10,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Les Laboratoires Servier
946,640,3078,180,Rotarix,rotavirus vaccine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,Rotavirus Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Rotavirus,Vaccine,No,Oral (PO),N,N,N,N,N,N,,,,04/03/08,02/27/06,07/01/11,,,06/27/07,10/22/03,,,,10/22/03,05/04/00,,N/A,,$   176.0,$   170.5,$   172.1,$    61.0,$   638.0,$   590.2,$   709.8,$   181.7,Q1 2019,"Celldex Therapeutics, Inc."
1909,640,3077,254,RotaTeq,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,Rotavirus Vaccines,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Rotavirus,Vaccine,No,Oral (PO),N,N,N,,N,N,,,,02/03/06,06/27/06,01/18/12,,,04/05/05,,,,,05/28/04,,,N/A,,$   483.0,$   481.0,$   496.0,$   258.0,$   651.0,$   686.0,$   728.0,$   383.0,Q2 2019,DRI Capital Inc.
20901,3134,27998,556,Roxicodone,oxycodone hydrochloride,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Neurology,Pain,Moderate to Severe Pain,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,08/31/00,,,,,09/30/98,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
34053,3134,47031,343,RoxyBond,oxycodone,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Neurology,Pain,Moderate to Severe Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/20/17,,,,,10/21/16,,,,,,,03/22/15,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Inspirion Delivery Technologies, LLC"
2277,291,3818,826,Rozerem,ramelteon,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Neurology,Insomnia,Insomnia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Melatonin Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/22/05,,04/16/10,,,09/24/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$    67.5,$    81.0,$    87.2,N/A,Q4 2018,"Meiji Seika Pharma Co., Ltd"
7878,224,9875,2737,Rubraca,rucaparib,"Clovis Oncology, Inc.",CLVS,Colorado,United States,North America,299930295,Oncology,Solid,Ovarian Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Poly ADP-Ribose Polymerase (PARP),New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,Y,Y,N,N,,,,12/19/16,05/24/18,,,,06/23/16,,,,,10/30/13,06/04/07,,N/A,,N/A,$    55.4,$    95.5,$    64.6,N/A,$    55.4,$    95.5,$    66.2,Q2 2019,Pfizer Inc.
2178,556,3621,797,Ruconest,conestat alfa,Pharming Group N.V.,PHARM:NA,,Netherlands,Europe,,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Y,Approved,Approved,100% (Same As Avg.),Protein,Complement Pathway,Biologic,No,Intravenous (IV),Y,Y,Y,N,N,N,,,,07/16/14,10/28/10,,,,12/28/10,02/22/11,12/21/04,,,02/28/11,04/28/04,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Bausch Health Companies Inc., CytoBioteck S.A.S., Hyupjin Corporation, MegaPharm Ltd., Swedish Orphan Biovitrum, Transmedic Pte Ltd."
19651,3093,37112,312,Ruxience,rituximab-pvvr,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,07/23/19,,,,,,10/06/14,,,,10/06/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
19651,200,57093,312,Ruxience,rituximab-pvvr,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,07/23/19,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
19651,629,57094,312,Ruxience,rituximab-pvvr,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Vasculitis,Antineutrophil Cytoplasmic Antibodies (ANCA) Associated Vasculitis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,07/23/19,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23175,2886,31709,4487,Ruzurgi,amifampridine,Jacobus Pharmaceutical Company,,New Jersey,United States,North America,,Autoimmune/immunology,Other,Lambert-Eaton Myasthenic Syndrome (LEMS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Potassium channels,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,05/06/19,,,,,06/15/18,,09/28/12,,,,09/28/12,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23877,726,32914,2403,Ryanodex,,"Eagle Pharmaceuticals, Inc.",EGRX,New Jersey,United States,North America,860638405,Not Specified,Other,Drug Toxicity,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Ryanodine Receptor (RyRs),Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,07/23/14,,,,,01/22/14,,,,,,,,N/A,,N/A,$    12.9,$    20.2,$     4.0,N/A,$    12.9,$    20.2,$     4.0,Q1 2019,N/A
1850,97,2968,289,Rydapt,midostaurin,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Protein Kinase C (PKC)^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,10/01/2017 - 12/31/2017,04/28/17,09/20/17,,,,,04/01/08,01/31/06,,,04/01/08,01/31/06,10/06/04,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
1850,663,18751,289,Rydapt,midostaurin,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Other,Mastocytosis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Protein Kinase C (PKC)^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,10/01/2017 - 12/31/2017,04/28/17,09/20/17,,,,,,,,,10/25/12,10/04/05,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
15820,194,20222,4452,Rytary,carbidopa/levodopa,"Amneal Pharmaceuticals, Inc.",AMRX,New Jersey,United States,North America,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Aromatic L-amino acid decarboxylase (AADC)^ Dopamine Receptor - Unspecified,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/08/15,11/19/15,,,,12/21/11,04/20/09,,,,04/14/08,,,N/A,,N/A,N/A,$    95.6,$    29.4,N/A,N/A,$    95.6,$    29.4,Q1 2019,N/A
15019,3548,19064,180,Rythmol SR,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Cardiovascular,Dysrythmia (Arrythmia),Atrial Fibrillation/Flutter,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/04/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2546,157,4325,292,Ryzodeg 70/30,insulin degludec and insulin aspart,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/25/15,01/21/13,12/25/12,,,09/29/11,09/16/09,,,,09/16/09,01/31/08,10/27/06,100%,94,N/A,N/A,N/A,N/A,N/A,$    75.0,$   106.2,$    32.2,Q1 2019,N/A
2546,137,4326,292,Ryzodeg 70/30,insulin degludec and insulin aspart,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/25/15,01/21/13,12/25/12,,,09/29/11,11/05/09,01/31/08,10/27/06,,11/05/09,01/31/08,10/27/06,100%,1163.6,N/A,N/A,N/A,N/A,N/A,$    75.0,$   106.2,$    32.2,Q1 2019,N/A
2810,3128,4789,325,Ryzolt,tramadol,Purdue Pharma L.P.,,Connecticut,United States,North America,,Neurology,Pain,Chronic Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/30/08,09/06/05,03/26/15,,,11/30/05,,,,,04/22/02,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Endo International plc, Johnson &amp; Johnson, Nippon Shinyaku Co., Ltd., Pfizer Inc., Sanofi, SciClone Pharmaceuticals, Inc."
11697,3009,14738,240,Sabril,vigabatrin,H. Lundbeck A/S,HLUKF,,Denmark,Europe,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/21/09,01/01/89,,,,05/02/94,,,,,04/28/95,,,N/A,,N/A,N/A,$   199.5,N/A,$   197.4,$   232.4,$   199.5,$    38.6,Q1 2019,Sanofi
11697,3007,22801,240,Sabril,vigabatrin,H. Lundbeck A/S,HLUKF,,Denmark,Europe,,Neurology,Seizure Disorders (Epilepsy),Infantile Spasms (West Syndrome; Epilepsy),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/21/09,,,,,10/18/06,,,,,04/05/07,,,N/A,,N/A,N/A,$   199.5,N/A,$   197.4,$   232.4,$   199.5,$    38.6,Q1 2019,Sanofi
17778,239,23190,59,Safyral,drospirenone/ethinyl estradiol/levomefolate calcium,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Contraception,Contraception,Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Folate Receptor (FOLR1)^ Mineralocorticoid Receptor^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,12/16/10,,,,,11/16/09,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
3227,692,5537,636,Samsca,tolvaptan,"Otsuka Holdings Co., Ltd.",4768:JP,,Japan,Asia,,Endocrine,Other,Hyponatremia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Vasopressin receptors,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/19/09,08/03/09,10/27/10,,,10/23/07,,,,,05/01/03,,,100%,,$    82.1,$   376.2,$   213.1,N/A,$   326.4,$   589.2,$   832.0,$   276.9,Q1 2019,N/A
886,543,1961,142,Sanctura,trospium chloride,Endo International plc,ENDP,,Ireland,Europe,554131557,Urology,Other,Overactive Bladder (OAB),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/28/04,,,,,04/28/03,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2012,"Allergan plc, Mylan N.V."
2227,543,3737,142,Sanctura XR,trospium chloride,Endo International plc,ENDP,,Ireland,Europe,554131557,Urology,Other,Overactive Bladder (OAB),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/03/07,10/31/08,,,,10/12/06,09/08/05,,,,09/08/05,04/07/04,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Mylan N.V., Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd."
13024,767,16416,410,Sancuso,granisetron,"Kyowa Hakko Kirin Co., Ltd.",4151:JP,,Japan,Asia,,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT3 receptor,Non-NME,No,Transdermal,N,N,N,,N,N,,,,09/12/08,04/26/12,,,,06/29/07,,,,,02/08/06,09/15/05,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    27.4,$    12.8,Q2 2019,"Lee's Pharmaceutical Holdings Limited, NewBridge Pharmaceuticals, Solasia Pharma K.K."
2070,170,3390,395,Saphris,asenapine maleate,Allergan plc,AGN,,Ireland,Europe,53945515162,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,08/13/09,,,,,08/30/07,,,,,10/20/03,,,100%,86.5,$   166.8,$   155.2,$    66.5,N/A,$   166.8,$   155.2,$    66.5,N/A,Q2 2018,"H. Lundbeck A/S, Merck &amp; Co., Inc."
2070,168,3391,395,Saphris,asenapine maleate,Allergan plc,AGN,,Ireland,Europe,53945515162,Psychiatry,Bipolar,Bipolar Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,08/13/09,09/01/10,,,,08/30/07,,,,,10/20/03,,,100%,438.4,$   166.8,$   155.2,$    66.5,N/A,$   166.8,$   155.2,$    66.5,N/A,Q2 2018,"H. Lundbeck A/S, Merck &amp; Co., Inc."
891,566,1962,142,Sarafem,fluoxetine hydrochloride,Endo International plc,ENDP,,Ireland,Europe,554131557,Neurology,Other,Premenstrual Dysphoric Disorder (PMDD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,07/06/00,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Allergan plc, Eli Lilly &amp; Company"
2736,346,4672,343,Savaysa,edoxaban,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Hematology,Antithrombotic,Venous Thromboembolism (VTE),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/08/15,06/19/15,04/22/11,,,01/08/14,02/03/10,,,,02/03/10,03/12/06,,N/A,,N/A,$    20.0,$    20.9,N/A,N/A,$   686.4,"$  1,068.5",N/A,Q4 2018,"Daewoong Pharmaceutical Company Ltd., Les Laboratoires Servier, Merck &amp; Co., Inc."
2736,2965,17680,343,Savaysa,edoxaban,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Hematology,Antithrombotic,Stroke Prevention in Atrial Fibrillation (SPAF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/08/15,06/19/15,09/26/14,,,01/08/14,12/07/08,,,,12/08/08,02/01/08,,N/A,,N/A,$    20.0,$    20.9,N/A,N/A,$   686.4,"$  1,068.5",N/A,Q4 2018,"Daewoong Pharmaceutical Company Ltd., Les Laboratoires Servier, Merck &amp; Co., Inc."
1703,588,2730,395,Savella,milnacipran,Allergan plc,AGN,,Ireland,Europe,53945515162,Neurology,Pain,Fibromyalgia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/14/09,,,,,12/31/07,10/15/03,,,,09/09/04,,,N/A,,$   133.6,$    98.2,$    39.0,N/A,$   133.6,$    98.2,$    39.0,N/A,Q2 2018,"Asahi Kasei Corporation, Pierre Fabre Medicament S.A., Royalty Pharma AG"
18391,239,24090,7817,Seasonique,ethinyl estradiol and levonorgestrel,CVC Capital Partners SICAV-FIS S.A.,,,Luxembourg,Europe,,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/25/06,01/12/15,,,,10/21/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2381,73,4026,686,Seebri Neohaler,glycopyrronium bromide,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,10/29/15,09/28/12,09/28/12,,,,06/29/09,,,,06/29/09,05/23/05,,85%,1145.2,N/A,N/A,N/A,N/A,$   149.0,$   151.0,$   148.0,$    65.0,Q2 2019,"Glenmark Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Sosei Co., Ltd, Vectura Group plc"
36158,137,50296,254,Segluromet,ertugliflozin/metformin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/19/17,03/23/18,,,,12/19/16,01/27/14,,,,01/27/14,04/29/13,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Pfizer Inc.
40574,272,56863,312,Seizalam,midazolam hydrochloride,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Seizure Disorders (Epilepsy),Seizure Disorders (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Intramuscular (IM),N,N,Y,N,N,N,,,,09/14/18,,,,,11/16/17,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2137,78,3544,180,Selzentry,maraviroc,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Chemokine Receptor 5 (CCR5),New Molecular Entity (NME),No,"Oral (PO), Rectal, Intravaginal",Y,N,N,,N,N,,,,08/06/07,09/18/07,12/25/08,,,12/20/06,,12/07/04,,,12/06/04,,,75%,73.3,$    88.0,$    86.0,$    77.0,$    34.0,$   170.0,$   166.0,$   153.0,$    63.0,Q2 2019,"International Partnership for Microbicides, Pfizer Inc."
31,343,45,30,Sensipar,cinacalcet hydrochloride,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Endocrine,Hyperparathyroidism,Hyperparathyroidism (Primary),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcium-Sensing Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,03/01/2014 - 09/30/2014,02/25/11,06/24/08,,,,04/26/10,,,,,,05/25/99,,92%,21.8,"$  1,240.0","$  1,374.0","$  1,436.0",$   178.0,"$  1,667.1","$  1,718.0","$  1,774.0",$   390.4,Q2 2019,"DRI Capital Inc., Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Company Ltd"
31,367,306,30,Sensipar,cinacalcet hydrochloride,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Endocrine,Hyperparathyroidism,Hyperparathyroidism (Secondary),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Calcium-Sensing Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,03/08/04,10/28/04,10/25/07,,,09/05/03,12/15/01,,,,12/20/01,08/11/98,,92%,1021.4,"$  1,240.0","$  1,374.0","$  1,436.0",$   178.0,"$  1,667.1","$  1,718.0","$  1,774.0",$   390.4,Q2 2019,"DRI Capital Inc., Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Company Ltd"
25786,155,35899,7731,Sernivo,betamethasone dipropionate,"Encore Dermatology, Inc.",,Pennsylvania,United States,North America,,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,02/05/16,,,,,04/08/15,,,,,11/20/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1937,168,3125,45,Seroquel,quetiapine fumarate,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Psychiatry,Bipolar,Bipolar Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/12/04,10/13/03,,,,01/02/03,08/31/00,,,,08/31/00,,,100%,330.3,N/A,N/A,$    80.0,$    20.0,N/A,N/A,$   361.0,$    44.3,Q1 2019,"Astellas Pharma, Inc., Hutchison MediPharma Limited, Luye Pharma Group, Ltd."
2734,170,4668,45,Seroquel XR,quetiapine fumarate,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/17/07,01/01/08,,,,07/18/06,,,,,,,,100%,,$   515.0,$   175.0,N/A,N/A,$   735.0,$   388.6,N/A,N/A,Q4 2017,"Astellas Pharma, Inc., Lupin Limited, Luye Pharma Group, Ltd."
2734,167,5311,45,Seroquel XR,quetiapine fumarate,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,01/01/2011 - 01/01/2011,12/02/09,09/02/10,,,,02/29/08,02/02/06,,,,02/02/06,,,100%,,$   515.0,$   175.0,N/A,N/A,$   735.0,$   388.6,N/A,N/A,Q4 2017,"Astellas Pharma, Inc., Lupin Limited, Luye Pharma Group, Ltd."
2734,168,5313,45,Seroquel XR,quetiapine fumarate,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Psychiatry,Bipolar,Bipolar Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha Adrenergic Receptors^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT1 receptor^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2B receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/10/08,09/29/09,07/03/17,,,01/02/08,,,,,01/12/07,,,100%,,$   515.0,$   175.0,N/A,N/A,$   735.0,$   388.6,N/A,N/A,Q4 2017,"Astellas Pharma, Inc., Lupin Limited, Luye Pharma Group, Ltd."
1534,581,10370,255,Serostim,somatropin recombinant,Merck KGaA,MKGAY,,Germany,Europe,,Gastroenterology (non inflammatory bowel disease),Other,Short Bowel Syndrome (SBS),N,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),Biologic,No,Subcutaneous (SQ),N,N,Y,,N,N,,,,12/02/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2010,N/A
20558,603,27408,774,Seysara,sarecycline,"Almirall Prodesfarma, S.A.",ALM:SM,,Spain,Europe,,Dermatology,General,Acne,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/01/18,,,,,10/20/17,,06/22/12,,,12/18/14,06/22/12,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Paratek Pharmaceuticals, Inc."
17210,641,22330,180,Shingrix,,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,Chickenpox and Shingles - Vaccines and Treatments,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Varicella Zoster Virus (VSV),Vaccine,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,N,N,N,,,,10/20/17,03/23/18,03/23/18,,,10/21/16,08/23/10,,,,08/23/10,02/22/07,,N/A,,N/A,$    29.8,$   997.3,$   444.8,N/A,N/A,"$  1,066.6",$   484.2,Q1 2019,"Agenus Inc., Oberland Capital Management, LLC"
1888,637,3044,1008,Signifor,pasireotide diaspartate,Recordati SpA,REC:IM,,Italy,Europe,,Endocrine,Other,Cushing's Syndrome,Y,Approved,Approved,100% (Same As Avg.),Peptide,Somatostatin Receptors,Non-NME,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,N,N,N,,,01/01/2014 - 01/01/2014,12/14/12,04/24/12,,,,03/31/12,01/31/07,,,,01/31/07,04/01/04,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
1888,680,5059,1008,Signifor,pasireotide diaspartate,Recordati SpA,REC:IM,,Italy,Europe,,Endocrine,Other,Acromegaly,N,Approved,Approved,100% (Same As Avg.),Peptide,Somatostatin Receptors,Non-NME,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,Y,N,N,N,,,01/01/2014 - 01/01/2015,12/16/14,11/24/14,,,,11/15/13,01/14/08,,,,01/14/08,01/31/07,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Novartis AG
37723,576,52598,8299,Siklos,Hydroxyurea,Addmedica  SAS,,,France,Europe,,Hematology,Other,Sickle Cell Anemia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Fetal hemoglobin,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,12/21/17,06/29/07,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2328,291,3926,4140,Silenor,doxepin hydrochloride,Currax Pharmaceuticals LLC,,New Jersey,United States,North America,,Neurology,Insomnia,Insomnia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,03/17/10,,,,,01/31/08,06/09/05,,,,06/09/05,,,N/A,,$    16.9,$    22.3,$    11.7,N/A,N/A,$    22.3,$    11.7,N/A,Q2 2018,"Endo International plc, Procter &amp; Gamble"
14327,155,20989,470,Siliq,brodalumab,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-17 Receptor (IL-17R),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,02/15/17,07/17/17,07/04/16,,,11/16/15,10/16/12,12/01/09,,,10/15/12,09/10/09,,100%,,N/A,N/A,N/A,N/A,N/A,$    11.1,$    33.2,$     9.5,Q1 2019,"AstraZeneca PLC, Kyowa Hakko Kirin Co., Ltd., LEO Pharma A/S"
18803,278,24716,289,Simbrinza,brinzolamide/brimonidine tartrate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor^ Carbonic Anhydrase,Non-NME,No,Topical,N,N,N,N,N,N,,,,04/19/13,07/18/14,,,,06/19/12,03/09/11,,,,03/09/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
463,252,820,223,Simponi (SQ),golimumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/24/09,10/01/09,,,,06/27/08,,,,,11/01/05,,,95%,106.8,$   959.0,$   954.0,$   980.0,$   544.0,"$  2,511.0","$  2,652.0","$  3,325.7","$  1,693.4",Q2 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
463,336,831,223,Simponi (SQ),golimumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,10/01/2010 - 10/01/2010,04/24/09,10/01/09,,,,06/27/08,12/01/05,,,,12/01/05,,,95%,,$   959.0,$   954.0,$   980.0,$   544.0,"$  2,511.0","$  2,652.0","$  3,325.7","$  1,693.4",Q2 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
463,154,832,223,Simponi (SQ),golimumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,04/24/09,10/01/09,07/01/11,,,06/27/08,12/12/05,,,,12/12/05,11/16/05,,95%,748.9,$   959.0,$   954.0,$   980.0,$   544.0,"$  2,511.0","$  2,652.0","$  3,325.7","$  1,693.4",Q2 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
463,321,15231,223,Simponi (SQ),golimumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,05/15/13,09/23/13,03/30/17,,,07/16/12,,,,,06/26/08,,,95%,,$   959.0,$   954.0,$   980.0,$   544.0,"$  2,511.0","$  2,652.0","$  3,325.7","$  1,693.4",Q2 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
20608,154,27514,223,Simponi Aria (IV),golimumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,07/18/13,,,,,09/18/12,,,,,08/17/06,,,95%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Bristol-Myers Squibb Company, Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
20608,336,33740,223,Simponi Aria (IV),golimumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,10/20/17,,,,,12/20/16,07/02/14,,,,07/02/14,,,95%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Bristol-Myers Squibb Company, Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
20608,252,33802,223,Simponi Aria (IV),golimumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Arthritis,Axial Spondyloarthritis,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Tumor Necrosis Factor-alpha (TNF-alpha),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,10/20/17,,,,,12/20/16,07/08/14,,,,07/08/14,,,95%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Bristol-Myers Squibb Company, Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation"
1464,236,2245,254,Singulair,montelukast sodium,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Allergy,General,Allergic Rhinitis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,CysLT receptors,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,12/31/02,06/26/03,,,,03/01/02,,,,,03/23/00,,,100%,,$    41.0,$    40.0,$    20.0,$    13.0,$   915.0,$   732.0,$   708.0,$   351.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Kyorin Pharmaceutical Co., Ltd."
25209,152,35068,4881,SINUVA Steroid Releasing Sinus Implant,,Intersect ENT,XENT,California,United States,North America,510272875,Allergy,General,Allergy,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intranasal,N,N,N,N,N,N,,,,12/08/17,,,,,03/07/17,,,,,06/23/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$     2.4,$     0.9,Q1 2019,N/A
15452,455,19641,223,Sirturo,bedaquiline,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Tuberculosis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,ATP Synthase^ Tuberculosis,New Molecular Entity (NME),No,Oral (PO),Y,Y,Y,N,N,N,,,,12/31/12,03/05/14,,,,06/29/12,,,,,,08/26/05,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Global Alliance for TB Drug Development, Pharmstandard JSC"
20306,665,27047,7417,Sitavig,acyclovir,"EPI Group, LLC",,North Carolina,United States,North America,,Infectious disease,Antiviral,Herpes Simplex Virus (HSV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Thymidine Kinase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/15/13,,,,,03/12/12,,,,,10/19/09,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Bruno Farmaceutici SpA, Daewoong Pharmaceutical Company Ltd., Teva Pharmaceutical Industries Ltd., Vectans Pharma"
10979,440,13784,254,Sivextro,tedizolid phosphate,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,Y,N,N,N,Y,,,,06/20/14,03/23/15,03/23/18,,,10/22/13,08/30/10,09/22/08,01/07/08,,06/16/10,09/22/08,01/07/08,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q3 2014,"Dong-A Socio Holdings Co., Ltd"
19513,81,25739,51,Sklice Lotion,ivermectin,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutamate-gated chloride ion channels (invertebrates),Non-NME,No,Topical,N,N,N,N,N,N,,,,02/07/12,,,,,04/07/11,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Arbor Pharmaceuticals, LLC, Kaken Pharmaceutical Company, Ltd"
21274,239,28650,59,Skyla,,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Contraception,Contraception,N,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Intrauterine,N,N,N,,N,N,,,,01/09/13,12/05/12,,,,12/09/11,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
19926,155,26430,5,Skyrizi,risankizumab-rzaa,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-23 (Interleukin-23),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,04/23/19,04/30/19,03/26/19,,,04/23/18,02/29/16,02/19/14,,,02/29/16,02/19/14,04/10/12,N/A,,N/A,N/A,N/A,$    42.0,N/A,N/A,N/A,$    48.0,Q2 2019,Boehringer Ingelheim GmbH
26442,239,36888,5409,Slynd,drospirenone,Insud Pharma,,,Austria,Europe,,Endocrine,Contraception,Contraception,N,Approved,Approved,100% (Same As Avg.),Steroid,Mineralocorticoid Receptor^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/23/19,,,,,07/27/18,,,,,10/20/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38668,690,53970,818,Solaraze,diclofenac sodium,Vectura Group plc,VEC:LN,,United Kingdom,Europe,,Dermatology,General,Actinic Keratoses,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Topical,N,N,N,N,N,N,,,,10/16/00,,,,,10/20/98,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    38.7,$    17.0,Q2 2019,N/A
21473,543,28938,814,Solifenacin/Mirabegron,,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Urology,Other,Overactive Bladder (OAB),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-3 adrenergic receptor (ß3 adrenoceptor)^ Muscarinic acetylcholine receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/27/18,,,,,06/27/17,,,,,08/01/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
17888,137,23368,51,Soliqua 100/33,insulin glargine/lixisenatide,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor^ Insulin Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,01/01/2019 - 01/01/2019,11/21/16,01/11/17,,,,12/23/15,,11/21/11,,,01/15/14,11/21/11,02/10/10,82%,679.3,N/A,$    26.1,$    27.6,N/A,N/A,$    26.1,$    83.2,$    31.5,Q1 2019,"Alkermes plc, Royalty Pharma AG, Zealand Pharma A/S"
279,394,526,21,Soliris,eculizumab,"Alexion Pharmaceuticals, Inc.",ALXN,Connecticut,United States,North America,24868581569,Autoimmune/immunology,Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria (PNH),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Complement Pathway,Biologic,No,Intravenous (IV),N,Y,Y,,N,N,,,,03/16/07,06/22/07,04/16/10,,,09/20/06,11/01/04,,,,07/23/04,02/06/04,12/12/02,100%,1045.1,N/A,"$  1,235.0","$  1,588.4",$   960.0,"$  2,844.0","$  3,144.1","$  3,563.0","$  1,942.8",Q2 2019,"DRI Capital Inc., Lonza Group AG"
279,469,17066,21,Soliris,eculizumab,"Alexion Pharmaceuticals, Inc.",ALXN,Connecticut,United States,North America,24868581569,Autoimmune/immunology,Other,Myasthenia Gravis (MG),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Complement Pathway,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,10/23/17,08/14/17,12/26/17,,,12/23/16,,,,,03/05/14,10/07/08,,100%,,N/A,"$  1,235.0","$  1,588.4",$   960.0,"$  2,844.0","$  3,144.1","$  3,563.0","$  1,942.8",Q2 2019,"DRI Capital Inc., Lonza Group AG"
279,2893,17704,21,Soliris,eculizumab,"Alexion Pharmaceuticals, Inc.",ALXN,Connecticut,United States,North America,24868581569,Hematology,General,Hemolytic Uremic Syndrome (HUS),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Complement Pathway,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,09/23/11,06/20/07,09/13/13,,,04/07/11,,07/23/09,,,,07/23/09,12/07/08,100%,169.2,N/A,"$  1,235.0","$  1,588.4",$   960.0,"$  2,844.0","$  3,144.1","$  3,563.0","$  1,942.8",Q2 2019,"DRI Capital Inc., Lonza Group AG"
279,703,20518,21,Soliris,eculizumab,"Alexion Pharmaceuticals, Inc.",ALXN,Connecticut,United States,North America,24868581569,Autoimmune/immunology,Other,"Neuromyelitis Optica (Devic's syndrome, NMO)",N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Complement Pathway,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,07/25/2019 - 09/30/2019,12/01/2019 - 06/30/2020,06/27/19,,,,,12/31/18,03/06/14,05/19/09,,,03/06/14,05/19/09,,100%,,N/A,"$  1,235.0","$  1,588.4",$   960.0,"$  2,844.0","$  3,144.1","$  3,563.0","$  1,942.8",Q2 2019,"DRI Capital Inc., Lonza Group AG"
7373,603,8920,470,Solodyn,"minocycline hydrochloride, minocycline HCl",Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Dermatology,General,Acne,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/08/06,,,,,06/30/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    70.0,$    38.0,$     4.0,Q1 2019,N/A
25842,534,35985,3356,Solosec,secnidazole,Lupin Limited,LPC:IN,,India,Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Microbial DNA^ Reactive Oxygen Species/Free Radicals,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,Y,,,,09/15/17,,,,,01/17/17,05/04/15,,,,05/04/15,05/28/14,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Symbiomix Therapeutics, LLC"
19332,214,25481,3464,Soltamox,tamoxifen citrate,Midatech Pharma PLC,MTP,,United Kingdom,Europe,40926371,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/29/05,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Perrigo Company PLC
3015,680,5145,220,Somatuline Autogel,lanreotide acetate,Ipsen SA,IPSEY,,France,Europe,,Endocrine,Other,Acromegaly,Y,Approved,Approved,100% (Same As Avg.),Peptide,Somatostatin Receptors,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,Y,,N,N,,,,08/30/07,12/31/05,06/29/12,,,10/30/06,,,,,10/16/06,,,N/A,,N/A,N/A,N/A,N/A,$   594.8,$   807.6,$   997.7,$   319.0,Q1 2019,Teijin Pharma Limited
3015,347,5146,220,Somatuline Autogel,lanreotide acetate,Ipsen SA,IPSEY,,France,Europe,,Oncology,Solid,Neuroendocrine Tumors (NET),N,Approved,Approved,98% (2% Below Avg.),Peptide,Somatostatin Receptors,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/16/14,02/27/15,07/03/17,,,06/30/14,03/20/09,,,,06/01/06,,,N/A,,N/A,N/A,N/A,N/A,$   594.8,$   807.6,$   997.7,$   319.0,Q1 2019,Teijin Pharma Limited
1227,680,1862,210,Somavert,pegvisomant,Nektar Therapeutics,NKTR,California,United States,North America,3262656604,Endocrine,Other,Acromegaly,Y,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,03/27/03,11/13/02,,,,,,,,,02/14/01,,,N/A,,$    70.0,$    95.0,$   103.0,$    50.0,$   232.0,$   253.0,$   268.0,$   127.0,Q2 2019,"DRI Capital Inc., Pfizer Inc."
23887,584,32933,587,Soolantra,ivermectin,Galderma S.A.,,,Switzerland,Europe,,Dermatology,General,Rosacea,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutamate-gated chloride ion channels (invertebrates),Non-NME,No,Topical,N,N,N,N,N,N,,,,12/23/14,03/24/15,,,,,,,,,12/21/11,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
21062,155,28307,8963,Sorilux,calcipotriene,Mayne Pharma Group Limited,MYX: ASX,,Australia,Oceania,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Vitamin D receptor,Non-NME,No,Topical,N,N,N,,N,N,,,,10/06/10,,,,,12/21/09,,,,,07/22/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
30832,3581,42637,4042,Sotylize,sotalol hydrochloride,"Arbor Pharmaceuticals, LLC",,Georgia,United States,North America,,Cardiovascular,Dysrythmia (Arrythmia),Ventricular Tachycardia or Fibrillation,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Potassium channels,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,10/22/14,,,,,12/23/13,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
16284,176,20973,179,Sovaldi,sofosbuvir,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HCV Polymerase - Nucleoside Binding Site,New Molecular Entity (NME),No,Oral (PO),Y,N,N,Y,N,N,,,,12/06/13,01/16/14,03/26/15,,,04/08/13,11/01/11,01/21/10,,,11/01/11,01/21/10,,100%,,"$  1,895.0",$   130.0,N/A,N/A,"$  4,001.0",$   964.0,N/A,N/A,Q4 2017,Biotoscana International
2010,440,3275,3612,Spectracef,cefditoren pivoxil,Vansen Pharma Inc.,VNSN,,Canada,North America,2574000,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,08/29/01,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    68.2,$    42.3,N/A,Q4 2018,"Meiji Seika Pharma Co., Ltd"
2010,643,5629,3612,Spectracef,cefditoren pivoxil,Vansen Pharma Inc.,VNSN,,Canada,North America,2574000,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Respiratory Tract Infections (Excluding Pneumonia) (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,08/29/01,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    68.2,$    42.3,N/A,Q4 2018,"Meiji Seika Pharma Co., Ltd"
2010,488,5630,3612,Spectracef,cefditoren pivoxil,Vansen Pharma Inc.,VNSN,,Canada,North America,2574000,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,08/21/02,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,$    68.2,$    42.3,N/A,Q4 2018,"Meiji Seika Pharma Co., Ltd"
18461,3065,24189,64,Spinraza,nusinersen,"Biogen, Inc.",BIIB,Massachusetts,United States,North America,46991785631,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Spinal Muscular Atrophy,Y,Approved,Approved,100% (Same As Avg.),Antisense,Survival of Motor Neuron (SMN) Protein,New Molecular Entity (NME),No,Intrathecal,Y,N,Y,N,N,N,,,,12/23/16,06/01/17,06/30/17,,,09/26/16,08/01/14,10/24/12,12/19/11,,08/01/14,10/24/12,12/19/11,N/A,,$     5.0,$   657.0,$   854.0,$   453.9,$     5.0,$   883.7,"$  1,724.3","$  1,006.7",Q2 2019,"Ionis Pharmaceuticals, Inc."
2380,73,4025,70,Spiriva,tiotropium bromide,Boehringer Ingelheim GmbH,,,Germany,Europe,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,01/30/04,10/09/01,10/22/04,,,12/18/01,,,,,10/09/01,,,90%,2060.5,N/A,N/A,N/A,N/A,N/A,"$  3,427.6","$  2,669.9",N/A,Q4 2018,Pfizer Inc.
2380,72,21839,70,Spiriva,tiotropium bromide,Boehringer Ingelheim GmbH,,,Germany,Europe,,Respiratory,Asthma,Asthma,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,09/16/15,09/08/14,,,,,,,,,11/12/08,08/01/06,,90%,2735.1,N/A,N/A,N/A,N/A,N/A,"$  3,427.6","$  2,669.9",N/A,Q4 2018,Pfizer Inc.
20638,167,27566,223,Spravato,esketamine,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,NMDA Glutamate Receptor,Non-NME,No,"Intranasal, Intravenous (IV)",Y,N,N,Y,N,N,,09/01/2019 - 03/31/2020,,03/05/19,,,,,09/04/18,08/21/15,,,,08/21/15,03/21/13,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
26548,3009,37026,5428,Spritam,levetiracetam,Aprecia Pharmaceuticals Company,,Pennsylvania,United States,North America,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,SV2A synaptic vesicle protein,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/31/15,,,,,10/01/14,,,,,06/04/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
17759,3127,23160,3445,Sprix,ketorolac tromethamine,Zyla Life Sciences,ZCOR,Pennsylvania,United States,North America,,Neurology,Pain,Acute Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Intranasal,N,N,N,,N,N,,,,05/14/10,,,,,12/05/08,,,,,,,,N/A,,N/A,$    20.0,$    23.4,$     5.2,N/A,$    20.0,$    23.4,$     5.2,Q1 2019,"Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd."
2179,198,3624,73,Sprycel,dasatinib,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Hematologic,Chronic Myelogenous Leukemia (CML),N,Approved,Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ Src Kinase Family^ Tyrosine Kinases,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,06/28/06,11/20/06,01/21/09,,,12/28/05,,,,,,07/28/05,12/05/04,N/A,,$   969.0,"$  1,105.0","$  1,091.0",$   547.0,"$  1,824.0","$  2,287.6","$  2,136.5","$  1,073.8",Q2 2019,"Otsuka Holdings Co., Ltd."
2179,199,4640,73,Sprycel,dasatinib,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ Src Kinase Family^ Tyrosine Kinases,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,06/28/06,11/20/06,01/21/09,,,12/28/05,,,,,,11/18/05,,N/A,,$   969.0,"$  1,105.0","$  1,091.0",$   547.0,"$  1,824.0","$  2,287.6","$  2,136.5","$  1,073.8",Q2 2019,"Otsuka Holdings Co., Ltd."
1791,194,2855,289,Stalevo,"carbidopa, entacapone, levodopa",Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Aromatic L-amino acid decarboxylase (AADC)^ Catechol-O-methyltransferase (COMT)^ Dopamine Receptor - Unspecified,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/13/03,10/17/03,07/17/14,,,08/26/02,,,,,,,,60%,17.5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2015,"Eisai Co., Ltd., Orion Corporation"
1693,137,2718,289,Starlix,nateglinide,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,ATP-sensitive potassium channel - pancreatic beta-cells,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,12/22/00,04/05/01,12/22/08,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Ajinomoto Bio-Pharma Services, Astellas Pharma, Inc."
8365,168,10371,2672,Stavzor,valproic acid,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Psychiatry,Bipolar,Bipolar Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA Receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/29/08,,,,,12/22/06,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Thermo Fisher Scientific
8365,288,10372,2672,Stavzor,valproic acid,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA Receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/29/08,,,,,12/22/06,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Thermo Fisher Scientific
8365,3009,10373,2672,Stavzor,valproic acid,"Hisamitsu Pharmaceutical Co., Inc.",4530:JP,,Japan,Asia,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA Receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/29/08,,,,,12/22/06,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Thermo Fisher Scientific
17231,137,22363,254,Steglatro,ertugliflozin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/19/17,03/21/18,,,,12/19/16,10/07/13,03/09/10,,,10/07/13,03/09/10,01/27/10,60%,403.9,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Pfizer Inc.
24323,137,33696,254,Steglujan,ertugliflozin/sitagliptin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl peptidase IV (DPP-IV)^ SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/19/17,03/23/18,,,,12/19/16,05/22/14,,,,04/09/14,04/29/13,,N/A,367,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Pfizer Inc.
464,155,821,223,Stelara,ustekinumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-12 (Interleukin-12) and IL-12 receptor^ IL-23 (Interleukin-23),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,09/25/09,01/16/09,01/25/11,,,12/04/07,12/01/05,,,,12/20/05,11/11/04,,N/A,,"$  2,263.0","$  2,767.0","$  3,469.0",$   882.0,"$  3,232.0","$  4,011.0","$  5,252.3","$  1,449.5",Q1 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Mitsubishi Tanabe Pharma Corporation"
464,156,3729,223,Stelara,ustekinumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-12 (Interleukin-12) and IL-12 receptor^ IL-23 (Interleukin-23),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,09/26/16,11/11/16,03/30/17,,,11/30/15,08/04/11,05/31/05,,,08/04/11,05/31/05,,N/A,,"$  2,263.0","$  2,767.0","$  3,469.0",$   882.0,"$  3,232.0","$  4,011.0","$  5,252.3","$  1,449.5",Q1 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Mitsubishi Tanabe Pharma Corporation"
464,336,4421,223,Stelara,ustekinumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-12 (Interleukin-12) and IL-12 receptor^ IL-23 (Interleukin-23),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,09/23/13,09/23/13,,,,12/06/12,12/17/09,,,,12/17/09,12/20/05,,N/A,,"$  2,263.0","$  2,767.0","$  3,469.0",$   882.0,"$  3,232.0","$  4,011.0","$  5,252.3","$  1,449.5",Q1 2019,"Bristol-Myers Squibb Company, DRI Capital Inc., Mitsubishi Tanabe Pharma Corporation"
969,160,2278,6571,Stendra,avanafil,Metuchen Pharmaceuticals LLC,,New Jersey,United States,North America,,Urology,Male Sexual Dysfunction,Erectile Dysfunction (ED),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphodiesterase 5 (PDE5),New Molecular Entity (NME),No,Oral (PO),N,Y,N,N,N,N,,,,04/27/12,06/21/13,,,,06/30/11,12/12/08,04/22/04,,,05/08/08,04/22/04,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q3 2014,"Acerus Pharmaceuticals Corporation, Mitsubishi Tanabe Pharma Corporation, The Menarini Group, Vivus, Inc."
18856,73,24790,70,Stiolto Respimat,tiotropium and olodaterol,Boehringer Ingelheim GmbH,,,Germany,Europe,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,05/21/15,05/20/15,09/28/15,,,,09/21/11,,,,09/21/11,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
15117,213,19372,59,Stivarga,regorafenib,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Solid,Colorectal Cancer (CRC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Raf kinase^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,09/27/12,08/26/13,03/25/13,,,04/30/12,05/07/10,,,,05/07/10,,05/17/09,80%,567,$   157.3,$   148.3,$   174.7,N/A,$   304.7,$   360.7,$   369.6,$   225.8,Q2 2019,"Amgen, Inc."
15117,626,23280,59,Stivarga,regorafenib,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Solid,Gastrointestinal Stromal Tumor (GIST),N,Approved,Approved,100% (Same As Avg.),Small Molecule,KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Raf kinase^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,06/26/2014 - 09/01/2014,09/01/2013 - 09/01/2013,02/25/13,,08/20/13,,,08/30/12,01/10/11,,,,01/10/11,,05/19/09,80%,,$   157.3,$   148.3,$   174.7,N/A,$   304.7,$   360.7,$   369.6,$   225.8,Q2 2019,"Amgen, Inc."
15117,297,24812,59,Stivarga,regorafenib,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),N,Approved,Approved,100% (Same As Avg.),Small Molecule,KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ Raf kinase^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,04/27/17,08/02/17,06/26/17,,,10/30/16,05/15/13,09/01/09,,,05/15/13,10/27/09,02/28/07,80%,,$   157.3,$   148.3,$   174.7,N/A,$   304.7,$   360.7,$   369.6,$   225.8,Q2 2019,"Amgen, Inc."
2145,246,3553,136,Strattera,atomoxetine hydrochloride,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/26/02,,04/22/09,,,,,,,,,,,N/A,,$   534.9,$   284.8,$    89.6,$    22.7,$   854.7,$   618.0,$   450.7,$   148.8,Q2 2019,N/A
17360,2997,22575,21,Strensiq,asfotase alfa,"Alexion Pharmaceuticals, Inc.",ALXN,Connecticut,United States,North America,24868581569,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Hypophosphatasia,Y,Approved,Approved,100% (Same As Avg.),Protein,Tissue-nonspecific alkaline phosphatase (TNSALP),Biologic,No,Subcutaneous (SQ),Y,N,Y,Y,N,N,,,,10/23/15,08/28/15,07/06/15,,,12/23/14,08/04/10,12/01/08,08/20/08,,08/04/10,12/01/08,08/20/08,N/A,,$   177.5,$   280.1,$   374.3,$   205.7,$   209.4,$   339.8,$   475.1,$   271.4,Q2 2019,N/A
14843,549,18822,142,Striant,testosterone buccal system,Endo International plc,ENDP,,Ireland,Europe,554131557,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,06/19/03,02/29/04,,,,08/09/02,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2012,"Catalent, Inc, Plethora Solutions Holdings plc"
13579,78,17148,179,Stribild,,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV Integrase^ Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/27/12,05/24/13,03/25/13,,,10/27/11,03/26/10,04/06/09,,,03/26/10,04/17/09,10/16/08,95%,2192.8,"$  1,523.0",$   811.0,$   505.0,$   145.0,"$  1,914.0","$  1,053.0",$   644.0,$   204.0,Q2 2019,Mylan N.V.
12092,73,15252,70,Striverdi Respimat,Olodaterol,Boehringer Ingelheim GmbH,,,Germany,Europe,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,07/31/14,,,,,05/14/12,07/01/09,,,,05/20/09,02/13/08,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
23746,560,32705,2679,Sublocade,buprenorphine hydrochloride,Indivior plc,INDV:LN,,United Kingdom,Europe,541889368,Psychiatry,Other,Substance Use Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Subcutaneous (SQ),Y,N,N,N,N,N,,,,11/30/17,,,,,05/30/17,02/05/15,11/29/12,,,07/28/14,11/29/12,,N/A,,N/A,N/A,$    12.0,$    28.0,N/A,N/A,$    12.0,$    28.0,Q2 2019,Novelion Therapeutics Inc.
21052,560,28289,2679,Suboxone Film,buprenorphine hydrochloride/naloxone hydrochloride,Indivior plc,INDV:LN,,United Kingdom,Europe,541889368,Psychiatry,Other,Substance Use Disorder,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,02/01/2020 - 08/31/2020,,08/30/10,,,,,10/20/08,,,,,10/08/02,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Aquestive Therapeutics, Inc."
17556,3125,22869,492,Subsys,,"INSYS Therapeutics, Inc.",INSY,Arizona,United States,North America,,Neurology,Pain,Cancer Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,01/04/12,,,,,03/07/11,10/04/07,,,,11/14/07,,,N/A,,$   242.3,$   139.9,$    78.9,$     7.2,$   242.3,$   139.9,$    78.9,$     7.2,Q1 2019,Lunatus
18389,560,24088,2679,Subutex,buprenorphine hydrochloride,Indivior plc,INDV:LN,,United Kingdom,Europe,541889368,Psychiatry,Other,Substance Use Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,09/10/02,01/02/96,,,,03/28/97,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
21426,603,28873,4008,Sulfacetamide Sodium Ointment (generic),sulfacetamide sodium,Fera Pharmaceuticals,,New York,United States,North America,,Dermatology,General,Acne,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Not Specified,Dihydropteroate Synthetase (DHPS),Non-NME,No,N/A,N,N,N,,N,N,,,,11/17/06,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
11015,288,13835,142,Sumavel DosePro,sumatriptan,Endo International plc,ENDP,,Ireland,Europe,554131557,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT1 receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,,N,N,,,,07/16/09,12/02/10,,,,01/15/08,,,,,,09/13/07,,N/A,67.1,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,Q4 2014,"Aradigm Corporation, Desitin Pharmaceuticals GmbH, Zogenix, Inc."
15114,433,19200,508,Sunosi,solriamfetol,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Neurology,Other,Narcolepsy,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,10/01/2019 - 04/30/2020,,03/20/19,,,,,12/20/17,01/13/14,12/16/11,,,01/13/14,12/16/11,05/13/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Aerial BioPharma, LLC, Shionogi &amp; Co. Ltd., SK Biopharmaceuticals Co., Ltd."
15114,578,32416,508,Sunosi,solriamfetol,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Neurology,Other,Sleep Apnea,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,10/01/2019 - 04/30/2020,,03/20/19,,,,,12/20/17,01/13/14,,,,01/13/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Aerial BioPharma, LLC, Shionogi &amp; Co. Ltd., SK Biopharmaceuticals Co., Ltd."
40532,3359,56785,220,SuPrep,"sodium sulfate, potassium sulfate, magnesium sulfate",Ipsen SA,IPSEY,,France,Europe,,Gastroenterology (non inflammatory bowel disease),General,Colon Cleansing/Laxatives,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Osmosis/Osmotic Pressure,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,08/05/10,,,,,07/01/08,,,,,07/18/07,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Sebela Pharmaceuticals, Inc."
1790,616,2854,685,Surfaxin,lucinactant,"Windtree Therapeutics, Inc.",WINT,Pennsylvania,United States,North America,14699443,Respiratory,Other,Respiratory Distress Syndrome (RDS),Y,Approved,Approved,100% (Same As Avg.),Peptide,Alveolar Surface,New Molecular Entity (NME),No,Intratracheal,N,N,N,,N,N,,,,03/06/12,,,,,04/13/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2015,"Dompé Farmaceutici S.p.A., Esteve, S.A., Lee's Pharmaceutical Holdings Limited"
8118,767,10021,1330,Sustol,granisetron,"Heron Therapeutics, Inc.",HRTX,California,United States,North America,1417605793,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT3 receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/09/16,,,,,05/18/09,01/24/06,,,,01/24/06,04/28/05,04/12/04,N/A,,N/A,$    30.8,$    21.3,$     3.6,N/A,$    30.8,$    21.3,$     3.6,Q1 2019,N/A
1788,216,2852,312,Sutent,sunitinib malate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Renal Cell Cancer (RCC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,01/26/06,07/19/06,04/16/08,,,08/10/05,08/01/04,,,,08/01/04,,,100%,179.4,$   390.0,$   374.0,$   358.0,$   153.0,"$  1,095.0","$  1,081.0","$  1,049.0",$   480.0,Q2 2019,N/A
1788,626,3217,312,Sutent,sunitinib malate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Gastrointestinal Stromal Tumor (GIST),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,01/26/06,07/19/06,04/16/08,,,08/10/05,10/01/04,,,,10/01/04,,,100%,23.8,$   390.0,$   374.0,$   358.0,$   153.0,"$  1,095.0","$  1,081.0","$  1,049.0",$   480.0,Q2 2019,N/A
1788,347,18641,312,Sutent,sunitinib malate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Neuroendocrine Tumors (NET),N,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/20/11,12/02/10,08/10/12,,,12/31/09,06/25/07,,,,06/25/07,,,100%,,$   390.0,$   374.0,$   358.0,$   153.0,"$  1,095.0","$  1,081.0","$  1,049.0",$   480.0,Q2 2019,N/A
7938,3366,31244,5632,Sylvant,siltuximab,EUSA Pharma Ltd.,,,United Kingdom,Europe,,Autoimmune/immunology,Other,Castleman's Disease,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-6 (Interleukin-6),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,04/23/14,06/05/14,,,,09/03/13,,02/26/10,,,,02/26/10,05/26/06,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1944,72,3138,45,Symbicort,"budesonide, formoterol fumarate dihydrate",AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,N,N,N,,,,07/21/06,01/04/01,10/16/09,,,09/23/05,,,,,01/04/01,,,100%,622.8,"$  1,242.0","$  1,099.0",$   862.0,$   176.0,"$  2,989.0","$  2,803.0","$  2,933.8",$   667.6,Q1 2019,"Astellas Pharma, Inc."
1944,73,3139,45,Symbicort,"budesonide, formoterol fumarate dihydrate",AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,N,N,N,,,,02/27/09,02/01/03,08/10/12,,,04/30/08,,,,,01/30/03,,,100%,568,"$  1,242.0","$  1,099.0",$   862.0,$   176.0,"$  2,989.0","$  2,803.0","$  2,933.8",$   667.6,Q1 2019,"Astellas Pharma, Inc."
2143,168,3550,136,Symbyax,"fluoxetine hydrochloride, olanzapine",Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Bipolar,Bipolar Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,12/29/03,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2012,N/A
2143,167,3568,136,Symbyax,"fluoxetine hydrochloride, olanzapine",Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,03/23/09,,,,,10/19/06,,,,,05/23/02,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2012,N/A
18177,74,23779,389,Symdeko,tezacaftor,Vertex Pharmaceuticals Incorporated,VRTX,Massachusetts,United States,North America,46999678216,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,CF transmembrane conductance regulator (CFTR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,02/12/18,10/31/18,,,,07/26/17,02/02/15,02/02/12,,,02/02/15,02/02/12,,95%,,N/A,N/A,$   769.0,$   682.0,N/A,N/A,$   769.0,$   682.0,Q2 2019,Royalty Pharma AG
37748,78,52642,266,Symfi,"efavirenz, lamivudine tenofovir disoproxil fumarate",Mylan N.V.,MYL,Pennsylvania,United States,North America,,Infectious disease,Antiviral,HIV / AIDS,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/22/18,,,,,03/02/09,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
24167,3076,33429,289,Symjepi,epinephrine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Allergy,General,Anaphylaxis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,06/15/17,,,,,05/28/14,,,,,06/03/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Adamis Pharmaceuticals Corporation
204,157,236,45,Symlin (Pramlintide),pramlintide acetate,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Y,Approved,Approved,100% (Same As Avg.),Protein,Amylin Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,03/16/05,,,,,12/07/00,01/01/96,,,,06/12/96,08/15/95,,50%,15.7,N/A,$    34.0,$    34.0,$    15.0,N/A,$    34.0,$    34.0,$    15.0,Q2 2019,Bristol-Myers Squibb Company
204,137,237,45,Symlin (Pramlintide),pramlintide acetate,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Protein,Amylin Receptor,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,03/16/05,,,,,12/07/00,07/31/95,,,,07/31/95,01/10/95,,50%,88.5,N/A,$    34.0,$    34.0,$    15.0,N/A,$    34.0,$    34.0,$    15.0,Q2 2019,Bristol-Myers Squibb Company
37135,3008,51784,3465,Sympazan,clobazam,"Aquestive Therapeutics, Inc.",AQST,New Jersey,United States,North America,97523943,Neurology,Seizure Disorders (Epilepsy),Lennox-Gastaut Syndrome (LGS; Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,08/31/18,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.6,N/A,N/A,N/A,$     0.6,Q1 2019,N/A
17646,551,22988,1020,Symproic,naldemedine tosilate,"BioDelivery Sciences International, Inc.",BDSI,North Carolina,United States,North America,311043119,Gastroenterology (non inflammatory bowel disease),Other,Opioid Induced Constipation (OIC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/23/17,02/18/19,03/30/17,,,03/23/16,10/17/13,,,,10/15/13,11/02/10,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    14.4,N/A,Q4 2018,"Grupo Ferrer Internacional, S.A., Molteni Farmaceutici S.p.A., Novartis AG, Shionogi &amp; Co. Ltd."
19495,78,25712,223,Symtuza,,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ HIV-1 protease (HIV PR)^ Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,11/01/2019 - 05/31/2020,07/17/18,09/21/17,,,,09/22/17,05/12/15,04/25/12,,,05/12/15,04/25/12,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Gilead Sciences, Inc."
23581,767,32414,492,Syndros,dronabinol,"INSYS Therapeutics, Inc.",INSY,Arizona,United States,North America,,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cannabinoid-1 (CB1) receptor,Non-NME,No,"Inhaled, Oral (PO)",N,N,N,N,N,N,,,,07/01/16,,,,,06/02/15,,,,,08/11/14,,10/06/11,N/A,,N/A,$     1.5,$     3.3,$     0.4,N/A,$     1.5,$     3.3,$     0.4,Q1 2019,N/A
23581,638,34042,492,Syndros,dronabinol,"INSYS Therapeutics, Inc.",INSY,Arizona,United States,North America,,Metabolic,Other,HIV / AIDS Cachexia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cannabinoid-1 (CB1) receptor,Non-NME,No,"Inhaled, Oral (PO)",N,N,N,N,N,N,,,,07/01/16,,,,,06/02/15,,,,,08/11/14,,10/06/11,N/A,,N/A,$     1.5,$     3.3,$     0.4,N/A,$     1.5,$     3.3,$     0.4,Q1 2019,N/A
18336,531,24005,5754,Synera,lidocaine/tetracaine,"Crescita Therapeutics, Inc.",TSX:CTX,Ontario,Canada,North America,,Neurology,Pain,Anesthesia,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,Non-NME,No,Topical,N,N,N,,N,N,,,,06/23/05,01/01/07,,,,03/31/03,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"Almac Group, Endo International plc, Eurocept BV"
23643,137,32534,70,Synjardy,empagliflozin/metformin hydrochloride,Boehringer Ingelheim GmbH,,,Germany,Europe,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ SGLT,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/26/15,05/27/15,,,,08/04/14,,,,,01/11/11,,,N/A,,N/A,$   114.5,N/A,$     0.0,N/A,$   177.2,N/A,$     0.0,Q2 2017,Eli Lilly &amp; Company
32626,137,45080,70,Synjardy XR,empagliflozin/metformin hydrochloride,Boehringer Ingelheim GmbH,,,Germany,Europe,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ SGLT,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/09/16,,,,,02/10/16,,,,,01/11/11,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Eli Lilly &amp; Company, PDL BioPharma, Inc."
2356,198,3967,375,Synribo,omacetaxine mepesuccinate,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Hematologic,Chronic Myelogenous Leukemia (CML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Mitochondria^ Protein synthesis,New Molecular Entity (NME),No,Subcutaneous (SQ),Y,N,Y,,N,N,,,,10/26/12,,,,,09/09/09,,10/05/05,,,06/13/06,10/05/05,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Pfizer Inc.
3057,139,5225,5,Synthroid,levothyroxine sodium,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Endocrine,Thyroid,Hypothyroidism,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Thyroid hormone receptors (TRs),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/24/02,,,,,,,,,,,,,N/A,,$   763.0,$   781.0,$   776.0,$   385.0,N/A,$   781.0,$   776.0,$   385.0,Q2 2019,Abbott Laboratories
27589,1578,38709,826,TachoSil,,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,General,Wound Healing,N,Approved,Approved,100% (Same As Avg.),Protein,Fibrinogen (Coagulation Factor I)^ Thrombin (Coagulation Factor IIa),Biologic,No,Topical,N,N,N,N,N,N,,,,04/06/10,06/08/04,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Baxter International Inc., Johnson &amp; Johnson"
17225,155,22354,589,Taclonex Ointment,calcipotriene hydrate; betamethasone dipropionate,LEO Pharma A/S,,,Denmark,Europe,,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Vitamin D receptor,Non-NME,No,Topical,N,N,N,N,N,N,,,,01/09/06,,07/04/14,,,03/09/05,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    53.5,$    30.9,Q2 2019,"Kyowa Hakko Kirin Co., Ltd."
17229,155,22361,589,Taclonex Scalp,calcipotriene hydrate; betamethasone dipropionate,LEO Pharma A/S,,,Denmark,Europe,,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Vitamin D receptor,Non-NME,No,Topical,N,N,N,,N,N,,,,05/09/08,08/18/08,,,,06/29/07,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16782,221,21730,289,Tafinlar,dabrafenib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Raf kinase,New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,05/29/13,08/26/13,03/31/16,,,08/03/12,01/24/11,07/02/09,,,01/24/11,07/02/09,,100%,279.2,$   298.0,$   339.0,$   457.0,$   230.0,$   672.0,$   873.0,"$  1,155.0",$   637.0,Q2 2019,N/A
16782,211,29820,289,Tafinlar,dabrafenib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Raf kinase,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,09/01/2017 - 03/31/2018,06/22/17,03/29/17,,,,09/22/16,,07/15/11,,,,02/15/13,,100%,,$   298.0,$   339.0,$   457.0,$   230.0,$   672.0,$   873.0,"$  1,155.0",$   637.0,Q2 2019,N/A
16782,532,48512,289,Tafinlar,dabrafenib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Thyroid Cancer,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Raf kinase,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,05/04/18,,,,,11/07/17,,,,,,03/28/14,,100%,,$   298.0,$   339.0,$   457.0,$   230.0,$   672.0,$   873.0,"$  1,155.0",$   637.0,Q2 2019,N/A
22361,211,30305,45,Tagrisso,osimertinib,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,,,11/13/15,02/02/16,03/29/16,,,06/05/15,08/20/14,11/29/13,03/15/13,,08/20/14,11/29/13,03/15/13,N/A,,$   254.0,$   405.0,$   869.0,$   559.0,$   423.0,$   955.0,"$  1,860.0","$  1,414.0",Q2 2019,N/A
20691,556,27659,826,Takhzyro,lanadelumab-flyo,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Kinin-Kallikrein System,Biologic,No,Subcutaneous (SQ),Y,N,Y,Y,N,N,,,,08/23/18,11/22/18,,,,12/26/17,11/17/15,,08/15/13,06/25/13,11/17/15,,08/15/13,N/A,,N/A,N/A,$   139.1,N/A,N/A,N/A,$   139.1,N/A,Q4 2018,N/A
14735,155,22111,136,Taltz,ixekizumab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-17 (Interleukin 17),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,03/22/16,04/25/16,07/04/16,,,03/23/15,11/17/11,04/23/10,,,11/17/11,04/23/10,,N/A,,$   110.8,$   486.0,$   738.8,$   448.9,$   113.1,$   559.1,$   937.5,$   606.3,Q2 2019,"Torii Pharmaceutical Co., Ltd."
14735,336,24272,136,Taltz,ixekizumab,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-17 (Interleukin 17),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/01/17,01/25/18,07/26/16,,,01/31/17,09/25/12,,,,09/26/12,,,N/A,,$   110.8,$   486.0,$   738.8,$   448.9,$   113.1,$   559.1,$   937.5,$   606.3,Q2 2019,"Torii Pharmaceutical Co., Ltd."
17726,214,30496,312,Talzenna,talazoparib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Poly ADP-Ribose Polymerase (PARP),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/16/18,06/21/19,,,,04/06/18,09/18/13,,01/11/11,,06/03/13,01/11/11,10/12/11,100%,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,BioMarin Pharmaceutical Inc.
77,211,182,149,Tarceva,erlotinib,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor),New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,N,N,N,N,,,,11/18/04,09/19/05,10/22/07,,,08/02/04,09/10/04,,,,07/25/01,09/13/00,,60%,534.5,$   571.8,$   660.2,$   236.6,$    13.0,"$  1,045.6","$  1,127.7",$   546.3,$   117.2,Q1 2019,"Astellas Pharma, Inc., Chugai Pharmaceutical Co., Ltd."
77,220,247,149,Tarceva,erlotinib,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Pancreatic Cancer,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor),New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,11/02/05,01/29/07,07/01/11,,,05/02/05,10/24/01,,,,10/24/01,09/27/00,,60%,96,$   571.8,$   660.2,$   236.6,$    13.0,"$  1,045.6","$  1,127.7",$   546.3,$   117.2,Q1 2019,"Astellas Pharma, Inc., Chugai Pharmaceutical Co., Ltd."
714,417,1824,470,Targretin gel,bexarotene,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Oncology,Hematologic,Cutaneous T-Cell Lymphoma (CTCL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Retinoid Receptors (RAR and RXR),Non-NME,No,Topical,N,N,N,,N,N,,,,06/28/00,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Alfasigma S.p.A., Eisai Co., Ltd., Ewopharma AG, Grupo Ferrer Internacional, S.A., Minophagen Pharmaceutical Co., Ltd., Perrigo Company PLC, Teva Pharmaceutical Industries Ltd."
1875,198,3027,289,Tasigna,nilotinib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Chronic Myelogenous Leukemia (CML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,BCR-ABL Fusion Protein^ KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,10/29/07,11/19/07,01/21/09,,,09/29/06,03/09/06,07/14/05,,,03/09/06,07/14/05,01/20/05,N/A,,$   722.0,$   810.0,$   806.0,$   384.0,"$  1,739.0","$  1,841.0","$  1,874.0",$   902.0,Q2 2019,N/A
1452,649,4379,335,Tavalisse,fostamatinib disodium hexahydrate,"Rigel Pharmaceuticals, Inc.",RIGL,California,United States,North America,334947348,Autoimmune/immunology,Idiopathic Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura (ITP),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Spleen Tyrosine Kinase (syk),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,09/01/2019 - 03/31/2020,,04/17/18,,,,,04/17/17,05/23/14,,,,05/23/14,01/08/07,,100%,,N/A,N/A,$    14.0,$     8.1,N/A,N/A,$    14.0,$     8.1,Q1 2019,"Grifols, S.A., Kissei Pharmaceutical Co., Ltd"
1515,215,2886,51,Taxotere,docetaxel,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Solid,Prostate Cancer,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,05/19/04,11/04/04,09/01/08,,,01/27/04,,,,,,,,N/A,,$     4.4,$     -0.1,$     2.3,N/A,$    54.6,$   197.8,$   193.0,$   100.6,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
1515,223,3099,51,Taxotere,docetaxel,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Solid,Gastric Cancer,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,03/23/06,02/13/07,,,,12/02/05,,,,,05/21/02,,,N/A,,$     4.4,$     -0.1,$     2.3,N/A,$    54.6,$   197.8,$   193.0,$   100.6,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
1515,230,3100,51,Taxotere,docetaxel,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Solid,Head and Neck Cancer,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Microtubules (Tubulin),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,10/17/06,11/07/06,,,,08/02/06,04/01/99,,,,06/08/04,,,N/A,,$     4.4,$     -0.1,$     2.3,N/A,$    54.6,$   197.8,$   193.0,$   100.6,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
22325,239,30258,395,Taytulla,Norethindrone Acetate; Ethinyl Estradiol; Ferrous Fumarate,Allergan plc,AGN,,Ireland,Europe,53945515162,Endocrine,Contraception,Contraception,Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/19/13,,,,,07/21/12,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1841,603,2946,774,Tazorac,tazarotene,"Almirall Prodesfarma, S.A.",ALM:SM,,Spain,Europe,,Dermatology,General,Acne,N,Approved,Approved,100% (Same As Avg.),Steroid,Retinoic acid receptor (RARs),New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,10/16/01,,,,,,,,,,,,,N/A,,$    95.5,$    65.4,$    33.4,N/A,$    96.3,$    66.1,$    34.4,N/A,Q4 2018,Pfizer Inc.
20599,211,30207,149,Tecentriq,atezolizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,10/18/16,09/21/17,01/19/18,,,02/19/16,02/27/14,,,,02/27/14,06/04/13,07/21/11,N/A,,$   155.4,$   575.7,$   476.2,$   507.9,$   157.4,$   611.6,$   783.8,$   781.9,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
20599,217,33048,149,Tecentriq,atezolizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Bladder Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,Y,N,N,,,,05/18/16,09/21/17,,,,01/12/16,12/08/14,04/07/14,,,12/08/14,04/07/14,,N/A,,$   155.4,$   575.7,$   476.2,$   507.9,$   157.4,$   611.6,$   783.8,$   781.9,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
20599,214,35239,149,Tecentriq,atezolizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Breast Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,06/27/2019 - 09/02/2019,09/01/2019 - 03/31/2020,03/08/19,,,,,09/12/18,05/29/15,,,,05/29/15,,06/22/12,N/A,,$   155.4,$   575.7,$   476.2,$   507.9,$   157.4,$   611.6,$   783.8,$   781.9,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
20599,111,41005,149,Tecentriq,atezolizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Small Cell Lung Cancer (SCLC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immune system^ Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,07/25/2019 - 09/30/2019,,03/18/19,,,,,09/18/18,05/16/16,,,,05/16/16,,08/22/11,N/A,,$   155.4,$   575.7,$   476.2,$   507.9,$   157.4,$   611.6,$   783.8,$   781.9,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
320,153,2676,64,Tecfidera,dimethyl fumarate,"Biogen, Inc.",BIIB,Massachusetts,United States,North America,46991785631,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,NF-Kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells)^ NRF2,New Molecular Entity (NME),No,Oral (PO),Y,Y,N,N,N,N,,,,03/27/13,01/30/14,12/31/16,,,02/28/12,01/09/07,,,,01/09/07,07/28/04,,90%,3459.3,"$  3,169.4","$  3,293.9","$  3,253.1","$  1,587.5","$  3,969.0","$  4,214.2","$  4,274.1","$  2,149.0",Q2 2019,"Eisai Co., Ltd., Forward Pharma A/S, Royalty Pharma AG, UCB SA"
2170,440,3607,395,Teflaro,ceftaroline fosamil,Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,N,,,,10/29/10,08/22/12,,,,12/29/09,03/23/07,10/19/05,05/20/04,,03/23/07,10/19/05,05/20/04,N/A,,$   103.2,$   121.9,$   128.0,$    70.5,$   103.2,$   121.9,$   128.6,$    70.7,Q2 2019,"AstraZeneca PLC, Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Ltd"
2170,488,5217,395,Teflaro,ceftaroline fosamil,Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,10/29/10,08/22/12,,,,12/29/09,,,,,07/27/07,01/11/07,,N/A,,$   103.2,$   121.9,$   128.0,$    70.5,$   103.2,$   121.9,$   128.6,$    70.7,Q2 2019,"AstraZeneca PLC, Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Ltd"
18210,3092,23822,7298,Tegsedi,inotersen,"Akcea Therapeutics, Inc.",AKCA,Massachusetts,United States,North America,1913574384,Metabolic,Other,Hereditary Transthyretin (hATTR) Amyloidosis With Polyneuropathy (Familial Amyloid Polyneuropathy),Y,Approved,Approved,100% (Same As Avg.),Antisense,Transthyretin (TTR),New Molecular Entity (NME),No,Subcutaneous (SQ),Y,N,Y,N,N,N,,,,10/05/18,07/06/18,,,,11/06/17,02/19/13,,05/19/11,,02/19/13,,04/13/11,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$     2.2,$     6.8,Q1 2019,"Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc."
15148,244,19263,289,Tekamlo,aliskiren and amlodipine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel^ Renin,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/26/10,04/14/11,,,,10/31/09,,,,,09/28/08,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Noden Pharma DAC
1813,244,2891,6221,Tekturna,aliskiren,Noden Pharma DAC,,,Ireland,Europe,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Renin,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/05/07,08/22/07,07/08/09,,,02/13/06,03/31/04,,,,03/31/04,11/19/03,,100%,79.2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2014,Lee's Pharmaceutical Holdings Limited
2964,244,5042,6221,Tekturna HCT,aliskiren and hydrochlorothiazide,Noden Pharma DAC,,,Ireland,Europe,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Na/Cl transporter - Thiazide-sensitive^ Renin,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/18/08,01/16/09,,,,03/19/07,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
39686,78,55492,3597,Temixys,lamivudine and tenofovir disoproxil fumarate,"Celltrion, Inc.",,,Korea (South),Asia,,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/16/18,,,,,01/15/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
20947,3197,28093,51,TENIVAC,,Sanofi,SNY,,France,Europe,1.05588E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Diphtheria, pertussis, and tetanus (DT, Td, DTaP and Tdap) Vaccines",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Clostridium tetani^ Corynebacterium diptheriae^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,11/03/03,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
8178,549,10108,142,Testim,transdermal testosterone,Endo International plc,ENDP,,Ireland,Europe,554131557,Endocrine,Other,Hypogonadism,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Transdermal,N,N,N,N,N,N,,,,10/31/02,06/30/03,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q3 2014,"CPEX Pharmaceuticals, Inc., Ferring Pharmaceuticals"
21833,549,29492,3822,Testosterone Gel 1%,,Perrigo Company PLC,PRGO,Michigan,United States,North America,,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Topical,N,N,N,,N,N,,,,01/31/13,,,,,07/05/11,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
27627,531,38758,289,Tetracaine Hydrochloride Ophthalmic Solution 0.5%,tetracaine hydrochloride,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Pain,Anesthesia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,Non-NME,No,Topical,N,N,N,N,N,N,,,,02/29/16,,,,,04/30/15,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
22004,244,29767,5,Teveten HCT,eprosartan mesylate/hydrochlorothiazide,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/01/01,,,,,08/30/00,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Abbott Laboratories, Mylan N.V."
139,207,191,82,Thalomid,thalidomide,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Multiple Myeloma (MM),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiogenesis^ E3 ubiquitin ligase^ Immune system,New Molecular Entity (NME),No,Oral (PO),N,Y,Y,N,N,N,,,,05/25/06,04/16/08,,,,12/23/03,02/15/03,09/15/01,,,,,,98.5%,154.4,$    97.1,$    80.0,$    72.0,$    31.0,$   152.1,$   132.0,$   114.0,$    48.0,Q2 2019,"CASI Pharmaceuticals, Inc., DRI Capital Inc."
39546,735,55301,3579,Thiola EC,tiopronin,"Retrophin, Inc.",RTRX,New York,United States,North America,736682296,Metabolic,Inborn Errors Of Metabolism,Cystinuria,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,06/28/19,,,,,08/31/18,,,,,,,07/26/18,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Mission Pharmacal Company
21887,97,29578,4112,Tibsovo,ivosidenib,"Agios Pharmaceuticals, Inc.",AGIO,Massachusetts,United States,North America,2494701626,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Isocitrate Dehydrogenase (IDH),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,11/01/2019 - 05/31/2020,,07/20/18,,,,,12/21/17,06/20/17,03/30/16,03/19/14,01/13/14,06/20/17,03/30/16,03/19/14,N/A,,N/A,N/A,$    13.9,$    22.8,N/A,N/A,$    13.9,$    22.8,Q2 2019,"CStone Pharmaceuticals (Suzhou) Co., Ltd"
39008,193,54541,2603,Tiglutik,riluzole,Italfarmaco S.p.A.,,,Italy,Europe,,Neurology,Neurodegenerative,Amyotrophic Lateral Sclerosis (ALS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glutamine,Non-NME,No,Oral (PO),Y,N,Y,N,N,N,,,,09/05/18,,,,,,,,,,09/15/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Ethypharm
18022,81,23537,3203,Tindamax,tinidazole,Mission Pharmacal Company,,Texas,United States,North America,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Microbial DNA^ Reactive Oxygen Species/Free Radicals,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/17/04,,,,,07/17/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
18022,534,23538,3203,Tindamax,tinidazole,Mission Pharmacal Company,,Texas,United States,North America,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Microbial DNA^ Reactive Oxygen Species/Free Radicals,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/21/07,,,,,07/21/06,,,,,04/20/06,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
22735,139,30959,312,Tirosint,levothyroxine sodium,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Thyroid,Hypothyroidism,N,Approved,Approved,100% (Same As Avg.),Steroid,Thyroid hormone receptors (TRs),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/13/06,03/20/11,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Institut Biochimique SA
15003,78,19040,180,Tivicay,dolutegravir,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV Integrase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,11/21/2013 - 01/27/2014,,08/12/13,01/16/14,03/24/14,,,12/17/12,10/21/10,06/01/08,,,10/21/10,10/27/08,,70%,1879.4,$   864.0,"$  1,200.0","$  1,378.0",$   600.0,"$  1,296.0","$  1,825.0","$  2,180.0","$  1,026.0",Q2 2019,"Pfizer Inc., Shionogi &amp; Co. Ltd."
21748,3130,29365,3445,Tivorbex,,Zyla Life Sciences,ZCOR,Pennsylvania,United States,North America,,Neurology,Pain,Postsurgical Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)^ Glucocorticoid Receptor (GR)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/24/14,,,,,04/30/13,12/07/12,,,,12/07/12,01/05/10,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
64,179,605,149,TNKase,tenecteplase,Roche Holding AG,RHHBY,,Switzerland,Europe,,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrin (Coagulation Factor Ia)^ Plasminogen^ Tissue Plasminogen Activator (TPA),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,06/02/00,02/23/01,,,,,,,,,,,,100%,439.2,N/A,N/A,"$  1,249.9",$   661.3,N/A,N/A,"$  1,303.8",$   686.4,Q2 2019,Boehringer Ingelheim GmbH
2355,74,3966,266,TOBI Podhaler,tobramycin,Mylan N.V.,MYL,Pennsylvania,United States,North America,,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Gram-Negative Bacteria^ Protein synthesis,Non-NME,No,Inhaled,N,N,Y,N,N,N,,,01/01/2014 - 01/01/2014,03/22/13,07/20/11,,,,12/21/11,10/05/05,,,,10/05/05,04/17/03,,N/A,83.4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
17254,3023,22392,289,TobraDex ST,tobramycin and dexamethasone,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Glucocorticoid Receptor (GR)^ Gram-Negative Bacteria^ Protein synthesis,Non-NME,No,Topical,N,N,N,,N,N,,,,02/13/09,,,,,06/14/07,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
31992,690,44191,6653,Tolak,fluorouracil,"Hill Dermaceuticals, Inc.",,Florida,United States,North America,,Dermatology,General,Actinic Keratoses,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Thymidylate Synthase,Non-NME,No,Topical,N,N,N,N,N,N,,,,09/18/15,,,,,08/17/07,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Pierre Fabre Medicament S.A.
23759,3116,53441,8963,Tolsura,itraconazole,Mayne Pharma Group Limited,MYX: ASX,,Australia,Oceania,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Ergosterol biosynthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/12/18,,,,,12/11/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"HedgePath Pharmaceuticals, Inc., Pfizer Inc."
1903,288,3070,223,Topamax,topiramate,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Neurology,Headache,Migraine and Other Headaches,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,08/12/04,,,,,12/23/02,,,,,09/23/02,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2011,"Kyowa Hakko Kirin Co., Ltd."
1903,3008,22783,223,Topamax,topiramate,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Neurology,Seizure Disorders (Epilepsy),Lennox-Gastaut Syndrome (LGS; Epilepsy),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,08/28/01,,,,,07/31/97,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2011,"Kyowa Hakko Kirin Co., Ltd."
22299,155,30208,4239,Topicort Topical Spray,desoximetasone,Taro Pharmaceutical Industries Ltd.,TARO,,Israel,Asia,3297717354,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,04/11/13,,,,,06/12/12,,,,,11/05/10,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2556,264,4343,9237,Toprol-XL,metoprolol succinate,Deerfield Management Company,,New York,United States,North America,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,07/10/00,,,,,,,,,,,,,N/A,,$    95.0,$    37.0,$    26.0,N/A,$   737.0,$   695.0,$   373.0,N/A,Q2 2018,"AstraZeneca PLC, Recordati SpA"
1677,216,2696,312,Torisel,temsirolimus,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Renal Cell Cancer (RCC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Mammalian Target of Rapamycin (mTOR)/mTORC,New Molecular Entity (NME),No,Intravenous (IV),Y,N,Y,N,N,N,,,,05/30/07,11/19/07,07/23/10,,,10/06/06,,,,,03/06/02,,,100%,0,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q1 2013,N/A
30866,288,42678,2817,Tosymra,sumatriptan nasal spray,"Sawai Pharmaceutical Co., Ltd.",4555:JP,Minnesota,United States,North America,,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT1 receptor,Non-NME,No,Intranasal,N,N,N,N,N,N,,,,01/25/19,,,,,03/27/18,,,,,09/30/14,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Dr. Reddy's Laboratories
19216,726,25313,4161,Totect,dexrazoxane HCl,Clinigen Group plc,CLIN:LN,,United Kingdom,Europe,,Not Specified,Other,Drug Toxicity,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Topoisomerase II (DNA gyrase),Non-NME,No,Intravenous (IV),N,N,Y,N,N,N,,,,09/06/07,07/28/06,01/17/14,,,,,,,,03/25/04,,,N/A,,N/A,$     4.0,$     0.9,$     0.1,N/A,$     4.0,$     0.9,$     0.1,Q1 2019,"Accord Healthcare Ltd., Cumberland Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd, Laboratoires Biocodex, Seelos Therapeutics, Inc."
19040,157,25065,51,Toujeo,insulin glargine,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",N,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,02/26/15,04/28/15,07/03/15,,,06/14/14,,,09/06/11,,09/12/12,08/06/12,05/31/11,100%,,$   526.3,$   521.0,$   397.1,$   157.1,$   698.0,$   937.5,$   969.2,$   486.8,Q2 2019,N/A
19040,137,25066,51,Toujeo,insulin glargine,Sanofi,SNY,,France,Europe,1.05588E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,02/26/15,04/28/15,07/03/15,,,06/14/14,02/08/12,,09/06/11,,02/08/12,,09/06/11,100%,1327.8,$   526.3,$   521.0,$   397.1,$   157.1,$   698.0,$   937.5,$   969.2,$   486.8,Q2 2019,N/A
2621,543,4471,312,Toviaz,fesoterodine,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Urology,Other,Overactive Bladder (OAB),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,04/01/2013 - 04/01/2013,10/31/08,04/20/07,12/31/12,,,04/13/06,,,,,08/23/04,,,N/A,,$    99.0,$    85.0,$   133.0,$    36.0,$   258.0,$   257.0,$   271.0,$   125.0,Q2 2019,UCB SA
2642,660,4511,891,Tpoxx,tecovirimat,"SIGA Technologies, Inc.",SIGA,New York,United States,North America,416916743,Infectious disease,Antiviral,Smallpox,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Immune system^ Smallpox virus,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,Y,N,N,N,,,,07/13/18,,,,,12/08/17,06/26/15,06/15/09,05/02/06,,06/01/15,06/15/09,05/02/06,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Altimmune, Inc., Pfizer Inc."
252,245,397,223,Tracleer,bosentan,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Endothelin Receptor Type A (EDNRA)^ Endothelin Receptor Type B (EDNRB),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,11/20/01,05/15/02,04/11/05,,,11/15/00,,,,,05/02/00,,,90%,373.3,$   376.8,$   161.0,$   268.0,$   102.0,"$  1,048.0",$   403.0,$   546.0,$   220.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Roche Holding AG"
7121,137,8290,70,Tradjenta,linagliptin,Boehringer Ingelheim GmbH,,,Germany,Europe,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dipeptidyl peptidase IV (DPP-IV),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/02/11,08/24/11,07/21/11,,,07/02/10,01/01/08,,,,01/14/08,06/26/07,,50%,474.3,$   331.6,$   213.2,N/A,N/A,$   873.2,"$  2,154.7","$  1,546.4",N/A,Q4 2018,"Eli Lilly &amp; Company, Lupin Limited"
1783,278,2844,289,Travatan/Travatan Z,travoprost,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostaglandin F receptor (FP)/PGF2 alpha receptor,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,03/16/01,11/27/01,07/31/07,,,,,,,,,,,N/A,,$   211.0,$   216.0,$    98.0,N/A,$   619.0,$   589.0,$   258.0,N/A,Q2 2018,N/A
20831,214,27885,312,Trazimera,trastuzumab-qyyp,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,03/11/19,07/31/18,09/21/18,,,,02/18/14,,,,02/18/14,,05/25/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
20831,223,54007,312,Trazimera,trastuzumab-qyyp,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Gastric Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,HER2/neu or ErbB-2,Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,03/11/19,07/31/18,09/21/18,,,,,,,,07/31/17,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2191,3093,3667,375,Treanda,bendamustine hydrochloride,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA^ p53,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,Y,Y,N,N,N,,,,10/31/08,07/15/10,10/27/10,,,12/31/07,08/02/05,,,,08/02/05,05/12/05,,95%,,$   661.0,$   656.0,N/A,N/A,$   699.6,$   720.6,N/A,N/A,Q4 2017,"Astellas Pharma, Inc., Eisai Co., Ltd., H. Lundbeck A/S, InnoPharmax Inc., Mundipharma International Limited, SymBio Pharmaceuticals Ltd."
2191,200,8758,375,Treanda,bendamustine hydrochloride,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA^ p53,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,Y,N,N,N,,,,03/20/08,07/15/10,08/26/16,,,09/19/07,,,,,01/31/01,,,95%,95.2,$   661.0,$   656.0,N/A,N/A,$   699.6,$   720.6,N/A,N/A,Q4 2017,"Astellas Pharma, Inc., Eisai Co., Ltd., H. Lundbeck A/S, InnoPharmax Inc., Mundipharma International Limited, SymBio Pharmaceuticals Ltd."
2191,205,28537,375,Treanda,bendamustine hydrochloride,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Hematologic,Non-Hodgkin's Lymphoma (NHL),N,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA^ p53,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,03/20/08,,,,,,,,,,,,,95%,479,$   661.0,$   656.0,N/A,N/A,$   699.6,$   720.6,N/A,N/A,Q4 2017,"Astellas Pharma, Inc., Eisai Co., Ltd., H. Lundbeck A/S, InnoPharmax Inc., Mundipharma International Limited, SymBio Pharmaceuticals Ltd."
24370,73,33780,180,Trelegy Ellipta,fluticasone furoate/umeclidinium bromide/vilanterol,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Glucocorticoid Receptor (GR)^ Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,09/18/17,11/16/17,05/01/19,,,11/18/16,07/16/14,,,,07/16/14,,,N/A,,N/A,$     3.0,$   161.0,$   195.0,N/A,$     3.0,$   207.0,$   267.0,Q2 2019,"Innoviva, Inc., Theravance Biopharma, Inc."
10858,215,13616,856,Trelstar,triptorelin pamoate,Debiopharm S.A.,,,Switzerland,Europe,,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Peptide,Gonadotropin-Releasing Hormone (GnRH) Receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,,N,N,,,,06/15/00,10/13/09,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,$   375.8,$   401.0,$   456.6,$   120.2,Q1 2019,"Ipsen SA, Orient EuroPharma Co., Ltd., Vifor Pharma Group"
15478,155,19681,223,Tremfya,guselkumab,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Autoimmune/immunology,Psoriasis,Psoriasis,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,IL-23 (Interleukin-23),Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,07/13/17,11/10/17,03/23/18,,,11/16/16,09/17/14,12/08/11,06/29/09,,09/17/14,12/01/11,06/29/09,N/A,,N/A,N/A,$   453.0,$   344.0,N/A,N/A,$   544.0,$   452.0,Q2 2019,"MorphoSys AG, Otsuka Holdings Co., Ltd."
10482,157,13112,292,Tresiba,degludec,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/25/15,01/21/13,09/28/12,,,09/29/11,09/22/09,,,,09/22/09,01/31/08,,100%,2033.5,N/A,$   753.2,$   812.0,$   196.2,$   627.3,"$  1,111.1","$  1,257.0",$   326.6,Q1 2019,N/A
10482,137,13113,292,Tresiba,degludec,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,Insulin Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/25/15,01/21/13,09/28/12,,,09/29/11,09/03/09,,,,09/03/09,01/31/08,,100%,3087.1,N/A,$   753.2,$   812.0,$   196.2,$   627.3,"$  1,111.1","$  1,257.0",$   326.6,Q1 2019,N/A
17161,2976,22266,292,Tretten,,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Hematology,Factor Augmentation,Factor XIII Deficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,Fibrin (Coagulation Factor Ia),Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,,12/22/13,09/03/12,,,,02/23/11,08/31/08,,,,09/26/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Bristol-Myers Squibb Company, CSL Limited"
1840,154,2943,375,Trexall,methotrexate,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,03/21/01,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
833,288,954,4140,Treximet,sumatriptan and naproxen sodium,Currax Pharmaceuticals LLC,,New Jersey,United States,North America,,Neurology,Headache,Migraine and Other Headaches,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)^ Serotonin 5-HT1 receptor",Non-NME,No,Oral (PO),N,N,N,,N,N,,,,04/15/08,,,,,08/08/05,,11/28/00,,,05/18/04,11/28/00,,N/A,,$    58.1,$    68.4,$    13.9,N/A,$    58.1,$    68.4,$    13.9,N/A,Q2 2018,"Nuvo Pharmaceuticals, Inc."
23374,3555,32055,587,Tri-Luma Cream,"fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%",Galderma S.A.,,,Switzerland,Europe,,Dermatology,General,Benign Pigmented Lesions,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Melanin^ Retinoic acid receptor (RARs),Non-NME,No,Topical,N,N,N,N,N,N,,,,01/18/02,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
14963,244,18989,343,Tribenzor,"olmesartan medoxomil, amlodipine, hydrochlorothiazide","Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1)^ Calcium Channel^ Na/Cl transporter - Thiazide-sensitive,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/23/10,12/20/10,,,,09/30/09,05/29/08,,,,05/29/08,,,N/A,,N/A,$   193.9,N/A,N/A,$    67.0,$   489.8,N/A,N/A,Q4 2017,N/A
18141,187,23724,3234,Triferic,ferric pyrophosphate,Rockwell Medical Inc.,RMTI,Michigan,United States,North America,144153469,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Dependent",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,Non-NME,No,"Intravenous (IV), Oral (PO), Intracavitary",N,N,N,N,N,N,,,,01/23/15,,,,,03/24/14,03/24/11,,,,03/24/11,10/29/08,01/23/08,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
3201,506,5477,618,Triglide,fenofibrate,Shionogi & Co. Ltd.,4507:JP,,Japan,Asia,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,PPAR alpha,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/07/05,,,,,06/25/01,,,,,,,,75%,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Vectura Group plc
2917,3009,4971,289,Trileptal,oxcarbazepine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,01/14/00,11/30/99,,,,09/25/98,,,,,06/08/90,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,N/A
2634,506,4500,5,TriLipix,choline fenofibrate,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,PPAR alpha,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/15/08,,,,,12/07/07,,,,,03/07/06,,,70%,0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Abbott Laboratories, AstraZeneca PLC"
8410,167,10444,826,Trintellix,vortioxetine,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT1A receptor^ Serotonin 5-HT1B receptor^ Serotonin 5-HT1D receptor^ Serotonin 5-HT3 receptor^ Serotonin 5-HT7 receptor^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,06/01/2019 - 12/31/2019,09/30/13,12/18/13,,,,10/01/12,12/18/07,06/21/06,,,12/18/07,06/21/06,12/19/03,80%,524.2,$    56.1,$   432.2,$   713.4,$   165.3,$   116.2,$   689.5,$   855.3,$   256.0,Q1 2019,H. Lundbeck A/S
34481,182,47652,4042,Triptodur,triptorelin pamoate,"Arbor Pharmaceuticals, LLC",,Georgia,United States,North America,,Endocrine,General,Endocrine Disorder,Y,Approved,Approved,100% (Same As Avg.),Peptide,Gonadotropin-Releasing Hormone (GnRH),Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,06/30/17,01/09/17,,,,08/29/16,05/30/12,,,,05/30/12,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Debiopharm S.A., Ipsen SA"
855,3089,1174,375,Trisenox,arsenic trioxide,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Hematologic,Acute Promyelocytic Leukemia (APL),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,PML/RARalpha,New Molecular Entity (NME),No,Intravenous (IV),N,N,Y,N,N,N,,,,09/26/00,03/05/02,10/25/04,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"CTI BioPharma Corporation, Nippon Shinyaku Co., Ltd., Pharma Services Holding, Inc."
17950,78,23444,180,Triumeq,abacavir; dolutegravir; lamivudine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HIV Integrase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/22/14,09/01/14,03/16/15,,,10/22/13,,,,,02/01/11,,,N/A,,"$  1,577.0","$  2,121.0","$  2,221.0","$  1,018.0","$  2,360.0","$  3,199.0","$  3,522.0","$  1,625.0",Q2 2019,"Pfizer Inc., Shionogi &amp; Co. Ltd., Takeda Pharmaceutical Company Ltd"
2120,78,3527,180,Trizivir,"abacavir, lamivudine and zidovudine",GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/14/00,12/28/00,,,,12/16/99,,,,,,,,N/A,,$     7.0,N/A,N/A,N/A,$    22.0,N/A,N/A,N/A,Q4 2016,"Pfizer Inc., Takeda Pharmaceutical Company Ltd"
213,78,253,459,Trogarzo,ibalizumab,Theratechnologies Inc.,THERF,,Canada,North America,256232330,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 4 (CD4),Biologic,No,"Intramuscular (IM), Intravenous (IV), Subcutaneous (SQ)",Y,N,Y,Y,N,N,,07/25/2019 - 09/30/2019,,03/06/18,,,,,05/03/17,08/18/15,05/05/04,08/01/01,,08/18/15,05/05/04,08/01/01,70%,180.1,N/A,N/A,$     8.8,$     6.0,N/A,N/A,$     8.8,$     6.0,Q1 2019,"Biogen, Inc., Roche Holding AG, TaiMed Biologics"
17793,272,23212,2995,Trokendi XR,topiramate,"Supernus Pharmaceuticals, Inc.",SUPN,Maryland,United States,North America,1504479404,Neurology,Seizure Disorders (Epilepsy),Seizure Disorders (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/16/13,,,,,01/14/11,,,,,12/23/10,,,N/A,,$   158.3,$   226.5,$   315.2,$   142.7,$   158.3,$   226.5,$   315.2,$   142.7,Q2 2019,"Aequus Pharmaceuticals, Inc."
17793,3008,31273,2995,Trokendi XR,topiramate,"Supernus Pharmaceuticals, Inc.",SUPN,Maryland,United States,North America,1504479404,Neurology,Seizure Disorders (Epilepsy),Lennox-Gastaut Syndrome (LGS; Epilepsy),N,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/16/13,,,,,01/14/11,,,,,,,,N/A,,$   158.3,$   226.5,$   315.2,$   142.7,$   158.3,$   226.5,$   315.2,$   142.7,Q2 2019,"Aequus Pharmaceuticals, Inc."
17793,288,37623,2995,Trokendi XR,topiramate,"Supernus Pharmaceuticals, Inc.",SUPN,Maryland,United States,North America,1504479404,Neurology,Headache,Migraine and Other Headaches,N,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/05/17,,,,,10/22/15,,,,,,,,N/A,,$   158.3,$   226.5,$   315.2,$   142.7,$   158.3,$   226.5,$   315.2,$   142.7,Q2 2019,"Aequus Pharmaceuticals, Inc."
11867,435,14948,470,Trulance,plecanatide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),Other,Irritable Bowel Syndrome (IBS),N,Approved,Approved,100% (Same As Avg.),Peptide,Guanylyl cyclase c Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/24/18,,,,,03/27/17,12/18/14,12/27/12,,,12/18/14,12/27/12,06/04/08,N/A,,N/A,N/A,N/A,$     6.0,N/A,N/A,N/A,$     6.0,Q1 2019,"Cipher Pharmaceuticals Inc., Ironwood Pharmaceuticals, Inc., Luoxin Pharmaceutical Group Co., Ltd."
11867,661,14949,470,Trulance,plecanatide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),Other,Chronic Idiopathic Constipation,Y,Approved,Approved,100% (Same As Avg.),Peptide,Guanylyl cyclase c Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/19/17,,,,,01/29/16,10/07/11,02/19/10,,,10/07/11,03/19/10,06/04/08,N/A,,N/A,N/A,N/A,$     6.0,N/A,N/A,N/A,$     6.0,Q1 2019,"Cipher Pharmaceuticals Inc., Ironwood Pharmaceuticals, Inc., Luoxin Pharmaceutical Group Co., Ltd."
9921,137,12378,136,Trulicity,dulaglutide,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/18/14,11/21/14,07/03/15,,,,08/28/08,,,,08/28/08,07/11/08,12/07/06,100%,1901.9,$   737.6,"$  1,609.9","$  2,515.8","$  1,457.7",$   988.3,"$  2,176.3","$  3,394.1","$  2,025.0",Q2 2019,"Lupin Limited, Sumitomo Dainippon Pharma Co., Ltd."
11380,524,14299,312,Trumenba,,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Meningococcal Vaccines and Other Meningococcus-Specific Agents (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Neisseria meningitidis - Group B,Vaccine,No,Intramuscular (IM),N,N,N,Y,N,N,,,,10/29/14,05/30/17,,,,06/17/14,11/08/12,,,,11/08/12,02/26/07,,N/A,,N/A,N/A,$    77.0,N/A,N/A,N/A,$    82.0,N/A,Q4 2018,HealthCare Royalty Partners
1664,78,2677,179,Truvada,emtricitabine and tenofovir disoproxil fumarate,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/02/04,02/21/05,01/01/06,,,03/12/04,,,,,,,,100%,2137.8,"$  2,384.0","$  2,266.0","$  2,605.0","$  1,208.0","$  3,566.0","$  3,134.0","$  2,997.0","$  1,324.0",Q2 2019,Mylan N.V.
1664,696,23367,179,Truvada,emtricitabine and tenofovir disoproxil fumarate,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV Prevention,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/16/12,08/22/16,,,,12/15/11,,,,,11/14/07,,,100%,,"$  2,384.0","$  2,266.0","$  2,605.0","$  1,208.0","$  3,566.0","$  3,134.0","$  2,997.0","$  1,324.0",Q2 2019,Mylan N.V.
19644,3093,44889,375,Truxima,rituximab,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cluster of Differentiation 20 (CD20),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,11/28/18,02/17/17,,,,04/27/17,,,,,10/06/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Celltrion, Inc., Nippon Kayaku Co., Ltd., Vcell Healthcare Limited"
2622,73,4475,3266,Tudorza Pressair,aclidinium bromide,Circassia Ltd.,CIR:LN,,United Kingdom,Europe,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,07/23/12,07/20/12,03/26/15,,,06/23/11,04/10/06,,,,04/10/06,06/27/05,,95%,350.4,$    61.0,$    66.0,$    29.0,$     2.0,$   134.0,$   150.0,$   110.0,$    33.0,Q1 2019,"Allergan plc, AstraZeneca PLC, Daewoong Pharmaceutical Company Ltd., IQVIA Holdings Inc., The Menarini Group"
15903,3414,33269,343,Turalio,pexidartinib,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Oncology,Solid,Pigmented Villonodular Synovitis (PVNS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,FMS-like tyrosine kinase 3 (FLT-3)^ KIT/c-KIT^ Macrophage Colony Stimulating Factor 1 (M-CSF1)/M-CSF Receptor/FMS/CD115/CSF-1/CSF1R,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,03/01/2020 - 09/30/2020,,08/02/19,,,,,12/03/18,03/25/15,,,,03/25/15,,10/29/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
22024,706,29795,5817,Tuzistra XR,codeine polistirex and chlorpheniramine polistirex,"Aytu BioScience, Inc.",AYTU,Colorado,United States,North America,12001401,Infectious disease,Antiviral,Viral Rhinitis (Common Cold),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,04/30/15,,,,,06/30/14,,,,,11/25/13,,03/06/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Tris Pharma
3244,318,5567,180,Twinrix,Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,Hepatitis A Prevention (Antiviral Vaccines),Y,Approved,Approved,100% (Same As Avg.),Vaccine,Hepatitis A^ Hepatitis B/HBV^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,05/14/01,09/20/96,,,,,,,,,09/20/96,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
3244,1328,5568,180,Twinrix,Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Infectious disease,Antiviral,"Hepatitis B Prevention (Vaccines, Antiviral)",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Hepatitis A^ Hepatitis B/HBV^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,,N,N,,,,05/14/01,09/20/96,,,,,,,,,09/20/96,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
7985,244,9813,70,Twynsta,amlodipine besylate and telmisartan,Boehringer Ingelheim GmbH,,,Germany,Europe,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiotensin II Receptor Type 1 (AT1),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/16/09,10/12/10,07/23/10,,,12/18/08,,,,,01/24/06,,,N/A,,N/A,N/A,N/A,N/A,$   235.8,$   125.4,$    50.7,N/A,Q3 2018,"Astellas Pharma, Inc., Bayer AG"
13480,78,17020,179,Tybost,cobicistat,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/24/14,09/19/13,,,,06/28/12,04/20/10,04/06/09,07/22/08,,04/20/10,04/30/09,07/22/08,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
1860,440,2986,312,Tygacil,tigecycline,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Gram-Negative Bacteria^ Protein synthesis,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,06/15/05,04/24/06,09/28/12,,,12/15/04,,,,,05/01/04,,,100%,37.3,$    81.0,$    45.0,$    26.0,N/A,$   274.0,$   260.0,$   249.0,N/A,Q4 2018,N/A
1860,536,2987,312,Tygacil,tigecycline,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Intra-Abdominal Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Gram-Negative Bacteria^ Protein synthesis,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,07/01/2011 - 07/01/2011,06/15/05,04/24/06,09/28/12,,,12/15/04,,,,,11/03/04,,,100%,14.9,$    81.0,$    45.0,$    26.0,N/A,$   274.0,$   260.0,$   249.0,N/A,Q4 2018,N/A
1860,488,3762,312,Tygacil,tigecycline,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Gram-Negative Bacteria^ Protein synthesis,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,03/24/09,,,,,08/24/07,,,,,04/15/04,,,100%,61.9,$    81.0,$    45.0,$    26.0,N/A,$   274.0,$   260.0,$   249.0,N/A,Q4 2018,N/A
1620,214,2599,289,Tykerb,lapatinib ditosylate,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor)^ HER2/neu or ErbB-2,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/13/07,06/10/08,04/22/09,,,09/18/06,,,,,06/02/04,,,N/A,68.1,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,"GlaxoSmithKline plc, Nippon Kayaku Co., Ltd."
8465,242,10521,1382,Tymlos,,"Radius Health, Inc.",RDUS,Massachusetts,United States,North America,1045587287,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,Y,Approved,Approved,100% (Same As Avg.),Protein,Parathyroid Hormone Receptor (PTHR),New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/28/17,,,,,03/30/16,04/26/11,,,,04/26/11,03/20/07,12/13/05,N/A,,N/A,$    12.2,$    99.1,$    29.8,N/A,$    12.2,$    99.1,$    29.8,Q1 2019,"Ipsen SA, Novartis AG, Teijin Pharma Limited"
158,153,153,64,Tysabri,natalizumab,"Biogen, Inc.",BIIB,Massachusetts,United States,North America,46991785631,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Integrin Alpha-4 beta-1/VLA-4^ Integrin Alpha-4 beta-7/LPAM,Biologic,No,Intravenous (IV),N,N,N,N,N,N,,,01/01/2014 - 06/30/2014,11/23/04,06/27/06,,,,05/25/04,01/15/02,01/15/01,,,07/25/03,,,79%,711,"$  1,137.3","$  1,114.3","$  1,025.2",$   509.3,"$  1,962.9","$  1,973.1","$  1,863.9",$   935.7,Q2 2019,"DRI Capital Inc., Eisai Co., Ltd., PDL BioPharma, Inc., Royalty Pharma AG, UCB SA"
158,156,220,64,Tysabri,natalizumab,"Biogen, Inc.",BIIB,Massachusetts,United States,North America,46991785631,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Integrin Alpha-4 beta-1/VLA-4^ Integrin Alpha-4 beta-7/LPAM,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,01/14/08,,,,,12/15/06,12/15/01,,,,07/24/03,,,79%,1189.9,"$  1,137.3","$  1,114.3","$  1,025.2",$   509.3,"$  1,962.9","$  1,973.1","$  1,863.9",$   935.7,Q2 2019,"DRI Capital Inc., Eisai Co., Ltd., PDL BioPharma, Inc., Royalty Pharma AG, UCB SA"
4889,245,5677,385,Tyvaso,treprostinil sodium,United Therapeutics Corporation,UTHR,Maryland,United States,North America,3493948188,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostacyclin Receptors,Non-NME,No,Inhaled,N,N,N,N,N,N,,01/01/2017 - 01/01/2017,,07/30/09,,,,,06/27/08,,,,,06/01/05,04/14/04,,N/A,284,$   405.0,$   372.9,$   415.2,$   213.4,$   405.0,$   372.9,$   415.2,$   213.4,Q2 2019,"GlaxoSmithKline plc, Mochida Pharmaceutical Co., Ltd., Pfizer Inc."
1760,319,2799,289,Tyzeka,telbivudine,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Infectious disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,10/25/06,04/30/07,,,,01/03/06,,,,,01/08/03,04/12/02,,N/A,141.8,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q4 2011,N/A
17196,321,22313,470,Uceris,Budesonide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR),Non-NME,No,Oral (PO),N,Y,N,N,N,N,,,,01/14/13,10/20/14,,,,12/20/11,,,,,10/10/07,,,88%,1341.6,$   112.0,N/A,N/A,N/A,N/A,$   137.0,$    95.0,$    11.0,Q1 2019,"Cosmo Pharmaceuticals N.V., Ferring Pharmaceuticals, NovaMedica LLC"
24670,91,34278,3712,Udenyca,pegfilgrastim-cbqv,"Coherus BioSciences, Inc.",CHRS,California,United States,North America,1317644211,Hematology,Marrow Or Peripheral Blood Stimulator,Neutropenia / Leukopenia,Y,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,11/02/18,09/25/18,,,,08/09/16,,,,,,,09/25/14,N/A,,N/A,N/A,N/A,$   120.5,N/A,N/A,N/A,$   120.5,Q2 2019,N/A
18025,81,23542,2647,Ulesfia,benzyl alcohol,ADVANZ PHARMA Corp.,ADVZ:CN,Ontario,Canada,North America,,Infectious disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Insect Respiration,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,04/09/09,,,,,06/15/07,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Shionogi &amp; Co. Ltd.
1767,539,2808,826,Uloric,febuxostat,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Autoimmune/immunology,Arthritis,Gout,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Xanthine oxidase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/13/09,04/21/08,,,,12/15/04,,,,,10/19/04,,,N/A,,$   363.9,$   409.1,$   454.0,N/A,$   376.1,$   418.8,$   463.9,N/A,Q4 2018,"AbbVie Inc., Astellas Pharma, Inc., Ipsen SA, Teijin Pharma Limited, The Menarini Group"
25373,394,35315,21,Ultomiris,ravulizumab-cwvz,"Alexion Pharmaceuticals, Inc.",ALXN,Connecticut,United States,North America,24868581569,Autoimmune/immunology,Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria (PNH),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,C5a Receptor,Biologic,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,Y,N,N,N,,,,12/21/18,07/03/19,06/18/19,,,06/18/18,10/27/16,12/23/15,,,10/27/16,11/05/15,09/30/14,N/A,,N/A,N/A,N/A,$    78.8,N/A,N/A,N/A,$    78.8,Q2 2019,"Xencor, Inc."
20019,3128,26585,470,Ultram ER,tramadol hydrochloride,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Neurology,Pain,Chronic Pain,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Opioid receptors^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,09/08/05,,,,,12/31/03,,,,,07/18/03,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Johnson &amp; Johnson
20211,155,50368,3285,Ultravate,halobetasol propionate,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Autoimmune/immunology,Psoriasis,Psoriasis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Topical,N,N,N,N,N,N,,,,11/06/15,,,,,12/23/14,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Daiichi Sankyo Co., Ltd."
8158,705,10074,395,Ultresa,pancrelipase,Allergan plc,AGN,,Ireland,Europe,53945515162,Gastroenterology (non inflammatory bowel disease),Other,Exocrine Pancreatic Insufficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,"Protein, fat, and/or carbohydrate absorption",Biologic,No,Oral (PO),Y,N,N,N,N,N,,,,03/01/12,06/29/16,,,,08/02/07,,,,,06/13/00,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q3 2010,N/A
18669,347,24512,385,Unituxin,dinutuximab,United Therapeutics Corporation,UTHR,Maryland,United States,North America,3493948188,Oncology,Solid,Neuroendocrine Tumors (NET),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Ganglioside GD2,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,03/10/15,08/14/15,,,,04/11/14,10/01/01,,,,10/01/01,,,N/A,,$    50.0,$    76.0,$    84.8,$    50.0,$    63.0,$    76.0,$    84.8,$    50.0,Q2 2019,N/A
10827,245,13571,223,Uptravi,selexipag,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostacyclin Receptors,New Molecular Entity (NME),No,Oral (PO),N,Y,Y,N,N,N,,,,12/21/15,05/12/16,09/28/16,,,12/23/14,01/11/10,,,,01/11/10,08/26/05,,N/A,422.3,$   236.0,$   431.0,$   598.0,$   351.0,$   249.2,$   473.0,$   703.2,$   411.1,Q2 2019,"Nippon Shinyaku Co., Ltd."
1260,569,1623,2647,UroXatral,alfuzosin HCL,ADVANZ PHARMA Corp.,ADVZ:CN,Ontario,Canada,North America,,Urology,General,Benign Prostatic Hyperplasia (BPH),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,06/16/03,,,,,,,,,,,,,100%,,N/A,N/A,N/A,$     0.0,$   111.1,N/A,N/A,$     0.0,Q4 2016,"Sanofi, Vectura Group plc"
2394,73,4049,686,Utibron Neohaler,glycopyrronium bromide/indacaterol maleate,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors^ Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,10/29/15,09/19/13,09/20/13,,,,05/10/10,,,,05/10/10,12/22/05,,85%,1838.1,N/A,N/A,N/A,N/A,$   363.0,$   411.0,$   454.0,$   220.2,Q2 2019,"Glenmark Pharmaceuticals Limited, Lupin Limited, Novartis AG, Pfizer Inc., Sosei Co., Ltd, Vectura Group plc"
20993,534,28166,2685,Vabomere,meropenem/vaborbactam,"Melinta Therapeutics, Inc.",MLNT,Connecticut,United States,North America,141731242,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,Y,,,,08/29/17,11/27/18,,,,12/29/16,,,,,06/16/14,,03/19/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,The Menarini Group
20922,660,28034,1298,Vaccinia Immune Globulin Intravenous (Human),,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Infectious disease,Antiviral,Smallpox,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Smallpox virus,Vaccine,No,Intravenous (IV),N,N,N,,N,N,,,,05/02/05,,,,,,,,,,08/31/02,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
17355,417,22569,462,Valchlor,mechlorethamine,Helsinn Healthcare SA,,,Switzerland,Europe,,Oncology,Hematologic,Cutaneous T-Cell Lymphoma (CTCL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA synthesis,Non-NME,No,Topical,Y,N,Y,N,N,N,,,,08/23/13,03/07/17,,,,07/28/11,,,,,09/24/10,,,N/A,,$    33.6,N/A,N/A,N/A,$    36.7,N/A,N/A,N/A,Q4 2016,Recordati SpA
17139,411,22235,149,Valcyte,valganciclovir hydrochloride,Roche Holding AG,RHHBY,,Switzerland,Europe,,Infectious disease,Antiviral,Cytomegalovirus (CMV) Infection (Antiviral),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA polymerase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,03/29/01,09/27/01,11/05/04,,,,,,,,,,,N/A,,N/A,N/A,$    46.7,N/A,N/A,N/A,$   310.7,N/A,Q4 2018,Mitsubishi Tanabe Pharma Corporation
11079,285,13921,790,Valtropin,somatropin,"LG Chem, Ltd.",051910:KS,,Korea (South),Asia,,Endocrine,Short Stature,Short Stature / Growth Hormone Deficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),Biosimilar,No,Subcutaneous (SQ),N,N,N,,N,N,,,,04/19/07,05/04/06,,,,12/01/05,,,,,11/29/04,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Bioton S.A.
11079,306,46107,790,Valtropin,somatropin,"LG Chem, Ltd.",051910:KS,,Korea (South),Asia,,Endocrine,Short Stature,Turner Syndrome,N,Approved,Approved,100% (Same As Avg.),Protein,Growth hormone receptor (GHR),Biosimilar,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,04/19/07,05/04/06,,,,12/01/05,,,,,11/29/04,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Bioton S.A.
34807,182,48217,774,Vaniqa,eflornithine,"Almirall Prodesfarma, S.A.",ALM:SM,,Spain,Europe,,Endocrine,General,Endocrine Disorder,N,Approved,Approved,100% (Same As Avg.),Not Specified,Ornithine Decarboxylase,Non-NME,No,Topical,N,N,N,N,N,N,,,,07/27/00,03/20/01,,,,09/24/99,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
7376,151,8925,470,Vanos,fluocinonide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Dermatology,General,Dermatology,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR),New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,02/11/05,,,,,04/07/04,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
16756,3629,21679,375,Vantrela ER,,Teva Pharmaceutical Industries Ltd.,TEVA,,Israel,Asia,7171728558,Neurology,Pain,Chronic Low Back Pain (CLBP),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/17/17,,,,,10/08/14,10/18/10,,,,10/18/10,,05/04/10,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
2960,692,5035,3014,Vaprisol,conivaptan hydrochloride,Cumberland Pharmaceuticals Inc.,CPIX,Tennessee,United States,North America,89128556,Endocrine,Other,Hyponatremia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Vasopressin receptors,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,,N,N,,,,12/29/05,,,,,01/30/04,,,,,,,,N/A,,N/A,N/A,$     2.6,$     0.3,N/A,N/A,$     2.6,$     0.3,Q1 2019,N/A
18569,1455,24372,534,Varithena,,BTG plc,BTG:LN,,United Kingdom,Europe,,Cardiovascular,Peripheral Vascular Disease,Varicose Veins,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cell Membrane,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,11/25/13,,,,,02/04/13,09/16/10,,,,09/16/10,07/13/05,,N/A,,N/A,$     8.1,N/A,N/A,N/A,$     8.1,N/A,N/A,Q4 2017,"BL&amp;H Co., Ltd."
21584,641,29110,7775,VariZIG,,Saol Therapeutics,,Georgia,United States,North America,,Infectious disease,Antiviral,Chickenpox and Shingles - Vaccines and Treatments,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Varicella Zoster Virus (VSV),Vaccine,No,"Intramuscular (IM), Intravenous (IV)",N,N,Y,,N,N,,,,12/20/12,,,,,06/29/12,,,,,01/18/01,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,N/A
15913,767,20386,7142,Varubi,rolapitant,TerSera Therapeutics LLC,,Illinois,United States,North America,,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Neurokinin Receptor,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,09/01/15,04/20/17,,,,09/08/14,12/27/11,09/01/06,,,12/27/11,05/28/08,,N/A,,$     4.4,$     7.3,N/A,N/A,$     4.4,$    11.8,$     4.3,N/A,Q3 2018,"GlaxoSmithKline plc, Jiangsu Hengrui Medicine Co., Ltd., Opko Health"
1008,506,15301,528,Vascepa,icosapent ethyl,Amarin Corporation plc,AMRN,,Ireland,Europe,4393620390,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Diglycerol Acyltransferase (DGAT)^ Lipoprotein lipase^ PPAR gamma,Non-NME,No,Oral (PO),N,Y,N,,N,N,,,,07/26/12,,,,,09/26/11,01/11/10,,,,05/06/09,07/22/08,,N/A,,N/A,N/A,$   228.4,$   173.1,N/A,N/A,$   228.4,$   173.1,Q2 2019,"Eddingpharm, HLS Therapeutics, Inc."
24914,3577,34629,142,Vasostrict,,Endo International plc,ENDP,,Ireland,Europe,554131557,Cardiovascular,Other,Hypotension/Shock,Y,Approved,Approved,100% (Same As Avg.),Peptide,,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,04/17/14,,,,,09/26/12,,,,,,,,N/A,,$   343.5,$   399.9,$   453.7,$   255.1,$   343.5,$   399.9,$   453.7,$   255.1,Q2 2019,N/A
19721,77,26115,1298,Vaxchora,,"Emergent BioSolutions, Inc.",EBS,Maryland,United States,North America,2223242243,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial and Antifungal - Miscellaneous Vaccines and Treatments,N,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Vibrio cholerae,Vaccine,No,Oral (PO),Y,N,N,N,N,N,,,,06/10/16,,,,,10/16/15,,,,,03/19/12,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
11030,1328,13857,254,Vaxelis,,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,"Hepatitis B Prevention (Vaccines, Antiviral)",Y,Approved,Approved,100% (Same As Avg.),Vaccine,Hepatitis B/HBV^ Immune system,Vaccine,No,Intramuscular (IM),N,N,N,N,N,N,,,,12/21/18,02/15/16,,,,08/13/14,,,,,04/21/11,10/29/07,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Sanofi
22435,726,30439,831,Vazculep,phenylephrine hydrochloride,Avadel Pharmaceuticals plc,AVDL,,Ireland,Europe,75874628,Not Specified,Other,Drug Toxicity,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,06/27/14,,,,,07/01/13,,,,,04/05/13,,,N/A,,N/A,N/A,$    43.0,$     9.5,N/A,N/A,$    43.0,$     9.5,Q1 2019,N/A
23869,244,32898,5136,Vecamyl,mecamylamine hydrochloride,"Vyera Pharmaceuticals, LLC",,New York,United States,North America,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Nicotinic Acetylcholine Receptors (nAChR),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/19/13,,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
23,213,34,30,Vectibix,panitumumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Colorectal Cancer (CRC),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,EGFR (Epidermal Growth Factor Receptor),Biologic,No,Intravenous (IV),Y,Y,N,,N,N,,,,09/27/06,12/03/07,04/16/10,,,03/30/06,01/20/04,12/18/01,07/02/00,07/19/99,01/20/04,12/18/01,04/15/01,100%,129,$   229.0,$   251.0,$   288.0,$    78.0,$   788.1,$   813.0,$   691.0,$   170.0,Q1 2019,"Beta Pharma Inc., Takeda Pharmaceutical Company Ltd"
94,207,211,826,Velcade,bortezomib,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Oncology,Hematologic,Multiple Myeloma (MM),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Proteasome,New Molecular Entity (NME),No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,Y,N,N,N,,,,05/13/03,04/26/04,10/26/06,,,01/22/03,06/15/02,03/01/01,10/04/98,,06/17/02,03/01/01,10/14/98,100%,1567.2,$   707.0,"$  1,003.4",$   974.4,$   215.2,"$  1,657.0","$  2,341.2","$  2,297.2",$   513.6,Q1 2019,Johnson &amp; Johnson
94,205,562,826,Velcade,bortezomib,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Oncology,Hematologic,Non-Hodgkin's Lymphoma (NHL),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Proteasome,New Molecular Entity (NME),No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,,N,N,,,01/01/2013 - 01/01/2013,12/08/06,,,,,06/09/06,04/18/06,06/15/03,,,,,,100%,102.6,$   707.0,"$  1,003.4",$   974.4,$   215.2,"$  1,657.0","$  2,341.2","$  2,297.2",$   513.6,Q1 2019,Johnson &amp; Johnson
94,3094,28231,826,Velcade,bortezomib,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Oncology,Hematologic,Mantle Cell Lymphoma - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Proteasome,New Molecular Entity (NME),No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,N,N,N,N,,,,12/08/06,01/30/15,,,,06/09/06,,07/02/03,,,,06/03/03,,100%,,$   707.0,"$  1,003.4",$   974.4,$   215.2,"$  1,657.0","$  2,341.2","$  2,297.2",$   513.6,Q1 2019,Johnson &amp; Johnson
18114,245,23667,223,Veletri,epoprostenol,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostacyclin Receptors,Non-NME,No,Intravenous (IV),N,N,N,N,N,N,,,,06/27/08,03/21/13,02/18/13,,,08/27/07,,,,,,,,N/A,29.6,$    39.7,N/A,N/A,N/A,$    98.7,N/A,N/A,N/A,Q4 2016,N/A
17719,3179,23098,1307,Velphoro,sucroferric oxyhydroxide,Vifor Pharma Group,GNHAY,,Switzerland,Europe,,Renal,Chronic Renal Failure,Hyperphosphatemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Phosphate,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,11/27/13,08/27/14,09/28/15,,,02/01/13,03/25/11,01/09/09,,,03/25/11,01/09/09,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,"Fresenius SE &amp; Co. KGaA, Kissei Pharmaceutical Co., Ltd"
17220,2981,22347,1307,Veltassa,patiromer,Vifor Pharma Group,GNHAY,,Switzerland,Europe,,Endocrine,Other,Hyperkalemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Potassium,New Molecular Entity (NME),No,Oral (PO),N,Y,N,N,N,N,,,,10/21/15,07/21/17,,,,10/22/14,02/20/13,10/07/09,,,02/20/13,10/07/09,,N/A,,$    12.5,N/A,N/A,N/A,$    12.5,N/A,N/A,N/A,Q4 2016,"Fresenius SE &amp; Co. KGaA, Zeria Pharmaceutical Co., Ltd."
1042,319,28020,179,Vemlidy,tenofovir alafenamide fumarate,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/10/16,01/11/17,12/19/16,,,01/12/16,09/11/13,,,,09/11/13,,08/23/12,N/A,,N/A,N/A,$   245.0,$   136.0,N/A,N/A,$   321.0,$   217.0,Q2 2019,N/A
18303,200,23959,5,Venclexta,venetoclax,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,B-cell lymphoma 2 (Bcl-2)/Bcl-2 Family,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,04/11/16,12/05/16,,,,10/29/15,,,06/29/11,,07/26/13,07/25/13,06/29/11,N/A,,N/A,N/A,$   159.0,$   222.0,N/A,N/A,$   220.0,$   320.0,Q2 2019,Roche Holding AG
18303,97,32004,5,Venclexta,venetoclax,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),N,Approved,Approved,100% (Same As Avg.),Small Molecule,B-cell lymphoma 2 (Bcl-2)/Bcl-2 Family,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,11/21/18,,,,,07/11/18,12/27/16,,,,12/27/16,11/25/13,,N/A,,N/A,N/A,$   159.0,$   222.0,N/A,N/A,$   220.0,$   320.0,Q2 2019,Roche Holding AG
21845,167,29510,4104,Venlafaxine Hydrochloride ER,venlafaxine hydrochloride,Osmotica Pharmaceutical Corp,OSMT,North Carolina,United States,North America,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/20/08,,,,,12/11/06,,,,,,,,N/A,,$    90.0,N/A,$    66.1,$    21.6,N/A,N/A,$    66.1,$    21.6,Q1 2019,UCB SA
21845,635,29512,4104,Venlafaxine Hydrochloride ER,venlafaxine hydrochloride,Osmotica Pharmaceutical Corp,OSMT,North Carolina,United States,North America,,Psychiatry,Other,Social Anxiety Disorder (SAD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/20/08,,,,,12/11/06,,,,,,,,N/A,,$    90.0,N/A,$    66.1,$    21.6,N/A,N/A,$    66.1,$    21.6,Q1 2019,UCB SA
16427,187,21187,343,Venofer,iron sucrose injection,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Dependent",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,11/06/00,,,,,,,,,,,,,N/A,,N/A,$   279.0,$   261.0,N/A,N/A,$   279.0,$   261.0,N/A,Q4 2018,"Fresenius SE &amp; Co. KGaA, Vifor Pharma Group"
16427,371,21189,343,Venofer,iron sucrose injection,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Independent",N,Approved,Approved,100% (Same As Avg.),Small Molecule,Iron,Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,06/17/05,,,,,08/18/03,,,,,,,,N/A,,N/A,$   279.0,$   261.0,N/A,N/A,$   279.0,$   261.0,N/A,Q4 2018,"Fresenius SE &amp; Co. KGaA, Vifor Pharma Group"
1857,245,2979,223,Ventavis,iloprost,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostacyclin Receptors,New Molecular Entity (NME),No,Inhaled,N,N,N,,N,N,,,,12/29/04,09/16/03,,,,06/30/04,,,,,12/20/01,,,82%,58.3,$    74.3,N/A,N/A,$     0.0,$    74.3,N/A,N/A,$     0.0,Q4 2016,Bayer AG
1797,236,2868,180,Veramyst,fluticasone furoate,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intranasal,N,N,N,,N,N,,,,04/27/07,01/15/08,,,,06/28/06,,,,,10/28/04,,,N/A,,$    34.0,$     1.0,N/A,N/A,$   377.0,$   365.0,$   399.0,$   240.0,Q2 2019,N/A
18024,238,23540,289,Veregen,sinecatechins,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Infectious disease,Antiviral,Human Papillomavirus (HPV) Treatment (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Unknown,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,10/31/06,09/09/09,,,,09/28/05,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"AbbVie Inc., Azanta A/S, Bial Pharmaceuticals, Endo International plc, Epitome Pharmaceuticals Ltd., IFC Group, Kora Healthcare, Laboratoires Expanscience S.A., MediGene AG, Meditrina Pharmaceuticals, Nordic Group BV, PharmaNova, Inc., Pierre Fabre Medicament S.A., SynCore Biotechnology Co., Ltd, Takeda Pharmaceutical Company Ltd, Taurus Pharma GmbH, Will-Pharma"
18572,214,32677,136,Verzenio,abemaciclib,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Oncology,Solid,Breast Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cyclin Dependent Kinase (CDK),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,09/28/17,09/27/18,09/21/18,,,05/05/17,08/01/14,06/12/14,02/05/14,,08/01/14,06/12/14,02/05/14,N/A,,N/A,$    21.0,$   248.4,$   198.7,N/A,$    21.0,$   255.0,$   243.3,Q2 2019,N/A
1805,543,2879,814,VESIcare,solifenacin succinate,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Urology,Other,Overactive Bladder (OAB),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,11/22/04,07/09/04,06/01/06,,,12/19/02,,,,,,,,N/A,,N/A,N/A,N/A,N/A,"$  1,056.5",$   934.5,$   925.1,$   187.0,Q1 2019,GlaxoSmithKline plc
1855,3117,2976,312,Vfend,voriconazole,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,05/24/02,03/19/02,,,,,,,,,,,,N/A,,$    32.0,$    14.0,$    10.0,$     7.0,$   591.0,$   420.0,$   393.0,$   179.0,Q2 2019,"Ligand Pharmaceuticals, Inc."
1855,3116,23030,312,Vfend,voriconazole,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cytochrome p450,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,05/24/02,03/19/02,04/11/05,,,,,,,,,,,N/A,,$    32.0,$    14.0,$    10.0,$     7.0,$   591.0,$   420.0,$   393.0,$   179.0,Q2 2019,"Ligand Pharmaceuticals, Inc."
1810,440,2885,3014,Vibativ,telavancin,Cumberland Pharmaceuticals Inc.,CPIX,Tennessee,United States,North America,89128556,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Cell wall synthesis,New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,N,,,,09/11/09,,,,,12/07/06,,,,,11/02/04,,,98%,0,$    17.6,$    14.8,$    19.9,$     2.1,$    17.6,$    14.8,$    19.9,$     2.1,Q1 2019,"Astellas Pharma, Inc., Clinigen Group plc, Pharmascience Inc., R-PHARM JSC, SciClone Pharmaceuticals, Inc."
1810,673,3159,3014,Vibativ,telavancin,Cumberland Pharmaceuticals Inc.,CPIX,Tennessee,United States,North America,89128556,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial),N,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Cell wall synthesis,New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,N,,,,06/21/13,09/15/11,,,,01/26/09,01/26/05,,,,01/26/05,,,98%,,$    17.6,$    14.8,$    19.9,$     2.1,$    17.6,$    14.8,$    19.9,$     2.1,Q1 2019,"Astellas Pharma, Inc., Clinigen Group plc, Pharmascience Inc., R-PHARM JSC, SciClone Pharmaceuticals, Inc."
17347,435,22551,395,Viberzi,eluxadoline,Allergan plc,AGN,,Ireland,Europe,53945515162,Gastroenterology (non inflammatory bowel disease),Other,Irritable Bowel Syndrome (IBS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,07/21/2016 - 09/26/2016,,05/27/15,,,,,06/27/14,06/19/12,05/24/10,,,06/19/12,05/24/10,11/16/09,N/A,,$    93.3,$   156.6,$   176.5,$    88.0,N/A,$   157.1,$   177.8,$    88.6,Q2 2019,"Ironwood Pharmaceuticals, Inc., Johnson &amp; Johnson"
1712,137,2740,292,Victoza,liraglutide recombinant,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,01/25/10,06/30/09,01/20/10,,,03/23/08,01/27/06,,,,01/27/06,02/10/03,,95%,1944.3,N/A,N/A,N/A,$   585.2,"$  3,025.6","$  3,445.0","$  3,617.5",$   870.4,Q1 2019,Johnson &amp; Johnson
1712,135,5134,292,Victoza,liraglutide recombinant,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Metabolic,Obesity,Obesity,N,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,12/23/14,03/23/15,,,,12/20/13,10/01/08,10/06/06,,,10/01/08,10/27/06,,95%,,N/A,N/A,N/A,$   585.2,"$  3,025.6","$  3,445.0","$  3,617.5",$   870.4,Q1 2019,Johnson &amp; Johnson
1712,181,49477,292,Victoza,liraglutide recombinant,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Cardiovascular,General,Cardiovascular Disease,N,Approved,Approved,100% (Same As Avg.),Peptide,GLP-1 Receptor,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,08/25/17,07/27/17,,,,10/25/16,05/06/10,,,,05/06/10,,,95%,,N/A,N/A,N/A,$   585.2,"$  3,025.6","$  3,445.0","$  3,617.5",$   870.4,Q1 2019,Johnson &amp; Johnson
881,206,950,82,Vidaza,azacitidine,Celgene Corporation,CELG,New Jersey,United States,North America,65869523328,Oncology,Hematologic,Myelodysplastic Syndrome (MDS),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA Methyltransferase (DNMT),New Molecular Entity (NME),No,"Intravenous (IV), Subcutaneous (SQ)",Y,N,Y,N,N,N,,,,05/19/04,12/23/08,01/21/11,,,12/29/03,,,,,02/06/02,,,100%,36.8,$    11.9,$     8.0,$     9.0,$     3.0,$   607.9,$   628.0,$   724.6,$   182.7,Q1 2019,"BeiGene, Ltd., Nippon Shinyaku Co., Ltd., Novartis AG"
2025,3023,3301,289,Vigamox,moxifloxacin hydrochloride,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Topoisomerase II (DNA gyrase) and IV,Non-NME,No,Topical,N,N,N,N,N,N,,,,04/15/03,10/27/09,07/26/06,,,,,,,,02/22/02,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,Bayer AG
7083,167,8050,395,Viibryd,vilazodone hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT1 receptor^ Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/21/11,,,,,03/23/10,,,,,01/26/06,04/17/03,,N/A,,N/A,$   333.2,$   342.4,$   192.8,$   342.3,$   336.3,$   349.6,$   197.6,Q2 2019,"Merck KGaA, moksha8 Pharmaceuticals, Inc."
14777,2762,18739,65,Vimizim,elosulfase alfa,BioMarin Pharmaceutical Inc.,BMRN,California,United States,North America,13080442306,Metabolic,Inborn Errors Of Metabolism,Mucopolysaccharidosis IV (MPS IV; Morquio Syndrome),Y,Approved,Approved,100% (Same As Avg.),Protein,N-Acetylgalactosamine-6-Sulfate Sulfatase,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,02/14/14,04/28/14,12/29/14,,,04/01/13,02/01/11,,03/18/09,,02/01/11,03/18/09,,100%,440.4,N/A,N/A,$   482.0,$   248.5,$   260.4,$   413.5,$   482.0,$   248.5,Q2 2019,N/A
2773,1929,4720,2878,Vimovo,naproxen and esomeprazole,Horizon Pharma plc,HZNP,,Ireland,Europe,4452144302,Neurology,Pain,Arthritis Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)^ Proton pump",Non-NME,No,Oral (PO),N,Y,N,,N,N,,,,04/30/10,10/11/10,,,,06/30/09,09/07/07,,,,09/07/07,,05/03/07,N/A,,N/A,N/A,$    67.7,$    14.0,N/A,N/A,$    67.7,$    14.0,Q1 2019,"Grünenthal GmbH, Nuvo Pharmaceuticals, Inc."
6319,3009,6549,88,Vimpat,lacosamide,UCB SA,UCB:BB,,Belgium,Europe,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Collapsin Response Mediator Protein 2 (CRMP-2)^ Sodium Channels,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,10/28/08,08/29/08,07/04/16,,,09/28/07,,,,,02/18/04,04/07/03,,N/A,,$   685.0,$   904.8,$   933.5,N/A,$   903.0,"$  1,183.8","$  2,344.8",N/A,Q4 2018,"Daiichi Sankyo Co., Ltd., NewBridge Pharmaceuticals"
19626,705,25898,395,Viokace,pancrelipase,Allergan plc,AGN,,Ireland,Europe,53945515162,Gastroenterology (non inflammatory bowel disease),Other,Exocrine Pancreatic Insufficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,"Protein, fat, and/or carbohydrate absorption",Biologic,No,Oral (PO),N,N,N,,N,N,,,,03/01/12,,,,,12/31/09,,,,,10/01/96,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
10613,78,13294,70,Viramune XR,nevirapine,Boehringer Ingelheim GmbH,,,Germany,Europe,,Infectious disease,Antiviral,HIV / AIDS,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Reverse Transcriptase,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/25/11,09/21/11,,,,06/03/10,,,,,02/12/08,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
327,78,614,179,Viread,tenofovir disoproxil fumarate,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,HIV / AIDS,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,New Molecular Entity (NME),No,"Oral (PO), Topical",Y,N,N,N,N,N,,,,10/26/01,02/05/02,03/25/04,,,,,,,,,,,100%,57.4,$   591.0,$   514.0,$    50.0,$    21.0,"$  1,186.0","$  1,046.0",$   307.0,$   147.0,Q2 2019,"GlaxoSmithKline plc, Mylan N.V."
327,319,3652,179,Viread,tenofovir disoproxil fumarate,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ Reverse Transcriptase,New Molecular Entity (NME),No,"Oral (PO), Topical",N,N,N,N,N,N,,,,08/11/08,04/25/08,,,,10/11/07,07/19/05,,,,04/19/05,,,100%,472.9,$   591.0,$   514.0,$    50.0,$    21.0,"$  1,186.0","$  1,046.0",$   307.0,$   147.0,Q2 2019,"GlaxoSmithKline plc, Mylan N.V."
18021,2569,23536,3202,VisionBlue,,"DORC International, B.V.",,,Netherlands,Europe,,Ophthalmology,Other,Other Ophthalmological Indications (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Cell Membrane,Non-NME,No,Intraocular/Subretinal/Subconjunctival,N,N,N,,N,N,,,,12/16/04,,,,,10/24/03,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
27186,726,38017,534,Vistogard,uridine triacetate,BTG plc,BTG:LN,,United Kingdom,Europe,,Not Specified,Other,Drug Toxicity,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Nucleoside/Nucleotide,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,12/11/15,,,,,,,,,,05/01/09,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Wellstat Therapeutics Corporation
616,162,972,470,Visudyne,verteporfin,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Angiogenesis,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,04/12/00,07/27/00,10/16/03,,,08/16/99,,,,,08/09/99,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q2 2012,"Novartis AG, Novelion Therapeutics Inc."
23170,197,31698,59,Vitrakvi,larotrectinib,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Solid,Solid Tumors,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Trk (Tropomyosin Receptor Kinase) Receptors^ Tyrosine Kinases,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,07/25/2019 - 09/30/2019,,11/26/18,,,,,03/26/18,,10/14/15,,,,08/03/15,05/01/14,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Eli Lilly &amp; Company, Pfizer Inc."
1104,545,2083,470,Vitrase,hyaluronidase (ovine),Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Other,Spreading Agent,N,Approved,Approved,100% (Same As Avg.),Protein,Hyaluronic acid,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,05/05/04,,,,,08/05/03,,,,,,,,85%,9.5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2012,"Allergan plc, Otsuka Holdings Co., Ltd."
21974,152,29720,4140,Vituz,hydrocodone bitartrate; chlorpheniramine maleate,Currax Pharmaceuticals LLC,,New Jersey,United States,North America,,Allergy,General,Allergy,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1)^ Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,02/20/13,,,,,04/24/12,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
15068,423,19140,870,Vivaglobin,immune globulin subcutaneous (human),CSL Limited,CSL:AU,,Australia,Oceania,,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Subcutaneous (SQ),N,N,N,,N,N,,,,01/09/06,,,,,12/15/04,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2911,242,4960,289,Vivelle Dot,estradiol,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Osteoporosis / Osteopenia,Y,Approved,Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta),Non-NME,No,Transdermal,N,N,N,,N,N,,,,05/03/02,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q3 2013,"Hisamitsu Pharmaceutical Co., Inc."
1816,518,2894,22,Vivitrol,naltrexone,Alkermes plc,ALKS,,Ireland,Europe,3410652174,Psychiatry,Other,Alcohol Use Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,04/13/06,,,,,04/01/05,,,,,03/31/03,,,100%,,$   208.9,$   269.4,$   302.6,$   157.4,$   208.9,$   269.4,$   302.6,$   157.4,Q2 2019,Johnson &amp; Johnson
1816,560,12524,22,Vivitrol,naltrexone,Alkermes plc,ALKS,,Ireland,Europe,3410652174,Psychiatry,Other,Substance Use Disorder,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Intramuscular (IM),N,N,N,,N,N,,,,10/12/10,,,,,04/13/10,06/26/08,,,,06/26/08,06/14/06,,100%,,$   208.9,$   269.4,$   302.6,$   157.4,$   208.9,$   269.4,$   302.6,$   157.4,Q2 2019,Johnson &amp; Johnson
23605,249,32460,3445,Vivlodex,meloxicam,Zyla Life Sciences,ZCOR,Pennsylvania,United States,North America,,Rheumatology (non autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/22/15,,,,,12/23/14,03/04/13,,,,03/04/13,,,N/A,,N/A,N/A,N/A,$     3.8,N/A,N/A,N/A,$     3.8,Q1 2019,N/A
20663,1329,27611,28,Vizamyl,,General Electric,GE,Massachusetts,United States,North America,81327375250,Neurology,Neurodegenerative,Alzheimer's Disease - Imaging,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Amyloid Beta/Amyloid Plaques,New Molecular Entity (NME),Yes,Intravenous (IV),N,N,N,N,N,N,,,,10/25/13,08/22/14,,,,,,,,,09/16/10,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Merck &amp; Co., Inc."
7655,211,9398,312,Vizimpro,dacomitinib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,EGFR (Epidermal Growth Factor Receptor),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,09/27/18,04/02/19,01/08/19,,,01/31/18,01/28/10,09/30/08,,,01/12/10,09/30/08,06/04/07,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"SFJ Pharmaceuticals, Inc."
24196,549,33485,2817,Vogelxo,testosterone,"Sawai Pharmaceutical Co., Ltd.",4555:JP,Minnesota,United States,North America,,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Topical,N,N,N,N,N,N,,,,06/04/14,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
10854,1929,13607,142,Voltaren Gel,diclofenac sodium,Endo International plc,ENDP,,Ireland,Europe,554131557,Neurology,Pain,Arthritis Pain,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Topical,N,N,N,N,N,N,,,,10/17/07,,,,,12/19/06,,,,,,,,N/A,,$   100.7,$    68.8,$    44.2,N/A,$   100.7,$    68.8,$    44.2,N/A,Q3 2018,"Novartis AG, Phosphagenics Limited, Themis Medicare Ltd"
10504,574,13142,882,Voluven,hydroxyethyl starch 130/0.4,Fresenius SE & Co. KGaA,FSNUY,,Germany,Europe,0,Cardiovascular,Other,Hypovolemia,Y,Approved,Approved,100% (Same As Avg.),"Carbohydrate, Glycoprotein, or Glycopeptide",Blood plasma,Non-NME,No,Intravenous (IV),N,N,N,,N,N,,,,12/27/07,,,,,03/01/07,,,,,05/01/03,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
13981,2663,17682,826,Vonvendi,vonicog alfa,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Hematology,Factor Augmentation,Von Willebrand Disease,Y,Approved,Approved,100% (Same As Avg.),Protein,Von Willebrand Factor (vWF),Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,12/08/15,08/31/18,,,,12/19/14,08/04/11,,12/04/08,,08/04/11,,12/04/08,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
3047,726,5191,534,Voraxaze,glucarpidase,BTG plc,BTG:LN,,United Kingdom,Europe,,Not Specified,Other,Drug Toxicity,Y,Approved,Approved,100% (Same As Avg.),Protein,Methotrexate and Folate Analogues,Biologic,No,Intravenous (IV),Y,N,Y,,N,N,,01/01/2013 - 01/01/2013,01/01/2014 - 01/01/2014,01/17/12,,,,,07/18/11,,,,,02/03/03,,,100%,,N/A,N/A,N/A,N/A,N/A,$    33.2,N/A,N/A,Q4 2017,"Ohara Pharmaceutical Co., Ltd."
24018,176,33158,179,Vosevi,sofosbuvir/velpatasvir/voxilaprevir,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HCV Polymerase (NS5B) - Allosteric binding sites (Non-nucleosides)^ HCV Protease^ Non-structural 5A protein (NS5A),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,07/18/17,07/28/17,,,,12/08/16,12/09/15,08/14/14,07/09/14,,12/09/15,08/14/14,04/22/14,N/A,,N/A,$   267.0,$   304.0,$    98.0,N/A,$   293.0,$   396.0,$   138.0,Q2 2019,N/A
2454,216,4162,289,Votrient (Oral),pazopanib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Renal Cell Cancer (RCC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/19/09,06/14/10,03/17/14,,,12/19/08,,,,,05/03/06,11/30/05,,100%,215.1,$   357.0,$   407.0,$   404.0,$   172.0,$   729.0,$   808.0,$   828.0,$   380.0,Q2 2019,N/A
2454,610,7077,289,Votrient (Oral),pazopanib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Sarcoma,N,Approved,Approved,100% (Same As Avg.),Small Molecule,KIT/c-KIT^ Platelet-derived growth factor receptor (PDGFR)^ VEGF Receptor (VEGFR),New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,01/01/2015 - 01/01/2015,04/26/12,08/07/12,,,,07/06/11,09/01/08,,,,09/16/08,06/04/07,,100%,,$   357.0,$   407.0,$   404.0,$   172.0,$   729.0,$   808.0,$   828.0,$   380.0,Q2 2019,N/A
326,277,1092,826,Vpriv,velaglucerase alfa,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Metabolic,Inborn Errors Of Metabolism,Gaucher's Disease,Y,Approved,Approved,100% (Same As Avg.),Protein,Glucocerebroside (glucosylceramide),Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,07/01/2014 - 03/31/2015,02/26/10,08/26/10,07/03/14,,,08/31/09,07/31/06,,04/26/04,,07/31/06,04/26/04,,N/A,,$   155.3,$   150.3,$   113.9,N/A,$   345.7,$   349.9,$   440.8,N/A,Q3 2018,N/A
3054,170,5218,395,Vraylar,cariprazine hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/17/15,07/19/17,,,,11/19/12,03/15/10,11/09/06,,,03/09/10,11/09/06,11/22/04,80%,78.2,$    94.3,$   287.8,$   487.1,$   143.7,$    94.3,$   287.8,$   487.1,$   143.7,Q1 2019,"Gedeon Richter Plc, Mitsubishi Tanabe Pharma Corporation, Recordati SpA"
3054,168,5219,395,Vraylar,cariprazine hydrochloride,Allergan plc,AGN,,Ireland,Europe,53945515162,Psychiatry,Bipolar,Bipolar Disorder,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Serotonin 5-HT2B receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,09/17/15,,,,,11/19/12,02/01/10,05/30/07,,,02/01/10,05/30/07,11/22/04,80%,475.2,$    94.3,$   287.8,$   487.1,$   143.7,$    94.3,$   287.8,$   487.1,$   143.7,Q1 2019,"Gedeon Richter Plc, Mitsubishi Tanabe Pharma Corporation, Recordati SpA"
1093,275,2082,512,Vyleesi,bremelanotide,"AMAG Pharmaceuticals, Inc.",AMAG,Massachusetts,United States,North America,414082551,Obstetrics/Gynecology,Female Sexual Arousal Disorder,Female Sexual Arousal Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Melanocortin (MC) receptors,New Molecular Entity (NME),No,Subcutaneous (SQ),N,N,N,N,N,N,,,,06/21/19,,,,,03/23/18,12/29/14,02/07/06,02/01/01,,12/29/14,08/13/04,09/26/02,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Kwangdong Pharmaceutical Co., Ltd., Palatin Technologies, Inc., Shanghai Fosun Pharmaceutical Group Co., Ltd."
15046,3339,32002,312,Vyndaqel,tafamidis meglumine,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Metabolic,Other,"Transthyretin Amyloid Cardiomyopathy (ATTR-CM, Wild Type Or Hereditary)",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Transthyretin (TTR),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,,08/01/2019 - 02/29/2020,05/03/19,,,,,11/02/18,12/10/13,,,,12/10/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1908,506,3076,254,Vytorin,ezetimibe and simvastatin,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cholesterol Absorption^ HMG CoA Reductase (HMGR)^ Niemann-Pick C1-Like 1 (NPC1L1) protein,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/23/04,04/02/04,,,,09/24/03,,,,,,,,100%,975.8,$   473.0,$   125.0,$    11.0,$     6.0,"$  1,142.0",$   751.0,$   497.0,$   173.0,Q2 2019,"Laboratorios Farmacéuticos Rovi, S.A."
1993,246,3218,826,Vyvanse,lisdexamfetamine dimesylate,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Psychiatry,Other,Attention Deficit Hyperactivity Disorder (ADHD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine^ Norepinephrine (Noradrenaline),New Molecular Entity (NME),No,"Intranasal, Oral (PO)",N,N,N,N,N,N,,,,02/23/07,12/18/12,03/26/19,,,12/06/05,,,,,02/09/05,,,N/A,,"$  1,827.3","$  1,917.3","$  1,572.3",N/A,"$  2,013.9","$  2,161.1","$  2,853.8",N/A,Q3 2018,Shionogi &amp; Co. Ltd.
1993,2951,24141,826,Vyvanse,lisdexamfetamine dimesylate,Takeda Pharmaceutical Company Ltd,TAK,,Japan,Asia,,Psychiatry,Other,Eating Disorders,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dopamine^ Norepinephrine (Noradrenaline),New Molecular Entity (NME),No,"Intranasal, Oral (PO)",N,N,N,N,N,N,,,,01/30/15,,,,,07/24/14,10/17/12,05/18/11,,,10/17/12,04/28/11,,N/A,,"$  1,827.3","$  1,917.3","$  1,572.3",N/A,"$  2,013.9","$  2,161.1","$  2,853.8",N/A,Q3 2018,Shionogi &amp; Co. Ltd.
16722,97,21628,508,Vyxeos,,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule with Liposomal Delivery System,DNA polymerase^ DNA synthesis^ Topoisomerase II (DNA gyrase),Non-NME,No,Intravenous (IV),Y,N,Y,Y,N,N,,,,08/03/17,08/23/18,,,,10/03/16,12/26/12,,,,12/26/12,11/18/08,10/17/06,N/A,,N/A,$    34.0,$   100.6,$    28.9,N/A,$    34.0,$   100.6,$    28.9,Q1 2019,"Nippon Shinyaku Co., Ltd."
3237,278,5553,470,Vyzulta,latanoprostene bunod,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Nitric Oxide/ Nitrogen Monoxide^ Prostaglandin F receptor (FP)/PGF2 alpha receptor,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,11/02/17,,,,,07/24/15,01/29/13,03/28/07,,02/28/07,01/29/13,03/28/07,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Nicox S.A.
168,506,1666,343,WelChol,colesevelam hydrochloride,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bile Acids,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/26/00,03/10/04,,,,,,,,,,,,N/A,,$   277.0,$   306.0,$   123.4,N/A,N/A,$   306.0,$   123.4,N/A,Q4 2018,"Bausch Health Companies Inc., Sanofi"
168,137,10750,343,WelChol,colesevelam hydrochloride,"Daiichi Sankyo Co., Ltd.",DSKYF,,Japan,Asia,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bile Acids,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,01/18/08,,,,,12/22/06,,,,,06/10/06,,,N/A,,$   277.0,$   306.0,$   123.4,N/A,N/A,$   306.0,$   123.4,N/A,Q4 2018,"Bausch Health Companies Inc., Sanofi"
1216,167,1565,470,Wellbutrin XL,bupropion hydrochloride,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Dopamine Reuptake^ Norepinephrine (Noradrenaline) Reuptake/Transporter^ Serotonin Reuptake,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,08/29/03,01/16/07,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q4 2010,GlaxoSmithKline plc
20816,2663,27862,2684,Wilate,,Octapharma AG,,,Switzerland,Europe,,Hematology,Factor Augmentation,Von Willebrand Disease,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor VIII^ Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,Y,N,N,N,,,,12/04/09,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2204,194,3689,804,Xadago,safinamide mesylate,Newron Pharmaceuticals S.p.A.,NWRN:SW,,Italy,Europe,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Calcium Channel^ Dopamine Reuptake^ Monoamine oxidase B (MAO-B)^ Sodium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,07/01/2019 - 01/31/2020,03/21/17,02/24/15,,,,09/22/16,07/27/05,01/09/03,,,07/27/05,01/09/03,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"CSL Limited, Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd, US WorldMeds, LLC, Valeo Pharma Inc., Zambon Company S.p.A."
7681,211,9426,312,Xalkori,crizotinib,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Anaplastic lymphoma kinase (ALK)^ Hepatocyte growth factor receptor (c-Met, HGFR)^ RON receptor tyrosine kinase^ ROS kinase",New Molecular Entity (NME),No,Oral (PO),Y,N,Y,Y,N,N,,,,08/26/11,10/23/12,03/30/12,,,05/03/11,09/24/09,,,,09/24/09,,12/20/06,80%,523.3,$   251.0,$   222.0,$   158.0,$    75.0,$   560.0,$   595.0,$   524.0,$   256.0,Q2 2019,"Merck KGaA, OxOnc Development LP"
2859,634,4880,312,Xanax XR,alprazolam (extended release),Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Psychiatry,Anxiety,Panic Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/17/03,,,,,,,,,,,,,N/A,,$   170.0,$    47.0,$    11.0,N/A,$   342.0,$   225.0,$    54.0,N/A,Q1 2018,N/A
2859,169,4881,312,Xanax XR,alprazolam (extended release),Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Psychiatry,Anxiety,Generalized Anxiety Disorder (GAD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/17/03,,,,,,,,,,,,,N/A,,$   170.0,$    47.0,$    11.0,N/A,$   342.0,$   225.0,$    54.0,N/A,Q1 2018,N/A
2528,346,4290,223,Xarelto,rivaroxaban,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Hematology,Antithrombotic,Venous Thromboembolism (VTE),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/01/11,09/30/08,09/24/15,,,07/30/08,12/08/05,,,,12/08/05,07/25/05,,N/A,,"$  2,828.9","$  3,102.9","$  2,858.4","$  1,091.0","$  5,532.3","$  6,295.0","$  6,654.0","$  3,286.4",Q2 2019,Bayer AG
2528,2965,4291,223,Xarelto,rivaroxaban,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Hematology,Antithrombotic,Stroke Prevention in Atrial Fibrillation (SPAF),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,01/01/2013 - 01/01/2013,11/04/11,12/19/11,01/18/12,,,01/12/11,12/01/06,,,,07/17/07,12/08/05,,N/A,,"$  2,828.9","$  3,102.9","$  2,858.4","$  1,091.0","$  5,532.3","$  6,295.0","$  6,654.0","$  3,286.4",Q2 2019,Bayer AG
2528,267,29829,223,Xarelto,rivaroxaban,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,Coronary Artery Disease (General),Coronary Artery Disease,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,10/11/18,08/24/18,,,,12/11/17,11/13/12,,,,11/13/12,,,N/A,,"$  2,828.9","$  3,102.9","$  2,858.4","$  1,091.0","$  5,532.3","$  6,295.0","$  6,654.0","$  3,286.4",Q2 2019,Bayer AG
2528,390,34132,223,Xarelto,rivaroxaban,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Cardiovascular,Peripheral Vascular Disease,Peripheral Arterial Disease (PAD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Coagulation Factor X,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/11/18,08/24/18,,,,12/11/17,09/01/15,,,,11/13/12,,,N/A,,"$  2,828.9","$  3,102.9","$  2,858.4","$  1,091.0","$  5,532.3","$  6,295.0","$  6,654.0","$  3,286.4",Q2 2019,Bayer AG
21734,3127,29337,556,Xartemis XR,oxycodone and acetaminophen,Mallinckrodt plc,MNK,,United Kingdom,Europe,404069214,Neurology,Pain,Acute Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)^ Opioid receptors",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,03/11/14,,,,,05/28/13,11/30/11,,,,12/11/11,,11/24/08,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Assertio Therapeutics, Inc."
34641,199,47948,8134,Xatmep,methotrexate,Azurity Pharmaceuticals,,Massachusetts,United States,North America,,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR)^ Thymidylate Synthase,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,04/25/17,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
34641,365,47950,8134,Xatmep,methotrexate,Azurity Pharmaceuticals,,Massachusetts,United States,North America,,Autoimmune/immunology,Arthritis,Juvenile Rheumatoid Arthritis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Dihydrofolate reductase (DHFR)^ Thymidylate Synthase,Non-NME,No,Oral (PO),N,N,Y,N,N,N,,,,04/25/17,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
10177,154,12721,312,Xeljanz/Xeljanz XR,tofacitinib citrate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,JAK/STAT,New Molecular Entity (NME),No,"Oral (PO), Topical",N,N,N,N,N,N,,,,11/06/12,03/21/17,03/25/13,,,10/21/11,02/23/09,,,,02/23/09,11/15/06,,100%,2326.4,$   805.0,"$  1,133.0","$  1,393.0",$   756.0,$   927.0,"$  1,344.0","$  1,774.0","$  1,036.0",Q2 2019,N/A
10177,321,19627,312,Xeljanz/Xeljanz XR,tofacitinib citrate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),N,Approved,Approved,100% (Same As Avg.),Small Molecule,JAK/STAT,New Molecular Entity (NME),No,"Oral (PO), Topical",N,N,N,N,N,N,,,,05/30/18,08/01/18,05/25/18,,,05/04/17,07/20/12,03/05/09,,,05/10/12,03/05/09,,100%,,$   805.0,"$  1,133.0","$  1,393.0",$   756.0,$   927.0,"$  1,344.0","$  1,774.0","$  1,036.0",Q2 2019,N/A
10177,336,21020,312,Xeljanz/Xeljanz XR,tofacitinib citrate,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),N,Approved,Approved,100% (Same As Avg.),Small Molecule,JAK/STAT,New Molecular Entity (NME),No,"Oral (PO), Topical",N,N,N,N,N,N,,,,12/14/17,06/28/18,,,,,,,,,07/29/13,01/27/10,,100%,,$   805.0,"$  1,133.0","$  1,393.0",$   756.0,$   927.0,"$  1,344.0","$  1,774.0","$  1,036.0",Q2 2019,N/A
2620,213,4468,149,Xeloda,capecitabine,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Colorectal Cancer (CRC),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Thymidylate Synthase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,04/30/01,02/02/01,12/12/07,,,,,,,,,,,N/A,,$    80.8,$    36.6,$    35.4,$    15.0,$   516.8,$   462.1,$   433.7,$   216.0,Q2 2019,"Chugai Pharmaceutical Co., Ltd."
22445,278,30452,3285,Xelpros,latanoprost,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostaglandin F receptor (FP)/PGF2 alpha receptor,Non-NME,No,Topical,N,N,N,N,N,N,,,,09/14/18,,,,,02/26/14,,,,,05/30/10,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Sun Pharma Advanced Research Company Ltd.
30881,423,42701,2858,Xembify,"immune globulin subcutaneous, human-klhw","Grifols, S.A.",GRFS,,Spain,Europe,5717367155,Autoimmune/immunology,Other,Primary Immunodeficiencies,Y,Approved,Approved,100% (Same As Avg.),Protein,Immune system,Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,07/04/19,,,,,,06/20/16,,,,01/26/16,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2563,296,4353,470,Xenazine,tetrabenazine,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Neurology,Neurodegenerative,Huntington's Disease,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Vesicular monamine transporters (VMATs),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,08/15/08,02/14/07,,,,04/26/05,,,,,09/16/04,,,N/A,,$   234.0,$   113.0,$    62.2,N/A,$   234.0,$   159.5,$   116.3,N/A,Q4 2018,"H. Lundbeck A/S, Jazz Pharmaceuticals plc, Lupin Limited, UCB SA"
15894,257,20349,256,Xeomin,incobotulinumtoxinA,Merz Pharmaceuticals GmbH,,,Germany,Europe,,Neurology,"movement disorders, all",Cervical Dystonia,Y,Approved,Approved,100% (Same As Avg.),Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,Intramuscular (IM),N,N,N,,N,N,,,,07/30/10,10/24/07,,,,07/02/09,,,,,05/31/05,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Teijin Pharma Limited
15894,701,22439,256,Xeomin,incobotulinumtoxinA,Merz Pharmaceuticals GmbH,,,Germany,Europe,,Neurology,"movement disorders, all",Neuromuscular Spasm and Spasticity,Y,Approved,Approved,100% (Same As Avg.),Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,Intramuscular (IM),N,N,N,,N,N,,,,07/30/10,10/24/07,,,,07/02/09,,,,,05/31/05,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Teijin Pharma Limited
15894,1508,35884,256,Xeomin,incobotulinumtoxinA,Merz Pharmaceuticals GmbH,,,Germany,Europe,,Dermatology,General,Wrinkles,N,Approved,Approved,100% (Same As Avg.),Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,Intramuscular (IM),N,N,N,N,N,N,,,,07/20/11,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Teijin Pharma Limited
15894,192,48757,256,Xeomin,incobotulinumtoxinA,Merz Pharmaceuticals GmbH,,,Germany,Europe,,Neurology,General,Neurology - Other,N,Approved,Approved,100% (Same As Avg.),Protein,"SNARE Proteins (e.g. synaptobrevin, syntaxin, SNAP-25)",Biologic,No,Intramuscular (IM),N,N,N,N,N,N,,,,07/03/18,,,,,,04/29/14,,,,04/29/14,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,Teijin Pharma Limited
21141,440,28428,3641,Xepi,ozenoxacin,Biofrontera AG,BFRA,,Germany,Europe,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,12/11/17,,,,,06/23/16,,,,,01/19/12,09/15/09,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Cipher Pharmaceuticals Inc., Fujifilm Holdings Corp., Grupo Ferrer Internacional, S.A., Maruho Co., Ltd., Medimetriks Pharmaceuticals, Inc."
16847,536,21830,2854,Xerava,eravacycline,"Tetraphase Pharmaceuticals, Inc.",TTPH,Massachusetts,United States,North America,15551457,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Intra-Abdominal Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Gram-Negative Bacteria^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",Y,N,N,N,N,Y,,,,08/27/18,09/20/18,,,,12/28/17,09/03/13,03/24/11,,,09/03/13,03/24/11,06/01/10,N/A,,N/A,N/A,$     0.2,$     0.3,N/A,N/A,$     0.2,$     0.3,Q1 2019,Everest Medicines Limited
8074,665,9960,470,Xerese,acyclovir and hydrocortisone,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Infectious disease,Antiviral,Herpes Simplex Virus (HSV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR)^ Thymidine Kinase,Non-NME,No,Topical,N,N,N,,N,N,,,,07/31/09,10/15/09,,,,10/01/08,07/06/06,,,,07/06/06,10/25/00,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"GlaxoSmithKline plc, Medivir AB, Mylan N.V."
10895,347,13666,233,Xermelo,telotristat ethyl,"Lexicon Pharmaceuticals, Inc.",LXRX,Texas,United States,North America,154651086,Oncology,Solid,Neuroendocrine Tumors (NET),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Tryptophan hydroxylase,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,02/28/17,09/19/17,,,,03/30/16,10/12/12,05/27/09,,,05/03/12,05/27/09,03/06/08,100%,202.7,N/A,$    15.1,$    25.0,$    14.1,N/A,$    15.1,$    25.0,$    14.1,Q2 2019,Ipsen SA
1503,395,2375,30,Xgeva,denosumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Bone Complications (including bone metastases),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,RANK Ligand (RANKL),Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,11/18/10,07/15/11,01/18/12,,,05/14/10,07/20/06,,,,07/20/06,03/23/04,,100%,1277.3,"$  1,115.0","$  1,157.0","$  1,338.0",$   356.0,"$  1,654.9","$  1,716.0","$  1,786.0",$   504.6,Q1 2019,"AstraZeneca PLC, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories"
1503,684,31228,30,Xgeva,denosumab,"Amgen, Inc.",AMGN,California,United States,North America,1.31344E+11,Oncology,Solid,Bone Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,RANK Ligand (RANKL),Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,07/25/2014 - 09/29/2014,02/01/2014 - 08/31/2014,06/09/13,,,,,12/12/12,,,,,,05/31/08,,100%,,"$  1,115.0","$  1,157.0","$  1,338.0",$   356.0,"$  1,654.9","$  1,716.0","$  1,786.0",$   504.6,Q1 2019,"AstraZeneca PLC, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories"
23183,3159,31723,4325,Xhance,fluticasone propionate,"OptiNose, Inc.",OPTN,Pennsylvania,United States,North America,258084337,Allergy,General,Nasal Polyposis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucocorticoid Receptor (GR),Non-NME,No,Intranasal,N,N,N,N,N,N,,,,09/18/17,,,,,11/18/16,09/20/13,,,,09/20/13,,,N/A,,N/A,N/A,$     7.1,$     4.0,N/A,N/A,$     7.1,$     4.0,Q1 2019,N/A
2876,710,4917,142,Xiaflex,collagenase clostridium histolyticum,Endo International plc,ENDP,,Ireland,Europe,554131557,Urology,Other,Peyronie's Disease,N,Approved,Approved,100% (Same As Avg.),Protein,Collagen,Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,12/06/13,01/30/15,,,,11/07/12,10/11/10,,,,10/11/10,10/25/06,,N/A,,$   189.7,$   213.4,$   264.6,$   143.4,$   189.7,$   213.4,$   275.1,$   143.4,Q2 2019,"Asahi Kasei Corporation, BioSpecifics Technologies Corp., Johnson &amp; Johnson, Swedish Orphan Biovitrum"
2876,714,5016,142,Xiaflex,collagenase clostridium histolyticum,Endo International plc,ENDP,,Ireland,Europe,554131557,Orthopedics,General,Dupuytren's Contracture,Y,Approved,Approved,100% (Same As Avg.),Protein,Collagen,Biologic,No,Subcutaneous (SQ),N,N,Y,N,N,N,,,,02/02/10,02/28/11,07/20/15,,,02/27/09,,,,,06/21/06,09/30/02,,N/A,,$   189.7,$   213.4,$   264.6,$   143.4,$   189.7,$   213.4,$   275.1,$   143.4,Q2 2019,"Asahi Kasei Corporation, BioSpecifics Technologies Corp., Johnson &amp; Johnson, Swedish Orphan Biovitrum"
1107,554,2074,470,Xibrom,bromfenac sodium,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Topical,N,N,N,N,N,N,,,,03/28/05,05/18/11,,,,05/25/04,,,,,12/18/03,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,Q1 2012,"CROMA Pharma GmbH, Senju Pharmaceutical Co., Ltd."
1820,495,2905,470,Xifaxan,rifaximin,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),General,Gastroenteritis,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ RNA polymerase,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/26/04,,,,,12/17/01,07/13/99,,,,07/13/99,11/06/98,,90%,12.8,N/A,N/A,N/A,N/A,$   681.0,$   979.0,"$  1,195.0",$   306.0,Q1 2019,"Alfasigma S.p.A., Aska Pharmaceutical Company Limited, Norgine B.V."
1820,435,3664,470,Xifaxan,rifaximin,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),Other,Irritable Bowel Syndrome (IBS),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ RNA polymerase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/27/15,,,,,06/08/10,,,,,06/30/08,11/09/04,,90%,265.7,N/A,N/A,N/A,N/A,$   681.0,$   979.0,"$  1,195.0",$   306.0,Q1 2019,"Alfasigma S.p.A., Aska Pharmaceutical Company Limited, Norgine B.V."
1820,875,6494,470,Xifaxan,rifaximin,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Endocrine,Other,Hepatic Encephalopathy (HE),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ RNA polymerase,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,03/24/10,12/06/12,09/28/16,,,06/24/09,,,,,02/28/06,02/19/98,,90%,12.8,N/A,N/A,N/A,N/A,$   681.0,$   979.0,"$  1,195.0",$   306.0,Q1 2019,"Alfasigma S.p.A., Aska Pharmaceutical Company Limited, Norgine B.V."
10496,137,13131,45,Xigduo (IR and XR),,AstraZeneca PLC,AZN,,United Kingdom,Europe,28379095980,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Small Molecule,AMP-activated protein kinase (AMPK)^ SGLT,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/30/14,01/22/14,,,,,,,,,07/26/07,,,N/A,,N/A,N/A,N/A,$     0.0,N/A,N/A,N/A,$     0.0,N/A,"Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd."
12666,548,15992,289,Xiidra,lifitegrast,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Ophthalmology,Other,Dry Eye (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Lymphocyte function-associated antigen 1 (LFA-1)/(CD11a),New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,11/01/2019 - 05/31/2020,,07/11/16,,,,,02/25/15,08/17/11,06/22/09,,,08/17/11,06/22/09,01/04/07,N/A,,$    54.0,$   259.2,$   387.9,N/A,$    54.0,$   259.2,$   387.9,N/A,Q4 2018,N/A
26620,603,37159,3285,Ximino,Minocycline HCL,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Dermatology,General,Acne,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/11/12,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
16552,3134,21369,618,Xodol,hydrocodone bitartrate/acetaminophen,Shionogi & Co. Ltd.,4507:JP,,Japan,Asia,,Neurology,Pain,Moderate to Severe Pain,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,"Cannabinoid reuptake/Endocannabinoid system^ Cyclooxygenases (COX-1, COX-2, and COX-3)^ Opioid receptors",Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/30/04,,,,,,,,,,,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
17457,215,22717,59,Xofigo,radium Ra 223 dichloride,Bayer AG,BAYRY,,Germany,Europe,,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA^ Radiopharmaceutical^ Tumor Cells,New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,N,,,,05/15/13,11/13/13,03/29/16,,,12/14/12,12/11/09,,,12/31/07,12/11/09,01/30/09,08/12/08,100%,643.1,$   249.5,$   276.6,$   246.7,N/A,$   366.9,$   467.1,$   472.4,N/A,Q4 2018,N/A
25663,3302,35736,149,Xofluza,baloxavir marboxil,Roche Holding AG,RHHBY,,Switzerland,Europe,,Infectious disease,Antiviral,Influenza (excluding vaccines),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Influenza Virus^ Polymerase Acidic Protein (PA)^ RNA^ RNA polymerase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/24/18,,02/23/18,,,04/24/18,12/01/16,,,,12/01/16,,,N/A,,N/A,N/A,$    13.2,$     6.0,N/A,N/A,$    99.3,$   154.9,Q1 2019,Shionogi &amp; Co. Ltd.
73,72,181,149,Xolair,omalizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immunoglobulin E (IgE),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,06/20/03,10/25/05,01/21/09,,,06/02/00,,,,,,,,53%,1050.5,"$  1,524.7","$  1,777.1","$  1,941.5",$   470.5,"$  2,359.1","$  2,697.1","$  2,981.7",$   751.5,Q1 2019,"DRI Capital Inc., Novartis AG, PDL BioPharma, Inc."
73,647,16915,149,Xolair,omalizumab,Roche Holding AG,RHHBY,,Switzerland,Europe,,Allergy,General,Urticaria,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Immunoglobulin E (IgE),Biologic,No,Subcutaneous (SQ),N,N,N,N,N,N,,,02/01/2017 - 09/30/2017,03/21/14,03/06/14,,,,07/25/13,02/04/11,04/16/09,,,02/04/11,04/16/09,06/01/07,53%,,"$  1,524.7","$  1,777.1","$  1,941.5",$   470.5,"$  2,359.1","$  2,697.1","$  2,981.7",$   751.5,Q1 2019,"DRI Capital Inc., Novartis AG, PDL BioPharma, Inc."
603,72,1109,686,Xopenex HFA MDI,levalbuterol tartrate,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,03/11/05,,,,,05/13/04,,,,,12/02/03,,,95%,,$    52.0,$    33.0,N/A,N/A,$    52.0,$    33.0,$    41.0,$    21.0,Q2 2019,Bausch Health Companies Inc.
603,73,4084,686,Xopenex HFA MDI,levalbuterol tartrate,"Sumitomo Dainippon Pharma Co., Ltd.",4506:JP,,Japan,Asia,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta Adrenergic Receptors,Non-NME,No,Inhaled,N,N,N,N,N,N,,,,03/11/05,,,,,,,,,,,,,95%,,$    52.0,$    33.0,N/A,N/A,$    52.0,$    33.0,$    41.0,$    21.0,Q2 2019,Bausch Health Companies Inc.
22834,97,31124,814,Xospata,gilteritinib,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Anaplastic lymphoma kinase (ALK)^ Axl Receptor Tyrosine Kinase^ FMS-like tyrosine kinase 3 (FLT-3),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,10/01/2019 - 12/31/2019,,11/28/18,,09/21/18,,,03/29/18,,,,,04/16/15,12/17/13,08/01/13,N/A,,N/A,N/A,N/A,$    14.0,N/A,N/A,N/A,$    17.3,Q1 2019,N/A
20302,207,33546,3757,Xpovio,selinexor,Karyopharm Therapeutics,KPTI,Massachusetts,United States,North America,537264702,Oncology,Hematologic,Multiple Myeloma (MM),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Exportin-1/CRM1/XPO1,New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,12/01/2019 - 06/30/2020,,07/03/19,,,,,08/06/18,05/10/17,09/22/14,06/08/12,,05/10/17,09/22/14,06/18/12,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Antengene Corporation, Ono Pharmaceutical Company, Ltd."
18903,3629,24865,3447,Xtampza ER,extended-relesease oxycodone,"Collegium Pharmaceutical, Inc.",COLL,Massachusetts,United States,North America,392985272,Neurology,Pain,Chronic Low Back Pain (CLBP),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),Y,N,N,N,N,N,,,,04/26/16,,,,,12/12/14,02/22/12,,,,09/26/11,,,N/A,,N/A,$    28.6,$    69.3,$    25.1,N/A,$    28.6,$    69.3,$    25.1,Q1 2019,N/A
8138,215,10052,814,Xtandi,enzalutamide,"Astellas Pharma, Inc.",4503:JP,,Japan,Asia,,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Androgen receptors,New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,,,08/31/12,06/21/13,03/24/14,,,05/21/12,03/18/09,,,,03/18/09,11/05/07,,50%,2105.5,$   151.1,$   590.0,"$  2,080.1",$   517.5,"$  2,268.7","$  3,279.0","$  3,769.6",$   892.0,Q1 2019,"Pfizer Inc., Royalty Pharma AG, Tecnofarma International Ltd."
19434,3124,25624,4830,Xtoro,finafloxacin,MerLion Pharmaceuticals Pte Ltd,,,Singapore,Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO), Topical",Y,N,N,N,N,N,,,,12/17/14,,,,,04/30/14,,,,,01/25/12,,11/04/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16314,137,21036,292,Xultophy,degludec and liraglutide,Novo Nordisk A/S,NVO,,Denmark,Europe,1.01779E+11,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Y,Approved,Approved,100% (Same As Avg.),Protein,GLP-1 Receptor^ Insulin Receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,11/21/16,09/18/14,06/30/19,,,09/25/15,05/23/11,,09/22/09,,05/23/11,02/02/11,09/22/09,100%,4767,N/A,$    25.2,$    83.1,$    19.6,N/A,$   111.9,$   254.9,$    72.6,Q1 2019,N/A
12171,3163,35648,2333,Xuriden,uridine triacetate,Wellstat Therapeutics Corporation,,Maryland,United States,North America,,Metabolic,General,Metabolic - General,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Nucleoside/Nucleotide,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,09/04/15,,,,,01/08/15,,04/11/14,,,,09/03/09,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,BTG plc
10834,511,13580,312,Xyntha,"antihemophilic factor (recombinant), plasma/albumin-free",Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Hematology,Factor Augmentation,Hemophilia A,Y,Approved,Approved,100% (Same As Avg.),Protein,Coagulation Factor X,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,02/21/08,03/11/09,,,,04/25/07,,,,,,,,N/A,,N/A,$   112.0,$   109.0,$    49.0,N/A,$   551.0,$   514.0,$   214.0,Q2 2019,Swedish Orphan Biovitrum
21624,549,29169,1003,Xyosted,testosterone enanthate,"Antares Pharma, Inc.",ATRS,New Jersey,United States,North America,497830410,Endocrine,Other,Hypogonadism,Y,Approved,Approved,100% (Same As Avg.),Steroid,Androgen receptors,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,09/28/18,,,,,12/20/16,,,09/16/13,,07/22/14,09/16/13,,N/A,,N/A,N/A,N/A,$     4.8,N/A,N/A,N/A,$     4.8,Q1 2019,N/A
1131,433,2389,508,Xyrem,sodium oxybate,Jazz Pharmaceuticals plc,JAZZ,,Ireland,Europe,8251390296,Neurology,Other,Narcolepsy,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA Receptors^ GABA-B Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/17/02,10/13/05,,,,10/02/00,,,,,04/30/99,,,N/A,,N/A,N/A,"$  1,405.1",$   368.3,$   816.4,"$  1,186.3","$  1,405.1",$   368.3,Q1 2019,"Bausch Health Companies Inc., UCB SA"
2637,236,4506,88,Xyzal,levocetirizine,UCB SA,UCB:BB,,Belgium,Europe,,Allergy,General,Allergic Rhinitis,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/25/07,01/16/01,10/29/10,,,07/25/06,,,,,06/01/99,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    99.6,N/A,Q4 2018,"GlaxoSmithKline plc, Sanofi, Sumitomo Dainippon Pharma Co., Ltd."
19874,239,26350,59,Yasmin,drospirenone and ethinylestradiol,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Contraception,Contraception,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Mineralocorticoid Receptor^ Progesterone Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/11/01,,,,,,,,,,,,,N/A,,N/A,N/A,$    83.5,N/A,N/A,N/A,$   721.4,$   368.2,Q2 2019,N/A
3091,239,5297,59,Yaz,drospirenone and ethinyl estradiol,Bayer AG,BAYRY,,Germany,Europe,,Endocrine,Contraception,Contraception,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,03/16/06,05/06/08,,,,10/17/03,,,,,,,,N/A,,$   142.3,$    94.7,$    86.8,N/A,$   752.4,$   741.0,$   750.3,$   368.2,Q2 2019,N/A
3091,603,5298,59,Yaz,drospirenone and ethinyl estradiol,Bayer AG,BAYRY,,Germany,Europe,,Dermatology,General,Acne,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,01/29/07,,,,,03/27/06,,,,,,,,N/A,,$   142.3,$    94.7,$    86.8,N/A,$   752.4,$   741.0,$   750.3,$   368.2,Q2 2019,N/A
3091,566,5299,59,Yaz,drospirenone and ethinyl estradiol,Bayer AG,BAYRY,,Germany,Europe,,Neurology,Other,Premenstrual Dysphoric Disorder (PMDD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Steroid,Estrogen Receptor Alpha (ER1 or ER alpha)^ Estrogen Receptor Beta (ER2 or ER beta)^ Progesterone Receptor,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,10/05/06,,,,,12/23/04,,,,,,,,N/A,,$   142.3,$    94.7,$    86.8,N/A,$   752.4,$   741.0,$   750.3,$   368.2,Q2 2019,N/A
35,221,81,73,Yervoy,ipilimumab,Bristol-Myers Squibb Company,BMY,New York,United States,North America,75880921003,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Cytotoxic T-Lymphocyte Antigen 4 (CTLA4)^ Immune system,Biologic,No,Intravenous (IV),Y,Y,Y,N,N,N,,,,03/25/11,07/13/11,07/23/15,,,06/30/10,09/28/04,10/15/02,,,08/09/04,10/01/02,,N/A,,$   802.0,$   908.0,$   941.0,$   528.0,"$  1,053.0","$  1,244.0","$  1,330.0",$   751.0,Q2 2019,"Ono Pharmaceutical Company, Ltd."
23838,3095,32850,179,Yescarta,axicabtagene ciloleucel,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Oncology,Hematologic,Diffuse Large B-Cell Lymphoma (DLBCL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Cellular,Autologous Chimeric Antigen Receptor T-cells (CAR-T)^ Cluster of Differentiation 19 (CD19)^ Immune system^ Stem Cells/Other Cell Therapies^ T lymphocytes,Biologic,No,Intravenous (IV),N,N,Y,Y,N,N,,,,10/18/17,08/27/18,,,,12/04/16,,12/07/13,06/17/09,,,12/07/13,06/17/09,N/A,,N/A,N/A,$   263.0,$   189.0,N/A,N/A,$   264.0,$   216.0,Q2 2019,"Daiichi Sankyo Co., Ltd., Shanghai Fosun Pharmaceutical Group Co., Ltd."
2105,610,3467,223,Yondelis,trabectedin,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Oncology,Solid,Sarcoma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA,New Molecular Entity (NME),No,Intravenous (IV),N,N,Y,N,N,N,,,,10/23/15,09/17/07,09/28/15,,,11/24/14,05/26/11,,,,02/23/11,05/30/01,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$    82.0,$    41.0,Q2 2019,"Otsuka Holdings Co., Ltd., PharmaMar, S.A."
34794,215,48192,3285,Yonsa,abiraterone acetate,Sun Pharmaceutical Industries Ltd.,SUNP:IN,,India,Asia,,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome P450c17,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,05/22/18,,,,,05/23/17,,04/12/16,,,,04/12/16,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Churchill Pharmaceuticals LLC, Iroko Pharmaceuticals, LLC"
9719,73,12102,4724,Yupelri,revefenacin,"Theravance Biopharma, Inc.",TBPH,,Ireland,Europe,1177489360,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Muscarinic acetylcholine receptor,New Molecular Entity (NME),No,Inhaled,N,N,N,N,N,N,,,,11/09/18,,,,,11/10/17,09/14/15,11/14/11,12/12/07,,09/14/15,11/14/11,12/12/07,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Mylan N.V.
721,213,11775,51,Zaltrap,ziv-aflibercept,Sanofi,SNY,,France,Europe,1.05588E+11,Oncology,Solid,Colorectal Cancer (CRC),Y,Approved,Approved,100% (Same As Avg.),Protein,Placental growth factor (PlGF)^ VEGF (Vascular endothelial growth factor),Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,08/03/12,02/05/13,,,,02/03/12,12/01/07,,,,11/20/07,12/22/05,,50%,,$    12.3,$    10.3,$     2.2,$     0.5,$    52.6,$    86.5,$   100.9,$    49.8,Q1 2019,"Regeneron Pharmaceuticals, Inc."
15697,701,20027,8,Zanaflex,tizanidine hydrochloride,"Acorda Therapeutics, Inc.",ACOR,New York,United States,North America,129834265,Neurology,"movement disorders, all",Neuromuscular Spasm and Spasticity,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 2 Adrenergic Receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,08/29/02,,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q4 2015,Alkermes plc
19348,91,25501,289,Zarxio,filgrastim-sndz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Hematology,Marrow Or Peripheral Blood Stimulator,Neutropenia / Leukopenia,Y,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,03/06/15,02/06/09,03/24/14,,,05/08/14,,,,,01/19/12,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
19348,300,46116,289,Zarxio,filgrastim-sndz,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,"Surgical, Interventional Radiological, and Other Invasive Procedures",Bone Marrow Transplant and Stem Cell Transplant,N,Approved,Approved,100% (Same As Avg.),Protein,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,Biosimilar,No,"Intravenous (IV), Subcutaneous (SQ)",N,N,N,N,N,N,,,,03/06/15,02/06/09,,,,05/08/14,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
269,277,434,223,Zavesca,miglustat,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Metabolic,Inborn Errors Of Metabolism,Gaucher's Disease,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Glucosylceramide Synthase,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,07/31/03,11/20/02,,,,04/23/01,,,,,10/18/00,,,N/A,,$    34.6,N/A,N/A,N/A,$   107.9,N/A,N/A,N/A,Q4 2016,"Teva Pharmaceutical Industries Ltd., UCB SA"
16651,644,21514,470,Zegerid,omeprazole; sodium bicarbonate; magnesium hydroxide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),General,Gastroesophageal Reflux Disease (GERD),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gastric Acid^ Proton pump,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/15/04,,,,,08/15/03,,,,,,,,N/A,,N/A,$    16.0,$    21.0,N/A,N/A,$    16.0,$    21.0,N/A,Q4 2018,Norgine B.V.
16651,676,21517,470,Zegerid,omeprazole; sodium bicarbonate; magnesium hydroxide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Autoimmune/immunology,Other,Esophagitis,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gastric Acid^ Proton pump,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/15/04,,,,,08/15/03,,,,,,,,N/A,,N/A,$    16.0,$    21.0,N/A,N/A,$    16.0,$    21.0,N/A,Q4 2018,Norgine B.V.
16651,147,21518,470,Zegerid,omeprazole; sodium bicarbonate; magnesium hydroxide,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Gastroenterology (non inflammatory bowel disease),"Acid-Peptic (Gastritis Peptic Ulcer, Etc.)",Ulcers and other acid-peptic gastrointestinal disorders,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gastric Acid^ Proton pump,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/15/04,,,,,08/15/03,,,,,,,,N/A,,N/A,$    16.0,$    21.0,N/A,N/A,$    16.0,$    21.0,N/A,Q4 2018,Norgine B.V.
14378,224,18197,180,Zejula,niraparib,GlaxoSmithKline plc,GSK,,United Kingdom,Europe,1.09197E+11,Oncology,Solid,Ovarian Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Poly ADP-Ribose Polymerase (PARP),New Molecular Entity (NME),No,Oral (PO),Y,N,Y,N,N,N,,,,03/27/17,11/16/17,,,,09/12/16,07/23/13,,09/15/08,,02/14/13,,09/15/08,N/A,,N/A,$   108.6,$   165.9,$    76.0,N/A,$   108.6,$   165.9,$   128.0,Q2 2019,"Johnson &amp; Johnson, Medison Pharma Ltd., Merck &amp; Co., Inc., Takeda Pharmaceutical Company Ltd, Zai Laboratory, Inc."
1006,194,1363,470,Zelapar,selegiline,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Neurology,Neurodegenerative,Parkinson's Disease (PD),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Monoamine oxidase A (MAO-A)^ Monoamine oxidase B (MAO-B),Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,06/15/06,,,,,04/08/02,,,,,,,,77.5%,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2007,"Amarin Corporation plc, Cardinal Health Inc., Perrigo Company PLC, Teva Pharmaceutical Industries Ltd."
14736,221,18675,149,Zelboraf,vemurafenib,Roche Holding AG,RHHBY,,Switzerland,Europe,,Oncology,Solid,Melanoma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Raf kinase,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,08/17/11,02/17/12,12/26/14,,,05/10/11,01/08/10,09/29/09,,,10/15/09,09/29/09,01/08/09,95%,43.3,$    48.0,N/A,N/A,$     0.0,$   217.5,N/A,N/A,$     0.0,Q4 2016,"Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd."
14736,422,47388,149,Zelboraf,vemurafenib,Roche Holding AG,RHHBY,,Switzerland,Europe,,Autoimmune/immunology,General,Inflammatory Disorders,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Raf kinase,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,11/06/17,,,,,,,,,,,04/18/12,,95%,,$    48.0,N/A,N/A,$     0.0,$   217.5,N/A,N/A,$     0.0,Q4 2016,"Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd."
2364,435,3991,357,Zelnorm,tegaserod maleate,Alfasigma S.p.A.,,,Italy,Europe,,Gastroenterology (non inflammatory bowel disease),Other,Irritable Bowel Syndrome (IBS),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT4 receptor,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,07/24/02,,,,,02/16/00,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2007,N/A
20783,533,27812,870,Zemaira,,CSL Limited,CSL:AU,,Australia,Oceania,,Respiratory,Other,Emphysema,Y,Approved,Approved,100% (Same As Avg.),Peptide,Alpha-1-antitrypsin (A1AT)^ Protease,Biologic,No,Intravenous (IV),Y,N,N,N,N,N,,,,07/08/03,08/20/15,,,,01/06/03,,,,,12/20/00,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,N/A
25789,288,35902,2817,Zembrace SymTouch,sumatriptan succinate injection,"Sawai Pharmaceutical Co., Ltd.",4555:JP,Minnesota,United States,North America,,Neurology,Headache,Migraine and Other Headaches,N,Approved,Approved,100% (Same As Avg.),Not Specified,Serotonin 5-HT1 receptor,Non-NME,No,Subcutaneous (SQ),N,N,N,N,N,N,,,,01/28/16,,,,,03/30/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Dr. Reddy's Laboratories
16682,534,21566,4623,Zemdri,plazomicin,Cipla Limited,CIPLA:IN,,India,Asia,,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cell Membrane^ Gram-Negative Bacteria^ Protein synthesis,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,Y,N,Y,,09/01/2019 - 03/31/2020,,06/25/18,,,,,10/25/17,01/11/16,04/21/10,02/03/09,,01/11/16,04/21/10,02/03/09,N/A,,N/A,N/A,$     0.8,N/A,N/A,N/A,$     0.8,N/A,Q4 2018,"Ionis Pharmaceuticals, Inc."
1765,149,30884,5,Zemplar,paricalcitol,AbbVie Inc.,ABBV,Illinois,United States,North America,97789103418,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Parathyroid Hormone (PTH),New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,03/31/04,,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,Q2 2013,N/A
25788,584,35901,766,Zenavod,doxycycline,Dr. Reddy's Laboratories,RDY,,India,Asia,5864950562,Dermatology,General,Rosacea,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,01/27/16,,,,,03/30/15,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,N/A
3250,705,5581,395,Zenpep,pancrelipase,Allergan plc,AGN,,Ireland,Europe,53945515162,Gastroenterology (non inflammatory bowel disease),Other,Exocrine Pancreatic Insufficiency,Y,Approved,Approved,100% (Same As Avg.),Protein,"Protein, fat, and/or carbohydrate absorption",Biologic,No,Oral (PO),Y,N,N,,N,N,,07/01/2013 - 07/01/2013,,08/27/09,,,,,06/17/07,,,,,02/02/06,,,100%,,$   200.7,$   212.3,$   237.3,$   133.0,$   200.7,$   212.3,$   237.3,$   133.0,Q2 2019,"Samil Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd"
20096,176,26702,254,Zepatier,elbasvir and grazoprevir,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,Hepatitis C (HCV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HCV Protease^ Non-structural 5A protein (NS5A),New Molecular Entity (NME),No,Oral (PO),N,N,N,Y,N,N,,,,01/28/16,07/28/16,09/28/16,,,05/28/15,04/02/14,02/20/13,10/01/12,,04/02/14,02/20/13,10/01/12,N/A,558,$   488.0,$   772.0,$    18.0,$    72.0,$   555.0,"$  1,659.0",$   455.0,$   222.0,Q2 2019,N/A
16185,536,20801,254,Zerbaxa,ceftolozane sulfate/tazobactam sodium,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Intra-Abdominal Infections (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,Y,,,11/01/2018 - 05/31/2019,12/19/14,09/18/15,01/08/19,,,04/21/14,10/04/11,,,,10/04/11,06/30/10,09/15/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Astellas Pharma, Inc."
16185,534,20804,254,Zerbaxa,ceftolozane sulfate/tazobactam sodium,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,Y,,,11/01/2018 - 05/31/2019,12/19/14,09/18/15,01/08/19,,,04/21/14,06/20/11,06/30/10,,,06/20/11,,09/15/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Astellas Pharma, Inc."
16185,673,20805,254,Zerbaxa,ceftolozane sulfate/tazobactam sodium,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Beta-lactamase^ Gram-Negative Bacteria^ Penicillin Binding Proteins (PBP),New Molecular Entity (NME),No,Intravenous (IV),Y,N,N,N,N,Y,,07/25/2019 - 09/30/2019,,06/03/19,,,,,12/03/18,07/18/13,01/19/12,,,07/18/13,01/19/12,09/15/09,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Astellas Pharma, Inc."
24313,711,33678,7830,Zerviate,cetirizine,"Eyevance Pharmaceuticals, LLC",,,United States,North America,,Ophthalmology,General,Allergic Conjunctivitis (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histamine H1 Receptor (HRH1),Non-NME,No,Topical,N,N,N,N,N,N,,,,05/30/17,,,,,04/19/16,,,,,06/18/13,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Nicox S.A.
1907,506,3086,254,Zetia,ezetimibe,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Cholesterol Absorption^ Niemann-Pick C1-Like 1 (NPC1L1) protein,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,10/25/02,10/17/02,04/18/07,,,,,,,,,,,100%,2982.8,"$  1,494.0",$   352.0,$    45.0,$     6.0,"$  2,581.0","$  1,344.0",$   857.0,$   296.0,Q2 2019,"Bayer AG, Laboratorios Farmacéuticos Rovi, S.A."
11152,236,14003,8484,Zetonna,ciclesonide,Covis Pharma B.V.,,,Switzerland,Europe,,Allergy,General,Allergic Rhinitis,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Inhaled,N,N,N,,N,N,,,,01/20/12,,,,,03/31/11,,,,,10/28/08,01/28/08,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Q1 2015,N/A
15,3093,20,9097,Zevalin,ibritumomab tiuxetan,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ Cluster of Differentiation 20 (CD20)^ Radiopharmaceutical,Biologic,No,Intravenous (IV),Y,N,Y,N,N,N,,,,02/20/02,01/16/04,01/25/08,,,11/01/00,,,,,,,,85%,,$    10.7,$    11.7,$     7.0,N/A,N/A,$    11.7,$     7.0,N/A,Q4 2018,"Bayer AG, Biogen, Inc., CASI Pharmaceuticals, Inc., Les Laboratoires Servier, Mundipharma International Limited"
15,205,28534,9097,Zevalin,ibritumomab tiuxetan,Aurobindo Pharma Limited,ARBP:IN,,India,Asia,,Oncology,Hematologic,Non-Hodgkin's Lymphoma (NHL),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Antibody-drug Conjugate (ADC)^ Cluster of Differentiation 20 (CD20)^ Radiopharmaceutical,Biologic,No,Intravenous (IV),N,N,N,,N,N,,,,02/19/02,,,,,,,,,,,,,85%,18.1,$    10.7,$    11.7,$     7.0,N/A,N/A,$    11.7,$     7.0,N/A,Q4 2018,"Bayer AG, Biogen, Inc., CASI Pharmaceuticals, Inc., Les Laboratoires Servier, Mundipharma International Limited"
20305,249,27046,3758,Zilretta,triamcinolone acetonide,"Flexion Therapeutics, Inc.",FLXN,Massachusetts,United States,North America,451252305,Rheumatology (non autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,Y,Approved,Approved,100% (Same As Avg.),Steroid,Glucocorticoid Receptor (GR),Non-NME,No,Intraarticular,Y,N,N,N,N,N,,,,10/06/17,,,,,12/08/16,02/02/15,,,,09/03/14,12/05/11,,N/A,,N/A,$     0.4,$    22.6,$    10.6,N/A,$     0.4,$    22.6,$    10.6,Q1 2019,Thermo Fisher Scientific
8257,531,32837,5122,Zingo,lidocaine hydrochlorie,Marathon Pharmaceuticals LLC,,Illinois,United States,North America,,Neurology,Pain,Anesthesia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,Non-NME,No,Intradermal,N,N,N,N,N,N,,,,08/16/07,,,,,11/21/06,,,,,12/31/04,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,N/A,Lee's Pharmaceutical Holdings Limited
2078,487,3402,254,Zinplava,bezlotoxumab,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,Clostridium difficile toxins A and B,Biologic,No,Intravenous (IV),N,Y,N,N,N,N,,,,10/21/16,01/18/17,09/27/17,,,11/23/15,11/10/11,10/11/05,,,11/10/11,05/17/06,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Bristol-Myers Squibb Company
14998,278,19035,583,Zioptan,tafluprost,Akorn Inc.,AKRX,Illinois,United States,North America,352633568,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Prostaglandin Receptors,New Molecular Entity (NME),No,Intraocular/Subretinal/Subconjunctival,N,N,N,,N,N,,,,02/10/12,05/07/08,10/17/08,,,01/07/12,,,,,07/29/05,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   163.6,N/A,Q4 2018,"Merck &amp; Co., Inc., Santen Pharmaceutical Co., Ltd."
15668,3127,19989,120,Zipsor,diclofenac potassium,"Assertio Therapeutics, Inc.",ASRT,Illinois,United States,North America,,Neurology,Pain,Acute Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/16/09,,,,,09/11/07,,,,,,,,N/A,,N/A,N/A,$    16.3,$     4.2,N/A,N/A,$    16.3,$     4.2,Q1 2019,Ferring Pharmaceuticals
23464,211,32217,312,Zirabev,bevacizumab-bvzr,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,06/27/19,02/19/19,,,,06/29/18,04/23/15,,10/29/13,,04/23/15,,10/29/13,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23464,213,56149,312,Zirabev,bevacizumab-bvzr,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Colorectal Cancer (CRC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,06/27/19,02/19/19,06/18/19,,,06/29/18,,,,,03/31/18,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23464,216,56151,312,Zirabev,bevacizumab-bvzr,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Renal Cell Cancer (RCC),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,06/27/19,02/19/19,,,,06/29/18,,,,,03/31/18,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23464,255,56152,312,Zirabev,bevacizumab-bvzr,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Cervical Cancer,N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,06/27/19,02/19/19,,,,06/29/18,,,,,03/31/18,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
23464,228,56933,312,Zirabev,bevacizumab-bvzr,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),N,Approved,Approved,100% (Same As Avg.),Monoclonal Antibody,VEGF (Vascular endothelial growth factor),Biosimilar,No,Intravenous (IV),N,N,N,N,N,N,,,,06/27/19,,,,,06/29/18,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16859,665,21850,470,Zirgan,ganciclovir,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Infectious disease,Antiviral,Herpes Simplex Virus (HSV) (Antiviral),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,DNA polymerase^ DNA synthesis,Non-NME,No,Topical,N,N,Y,,N,N,,,,09/15/09,,,,,11/17/08,,,,,01/18/07,,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,"Laboratorios Théa, Sirion Holdings, Inc."
2034,3124,52636,312,Zithromax,azithromycin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,12/14/01,,,,,02/16/01,,12/31/08,,,,,,N/A,,$     7.0,$     3.0,$     3.0,N/A,$   272.0,$   270.0,$   162.0,N/A,Q2 2018,N/A
10503,488,13140,312,Zmax,azithromycin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/10/05,,,,,08/12/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
10503,643,13141,312,Zmax,azithromycin,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Respiratory Tract Infections (Excluding Pneumonia) (Antibacterial),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,Non-NME,No,Oral (PO),N,N,N,,N,N,,,,06/10/05,,,,,08/12/04,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
17288,3629,22436,4140,Zohydro ER,hydrocodone bitartrate,Currax Pharmaceuticals LLC,,New Jersey,United States,North America,,Neurology,Pain,Chronic Low Back Pain (CLBP),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/25/13,,,,,05/02/12,03/17/10,,,,03/17/10,11/27/07,,N/A,,N/A,$    24.0,$    22.0,N/A,$    17.5,$    24.0,$    22.0,N/A,Q3 2018,"Alkermes plc, Endo International plc, Purdue Pharma L.P., Zogenix, Inc."
27224,3065,38086,289,Zolgensma,onasemnogene abeparvovac-xioi,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Spinal Muscular Atrophy,Y,Approved,Approved,100% (Same As Avg.),Viral Gene Therapy,Survival of Motor Neuron (SMN) Protein,Biologic,No,"Intravenous (IV), Intrathecal",Y,N,Y,Y,N,N,,09/01/2019 - 03/31/2020,01/01/2019 - 06/30/2019,05/24/19,,,,,10/18/18,10/10/17,,05/16/14,,10/10/17,05/16/14,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Catalent, Inc, Genethon, Regenxbio Inc."
1849,417,2967,254,Zolinza,vorinostat,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Oncology,Hematologic,Cutaneous T-Cell Lymphoma (CTCL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Histone Deacetylase (HDAC),New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,10/06/06,,07/01/11,,,04/07/06,,,,,,12/09/03,,N/A,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2862,566,4887,312,Zoloft,sertraline hydrochloride,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Neurology,Other,Premenstrual Dysphoric Disorder (PMDD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,05/16/02,,,,,,,,,,,,,N/A,,$    61.0,$    52.0,$    57.0,$    23.0,$   304.0,$   291.0,$   298.0,$   142.0,Q2 2019,N/A
2862,635,4888,312,Zoloft,sertraline hydrochloride,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Psychiatry,Other,Social Anxiety Disorder (SAD),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Serotonin Reuptake,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,02/07/03,,,,,,,,,,,,,N/A,,$    61.0,$    52.0,$    57.0,$    23.0,$   304.0,$   291.0,$   298.0,$   142.0,Q2 2019,N/A
6937,291,7107,5817,ZolpiMist,zolpidem tartrate,"Aytu BioScience, Inc.",AYTU,Colorado,United States,North America,12001401,Neurology,Insomnia,Insomnia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,GABA-A Receptor,Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,12/19/08,,,,,11/21/07,,,,,08/08/06,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Akorn Inc., Amherst Pharmaceuticals, LLC, Eddingpharm, Rechon Life Science, SUDA Pharmaceuticals Ltd."
1769,395,2835,289,Zometa,zoledronic acid,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown,Bone Complications (including bone metastases),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Osteoclast,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,08/20/01,03/20/01,04/01/06,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,N/A
1769,207,21843,289,Zometa,zoledronic acid,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Hematologic,Multiple Myeloma (MM),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Osteoclast,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,N,N,N,,,,02/22/02,,,,,,,,,,,,,N/A,,N/A,$     0.0,$     0.0,$     0.0,N/A,$     0.0,$     0.0,$     0.0,Q4 2014,N/A
1388,3009,22787,2647,Zonegran,zonisamide,ADVANZ PHARMA Corp.,ADVZ:CN,Ontario,Canada,North America,,Neurology,Seizure Disorders (Epilepsy),Partial Seizures (Epilepsy),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Sodium and Calcium Channels,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,03/28/00,03/10/05,,,,03/19/97,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,$   144.7,$    38.2,Q1 2019,"Eisai Co., Ltd., Ewopharma AG, Sumitomo Dainippon Pharma Co., Ltd."
2633,181,4497,486,Zontivity,vorapaxar,Aralez Pharmaceuticals Inc.,ARLZ,Ontario,Canada,North America,,Cardiovascular,General,Cardiovascular Disease,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Thrombin Receptor (PAR-1),New Molecular Entity (NME),No,Oral (PO),Y,N,N,N,N,N,,10/01/2014 - 07/31/2015,,05/08/14,01/19/15,,,,05/10/13,,,,,04/18/07,04/19/06,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Merck &amp; Co., Inc."
2633,390,37241,486,Zontivity,vorapaxar,Aralez Pharmaceuticals Inc.,ARLZ,Ontario,Canada,North America,,Cardiovascular,Peripheral Vascular Disease,Peripheral Arterial Disease (PAD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Thrombin Receptor (PAR-1),New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,05/08/14,07/29/16,,,,05/10/13,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Merck &amp; Co., Inc."
1681,380,2703,289,Zortress,everolimus,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Transplant Rejection,Kidney Transplant Rejection,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Mammalian Target of Rapamycin (mTOR)/mTORC,New Molecular Entity (NME),No,Oral (PO),N,N,N,,N,N,,,,04/20/10,12/01/03,12/31/11,,,12/19/02,,,,,10/18/05,,,N/A,,N/A,N/A,$    40.0,$    82.0,$   398.0,$   414.0,$   464.0,$   240.0,Q2 2019,N/A
1681,727,13231,289,Zortress,everolimus,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Autoimmune/immunology,Transplant Rejection,Liver Transplant Rejection,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Mammalian Target of Rapamycin (mTOR)/mTORC,New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,,02/15/13,10/25/12,,,,10/24/11,,,,,12/19/05,,,N/A,,N/A,N/A,$    40.0,$    82.0,$   398.0,$   414.0,$   464.0,$   240.0,Q2 2019,N/A
21750,249,29367,3445,Zorvolex,diclofenac,Zyla Life Sciences,ZCOR,Pennsylvania,United States,North America,,Rheumatology (non autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,N,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,08/25/14,,,,,10/31/13,10/27/11,,,,10/27/11,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Algorithm S.A.L., Aspen Pharmacare Holdings Limited, EMS S.A., Landsteiner Scientific, S.A., PT Pratapa Nirmala-Fahrenheit"
21750,3133,29368,3445,Zorvolex,diclofenac,Zyla Life Sciences,ZCOR,Pennsylvania,United States,North America,,Neurology,Pain,Mild to Moderate Pain,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"Cyclooxygenases (COX-1, COX-2, and COX-3)",Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,10/18/13,,,,,10/20/12,,,,,02/27/12,09/25/09,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Algorithm S.A.L., Aspen Pharmacare Holdings Limited, EMS S.A., Landsteiner Scientific, S.A., PT Pratapa Nirmala-Fahrenheit"
1914,641,3085,254,Zostavax,varicella-zoster live virus,"Merck & Co., Inc.",MRK,New Jersey,United States,North America,2.2384E+11,Infectious disease,Antiviral,Chickenpox and Shingles - Vaccines and Treatments,Y,Approved,Approved,100% (Same As Avg.),Vaccine,Immune system^ Varicella Zoster Virus (VSV),Vaccine,No,"Intramuscular (IM), Subcutaneous (SQ)",N,N,N,,N,N,,,,05/26/06,05/19/06,,,,05/02/05,,,,,12/14/04,,,N/A,,$   518.0,$   421.0,$    23.0,N/A,$   685.0,$   669.0,$   217.0,N/A,Q4 2018,N/A
26932,3157,37639,3533,ZTlido,lidocaine,"Sorrento Therapeutics, Inc.",SRNE,California,United States,North America,262887954,Neurology,Pain,Postherpetic Neuralgia (PHN),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Sodium Channels,Non-NME,No,Transdermal,N,N,N,N,N,N,,10/01/2018 - 03/31/2019,,02/28/18,,,,,07/10/15,,,,,,,05/19/14,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
17198,560,22316,1229,Zubsolv,buprenorphine/naloxone,Orexo AB,ORX:SS,,Sweden,Europe,0,Psychiatry,Other,Substance Use Disorder,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Opioid receptors,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,N,N,N,,,,07/03/13,11/10/17,,,,09/06/12,,,,,05/03/12,,08/20/10,N/A,,N/A,N/A,$    67.8,$    37.1,N/A,N/A,$    71.7,$    37.1,Q2 2019,Mundipharma International Limited
22337,167,34590,4253,Zulresso,brexanolone,"Sage Therapeutics, Inc.",SAGE,Massachusetts,United States,North America,7763578270,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Y,Approved,Approved,100% (Same As Avg.),Steroid,GABA-A Receptor,New Molecular Entity (NME),No,Intravenous (IV),N,N,N,Y,N,N,,,,03/19/19,,,,,04/19/18,,,,,12/06/16,11/05/14,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Ligand Pharmaceuticals, Inc."
18962,767,24951,3464,Zuplenz,ondansetron,Midatech Pharma PLC,MTP,,United Kingdom,Europe,40926371,Oncology,General,Chemotherapy Induced Nausea and Vomiting (CINV),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT3 receptor,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,07/02/10,03/23/10,,,,,,,,,02/21/08,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"APR Applied Pharma Research SA, Aquestive Therapeutics, Inc., Norgine B.V., R-PHARM JSC, Tesa SE, Vestiq Pharmaceuticals"
18962,594,27465,3464,Zuplenz,ondansetron,Midatech Pharma PLC,MTP,,United Kingdom,Europe,40926371,Not Specified,Other,Emesis,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Serotonin 5-HT3 receptor,Non-NME,No,Sublingual (SL)/Oral Transmucosal,N,N,N,,N,N,,,,07/02/10,03/23/10,,,,,,,,,02/21/08,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"APR Applied Pharma Research SA, Aquestive Therapeutics, Inc., Norgine B.V., R-PHARM JSC, Tesa SE, Vestiq Pharmaceuticals"
12471,539,15730,916,Zurampic,lesinurad,"Ironwood Pharmaceuticals, Inc.",IRWD,Massachusetts,United States,North America,1322377638,Autoimmune/immunology,Arthritis,Gout,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,"URAT1 (urate trans-porter 1, SLC22A12/Solute carrier family 22, member 12)",New Molecular Entity (NME),No,Oral (PO),N,N,N,N,N,N,,,01/01/2018 - 12/31/2018,12/22/15,02/18/16,,,,12/25/14,12/19/11,04/20/09,08/21/08,,12/19/11,04/20/09,08/21/08,N/A,,N/A,N/A,$     3.4,N/A,N/A,N/A,$     3.4,N/A,Q4 2018,"AstraZeneca PLC, Grünenthal GmbH"
16561,690,21384,470,Zyclara,imiquimod,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Dermatology,General,Actinic Keratoses,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Immune system,New Molecular Entity (NME),No,Topical,N,N,N,N,N,N,,,,03/25/10,08/23/12,,,,12/19/08,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Mylan N.V.
16561,238,22014,470,Zyclara,imiquimod,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Infectious disease,Antiviral,Human Papillomavirus (HPV) Treatment (Antiviral),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Immune system,New Molecular Entity (NME),No,Topical,N,N,N,,N,N,,,,03/25/11,,,,,,,,,,,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,Mylan N.V.
15282,200,19424,179,Zydelig,idelalisib,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Oncology,Hematologic,Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,p110 delta/PIK3CD^ PI3K/AKT pathway,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,01/01/2018 - 01/01/2018,07/23/14,09/18/14,,,,12/06/13,,10/19/10,,,01/09/12,10/19/10,03/11/08,100%,735.4,N/A,N/A,$    61.0,$    23.0,$   168.0,$   149.0,$   133.0,$    53.0,Q2 2019,N/A
15282,3093,22789,179,Zydelig,idelalisib,"Gilead Sciences, Inc.",GILD,California,United States,North America,83179741051,Oncology,Hematologic,Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL,N,Approved,Approved,100% (Same As Avg.),Small Molecule,p110 delta/PIK3CD^ PI3K/AKT pathway,New Molecular Entity (NME),No,Oral (PO),N,N,Y,N,N,N,,,,07/23/14,09/18/14,,,,09/11/13,,01/21/11,,,02/04/13,01/21/11,03/11/08,100%,,N/A,N/A,$    61.0,$    23.0,$   168.0,$   149.0,$   133.0,$    53.0,Q2 2019,N/A
2472,72,4193,851,Zyflo CR,zileuton,Chiesi Farmaceutici S.p.A.,,,Italy,Europe,,Respiratory,Asthma,Asthma,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,5-lipoxygenase (5LO),Non-NME,No,Oral (PO),N,N,N,,N,N,,,,05/30/07,,,,,07/31/06,,,,,01/12/04,,,N/A,,N/A,N/A,$     0.0,$     0.0,N/A,N/A,$     0.0,$     0.0,N/A,"AbbVie Inc., Mylan N.V., Vansen Pharma Inc., Vectura Group plc"
18443,211,24167,289,Zykadia,ceritinib,Novartis AG,NVS,,Switzerland,Europe,2.10594E+11,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Anaplastic lymphoma kinase (ALK)^ IGF-1R (Insulin-like Growth Factor-1 Receptor)^ Insulin Receptor^ ROS kinase,New Molecular Entity (NME),No,Oral (PO),N,N,Y,Y,N,N,,,,04/29/14,05/08/15,03/31/16,,,12/24/13,07/31/13,01/18/13,06/07/11,,07/31/13,01/18/13,06/07/11,N/A,,N/A,N/A,N/A,$     0.0,$    91.0,N/A,N/A,$     0.0,Q4 2016,N/A
19801,554,26235,470,Zylet,loteprednol etabonate 0.5%/tobramycin 0.3%,Bausch Health Companies Inc.,BHC,Quebec,Canada,North America,7936757676,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Glucocorticoid Receptor (GR)^ Gram-Negative Bacteria^ Protein synthesis,Non-NME,No,Topical,N,N,N,,N,N,,,,12/24/04,,,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
16810,3023,21767,395,Zymar,gatifloxacin,Allergan plc,AGN,,Ireland,Europe,53945515162,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Bacterial Conjunctivitis (Ophthalmology),Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Gram-Negative Bacteria^ Topoisomerase II (DNA gyrase) and IV,Non-NME,No,Topical,N,N,N,,N,N,,,,03/28/03,,07/09/04,,,,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Kyorin Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd."
37544,506,52350,3380,Zypitamag,pitavastatin magnesium,Zydus Cadila,CDH:IN,,India,Asia,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,HMG CoA Reductase (HMGR),Non-NME,No,Oral (PO),N,N,N,N,N,N,,,,07/14/17,,,,,03/31/15,,,,,,,,N/A,,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,Medicure Inc.
2144,168,3551,136,Zyprexa (Oral and IM),olanzapine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Bipolar,Bipolar Disorder,N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 4 (D4) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,,N,N,,,,03/17/00,06/04/02,12/31/10,,,01/29/98,10/18/96,,,,10/18/96,,,100%,51,$    69.7,$    75.5,$    36.2,$    18.6,$   725.3,$   581.1,$   471.3,$   211.5,Q2 2019,N/A
2144,167,18766,136,Zyprexa (Oral and IM),olanzapine,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),N,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 4 (D4) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT2C receptor,New Molecular Entity (NME),No,"Intramuscular (IM), Oral (PO)",N,N,N,,N,N,,,,03/23/09,,,,,,,,,,,,,100%,,$    69.7,$    75.5,$    36.2,$    18.6,$   725.3,$   581.1,$   471.3,$   211.5,Q2 2019,N/A
3264,170,5621,136,Zyprexa Relprevv,olanzapine pamoate,Eli Lilly & Company,LLY,Indiana,United States,North America,1.22564E+11,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Alpha 1 Adrenergic Receptor^ Dopamine 1 (D1) Receptor^ Dopamine 2 (D2) Receptor^ Dopamine 3 (D3) Receptor^ Dopamine 4 (D4) Receptor^ Histamine H1 Receptor (HRH1)^ Serotonin 5-HT2A receptor^ Serotonin 5-HT6 receptor,Non-NME,No,Intramuscular (IM),N,N,N,N,N,N,,,,12/11/09,11/19/08,,,,04/30/07,,,,,04/01/06,,,100%,,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,$     0.0,N/A,N/A
2630,215,4492,223,Zytiga,abiraterone acetate,Johnson & Johnson,JNJ,New Jersey,United States,North America,3.5783E+11,Oncology,Solid,Prostate Cancer,Y,Approved,Approved,100% (Same As Avg.),Small Molecule,Cytochrome P450c17,New Molecular Entity (NME),No,Oral (PO),N,Y,N,N,N,N,,,,04/28/11,09/05/11,07/04/14,,,12/20/10,04/23/08,,,,04/23/08,09/30/05,10/25/04,95%,988.9,"$  1,089.0","$  1,228.0","$  1,771.0",$   383.0,"$  2,260.0","$  2,505.0","$  3,498.0","$  1,377.0",Q2 2019,"AstraZeneca PLC, BTG plc"
1753,440,2794,312,Zyvox,linezolid,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,04/18/00,01/05/01,04/04/01,,,,,,,,,,,100%,718.7,$    55.0,$    15.0,$     3.0,$    18.0,$   466.0,$   281.0,$   236.0,$   135.0,Q2 2019,N/A
1753,3110,3151,312,Zyvox,linezolid,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal","Septicemia or Bacteremia (Antibacterial, including Endocarditis)",Y,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,04/18/00,,,,,,,,,,,,,100%,,$    55.0,$    15.0,$     3.0,$    18.0,$   466.0,$   281.0,$   236.0,$   135.0,Q2 2019,N/A
1753,673,22804,312,Zyvox,linezolid,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,04/18/00,,,,,,,,,,,,,100%,,$    55.0,$    15.0,$     3.0,$    18.0,$   466.0,$   281.0,$   236.0,$   135.0,Q2 2019,N/A
1753,488,22805,312,Zyvox,linezolid,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Infectious disease,"Antibacterial, Mycobacterial, or Fungal",Community Acquired Pneumonia (CAP) (Antibacterial),N,Approved (Generic Competition),Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,N,N,N,,,,04/18/00,,,,,,,,,,,,,100%,,$    55.0,$    15.0,$     3.0,$    18.0,$   466.0,$   281.0,$   236.0,$   135.0,Q2 2019,N/A
1753,694,25973,312,Zyvox,linezolid,Pfizer Inc.,PFE,New York,United States,North America,2.03473E+11,Endocrine,Diabetes Mellitus,Diabetic Foot and Other Ulcers,N,Approved,Approved,100% (Same As Avg.),Small Molecule,Bacterial ribosome^ Protein synthesis,New Molecular Entity (NME),No,"Intravenous (IV), Oral (PO)",N,N,N,,N,N,,,,07/22/03,,,,,,,,,,,,,100%,,$    55.0,$    15.0,$     3.0,$    18.0,$   466.0,$   281.0,$   236.0,$   135.0,Q2 2019,N/A
